



(11) **EP 2 775 844 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
11.12.2019 Bulletin 2019/50

(51) Int Cl.:
C12Q 1/68 (2018.01) G01N 33/50 (2006.01)

(21) Application number: **12844605.1**

(86) International application number:
PCT/US2012/062263

(22) Date of filing: **26.10.2012**

(87) International publication number:
WO 2013/063496 (02.05.2013 Gazette 2013/18)

(54) **BIOMARKERS OF RESPONSE TO NAE INHIBITORS**

BIOMARKER FÜR DIE REAKTION AUF NAE-INHIBITOREN

BIOMARQUEURS DE RÉPONSE AUX INHIBITEURS DE NAE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(74) Representative: **Lau, Sarah Jane**
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL (GB)

(30) Priority: **28.10.2011 US 201161552686 P**

(56) References cited:
WO-A1-2011/068863

(43) Date of publication of application:
17.09.2014 Bulletin 2014/38

- **DATABASE GeO [Online] ncbi; 11 March 2002 (2002-03-11), "Affymetrix GeneChip Human Genome U133 Array Set HGU133A", XP002739655, retrieved from NCBI Database accession no. gl96**
- **GRAHAM R. BIGNELL ET AL: "Signatures of mutation and selection in the cancer genome", NATURE, vol. 463, no. 7283, 18 February 2010 (2010-02-18), pages 893-898, XP055189252, ISSN: 0028-0836, DOI: 10.1038/nature08768 & GRAHAM R. BIGNELL ET AL: "Signatures of mutation and selection in the cancer genome- Supplementary information", NATURE, vol. 463, no. 7283, 18 February 2010 (2010-02-18), pages 893-898, XP055189298, ISSN: 0028-0836, DOI: 10.1038/nature08768**
- **H. LIAO ET AL: "Quantitative Proteomic Analysis of Cellular Protein Modulation upon Inhibition of the NEDD8-Activating Enzyme by MLN4924", MOLECULAR & CELLULAR PROTEOMICS, vol. 10, no. 11, 26 August 2011 (2011-08-26), XP055151079, ISSN: 1535-9476, DOI: 10.1074/mcp.M111.009183**

(73) Proprietors:

- **Millennium Pharmaceuticals, Inc. Cambridge, MA 02139 (US)**
- **Massachusetts General Hospital Boston MA 02114 (US)**

(72) Inventors:

- **BENES, Cyril, H. Brookline, MA 02445 (US)**
- **BLAKEMORE, Stephen, J. Littleton, MA 01460 (US)**
- **BLANK, Jonathan, L. Westborough, MA 01581 (US)**
- **LIGHTCAP, Eric, S. Natick, MA 01760 (US)**
- **MULLIGAN, George, J. Lexington, MA 02421 (US)**
- **SCHU, Matthew, C. Durham, NC 27704 (US)**
- **SMITH, Peter, G. Arlington, MA 02446 (US)**
- **SETTLEMAN, Jeffrey E. Mill Valley, California 94941 (US)**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 775 844 B1

- BIN LI ET AL.: "Investigation of efficacy of the NAE inhibitor MLN4924 across large-scale cell line panels ,reveals potentially sensitive cancer indications and candidate predictive biomarkers.", PROCEEDINGS OF THE AACR-NCI-EORTC INTERNATIONAL CONFERENCE (IN: MOLECULAR TARGETS AND CANCER THERAPEUTICS) 2011 NOV 12-16; SAN FRANCISCO, CA. PHILADELPHIA (PA), vol. 10, no. Suppl., 12 November 2011 (2011-11-12), page A45, XP055153902, DOI: 10.1158/1535-7163.TARG-11-A45CiteNPL
- MICHAELA MILHOLLEN ET AL.: "Treatment-Emergent Mutations in NAE Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924", CANCER CELL, CELL PRESS, US, vol. 21, no. 3, 6 February 2012 (2012-02-06), pages 388-401, XP028473640, ISSN: 1535-6108, DOI: 10.1016/J.CCR.2012.02.009 [retrieved on 2012-02-15]
- SADDLER ET AL.: 'Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.' BLOOD vol. 111, 2007, pages 1584 - 1593, XP055139885
- XIRODIMAS ET AL.: 'Mdm2-Mediated NEDD8 Conjugation of p53 Inhibits Its Transcriptional Activity.' CELL vol. 118, 2004, pages 83 - 97, XP055151076
- LIN ET AL.: 'NEDD8-Targeting Drug MLN4924 Elicits DNA Rereplication by Stabilizing Cdt1 in S Phase, Triggering Checkpoint Activation, Apoptosis, and Senescence in Cancer Cells.' CANCER RES vol. 70, 2010, pages 10310 - 20, XP055151077
- LIAO ET AL.: 'Quantitative Proteomic Analysis of Cellular Protein Modulation upon Inhibition of the NEDD8-Activating Enzyme by MLN4924.' MOLECULAR & CELLULAR PROTEOMICS vol. 10, August 2011, pages 1 - 11, XP055151079
- LIPKOWITZ ET AL.: 'RINGS of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis.' NATURE REVIEWS CANCER vol. 11, September 2011, pages 629 - 643, XP055151080
- MILHOLLEN ET AL.: 'Treatment-emergent mutations in NAEbeta confer resistance to the NEDD8- activating enzyme inhibitor MLN4924.' CANCER CELL. vol. 21, no. 3, March 2012, pages 388 - 401, XP028473640
- JIA ET AL.: 'Induction of p21-Dependent Senescence by an NAE Inhibitor, MLN4924, as a Mechanism of Growth Suppression.' NEOPLASIA vol. 13, no. 6, June 2011, pages 561 - 569, XP055151081

Description**Related Applications**

5 [0001] This application claims priority to U.S. Provisional Application number 61/552,686 filed on October 28, 2011.

Sequence Listing

10 [0002] This application contains a Sequence Listing which is submitted herewith in electronically readable format. The Sequence Listing file was created on October 26, 2012, is named "sequencelisting.txt," and its size is 149 kb (153,088 bytes).

Background

15 [0003] Cells become cancerous when their genotype or phenotype alters in a way that there is uncontrolled growth that is not subject to the confines of the normal tissue environment. One or more genes is mutated, amplified, deleted, overexpressed or underexpressed. Chromosome portions can be lost or moved from one location to another. Some cancers have characteristic patterns by which genotypes or phenotypes are altered.

20 [0004] Many genes have mutations which are associated with cancer. Some genes have multiple sites where mutations can occur. Many cancers have mutations in and/or mis-expression of more than one gene. Gene mutations can facilitate tumor progression, tumor growth rate or whether a tumor will metastasize. Some mutations can affect whether a tumor cell will respond to therapy.

25 [0005] A variety of agents treat cancers. Cancers of the blood and bone marrow often are treated with steroids/glucocorticoids, imids, proteasome inhibitors and alkylating agents. Cancers of other tissues often are treated with alkylating agents, topoisomerase inhibitors, kinase inhibitors, microtubule inhibitors, angiogenesis inhibitors or other agents. Some patients respond to one therapy better than another, presenting the potential for a patient to follow multiple therapeutic routes to effective therapy. Valuable time early in a patient's treatment program can be lost pursuing a therapy which eventually is proven ineffective for that patient. Many patients cannot afford the time for trial-and-error choices of therapeutic regimens. Expedient and accurate treatment decisions lead to effective management of the disease.

30 [0006] DATABASE GeO [Online] ("Affymetrix GeneChip Human Genome U133 Array Set HGU133A", GeO, NCBI, (20020311), Database accession no. gl96, Pages 61, 243, 418) describes array with probes for marker genes NF2, SMAD4 and FBXW7.

[0007] Bignell, G. R. et al. (2010) (Signatures of mutation and selection in the cancer genome. Nature, 463(7283), 893) describes genes involved in cancer and describes the use of primers to screen for mutations in such genes.

35 [0008] International (PCT) Application published as WO 2011/068863 (A1) describes a combination of therapeutic agents for use in treating a patient suffering from cancer, the combination comprising at least one polyploidy inducing agent and at least one Bel-2 family protein inhibitor. Described also are diagnostic assays useful in classification of patients for treatment with one or more therapeutic agents.

Summary

40 [0009] The subject matter for which protection is sought is as defined in the claims. The present disclosure relates to prognosis and planning for treatment of tumors by measurement of the amount, presence or changes of markers provided herein. The markers are predictive of whether there will be a favorable outcome (e.g., good response, long time-to-progression, and/or long term survival) after treatment with a NEDD8-activating enzyme (NAE) inhibitor, such as a 1-substituted methyl sulfamate. Testing samples comprising tumor cells, e.g., *in vitro*, to determine the presence, amounts or changes of genetic markers, e.g., the mutational status of at least one marker gene, identifies particular patients who are expected to have a favorable outcome with treatment, e.g., with an NAE inhibitor, such as a 1-substituted methyl sulfamate, and whose disease may be managed by standard or less aggressive treatment, as well as those patients who are expected have an unfavorable outcome with the treatment and may require an alternative treatment to, a combination of treatments and/or more aggressive treatment with an NAE inhibitor to ensure a favorable outcome and/or successful management of the disease.

50 [0010] In one aspect, the invention provides kits useful in determination of characteristics, e.g., amounts, presence or changes, of the markers. In another aspect, the invention provides methods for determining prognosis and treatment or disease management strategies. In these aspects, the characteristic, e.g., size, sequence, composition or amount of marker in a sample comprising tumor cells is measured. In one embodiment, the tumor is a liquid, e.g., hematological tumor, e.g., acute myelogenous leukemia, myelodysplastic syndrome or multiple myeloma. In another embodiment, the tumor is a solid tumor, e.g., melanoma, non-small cell lung cancer, esophageal cancer, bladder cancer, neuroblastoma

cancer, mesothelioma, pancreatic cancer.

[0011] In various embodiments, the characteristic, e.g., size, sequence, composition or amount of DNA, the size, sequence, composition or amount of RNA and/or the size, sequence, composition or amount of protein corresponding to a marker gene with one or more mutation, e.g., somatic mutation, described herein is measured. Useful information leading to the prognosis or treatment or disease management strategies is obtained when assays reveal information about a marker gene, e.g., whether the gene is mutated, or not, the identity of the mutation, and/or whether the RNA or protein amount of a mutated gene or genes indicates overexpression or underexpression. In one embodiment, the strategy is determined for E1 enzyme inhibition, e.g., NAE inhibition, e.g., MLN4924, therapy.

[0012] A marker gene useful to test for determination of prognosis or treatment or disease management strategy according to methods of the disclosure is selected from the group consisting of neurofibromin 2 (NF2), mothers against decapentaplegic homolog 4 (SMAD4), lysine-specific demethylase 6A (KDM6A), tumor protein p53 (TP53), cyclin-dependent kinase inhibitor 2A (CDKN2A), cyclin-dependent kinase inhibitor 2A p14 variant (CDKN2A_p14), in some cases, F-box and WD repeat domain containing 7 (FBXW7) and, in some cases adenomatous polyposis coli (APC). Each marker gene includes mutations or alterations whose presence in DNA or whose effects, e.g., on marker RNA and/or protein characteristics, e.g., amounts, size, sequence or composition, can provide information for determination of prognosis or treatment or disease management. In some description, a gene or a mutant or modified form thereof useful as a marker, has a DNA, an RNA and/or protein characteristic, e.g., size, sequence, composition or amount, e.g., in a sample comprising tumor cells, which is different than a normal DNA, RNA and/or protein. Described herein are examples of modifications of these genes, referred to as "marker genes" whose mutation or amounts can provide such information.

[0013] The mutation of the markers of the present invention, provide information about outcome after treatment, e.g., with an NAE inhibitor, such as a 1-substituted methyl sulfamate. By examining the characteristic, e.g., size, sequence, composition or amount of one or more of the identified markers in a tumor, it is possible to determine which therapeutic agent, combination of agents, dosing and/or administration regimen is expected to provide a favorable outcome upon treatment. By examining the characteristic, e.g., size, sequence, composition or amount of one or more of the identified markers or marker sets in a cancer, it is also possible to determine which therapeutic agent, combination of agents, dosing and/or administration regimen is less likely to provide a favorable outcome upon treatment. By examining the characteristic, e.g., size, sequence, composition or amount of one or more of the identified markers, it is therefore possible to eliminate ineffective or inappropriate therapeutic agents or regimens. Importantly, these determinations can be made on a patient-by-patient basis. Thus, one can determine whether or not a particular therapeutic regimen is likely to benefit a particular patient or type of patient, and/or whether a particular regimen should be started or avoided, continued, discontinued or altered.

[0014] The present invention is directed to methods of identifying and/or selecting a cancer patient who is expected to demonstrate a favorable outcome upon administration of a therapeutic regimen, e.g., a therapeutic regimen comprising an NAE inhibitor, such as a 1-substituted methyl sulfamate treatment. Additionally provided are methods of identifying a patient who is expected to have an unfavorable outcome upon administration of such a therapeutic regimen. These methods typically include measuring, determining, receiving, storing or transmitting information about the characteristic, e.g., size, sequence, composition or amount of one or more markers or mutation of marker gene(s) in a patient's tumor (e.g., a patient's cancer cells, e.g., hematological cancer cells or solid tumor cells), optionally comparing that to the characteristic, e.g., size, sequence, composition or amount of a reference marker, and in a further embodiment, identifying or advising whether result from the sample corresponds to a favorable outcome of a treatment regimen, e.g., an NAE inhibitor, such as a 1-substituted methyl sulfamate treatment regimen.

[0015] Additionally provided methods include therapeutic methods which further include the step of beginning, continuing, or commencing a therapy accordingly where the presence of a mutation in a marker gene or the characteristic, e.g., size, sequence, composition or amount of a patient's marker or markers indicates that the patient is expected to demonstrate a favorable outcome with the therapy, e.g., the NAE inhibitor, such as a 1-substituted methyl sulfamate therapeutic regimen. In addition, the methods include therapeutic methods which further include the step of stopping, discontinuing, altering or halting a therapy accordingly where the presence of a mutation in a marker gene or the characteristic, e.g., size, sequence, composition or amount of a patient's marker indicates that the patient is expected to demonstrate an unfavorable outcome with the treatment, e.g., with the NAE inhibitor, such as a 1-substituted methyl sulfamate regimen, e.g., as compared to a patient identified as having a favorable outcome receiving the same therapeutic regimen. In another aspect, methods are provided for analysis of a patient not yet being treated with a therapy, e.g., an NAE inhibitor, such as a 1-substituted methyl sulfamate therapy and identification and prediction of treatment outcome based upon the presence of a mutation in a marker gene or characteristic, e.g., size, sequence, composition or amount of one or more of a patient's marker described herein. Such methods can include not being treated with the therapy, e.g., NAE inhibitor, such as a 1-substituted methyl sulfamate therapy, being treated with therapy, e.g., NAE inhibitor, or being treated with a 1-substituted methyl sulfamate therapy in combination with one more additional therapies, being treated with an alternative therapy to an NAE inhibitor, such as a 1-substituted methyl sulfamate therapy, or being treated with a more aggressive dosing and/or administration regimen of a therapy, e.g., E1 enzyme inhibitor, such as an NAE

inhibitor, e.g., as compared to the dosing and/or administration regimen of a patient identified as having a favorable outcome to standard NAE inhibitor, such as a 1-substituted methyl sulfamate therapy. Thus, the provided methods of the invention can eliminate ineffective or inappropriate use of therapy, e.g., NAE inhibitor, such as 1-substituted methyl sulfamate therapy regimens.

5 **[0016]** Additional methods of the disclosure include methods to determine the activity of an agent, the efficacy of an agent, or identify new therapeutic agents or combinations. Such methods include methods to identify an agent as useful, e.g., as an NAE inhibitor, such as a 1-substituted methyl sulfamate, for treating a cancer, e.g., a hematological cancer (e.g., multiple myeloma, leukemias, lymphoma, etc) or solid tumor cancer (e.g., melanoma, esophageal cancer or bladder cancer), based on its ability to affect the presence of a mutation in a marker gene or characteristic, e.g., size, sequence, composition or amount of a marker or markers of the invention. For example, an inhibitor which decreases or increases the presence of a mutation in a marker gene or characteristic, e.g., size, sequence, composition or amount of a marker or markers provided in a manner that indicates favorable outcome of a patient having cancer would be a candidate agent for the cancer. Alternatively, an agent which is able to decrease the viability of a tumor cell comprising a marker indicative of an unfavorable outcome would be a candidate agent for the cancer.

15 **[0017]** The present invention is also directed to an NAE inhibitor for use in methods of treating a cancer patient, with a therapeutic regimen, e.g., an NAE inhibitor, such as a 1-substituted methyl sulfamate therapy regimen (e.g., alone, or in combination with an additional agent such as a chemotherapeutic agent, e.g., a glucocorticoid agent, a proteasome inhibitor, an alkylating agent, a kinase inhibitor or a topoisomerase inhibitor), which includes the step of selecting for treatment a patient whose marker characteristic, e.g., size, sequence, composition or amount indicates that the patient is expected to have a favorable outcome with the therapeutic regimen, and treating the patient with the therapy, e.g., NAE inhibition, such as a 1-substituted methyl sulfamate therapy. In some embodiments, the method can include the step of selecting a patient whose marker characteristic, e.g., size, sequence, composition or amount or amounts indicates that the patient is expected have a favorable outcome and administering a therapy other than an NAE inhibitor therapy that demonstrates similar expected survival times as the NAE inhibitor, such as a 1-substituted methyl sulfamate therapy.

25 **[0018]** Additional methods of treating a cancer patient include selecting patients that are unlikely to experience a favorable outcome upon treatment with a cancer therapy (e.g., NAE inhibitor, such as a 1-substituted methyl sulfamate therapy). Such methods can further include one or more of: administering a higher dose or increased dosing schedule of a therapy, e.g., NAE inhibitor, such as a 1-substituted methyl sulfamate as compared to the dose or dosing schedule of a patient identified as having a favorable outcome with standard therapy; administering a cancer therapy other than an NAE inhibitor, such as a 1-substituted methyl sulfamate therapy; administering an NAE inhibitor, such as a 1-substituted methyl sulfamate agent in combination with an additional agent. Further provided are methods for selection of a patient having aggressive disease which is expected to demonstrate more rapid time to progression and death.

30 **[0019]** Additional methods of the disclosure include a method to evaluate whether to treat or pay for the treatment of cancer, e.g., hematological cancer (e.g., multiple myeloma, leukemias, lymphoma, etc.) or solid tumor cancer (e.g., melanoma, esophageal cancer or bladder cancer) by reviewing the amount of a patient's marker or markers for indication of outcome to a cancer therapy, e.g., an NAE inhibitor, such as a 1-substituted methyl sulfamate therapy regimen, and making a decision or advising on whether payment should be made.

[0020] The entire contents of all publications, patent applications, patents and other references mentioned herein are referred to.

40 **[0021]** Other features and advantages of the invention will be apparent from the following detailed description, drawings and from the claims.

Drawings

45 **[0022]**

Figure 1. General structure of 1-substituted methyl sulfamate. G¹ is -O- or -CH₂-; G² is -H or -OH; G³ is -H or -OH; G⁴ is -NH-, -O- or a covalent bond; and G⁵ is substituted heteroaryl.

50 Figure 2. General pathways for cullin-ring ligase (CRL) ubiquitination of protein substrates and for neddylation. In CRLs, the cullin subunit must be modified on a conserved lysine by the ubiquitin-like protein NEDD8 to activate holoenzyme activity. NEDD8 activation and conjugation to cullin proteins is catalyzed via an enzymatic cascade that is homologous to ubiquitination involving NEDD8's E1 (NAE) and E2 (Ubc12). Removal of NEDD8 from cullin is catalyzed by the COP9 signalosome. Deneddylation facilitates dissociation of CRL components. The cullin-RING core is sequestered in an inactive state by binding to CAND1 until it is recruited to form a new CRL.

55 Figure 3. Response of a cell line panel 2 to MLN4924. Each point represents one cell line.

Figures 4A-B. Comparison of responses of cell line panels to MLN4924. A. Ordering of cell line panel 2 by EC50. Darkened lines represent cell lines that are present in panel 1. There are 114 cell lines with identical names in both panels. B. Comparison of Percent of Control (POC) viability for the cell lines which are present in both panels. The

results of the overlapping cell lines have a Spearman Rank Order Correlation of 0.72, p-value < 2.2e-16.

Figure 5. Tissue association of resistance with TP53 mutations. TP53 mutant colon cancer cell lines are more resistant (higher percent of control viability) to MLN4924 treatment than TP53 wt cell lines.

Figures 6A-D. Effect of TP53 Loss on Viability of Cancer Cell Lines Following Treatment with Different Doses of MLN4924 at Multiple Time Points. The effect of TP53 knock-out on the sensitivity of paired HCT-116 colon cancer cell lines to MLN4924 was measured by ATPlite, across a range of MLN4924 concentrations and time points. Data are represented as mean \pm SEM, N = 3. Dotted line, p53 knock-out; solid line, p53 wild type.

Detailed Description

[0023] One of the continued problems with therapy in cancer patients is individual differences in response to therapies. While advances in development of successful cancer therapies progress, only a subset of patients respond to any particular therapy. With the narrow therapeutic index and the toxic potential of many available cancer therapies, such differential responses potentially contribute to patients undergoing unnecessary, ineffective and even potentially harmful therapy regimens. If a designed therapy could be optimized to treat individual patients, such situations could be reduced or even eliminated. Furthermore, targeted designed therapy may provide more focused, successful patient therapy overall. Accordingly, there is a need to identify particular cancer patients who are expected to have a favorable outcome when administered particular cancer therapies as well as particular cancer patients who may have a favorable outcome using more aggressive and/or alternative cancer therapies, e.g., alternative to previous cancer therapies administered to the patient. It would therefore be beneficial to provide for the diagnosis, staging, prognosis, and monitoring of cancer patients, including, e.g., hematological cancer patients (e.g., multiple myeloma, leukemias, lymphoma, etc.) or solid tumor cancer (e.g., melanoma, esophageal cancer or bladder cancer) who would benefit from particular cancer inhibition therapies as well as those who would benefit from a more aggressive and/or alternative cancer inhibition therapy, e.g., alternative to a cancer therapy or therapies the patient has received, thus resulting in appropriate preventative measures.

[0024] The present invention is based, in part, on the recognition that mutation of a marker gene can be associated with sensitivity of a cell comprising the mutated gene to an NAE inhibitor, such as a 1-substituted methyl sulfamate. In some embodiments, the marker gene is involved in the cullin ring ligase (CRL) pathway, e.g., a gene whose encoded protein interacts with a CRL or a CRL-associated protein, or is a CRL substrate. A protein encoded by a marker gene can have a wild type function as a tumor suppressor. Examples of marker genes include NF2, SMAD4 and/or KDM6A. Other examples of marker genes include TP53, APC, CDKN2A and/or CDKN2A_p14. Marker genes can exhibit mutations, e.g., somatic mutations, whose presence can affect expression or activity of the encoded gene product. In some embodiments, there can be more than one mutation in a marker gene or more than one marker gene with a mutation in a tumor cell or tumor. In additional embodiments, there can be marker gene mutations in cells which have mutations in additional genes, including mutations that can lead to tumorigenesis, but the additional mutated genes may not be marker genes as considered herein. In some embodiments, the mutation is an inactivating mutation. In other embodiments, the mutation affects the expression of the marker gene. In other embodiments, a mutation can result in an altered interaction of the encoded gene product with a cellular binding partner. The identification and/or measurement of the mutation in the marker gene can be used to determine whether a favorable outcome can be expected by treatment of a tumor, e.g., with an NAE inhibitor, such as a 1-substituted methyl sulfamate therapy or whether an alternative therapy to and/or a more aggressive therapy with, e.g., an NAE inhibitor, such as a 1-substituted methyl sulfamate inhibitor may enhance expected survival time. For example, the compositions and methods provided herein can be used to determine whether a patient is expected to have a favorable outcome to an NAE inhibitor, such as a 1-substituted methyl sulfamate therapeutic agent or an NAE inhibitor, such as a 1-substituted methyl sulfamate dosing or administration regimen. In general, mutation in the tumor suppressor marker genes described herein is associated with sensitivity to or favorable outcome of treatment with a NAE inhibitor. Examples of marker genes which can function as a tumor suppressor in pathways related to cullin ring ligase and whose mutation is associated with sensitivity to NAE inhibition include NF2, SMAD4, KDM6A, FBXW7, CDKN2A and/or CDKN2A_p14. However, TP53 and APC also are tumor suppressor marker genes. In particular, TP53 pathway genes are associated with NAE inhibitor effects. As described herein, in some embodiments for many tumor types, mutation in TP53, and in some cases, APC, leads to resistance to NAE inhibition. Accordingly, a wild type marker gene from the group consisting TP53 and APC can be associated with NAE sensitivity. In some embodiments, mutation of a marker gene selected from the group consisting of TP53 and APC is associated with resistance to an NAE inhibitor.

[0025] Based on these identifications, the present disclosure provides, without limitation: 1) methods and compositions for determining whether an NAE inhibitor, such as a 1-substituted methyl sulfamate therapy regimen will or will not be effective to achieve a favorable outcome and/or manage the cancer; 2) methods and compositions for monitoring the effectiveness of an NAE inhibitor, such as a 1-substituted methyl sulfamate therapy (alone or in a combination of agents) and dosing and administrations used for the treatment of tumors; 3) methods and compositions for treatments of tumors comprising, e.g., NAE inhibitor, such as a 1-substituted methyl sulfamate inhibition therapy regimen; 4) methods and

compositions for identifying specific therapeutic agents and combinations of therapeutic agents as well as dosing and administration regimens that are effective for the treatment of tumors in specific patients; and 5) methods and compositions for identifying disease management strategies.

[0026] Ubiquitin and other ubiquitin-like molecules (ubls) are activated by a specific enzyme (an E1 enzyme) which catalyzes the formation of an acyl-adenylate intermediate with the C-terminal glycine of the ubl. The activated ubl is then transferred to a catalytic cysteine residue within the E1 enzyme through formation of a thioester bond intermediate. The E1-ubl intermediate and an E2 associate, resulting in a thioester exchange wherein the ubl is transferred to the active site cysteine of the E2. The ubl is then conjugated to the target protein, either directly or in conjunction with an E3 ligase, through isopeptide bond formation with the amino group of a lysine side chain in the target protein. The ubl named Neural precursor cell-Expressed Developmentally Downregulated 8 (NEDD8) is activated by the heterodimer NEDD8-activating enzyme (NAE, also known as APPBP1-Uba3, UBE1C (ubiquitin-activating enzyme E1C)) and is transferred to one of two E2 conjugating enzymes (ubiquitin carrier protein 12 (UBC12) and UBC17), ultimately resulting in ligation of NEDD8 to cullin proteins by the cullin-RING subtype of ubiquitin ligases (see Figure 2). A function of neddylation is the activation of cullin-based ubiquitin ligases involved in the turnover of many cell cycle and cell signaling proteins, including p27 and I- κ B. See Pan et al., *Oncogene* 23:1985-97 (2004). Inhibition of NAE can disrupt cullin-RING ligase-mediated protein turnover and can lead to apoptotic death in cells, e.g., tumor cells or cells of a pathogenic organism, e.g. a parasite. See Soucy et al. (2010) *Genes & Cancer* 1:708-716.

[0027] As used herein, the term "E1," "E1 enzyme," or "E1 activating enzyme" refers to any one of a family of related ATP-dependent activating enzymes involved in activating or promoting ubiquitin or ubiquitin-like (collectively "ubl") conjugation to target molecules. E1 activating enzymes function through an adenylation/thioester intermediate formation to transfer the appropriate ubl to the respective E2 conjugating enzyme through a transthioylation reaction. The resulting activated ubl-E2 promotes ultimate conjugation of the ubl to a target protein. A variety of cellular proteins that play a role in cell signaling, cell cycle, and protein turnover are substrates for ubl conjugation which is regulated through E1 activating enzymes (e.g., NAE, UAE, SAE). Unless otherwise indicated by context, the term "E1 enzyme" is meant to refer to any E1 activating enzyme protein, including, without limitation, NEDD8 activating enzyme (NAE (APPBP1/Uba3)), ubiquitin activating enzyme (UAE (Uba1)), sumo activating enzyme (SAE (Aos1/Uba2)), UBA4, UBA5, UBA6, ATG7 or ISG15 activating enzyme (Ube1L).

[0028] The term "E1 enzyme inhibitor" or "inhibitor of E1 enzyme" is used to signify a compound having a structure as defined herein, which is capable of interacting with an E1 enzyme and inhibiting its enzymatic activity. Inhibiting E1 enzymatic activity means reducing the ability of an E1 enzyme to activate ubiquitin like (ubl) conjugation to a substrate peptide or protein (e.g., ubiquitination, neddylation, sumoylation). In some embodiments, an E1 enzyme inhibitor can inhibit more than one E1 enzyme. In other embodiments, an E1 enzyme inhibitor is specific for a particular E1 enzyme. In various embodiments, such reduction of E1 enzyme activity is at least about 50%, at least about 75%, at least about 90%, at least about 95%, or at least about 99%. In various embodiments, the concentration of E1 enzyme inhibitor required to reduce an E1 enzymatic activity is less than about 1 μ M, less than about 500 nM, less than about 100 nM, less than about 50 nM, or less than about 10 nM.

[0029] As used herein, the term "NAE inhibitor" refers to an inhibitor of the NAE heterodimer. Examples of NAE inhibitors include 1-substituted methyl sulfamates (see Figure 1), including MLN4924. Langston S. et al. U.S. patent application serial no. 11/700,614, whose PCT application was published as WO07/092213, WO06084281 and WO2008/019124, disclose compounds which are effective inhibitors of E1 activating enzymes, e.g., NAE. In some embodiments, NAE inhibitors do not inhibit, or are very poor at inhibiting, other (non-NAE) E1 enzymes. The compounds are useful for inhibiting E1 activity *in vitro* and *in vivo* and are useful for the treatment of disorders of cell proliferation, e.g., cancer, and other disorders associated with E1 activity, such as pathogenic infections and neurodegenerative disorders. One class of compounds described in Langston *et al.* are 4-substituted ((1S, 2S, 4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates.

[0030] MLN4924 (((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulphamate) is an NAE-specific E1 inhibitor which disrupts cullin-RING ligase-mediated protein turnover leading to apoptotic death in human tumor cells by perturbation of cellular protein homeostasis (Soucy et al. (2009) *Nature* 458:732-736). The evaluation of MLN4924 in cellular and tumor xenograft studies has revealed two distinct mechanisms of action. The first is the induction of DNA re-replication, DNA damage and cell death through MLN4924-mediated dysregulation of the CRL1^{SKP2} and CRL4^{DDB1} substrate Cdt-1 (Milhollen et al. (2011) *Cancer Res.* 71:3042-3051). It has been shown that p53 status does not impact the induction of DNA re-replication but may make cells more prone to undergo apoptosis or senescence depending on the appropriate genetic background (Milhollen et al. (2011) *supra*, Lin et al. (2010) *Nature* 464:374-379 and Lin et al. (2010) *Cancer Res.* 70:10310-20). The second mechanism is the inhibition of NF- κ B pathway activity in NF- κ B dependent Diffuse Large B-Cell Lymphomas primarily through dysregulation of CRL1 ^{β TRCP} mediated turnover of phosphorylated I κ B α (Milhollen et al. (2010) *Blood* 116:1515-1523). In addition, pre-clinical models of Acute Myelogenous Leukemia (AML) are sensitive to MLN4924 inhibition in both cell lines and primary patient blasts through mechanisms related to Cdt-1 dysregulation, NF- κ B inhibition

and induction of reactive oxygen species (Swords et al. (2010) Blood 115:3796-3800).

[0031] Genes such as NF2 (reviewed by Ahronowitz et al. (2007) Human Mutation 28:1-2), KDM6A (reviewed by van Haaften et al. (2009) Nat. Genet. 41:521-523), FBXW7, TP53, CDKN2A and CDKN2A_p14 are mutated in many cancer types. SMAD4 is mutated in a number of cancers, but many of SMAD4 mutations are found in cancers of the intestine,

pancreas (reviewed by Miyaki and Kuroki (2003) Biochem. Biophys. Res. Commun. 306:799-804) or thyroid gland.
[0032] As used herein, "NF2" refers to the longer isoform of the gene associated with GenBank Accession No. NM_000268, SEQ ID NO:1 (open reading frame is SEQ ID NO:2, nucleotides 444 to 2231 of SEQ ID NO:1), encoding GenPept Accession No. NP_000259, SEQ ID NO:3). Other names for NF2 include ACN, BANF, SCH and merlin (moesin-ezrin-radixin-like protein). NF2 functions as a tumor suppressor gene and can be found on chromosome 22. NF2 interacts with the cytoskeleton, cell surface proteins and may be involved in cytoskeletal dynamics and regulating ion transport. Functions of NF2 that can relate it to sensitivity to NAE inhibition, e.g., MLN4924 include its ability to inhibit the E3 ubiquitin ligase CRL4^{DCAF1} (Li et al. (2010) Cell 140:477-490). Mutations in NF2 can disrupt its inhibitory activity and lead to uncontrolled ubiquitination of substrates of CRL4^{DCAF1} and proliferation of cells harboring the mutated gene.

[0033] As used herein, "SMAD4" refers to the gene associated with GenBank Accession No. NM_005359, SEQ ID NO:4 (open reading frame is SEQ ID NO:5, nucleotides 539 to 2197 of SEQ ID NO:4), encoding GenPept Accession No. NP_005350, SEQ ID NO:6. Other names for SMAD4 include deleted in pancreatic carcinoma locus 4 (DPC4), JIP, or mothers against decapentaplegic, Drosophila, homolog of, 4 (MAD4). SMAD4 is a signal transduction protein involved in transforming growth factor (TGF)-beta signaling. SMAD4 can act as a tumor suppressor and can be targeted for degradation by ubiquitination by the Skp-Cullin-F-box protein (SCF) complex.

[0034] As used herein, "KDM6A" refers to the gene associated with GenBank Accession No. NM_021140, SEQ ID NO:7 (open reading frame is SEQ ID NO:8, nucleotides 376 to 4581 of SEQ ID NO:7, or SEQ ID NO:9), encoding GenPept Accession No. NP_066963, SEQ ID NO:10 or SEQ ID NO:11 (SEQ ID NO:10 with a V instead of an L at position 173 and an R instead of L at 584, an N instead of S at position 601 and/or K instead of E at position 629). Other names for KDM6A include ubiquitously-transcribed tetratricopeptide repeat protein X-linked or ubiquitously-transcribed TPR gene on the X chromosome (UTX), or bA286N14.2. KDM6A is a histone demethylase and can function as a tumor suppressor.

[0035] As used herein, "FBXW7" refers to the gene associated with GenBank Accession No. NM_033632, SEQ ID NO:12 (open reading frame is SEQ ID NO:13, nucleotides 150 to 2273 of SEQ ID NO:12), encoding GenPept Accession No. NP_361014, SEQ ID NO:14. Other names for FBXW7 include homolog of C elegans sel-10 (SEL10), archipelago homolog (AGO), F-box protein FBX30 (FBXO30), or cell division control protein 4 (CDC4). FBXW7 can associate into a ubiquitin protein ligase complex to participate in phosphorylation-dependent ubiquitination of proteins, including proteins involved in cell cycle and survival. FBXW7 can act as a tumor suppressor. Use of FBXW7 as marker gene may be organ-specific, i.e., it can be a marker of sensitivity in tumors arising in some tissues but not others. For example, FBXW7 can be a marker of sensitivity in tumors of the uterus, cervix or liver, but not a marker of sensitivity in tumors of the digestive tract, where mutations in other genes may dominate to result in the insensitivity or resistance of cells from those tumors to MLN4924.

[0036] As used herein, "TP53" refers to the gene associated with GenBank Accession No. NM_000546, SEQ ID NO:15 (open reading frame is SEQ ID NO:16, nucleotides 203 to 1384 of SEQ ID NO:15, or a variant wherein the nucleotide at position 417 is a guanine instead of a cytosine), encoding GenPept Accession No. NP_000537, SEQ ID NO:17 or a variant wherein the amino acid residue at position 72 is an arginine, R instead of a proline, P). Other names for TP53 include BCC7, LFS1 and p53. TP53 binds DNA and activates transcription factors and can function as a tumor suppressor.

[0037] As used herein, "CDKN2A" refers to the gene associated with GenBank Accession No. NM_000077, SEQ ID NO:18 (open reading frame is SEQ ID NO:19, nucleotides 307 to 777 of SEQ ID NO:18), encoding GenPept Accession No. NP_000068, SEQ ID NO:20. Other names for CDKN2A include alternate open reading frame (ARF), p16, p16ARF, inhibitor of cyclin-dependent kinase 4 (INK4) and multiple tumor suppressor gene-1 (MTS1). Variants of CDKN2A differ in the first exon. One variant is "CDKN2A_p14" or "CDKN2A.p14," also known as p14ARF, is associated with GenBank accession number NM_058195, SEQ ID NO:21 (open reading frame is SEQ ID NO:22, nucleotides 38 to 559 of SEQ ID NO:21); GenPept NP_478102, SEQ ID NO:23 or a variant which begins at amino acid residue 42 of SEQ ID NO:23. CDKN2A_p14 results from translation in a different reading frame than p16ARF (p16INK4a, CDKN2A). CDKN2A and CDKN2A_p14 inhibit cyclin dependent kinase 4, can stabilize p53 and can regulate cell cycle G1 progression. CDKN2A and CDKN2A_p14 can act as a tumor suppressor.

[0038] As used herein, "APC" refers to adenomatous polyposis coli, the gene associated with GenBank Accession No. NM_000038, SEQ ID NO:24 (open reading frame SEQ ID NO:25, or a variant with a thymine instead of a cytosine at nucleotide 1458), encoding GenPept Accession No. NP_000029, SEQ ID NO:26. Other names for APC include BTSP2, and DP2. APC binds microtubules and inhibits the Wnt-signalling pathway and can function as a tumor suppressor.

[0039] There has been interest in public cataloging mutations associated with cancers. Examples of public databases which include information about mutations associated with cancers are the Database of Genotypes and Phenotypes

(dbGaP) maintained by the National Center for Biotechnology Information (Bethesda, MD) and Catalogue of Somatic Mutations in Cancer (COSMIC) database maintained by the Wellcome Trust Sanger Institute (Cambridge, UK).

[0040] Compositions and methods are provided to determine the mutational status, e.g., to identify mutations in marker genes in hematological (e.g., multiple myeloma, leukemias, lymphoma, etc.) or solid (e.g., melanoma, esophageal cancer, lung cancer or bladder cancer) tumors to predict response to treatment, time-to-progression and survival upon treatment. Compositions and methods provided herein also can identify mutations in marker genes in solid tumors such as from colon cancer, breast cancer, head and neck cancer, or central nervous system cancer.

[0041] Markers were identified based on genetic profiles of tumor cells which exhibit sensitivity to treatment to MLN4924. TP53 marker also was identified based on the behavior of isogenic cell lines which differ in the deletion of the TP53 gene. Observed sensitivity can be consistent among tumor cells tested by more than one method.

[0042] Unless otherwise defined, all technical and scientific terms used herein have the meanings which are commonly understood by one of ordinary skill in the art to which this invention belongs. Generally, nomenclature utilized in connection with, and techniques of cell and tissue culture, molecular biology and protein and oligo- or polynucleotide chemistry and hybridization described herein are those known in the art. GenBank or GenPept accession numbers and useful nucleic acid and peptide sequences can be found at the website maintained by the National Center for Biotechnology Information, Bethesda, MD. The content of all database accession records (e.g., from Affymetrix HG133 annotation files, Entrez, GenBank, RefSeq, COSMIC) cited throughout this application (including the Tables) are referred to. Standard techniques are used for recombinant DNA, oligonucleotide synthesis, protein purification, tissue culture and transformation and transfection (e.g., electroporation, lipofection, etc). Enzymatic reactions are performed according to manufacturer's specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures generally are performed according to methods known in the art, e.g., as described in various general and more specific references that are cited and discussed throughout the present specification. See e.g., Sambrook et al. (2000) Molecular Cloning: A Laboratory Manual (3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY) or Harlow, E. and Lane, D. (1988) Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). The nomenclatures utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are known in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation and delivery, and treatment of patients. Furthermore, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. In the case of conflict, the present specification, including definitions, will control.

[0043] The articles "a," "an" and "at least one" are used herein to refer to one or to more than one of the grammatical object of the article. By way of example, "an element" means one or more than one element, at least one element. In the case of conflict, the present specification, including definitions, will control.

[0044] As used herein, a "favorable" outcome or prognosis refers to long term survival, long time-to-progression (TTP), and/or good response. Conversely, an "unfavorable" prognosis refers to short term survival, short time-to-progression (TTP) and/or poor response.

[0045] A "marker" as used herein, includes a material associated with a marker gene which has been identified as having a mutation in tumor cells of a patient and furthermore that mutation is characteristic of a patient whose outcome is favorable or unfavorable with treatment e.g., by an NAE inhibitor, such as a 1-substituted methyl sulfamate. Examples of a marker include a material, e.g., a chromosome locus, DNA for a gene, RNA for a gene or protein for a gene. For example, a marker includes a marker gene material, e.g., a chromosome locus, DNA, RNA or protein which demonstrates a characteristic, e.g., size, sequence, composition or amount indicative of a short term survival patient; alternatively a marker includes a marker gene material, e.g., a chromosome locus, DNA, RNA or protein which demonstrates a mutation or characteristic, e.g., size, sequence, composition or amount indicative of a long term survival patient. In another example, a marker includes a marker gene material, e.g., a chromosome locus, DNA, RNA or protein whose mutation or characteristic, e.g., size, sequence, composition or amount is indicative of a patient with a poor response to treatment; alternatively a marker includes a marker gene material, e.g., a chromosome locus, DNA, RNA or protein whose mutation or characteristic, e.g., size, sequence, composition or amount is indicative of a patient with a good response. In a further example, a marker includes a marker gene material, e.g., a chromosome locus, DNA, RNA or protein whose mutation or characteristic, e.g., size, sequence, composition or amount is indicative of a patient whose disease has a short time-to-progression (TTP) upon treatment; alternatively a marker includes a marker gene material, e.g., a chromosome locus, DNA, RNA or protein whose mutation or characteristic, e.g., size, sequence, composition or amount is indicative of a patient whose disease has a long TTP. In a yet a further example, a marker includes a marker gene material, e.g., a chromosome locus, DNA, RNA or protein whose mutation or characteristic, e.g., size, sequence, composition or amount is indicative of a patient whose disease has a short term survival upon treatment; alternatively a marker includes a marker gene material, e.g., a chromosome locus, DNA, RNA or protein whose mutation or characteristic, e.g., size, sequence, composition or amount is indicative of a patient whose disease has a long term survival. Thus, as used herein, marker is intended to include each and every one of these possibilities, and further can include each single marker individually as a marker; or alternatively can include one or more, or all of the characteristics collectively when reference

is made to "markers" or "marker sets."

[0046] A chromosome locus marker useful to measure for determination of prognosis or treatment or disease management strategy is selected from the group consisting of chromosome 22q12.2 (NF2), e.g., from base pair 29999545 to 30094589, chromosome 18q21.1-21.2 (SMAD4), e.g., from base pair 48556583 to 48611412, chromosome Xp11.2 (KDM6A), e.g., from base pair 44732423 to 44971847, chromosome 4q31.3 (FBXW7), e.g., from base pair 153242410-153456172, chromosome 17p13.1 (TP53), e.g., from base pair 7571720 to 7590868, and 9p21 (CDKN2A and CDKN2A_p14), e.g., from base pair 21967751 to 21994490. Chromosome locus numbers are based on the reference human genome Build 37.3 (current as of October 5, 2011) in the NCBI Gene database. A marker DNA, marker RNA or marker protein can correspond to base pairs on a chromosome locus marker. For example, a marker DNA can include genomic DNA from a chromosome locus marker, marker RNA can include a polynucleotide transcribed from a locus marker, and a marker protein can include a polypeptide resulting from expression at a chromosome locus marker in a sample, e.g., comprising tumor cells.

[0047] A "marker nucleic acid" is a nucleic acid (e.g., genomic DNA, mRNA, cDNA) encoded by or corresponding to a marker gene of the invention. Such marker nucleic acids include DNA, e.g., sense and anti-sense strands of genomic DNA (e.g., including any introns occurring therein), comprising the entire or a partial sequence, e.g., one or more of the exons of the genomic DNA, up to and including the open reading frame of any of the marker genes or the complement of such a sequence. The marker nucleic acids also include RNA comprising the entire or a partial sequence of any marker or the complement of such a sequence, wherein all thymidine residues are replaced with uridine residues, RNA generated by transcription of genomic DNA (*i.e.* prior to splicing), RNA generated by splicing of RNA transcribed from genomic DNA, and proteins generated by translation of spliced RNA (*i.e.* including proteins both before and after cleavage of normally cleaved regions such as transmembrane signal sequences). As used herein, a "marker nucleic acid" may also include a cDNA made by reverse transcription of an RNA generated by transcription of genomic DNA (including spliced RNA). A marker nucleic acid also includes sequences which differ, due to degeneracy of the genetic code, from the nucleotide sequence of nucleic acids encoding a protein which corresponds to a marker, e.g., a mutated marker, of the invention, and thus encode the same protein, e.g., mutated protein. As used herein, the phrase "allelic variant" refers to a nucleotide sequence which occurs at a given locus or to a polypeptide encoded by the nucleotide sequence. Such naturally occurring allelic variations can typically result in 1-5% variance in the nucleotide sequence of a given gene. Alternative alleles can be identified by sequencing the gene of interest in a number of different individuals, e.g., in cells, e.g., germline cells, of individuals without cancer. This can be readily carried out by using hybridization probes to identify the same genetic locus in a variety of individuals. Detection of any and all such nucleotide variations and resulting amino acid polymorphisms or variations that are the result of naturally occurring allelic variation and that do not alter the functional activity of a wild type marker gene is intended to be within the scope of the wild type version of a marker described herein. A "marker protein" is a protein encoded by or corresponding to a marker, e.g., a mutant nucleic acid, of the invention. The terms "protein" and "polypeptide" are used interchangeably. A protein of a marker specifically can be referred to by its name or amino acid sequence, but it is understood by those skilled in the art, that mutations, deletions and/or post-translational modifications can affect protein structure, appearance, cellular location and/or behavior. Unless indicated otherwise, such differences are not distinguished herein, and a marker described herein is intended to include any or all such varieties.

[0048] As used herein, a "marker gene" refers to a gene which can have a mutation such that its DNA, RNA and/or protein has a characteristic, e.g., size, sequence, composition or amount(s) which provide information about prognosis (*i.e.*, are "informative") upon treatment. Marker genes described herein as linked to outcome after NAE inhibitor, such as 1-substituted methyl sulfamate (e.g., MLN4924) treatment are examples of genes within the chromosome locus markers described above and are provided in Table 1. Sequences of mRNA, open reading frames and proteins corresponding to marker genes also are listed in Table 1. A marker gene listed in Table 1 can have isoforms which are either ubiquitous or have restricted expression. Except for the separate listing of the CDKN2A_p14 isoform, the DNA SEQ ID NOs in Table 1 refer to the mRNA encoding the major or longest isoform and the protein SEQ ID NOs represent at least a precursor of such isoform and not necessarily the mature protein. These sequences are not intended to limit the marker gene identity to that isoform or precursor. The additional isoforms and mature proteins are readily retrievable and understandable to one of skill in the art by reviewing the information provided under the Entrez Gene (database maintained by the National Center for Biotechnology Information, Bethesda, MD) identified by the ID number listed in Table 1.

Table 1 Marker Gene Description for NAE Inhibitor Treatment

Marker Gene ID	Marker Gene Name	Entrez Gene ID	Chromosome location	Start base pair	End base pair	SEQ ID NOs:
NF2	neurofibromin 2	4771	22q	29999545	30094589	1, 2, 3

(continued)

Marker Gene ID	Marker Gene Name	Entrez Gene ID	Chromosome location	Start base pair	End base pair	SEQ ID NOs:
SMAD4	mothers against decapentaplegic homolog 4	4089	18q	48556583	48611412	4, 5, 6
KDM6A	lysine-specific demethylase 6A	7403	Xp	44732423	44971847	7, 8, 9, 10, 11
FBXW7	F-box and WD repeat domain containing 7	55294	4q	153242410	153456172	12, 13, 14
TP53	tumor protein p53	7157	17p	7571720	7590868	15, 16, 17
CDKN2A	cyclin-dependent kinase inhibitor 2A	1029	9p	21967751	21994490	18, 19, 20
CDKN2A_p14	cyclin-dependent kinase inhibitor 2A p14 variant	1029	9p	21967751	21994490	21, 22, 23
APC	adenomatous polyposis coli	324	5q	112043202	112181936	24, 25, 26

[0049] As used herein, an "informative" characteristic, e.g., size, sequence, composition or amount of a marker refers to a characteristic, e.g., size, sequence, composition or amount whose value or difference is correlated to prognosis or outcome. The informative characteristic, e.g., size, sequence, composition or amount of a marker can be obtained by analyzing either nucleic acid, e.g., DNA or RNA, or protein corresponding to the marker gene. The characteristic, e.g., size (e.g., length or molecular weight), sequence (e.g., nucleic acid sequence or protein sequence), composition (e.g., base or amino acid composition or peptide digest or gene fragment pattern) or amount (e.g., copy number and/or expression level) of a marker, e.g., a chromosome locus marker or a marker in a sample from a patient can be "informative" if it is different than the wild type or allelic variant of the substance being analyzed. In some embodiments, a characteristic of a marker is informative if it indicates that the marker gene is wild type. In an embodiment where the amount of a marker is being measured, an amount is "informative" if it is greater than or less than a reference amount by a degree greater than the standard error of the assay employed to assess expression. The informative expression level of a marker can be determined upon statistical correlation of the measured expression level and the outcome, e.g., good response, poor response, long time-to-progression, short time-to-progression, short term survival or long term survival. The result of the statistical analysis can establish a threshold for selecting markers to use in the methods described herein. Alternatively, a marker, e.g., a chromosome locus marker, or a marker gene that has differential characteristic, e.g., size, sequence, composition or amounts will have typical ranges of amounts that are predictive of outcome. An informative characteristic, e.g., size, sequence, composition or amount is a characteristic, e.g., size, sequence, composition or amount that falls within the range of characteristic, e.g., size, sequence, composition or amounts determined for the outcome. Still further, a set of markers may together be "informative" if the combination of their characteristics, e.g., sizes, sequences, compositions or amounts either meets or is above or below a pre-determined score for a marker, e.g., a chromosome locus marker, or a marker gene, set as determined by methods provided herein. Gene translocation, transcript splice variation, deletion and truncation are examples of events which can change marker size, sequence or composition, in addition to point mutations which can change marker sequence or composition. Measurement of only one characteristic, e.g., marker, of a marker gene (i.e., DNA, RNA or protein) can provide a prognosis, i.e., indicate outcome. Measurement of more than one characteristic, e.g., marker, of a marker gene can provide a prognosis when the informative amounts of the two characteristics are consistent with each other, i.e., the biologies of the results are not contradictory. Examples of consistent results from measurement of multiple characteristics of a marker gene can be identification of a nonsense mutation or deletion in a DNA or RNA and a low amount or low molecular weight of encoded protein, or a mutation in a region which encodes a binding pocket or active site of a protein and low activity of the encoded protein. A different example can occur when a protein is in a pathway with a feedback loop controlling its synthesis based on its activity level. In this example, a low amount or activity of protein can be associated with a high amount of its mutated mRNA as a tissue, due to the marker gene mutation, thus is starved for the protein activity and repeatedly signals the production of the protein.

[0050] As used herein, "gene deletion" refers to an amount of DNA copy number less than 2 and "amplification" refers

to an amount of DNA copy number greater than 2. A "diploid" amount refers to a copy number equal to 2. The term "diploid or amplification" can be interpreted as "not deletion" of a gene copy. In a marker whose alternative informative amount is gene deletion, amplification generally would not be seen. Conversely, the term "diploid or deletion" can be interpreted as "not amplification" of copy number. In a marker whose alternative informative amount is amplification, gene deletion generally would not be seen. For the sake of clarity, sequence deletion can occur within a gene as a result of marker gene mutation and can result in absence of transcribed protein or a shortened mRNA or protein. Such a deletion may not affect copy number.

[0051] The terms "long term survival" and "short term survival" refer to the length of time after receiving a first dose of treatment that a cancer patient is predicted to live. A "long term survivor" refers to a patient expected have a slower rate of progression or later death from the tumor than those patients identified as short term survivors. "Enhanced survival" or "a slower rate of death" are estimated life span determinations based upon characteristic, e.g., size, sequence, composition or amount of one or more of markers described herein, e.g., as compared to a reference standard such that 70%, 80%, 90% or more of the population will be alive a sufficient time period after receiving a first dose of treatment. A "faster rate of death" or "shorter survival time" refer to estimated life span determinations based upon characteristic, e.g., size, sequence, composition or amount of one or more of markers described herein, e.g., as compared to a reference standard such that 50%, 40%, 30%, 20%, 10% or less of the population will not live a sufficient time period after receiving a first dose of treatment. In some embodiments, the sufficient time period is at least 6, 12, 18, 24 or 30 months measured from the first day of receiving a cancer therapy.

[0052] A cancer is "responsive" to a therapeutic agent or there is a "good response" to a treatment if its rate of growth is inhibited as a result of contact with the therapeutic agent, compared to its growth in the absence of contact with the therapeutic agent. Growth of a cancer can be measured in a variety of ways, for instance, the characteristic, e.g., size of a tumor or the expression of tumor markers appropriate for that tumor type may be measured. For example, the response definitions used to support the identification of markers associated with myeloma and its response to an NAE inhibitor, such as a 1-substituted methyl sulfamate therapy, the Southwestern Oncology Group (SWOG) criteria as described in Blade et al. (1998) Br J Haematol. 102:1115-23 can be used. These criteria define the type of response measured in myeloma and also the characterization of time to disease progression which is another important measure of a tumor's sensitivity to a therapeutic agent. For solid tumors, the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (Eisenhauer et al. (2009) E. J. Canc. 45:228-247) can be used to support the identification of markers associated with solid tumors and response of solid tumors to an NAE inhibitor. International Working Groups convene periodically to set, update and publish response criteria for various types of cancers. Such published reports can be followed to support the identification of markers of the subject tumors and their response to NAE inhibitors. Examples are criteria for Acute Myelogenous Leukemia (AML, Cheson et al. (2003) J.Clin. Oncol. 21:4642-4649), lymphomas, e.g., non-Hodgkin's and Hodgkin's lymphoma (Cheson et al. (2007) J.Clin. Oncol. 25:579-596). Criteria take into account analysis methods such as Positron Emission Tomography (PET), e.g., for identifying sites with measurable altered metabolic activity (e.g., at tumor sites) or to trace specific markers into tumors *in vivo*, immunohistochemistry, e.g., to identify tumor cells by detecting binding of antibodies to specific tumor markers, and flow cytometry, e.g., to characterize cell types by differential markers and fluorescent stains, in addition to traditional methods such as histology to identify cell composition (e.g., blast counts in a blood smear or a bone marrow biopsy, presence and number of mitotic figures) or tissue structure (e.g., disordered tissue architecture or cell infiltration of basement membrane). The quality of being responsive to an NAE inhibitor, such as a 1-substituted methyl sulfamate therapy can be a variable one, with different cancers exhibiting different levels of "responsiveness" to a given therapeutic agent, under different conditions. Still further, measures of responsiveness can be assessed using additional criteria beyond growth size of a tumor, including patient quality of life, degree of metastases, etc. In addition, clinical prognostic markers and variables can be assessed (e.g., M protein in myeloma, PSA levels in prostate cancer) in applicable situations.

[0053] A cancer is "non-responsive" or has a "poor response" to a therapeutic agent or there is a poor response to a treatment if its rate of growth is not inhibited, or inhibited to a very low degree, as a result of contact with the therapeutic agent when compared to its growth in the absence of contact with the therapeutic agent. As stated above, growth of a cancer can be measured in a variety of ways, for instance, the size of a tumor or the expression of tumor markers appropriate for that tumor type may be measured. For example, the response definitions used to support the identification of markers associated with non-response of tumors to therapeutic agents, guidelines such as those described above can be used. The quality of being non-responsive to a therapeutic agent can be a highly variable one, with different cancers exhibiting different levels of "non-responsiveness" to a given therapeutic agent, under different conditions. Still further, measures of non-responsiveness can be assessed using additional criteria beyond growth size of a tumor, including patient quality of life, degree of metastases, etc. In addition, clinical prognostic markers and variables can be assessed (e.g., M protein in myeloma, PSA levels in prostate cancer) in applicable situations.

[0054] As used herein, "long time-to-progression," "long TTP" and "short time-to-progression," "short TTP" refer to the amount of time until when the stable disease brought by treatment converts into an active disease. On occasion, a treatment results in stable disease which is neither a good nor a poor response, e.g., MR, the disease merely does not

get worse, e.g., become a progressive disease, for a period of time. This period of time can be at least 4-8 weeks, at least 3-6 months or more than 6 months.

5 [0055] "Treatment" shall mean the use of a therapy to prevent or inhibit further tumor growth, as well as to cause shrinkage of a tumor, and to provide longer survival times. Treatment is also intended to include prevention of metastasis of tumor. A tumor is "inhibited" or "treated" if at least one symptom (as determined by responsiveness/non-responsiveness, time to progression, or indicators known in the art and described herein) of the cancer or tumor is alleviated, terminated, slowed, minimized, or prevented. Any amelioration of any symptom, physical or otherwise, of a tumor pursuant to treatment using a therapeutic regimen (e.g., NAE inhibitor, such as a 1-substituted methyl sulfamate regimen) as further described herein, is within the scope of the invention.

10 [0056] As used herein, the term "agent" is defined broadly as anything that cancer cells, including tumor cells, may be exposed to in a therapeutic protocol. In the context of the present invention, such agents include, but are not limited to, an NAE inhibitor, such as a 1-substituted methyl sulfamate agents, as well as chemotherapeutic agents as known in the art and described in further detail herein.

15 [0057] The term "probe" refers to any molecule, e.g., an isolated molecule, which is capable of selectively binding to a specifically intended target molecule, for example a marker of the invention. Probes can be either synthesized by one skilled in the art, or derived from appropriate biological preparations. For purposes of detection of the target molecule, probes may be specifically designed to be labeled, as described herein. Examples of molecules that can be utilized as probes include, but are not limited to, RNA, DNA, proteins, antibodies, and organic monomers.

20 [0058] A "normal" characteristic, e.g., size, sequence, composition or amount of a marker may refer to the characteristic, e.g., size, sequence, composition or amount in a "reference sample." A reference sample can be a matched normal, e.g., germline, sample from the same patient from whom the tumor, e.g., with a somatic mutation, is derived. A reference sample can be a sample from a healthy subject not having the marker-associated disease or a reference characteristic e.g., the average characteristic, e.g., size, sequence, composition or amount of the wild type marker in several healthy subjects. A reference sample characteristic, e.g., size, sequence, composition or amount may be comprised of a characteristic, e.g., size, sequence, composition or amount of one or more markers from a reference database. Alternatively, a "normal" characteristic, e.g., size, sequence, composition or level of expression of a marker is the characteristic, e.g., size, sequence, composition or amount of the marker, e.g., marker gene in non-tumor cells in a similar environment or response situation from the same patient from whom the tumor is derived. The normal amount of DNA copy number is 2 or diploid, with the exception of X-linked genes in males, where the normal DNA copy number is 1.

25 [0059] "Over-expression" and "under-expression" of a marker gene, refer to expression of the marker gene of a patient at a greater or lesser level (e.g. more than three-halves-fold, at least two-fold, at least three-fold, greater or lesser level etc.), respectively, than normal level of expression of the marker gene, e.g., as measured by mRNA or protein, in a test sample that is greater than the standard error of the assay employed to assess expression. A "significant" expression level may refer to a level which either meets or is above or below a pre-determined score for a marker gene set as determined by methods provided herein.

30 [0060] "Complementary" refers to the broad concept of sequence complementarity between regions of two nucleic acid strands or between two regions of the same nucleic acid strand. It is known that an adenine residue of a first nucleic acid region is capable of forming specific hydrogen bonds ("base pairing") with a residue of a second nucleic acid region which is antiparallel to the first region if the residue is thymine or uracil. Similarly, it is known that a cytosine residue of a first nucleic acid strand is capable of base pairing with a residue of a second nucleic acid strand which is antiparallel to the first strand if the residue is guanine. A first region of a nucleic acid is complementary to a second region of the same or a different nucleic acid if, when the two regions are arranged in an antiparallel fashion, at least one nucleotide residue of the first region is capable of base pairing with a residue of the second region. In an embodiment, the first region comprises a first portion and the second region comprises a second portion, whereby, when the first and second portions are arranged in an antiparallel fashion, at least about 50%, at least about 75%, at least about 90%, or at least about 95% or all of the nucleotide residues of the first portion are capable of base pairing with nucleotide residues in the second portion.

35 [0061] "Homologous" as used herein, refers to nucleotide sequence similarity between two regions of the same nucleic acid strand or between regions of two different nucleic acid strands. When a nucleotide residue position in both regions is occupied by the same nucleotide residue, then the regions are homologous at that position. A first region is homologous to a second region if at least one nucleotide residue position of each region is occupied by the same residue. Homology between two regions is expressed in terms of the proportion of nucleotide residue positions of the two regions that are occupied by the same nucleotide residue (i.e., by percent identity). By way of example, a region having the nucleotide sequence 5'-ATTGCC-3' and a region having the nucleotide sequence 5'-TATGGC-3' share homology with 50% identity. In one embodiment, the first region comprises a first portion and the second region comprises a second portion, whereby, at least about 50%, at least about 75%, at least about 90%, or at least about 95% of the nucleotide residue positions of each of the portions are occupied by the same nucleotide residue. In an embodiment of 100% identity, all nucleotide residue positions of each of the portions are occupied by the same nucleotide residue.

[0062] Unless otherwise specified herewithin, the terms "antibody" and "antibodies" broadly encompass naturally-occurring forms of antibodies, e.g., polyclonal antibodies (e.g., IgG, IgA, IgM, IgE) and monoclonal and recombinant antibodies such as single-chain antibodies, two-chain and multi-chain proteins, chimeric, CDR-grafted, human and humanized antibodies and multi-specific antibodies, as well as fragments and derivatives of all of the foregoing, which fragments (e.g., dAbs, scFv, Fab, F(ab)₂, Fab') and derivatives have at least an antigenic binding site. Antibody derivatives may comprise a protein or chemical moiety conjugated to an antibody. The term "antibody" also includes synthetic and genetically engineered variants.

[0063] A "kit" is any article of manufacture (e.g., a package or container) comprising at least one reagent, e.g. a probe, for specifically detecting a marker or marker set of the invention. The article of manufacture may be promoted, distributed, sold or offered for sale as a unit for performing, e.g., *in vitro*, the methods of the present invention, e.g., on a sample having been obtained from a patient. The reagents included in such a kit can comprise at least one nucleic acid probe and, optionally, one or more primers and/or antibodies for use in detecting marker characteristics, e.g., size, sequence composition or amount, e.g., expression. In addition, a kit of the present invention can contain instructions which describe a suitable detection assay. Such a kit can be conveniently used, e.g., in a clinical or a contract testing setting, to generate information, e.g., on expression levels, characteristic, e.g., size, sequence or composition of one or more marker, to be recorded, stored, transmitted or received to allow for diagnosis, evaluation or treatment of patients exhibiting symptoms of cancer, in particular patients exhibiting the possible presence of a cancer capable of treatment with NAE inhibition therapy, including, e.g., hematological cancers e.g., myelomas (e.g., multiple myeloma), lymphomas (e.g., non-hodgkins lymphoma), leukemias (e.g., acute myelogenous leukemia), and solid tumors (e.g., tumors of skin, lung, breast, ovary, etc.).

[0064] The present methods and compositions are designed for use in diagnostics and therapeutics for a patient suffering from cancer. A cancer or tumor is treated or diagnosed according to the present methods. "Cancer" or "tumor" is intended to include any neoplastic growth in a patient, including an initial tumor and any metastases. The cancer can be of the hematological or solid tumor type. Hematological tumors include tumors of hematological origin, including, e.g., myelomas (*i.*, multiple myeloma), leukemias (e.g., Waldenstrom's syndrome, chronic lymphocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, other leukemias), lymphomas (e.g., B-cell lymphomas, non-Hodgkin's lymphoma) and myelodysplastic syndrome. Solid tumors can originate in organs, and include cancers such as in skin, lung, brain, breast, prostate, ovary, colon, kidney, pancreas, liver, esophagus, stomach, intestine, bladder, uterus, cervix, head and neck, central nervous system, bone, testis, adrenal gland, etc. The cancer can comprise a cell in which a marker gene has a mutation. As used herein, cancer cells, including tumor cells, refer to cells that divide at an abnormal (increased) rate or whose control of growth or survival is different than for cells in the same tissue where the cancer cell arises or lives. Cancer cells include, but are not limited to, cells in carcinomas, such as squamous cell carcinoma, basal cell carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, adenocarcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, undifferentiated carcinoma, bronchogenic carcinoma, melanoma, renal cell carcinoma, hepatoma-liver cell carcinoma, bile duct carcinoma, cholangiocarcinoma, papillary carcinoma, transitional cell carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, mammary carcinomas, gastrointestinal carcinoma, colonic carcinomas, bladder carcinoma, prostate carcinoma, and squamous cell carcinoma of the neck and head region; sarcomas, such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordosarcoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, synoviosarcoma and mesotheliosarcoma; hematologic cancers, such as myelomas, leukemias (e.g., acute myelogenous leukemia, chronic lymphocytic leukemia, granulocytic leukemia, monocytic leukemia, lymphocytic leukemia), and lymphomas (e.g., follicular lymphoma, mantle cell lymphoma, diffuse large Bcell lymphoma, malignant lymphoma, plasmocytoma, reticulum cell sarcoma, or Hodgkins disease); and tumors of the nervous system including glioma, meningoma, medulloblastoma, schwannoma or epidymoma.

[0065] As used herein, the term "noninvasive" refers to a procedure which inflicts minimal harm to a subject. In the case of clinical applications, a noninvasive sampling procedure can be performed quickly, e.g., in a walk-in setting, typically without anaesthesia and/or without surgical implements or suturing. Examples of noninvasive samples include blood, serum, saliva, urine, buccal swabs, throat cultures, stool samples and cervical smears. Noninvasive diagnostic analyses include x-rays, magnetic resonance imaging, positron emission tomography, etc.

[0066] Described herein is the assessment of outcome for treatment of a tumor through measurement of the amount of pharmacogenomic markers. Also described are assessing the outcome by noninvasive, convenient or low-cost means, for example, from blood samples. Typical methods to determine extent of cancer or outcome of a hematological tumor, e.g., lymphoma, leukemia, e.g., acute myelogenous leukemia, myeloma (e.g., multiple myeloma) can employ bone marrow biopsy to collect tissue for genotype or phenotype, e.g., histological analysis. The invention provides methods for determining, assessing, advising or providing an appropriate therapy regimen for treating a tumor or managing disease in a patient. Monitoring a treatment using the kits and methods disclosed herein can identify the potential for unfavorable outcome and allow their prevention, and thus a savings in morbidity, mortality and treatment costs through adjustment in the therapeutic regimen, cessation of therapy or use of alternative therapy.

[0067] The term "biological sample" is intended to include a patient sample, e.g., tissue, cells, biological fluids and isolates thereof, isolated from a subject, as well as tissues, cells and fluids present within a subject and can be obtained from a patient or a normal subject. In hematological tumors of the bone marrow, e.g., myeloma tumors, primary analysis of the tumor can be performed on bone marrow samples. However, some tumor cells, (e.g., clonotypic tumor cells, circulating endothelial cells), are a percentage of the cell population in whole blood. These cells also can be mobilized into the blood during treatment of the patient with granulocyte-colony stimulating factor (G-CSF) in preparation for a bone marrow transplant, a standard treatment for hematological tumors, e.g., leukemias, lymphomas and myelomas. Examples of circulating tumor cells in multiple myeloma have been studied e.g., by Pilarski et al. (2000) *Blood* 95:1056-65 and Rigolin et al. (2006) *Blood* 107:2531-5. Thus, noninvasive samples, e.g., for *in vitro* measurement of markers to determine outcome of treatment, can include peripheral blood samples. Accordingly, cells within peripheral blood can be tested for marker amount. For patients with hematological tumors, a control, reference sample for normal characteristic, e.g., size, sequence, composition or amount can be obtained from skin or a buccal swab of the patient. For solid tumors, a typical tumor sample is a biopsy of the tumor and thus comprises solid tumor cells. Alternatively, a sample of tumor cells shed or scraped from the tumor site can be collected noninvasively, such as in blood, sputum, a nipple aspirate, urine, stool, cervical smear, etc. For solid tumors, a control reference sample for normal characteristic, e.g., size, sequence, composition or amount can be obtained from blood of the patient.

[0068] Blood collection containers can comprise an anti-coagulant, e.g., heparin or ethylene-diaminetetraacetic acid (EDTA), sodium citrate or citrate solutions with additives to preserve blood integrity, such as dextrose or albumin or buffers, e.g., phosphate. If the amount of marker is being measured by measuring the level of its DNA in the sample, a DNA stabilizer, e.g., an agent that inhibits DNase, can be added to the sample. If the amount of marker is being measured by measuring the level of its RNA in the sample, an RNA stabilizer, e.g., an agent that inhibits RNase, can be added to the sample. If the amount of marker is being measured by measuring the level of its protein in the sample, a protein stabilizer, e.g., an agent that inhibits proteases, can be added to the sample. An example of a blood collection container is PAXGENE® tubes (PREANALYTIX, Valencia, CA), useful for RNA stabilization upon blood collection. Peripheral blood samples can be modified, e.g., fractionated, sorted or concentrated (e.g., to result in samples enriched with tumor or depleted of tumor (e.g., for a reference sample)). Examples of modified samples include clonotypic myeloma cells, which can be collected by e.g., negative selection, e.g., separation of white blood cells from red blood cells (e.g., differential centrifugation through a dense sugar or polymer solution (e.g., FICOLL® solution (Amersham Biosciences division of GE healthcare, Piscataway, NJ) or HISTOPAQUE®-1077 solution, Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co., St. Louis, MO)) and/or positive selection by binding B cells to a selection agent (e.g., a reagent which binds to a tumor cell or myeloid progenitor marker, such as CD34, CD38, CD138, or CD133, for direct isolation (e.g., the application of a magnetic field to solutions of cells comprising magnetic beads (e.g., from Miltenyi Biotec, Auburn, CA) which bind to the B cell markers) or fluorescent-activated cell sorting).

[0069] Alternatively, a tumor cell line, e.g., OCI-Ly3, OCI-Ly10 cell (Alizadeh et al. (2000) *Nature* 403:503-511), a RPMI 6666 cell, a SUP-B15 cell, a KG-1 cell, a CCRF-SB cell, an 8ES cell, a Kasumi-1 cell, a Kasumi-3 cell, a BDCM cell, an HL-60 cell, a Mo-B cell, a JM1 cell, a GA-10 cell or a B-cell lymphoma (e.g., BC-3) or a cell line or a collection of tumor cell lines (see e.g., McDermott et al. (2007) *PNAS* 104:19936-19941 or ONCOPANEL™ anti-cancer tumor cell profiling screen (Ricerca Biosciences, Bothell, WA)) can be assayed. A skilled artisan readily can select and obtain the appropriate cells (e.g., from American Type Culture Collection (ATCC®), Manassas, VA) that are used in the present method. If the compositions or methods are being used to predict outcome of treatment in a patient or monitor the effectiveness of a therapeutic protocol, then a tissue or blood sample having been obtained from the patient being treated is a useful source of cells or marker gene or gene products for an assay.

[0070] The sample, e.g., tumor, e.g., biopsy or bone marrow, blood or modified blood, (e.g., comprising tumor cells) and/or the reference, e.g., matched control (e.g., germline), sample can be subjected to a variety of well-known post-collection preparative and storage techniques (e.g., nucleic acid and/or protein extraction, fixation, storage, freezing, ultrafiltration, concentration, evaporation, centrifugation, etc.) prior to assessing the amount of the marker in the sample.

[0071] In an embodiment, mutational status of a marker gene, e.g., a mutation in a marker can be identified by sequencing a nucleic acid, e.g., a DNA, RNA, cDNA or a protein correlated with the marker gene. There are several sequencing methods known in the art to sequence nucleic acids. A nucleic acid primer can be designed to bind to a region comprising a potential mutation site or can be designed to complement the mutated sequence rather than the wild type sequence. Primer pairs can be designed to bracket a region comprising a potential mutation in a marker gene. A primer or primer pair can be used for sequencing one or both strands of DNA corresponding to the marker gene. A primer can be used in conjunction with a probe, e.g., a nucleic acid probe, e.g., a hybridization probe, to amplify a region of interest prior to sequencing to boost sequence amounts for detection of a mutation in a marker gene. Examples of regions which can be sequenced include an entire gene, transcripts of the gene and a fragment of the gene or the transcript, e.g., one or more of exons or untranslated regions. Examples of mutations to target for primer selection and sequence or composition analysis can be found in public databases which collect mutation information, such as COSMIC and dbGaP. Some mutations of marker genes such as NF2, SMAD, KDM6A or FBXW7 are listed in Tables 8-11 in the

Examples as examples of mutations that can be associated with sensitivity to NAE inhibition, e.g., inhibition by 1-methyl sulfamates, e.g., MLN4924.

[0072] Sequencing methods are known to one skilled in the art. Examples of methods include the Sanger method, the SEQUENOM™ method and Next Generation Sequencing (NGS) methods. The Sanger method, comprising using electrophoresis, e.g., capillary electrophoresis to separate primer-elongated labeled DNA fragments, can be automated for high-throughput applications. The primer extension sequencing can be performed after PCR amplification of regions of interest. Software can assist with sequence base calling and with mutation identification. SEQUENOM™ MASSARRAY® sequencing analysis (San Diego, CA) is a mass-spectrometry method which compares actual mass to expected mass of particular fragments of interest to identify mutations. NGS technology (also called "massively parallel sequencing" and "second generation sequencing") in general provides for much higher throughput than previous methods and uses a variety of approaches (reviewed in Zhang et al. (2011) J. Genet. Genomics 38:95-109 and Shendure and Hanlee (2008) Nature Biotech. 26:1135-1145). NGS methods can identify low frequency mutations in a marker in a sample. Some NGS methods (see, e.g., GS-FLX Genome Sequencer (Roche Applied Science, Branford, CT), Genome analyzer (Illumina, Inc. San Diego, CA) SOLID™ analyzer (Applied Biosystems, Carlsbad, CA), Polonator G.007 (Dover Systems, Salem, NH), HELISCOPE™ (Helicos Biosciences Corp., Cambridge, MA)) use cyclic array sequencing, with or without clonal amplification of PCR products spatially separated in a flow cell and various schemes to detect the labeled modified nucleotide that is incorporated by the sequencing enzyme (e.g., polymerase or ligase). In one NGS method, primer pairs can be used in PCR reactions to amplify regions of interest. Amplified regions can be ligated into a concatenated product. Clonal libraries are generated in the flow cell from the PCR or ligated products and further amplified ("bridge" or "cluster" PCR) for single-end sequencing as the polymerase adds a labeled, reversibly terminated base that is imaged in one of four channels, depending on the identity of the labeled base and then removed for the next cycle. Software can aid in the comparison to genomic sequences to identify mutations.

[0073] Composition of proteins and nucleic acids can be determined by many ways known in the art, such as by treating them in ways that cleave, degrade or digest them and then analyzing the components. Mass spectrometry, electrophoresis and chromatography can separate and define components for comparison. Mutations which cause deletions or insertions can be identified by size or charge differences in these methods. Protein digestion or restriction enzyme nucleic acid digestion can reveal different fragment patterns after some mutations. Antibodies that recognize particular mutant amino acids in their structural contexts can identify and detect these mutations in samples (see below).

[0074] In an embodiment, DNA, e.g., genomic DNA corresponding to the wild type or mutated marker can be analyzed both by *in situ* and by *in vitro* formats in a biological sample using methods known in the art. DNA can be directly isolated from the sample or isolated after isolating another cellular component, e.g., RNA or protein. Kits are available for DNA isolation, e.g., QIAAMP® DNA Micro Kit (Qiagen, Valencia, CA). DNA also can be amplified using such kits.

[0075] In another embodiment, mRNA corresponding to the marker can be analyzed both by *in situ* and by *in vitro* formats in a biological sample using methods known in the art. An example of a method for measuring expression level is included in the Examples. For example a nucleic acid probe can be used to hybridize to a marker and the amount of probe hybridized can be measured. Many expression detection methods use isolated RNA. For *in vitro* methods, any RNA isolation technique that does not select against the isolation of mRNA can be utilized for the purification of RNA from tumor cells (see, e.g., Ausubel et al., ed., Current Protocols in Molecular Biology, John Wiley & Sons, New York 1987-1999). Additionally, large numbers of tissue samples can readily be processed using techniques well known to those of skill in the art, such as, for example, the single-step RNA isolation process of Chomczynski (1989, U.S. Patent No. 4,843,155). RNA can be isolated using standard procedures (see e.g., Chomczynski and Sacchi (1987) Anal. Biochem. 162:156-159), solutions (e.g., trizol, TRI REAGENT® (Molecular Research Center, Inc., Cincinnati, OH; see U.S. Patent No. 5,346,994) or kits (e.g., a QIAGEN® RNeasy® isolation kit (Valencia, CA) or LEUKOLOCK™ Total RNA Isolation System, Ambion division of Applied Biosystems, Austin, TX).

[0076] Additional steps may be employed to remove DNA from RNA samples. Cell lysis can be accomplished with a nonionic detergent, followed by microcentrifugation to remove the nuclei and hence the bulk of the cellular DNA. DNA subsequently can be isolated from the nuclei for DNA analysis. In one embodiment, RNA is extracted from cells of the various types of interest using guanidinium thiocyanate lysis followed by CsCl centrifugation to separate the RNA from DNA (Chirgwin et al. (1979) Biochemistry 18:5294-99). Poly(A)+RNA is selected by selection with oligo-dT cellulose (see Sambrook et al. (1989) Molecular Cloning-A Laboratory Manual (2nd ed.), Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.). Alternatively, separation of RNA from DNA can be accomplished by organic extraction, for example, with hot phenol or phenol/chloroform/isoamyl alcohol. If desired, RNase inhibitors may be added to the lysis buffer. Likewise, for certain cell types, it may be desirable to add a protein denaturation/digestion step to the protocol. For many applications, it is desirable to enrich mRNA with respect to other cellular RNAs, such as transfer RNA (tRNA) and ribosomal RNA (rRNA). Most mRNAs contain a poly(A) tail at their 3' end. This allows them to be enriched by affinity chromatography, for example, using oligo(dT) or poly(U) coupled to a solid support, such as cellulose or SEPHADEX.R™. medium (see Ausubel et al. (1994) Current Protocols In Molecular Biology, vol. 2, Current Protocols Publishing, New York). Once bound, poly(A)+mRNA is eluted from the affinity column using 2 mM EDTA/0.1% SDS.

[0077] The characteristic of a marker of the invention in a biological sample, e.g., after obtaining a biological sample (e.g., a bone marrow sample, a tumor biopsy or a reference sample) from a test subject, may be assessed by any of a wide variety of well known methods for detecting or measuring the characteristic, e.g., of a nucleic acid (e.g., RNA, mRNA, genomic DNA, or cDNA) and/or translated protein. Non-limiting examples of such methods include immunological methods for detection of secreted, cell-surface, cytoplasmic, or nuclear proteins, protein purification methods, protein function or activity assays, nucleic acid hybridization methods, nucleic acid reverse transcription methods, and nucleic acid amplification methods. These methods include gene array/chip technology, RT-PCR, TAQMAN® gene expression assays (Applied Biosystems, Foster City, CA), e.g., under GLP approved laboratory conditions, *in situ* hybridization, immunohistochemistry, immunoblotting, FISH (fluorescence *in situ* hybridization), FACS analyses, northern blot, southern blot, INFINIUM® DNA analysis Bead Chips (Illumina, Inc., San Diego, CA), quantitative PCR, bacterial artificial chromosome arrays, single nucleotide polymorphism (SNP) arrays (Affymetrix, Santa Clara, CA) or cytogenetic analyses. The detection methods of the invention can thus be used to detect RNA, mRNA, protein, cDNA, or genomic DNA, for example, in a biological sample *in vitro* as well as *in vivo*. Furthermore, *in vivo* techniques for detection of a polypeptide or nucleic acid corresponding to a marker of the invention include introducing into a subject a labeled probe to detect the biomarker, e.g., a nucleic acid complementary to the transcript of a biomarker or a labeled antibody, Fc receptor or antigen directed against the polypeptide, e.g., wild type or mutant marker. For example, the antibody can be labeled with a radioactive isotope whose presence and location in a subject can be detected by standard imaging techniques. These assays can be conducted in a variety of ways. A skilled artisan can select from these or other appropriate and available methods based on the nature of the marker(s), tissue sample and mutation in question. Some methods are described in more detail in later sections. Different methods or combinations of methods could be appropriate in different cases or, for instance in different types of tumors or patient populations.

[0078] *In vitro* techniques for detection of a polypeptide corresponding to a marker of the invention include enzyme linked immunosorbent assays (ELISAs), Western blots, protein array, immunoprecipitations and immunofluorescence. In such examples, expression of a marker is assessed using an antibody (e.g., a radio-labeled, chromophore-labeled, fluorophore-labeled, or enzyme-labeled antibody), an antibody derivative (e.g., an antibody conjugated with a substrate or with the protein or ligand of a protein-ligand pair (e.g., biotin-streptavidin)), or an antibody fragment (e.g., a single-chain antibody, an isolated antibody hypervariable domain, etc.) which binds specifically with a marker protein or fragment thereof, e.g., a protein or fragment comprising a region which can be mutated or a portion comprising a mutated sequence, or a mutated residue in its structural context, including a marker protein which has undergone all or a portion of its normal post-translational modification. An antibody can detect a protein with an amino acid sequence selected from the group consisting of SEQ ID NO:3, 6, 10, 11, 14, 17, 20 and 23. Alternatively, an antibody can detect a mutated protein with a variant amino acid sequence selected from the group consisting of a mutant of SEQ ID NO:3, 6, 10, 11, 14, 17, 20 and 23. Residues listed as mutated in public databases such as COSMIC or dbGaP can be prepared in immunogenic compositions for generation of antibodies that will specifically recognize and bind to the mutant residues. Another method can employ pairs of antibodies, wherein one of the pair would bind a marker protein upstream, i.e. N-terminal to the region of expected mutation, e.g., nonsense or deletion and the other of the pair would bind the protein downstream. Wild type protein would bind both antibodies of the pair, but a protein with a nonsense or deletion mutation would bind only the N-terminal antibody of the pair. An assay such as a sandwich ELISA assay could detect a loss of quantity of the wild type protein in the tumor sample, e.g., in comparison to the reference sample, or a standard ELISA would compare the levels of binding of the antibodies to infer that a mutation is present in a tumor sample.

[0079] Indirect methods for determining the amount or functionality of a protein marker also include measurement of the activity of the protein. For example, a sample, or a protein isolated from the sample or expressed from nucleic acid isolated, cloned or amplified from the sample can be assessed for marker protein activity. NF2 activity can be measured by its ability to associate with binding partners, e.g., in a cell-free assay or in a cell-based assay. In an example, the ability of NF2 to bind to red blood cell membranes or p55/MPPI can be measured (Seo et al. (2009) Exp. Biol. Med. 234:255-262). In another example, SMAD4 activity can be measured by its activity in signal transduction, e.g., in a cell-free assay or in a cell-based assay. In an example, the phosphorylation state of SMAD4 can be measured, the binding of SMAD4 to DNA at a Smad-binding element, e.g., in a gel shift assay or in a reporter assay (see, e.g., Kuang and Chen (2004) Oncogene 23:1021-1029), can be measured or the translocation of SMAD4 between the nucleus and cytoplasm can be visualized and quantified on cell images. In another example KDM6A activity can be measured by its ability to demethylate proteins, e.g., histones. For example, an assay can measure the level of demethylation of lysine 27 of histone 3 (Hong et al. (2007) PNAS 104:18439-18444). In another example, FBXW7 activity can be measured by its ability to bind cyclin E or to associate into the Skp-cullin-F-box ubiquitin ligase complex. In another example, TP53 activity can be measured by the ability to bind to DNA or to form tetramers.

[0080] In one embodiment, expression of a marker is assessed by preparing mRNA/cDNA (i.e., a transcribed polynucleotide) from cells in a patient sample, and by hybridizing the mRNA/cDNA with a reference polynucleotide, e.g., an isolated nucleic acid probe, e.g., a hybridization probe, which is a complement of a marker nucleic acid, or a fragment thereof. cDNA can, optionally, be amplified using any of a variety of polymerase chain reaction methods prior to hybrid-

ization with the reference polynucleotide. Expression of one or more markers likewise can be detected using quantitative PCR to assess the level of expression of the marker(s). An example of the use of measuring mRNA levels is that an inactivating mutation in a marker gene can result in an altered level of mRNA in a cell. The level can be upregulated due to feedback signaling protein production in view of nonfunctional or absent protein or downregulated due to instability of an altered mRNA sequence. Alternatively, any of the many known methods of detecting mutations or variants (e.g. single nucleotide polymorphisms, deletions, etc., discussed above) of a marker of the invention may be used to detect occurrence of a mutation in a marker gene in a patient.

[0081] An example of direct measurement is quantification of transcripts. As used herein, the level or amount of expression refers to the absolute amount of expression of an mRNA encoded by the marker or the absolute amount of expression of the protein encoded by the marker. As an alternative to making determinations based on the absolute expression amount of selected markers, determinations may be based on normalized expression amounts. Expression amount can be normalized by correcting the absolute expression level of a marker upon comparing its expression to the expression of a control marker that is not a marker, e.g., in a housekeeping role that is constitutively expressed. Suitable markers for normalization also include housekeeping genes, such as the actin gene or beta-2 microglobulin. Reference markers for data normalization purposes include markers which are ubiquitously expressed and/or whose expression is not regulated by oncogenes. Constitutively expressed genes are known in the art and can be identified and selected according to the relevant tissue and/or situation of the patient and the analysis methods. Such normalization allows one to compare the expression level in one sample, to another sample, e.g., between samples from different times or different subjects. Further, the expression level can be provided as a relative expression level. The baseline of a genomic DNA sample, e.g., diploid copy number, can be determined by measuring amounts in cells from subjects without a tumor or in non-tumor cells from the patient. To determine a relative amount of a marker or marker set, the amount of the marker or marker set is determined for at least 1, or 2, 3, 4, 5, or more samples, e.g., 7, 10, 15, 20 or 50 or more samples in order to establish a baseline, prior to the determination of the expression level for the sample in question. To establish a baseline measurement, the mean amount or level of each of the markers or marker sets assayed in the larger number of samples is determined and this is used as a baseline expression level for the biomarkers or biomarker sets in question. The amount of the marker or marker set determined for the test sample (e.g., absolute level of expression) is then divided by the baseline value obtained for that marker or marker set. This provides a relative amount and aids in identifying abnormal levels of marker protein activity.

[0082] Probes based on the sequence of a nucleic acid molecule of the invention can be used to detect transcripts or genomic sequences corresponding to one or more markers of the invention. The probe can comprise a label group attached thereto, e.g., a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as part of a diagnostic test kit for identifying cells or tissues which express the protein, such as by measuring levels of a nucleic acid molecule encoding the protein in a sample of cells from a subject, e.g., detecting mRNA levels or determining whether a gene encoding the protein has been mutated or deleted.

[0083] In addition to the nucleotide sequences described in the database records described herein, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequence can exist within a population (e.g., the human population). Such genetic polymorphisms can exist among individuals within a population due to naturally occurring allelic variation. An allele is one of a group of genes which occur alternatively at a given genetic locus. In addition, it will be appreciated that DNA polymorphisms that affect RNA expression levels can also exist that may affect the overall expression level of that gene (e.g., by affecting regulation or degradation).

[0084] Primers or nucleic acid probes comprise a nucleotide sequence complementary to a specific a marker or a mutated region thereof and are of sufficient length to selectively hybridize with a marker gene or nucleic acid associated with a marker gene, e.g., they can bind to the nucleic acid with base sequence specificity and remain bound, after washing. Primers and probes can be used to aid in the isolation and sequencing of marker nucleic acids. In one embodiment, the primer or nucleic acid probe, e.g., a substantially purified oligonucleotide, an isolated nucleic acid, comprises a region having a nucleotide sequence which hybridizes, e.g., under stringent conditions, to about 6, 8, 10, 12, 15, 20, 25, 30, 40, 50, 60, 75, 100, 200, 350, 500 or more consecutive nucleotides of a marker gene or a region comprising a mutation in a marker gene or transcript therefrom or a complement. In another embodiment, the primer or nucleic acid probe is capable of hybridizing to a marker nucleic acid comprising a nucleotide sequence of any sequence set forth in any of SEQ ID NOs: 1, 2, 4, 5, 7, 8, 9, 12, 13, 15, 16, 18, 19, 21, 22, 24, 25 or a sequence on chromosome 22q from base pair 29999545 to 30094589, chromosome 18q from base pair 48556583 to 48611412, chromosome Xp from base pair 44732423 to 44971847, chromosome 4q from base pair 153242410 to 153456172, chromosome 17p from base pair 7571720 to 7590868, chromosome 9p from base pair 21967751 to 21994490, or a complement of any of the foregoing. For example, a primer or nucleic acid probe comprising a nucleotide sequence of at least about 10 consecutive nucleotides, at least about 15 consecutive nucleotides, at least about 25 consecutive nucleotides, at least about 35 consecutive nucleotides, at least about 50 consecutive nucleotides, or having from about 15 to about 20 nucleotides set forth in any of SEQ ID NOs: 1, 2, 4, 5, 7, 8, 9, 12, 13, 15, 16, 18, 19, 21, 22, 24, 25 or a sequence on chromosome 22q from base pair 29999545 to 30094589, chromosome 18q from base pair 48556583 to 48611412, chromosome Xp from

base pair 44732423 to 44971847, chromosome 4q from base pair 153242410 to 153456172, chromosome 17p from base pair 7571720 to 7590868, chromosome 9p from base pair 21967751 to 21994490, or a complement of any of the foregoing are provided by the invention. Primers or nucleic acid probes having a sequence of more than about 25, 40 or 50 nucleotides are also within the scope of the invention. In another embodiment, a primer or nucleic acid probe can have a sequence at least 70%, at least 75%, 80% or 85%, or at least, 90%, 95% or 97% identical to the nucleotide sequence of any sequence set forth in any of SEQ ID NOs: 1, 2, 4, 5, 7, 8, 9, 12, 13, 15, 16, 18, 19, 21, 22, 24, 25 or a sequence on chromosome 22q from base pair 29999545 to 30094589, chromosome 18q from base pair 48556583 to 48611412, chromosome Xp from base pair 44732423 to 44971847, chromosome 4q from base pair 153242410 to 153456172, chromosome 17p from base pair 7571720 to 7590868, chromosome 9p from base pair 21967751 to 21994490, or a complement of any of the foregoing. Nucleic acid analogs can be used as binding sites for hybridization. An example of a suitable nucleic acid analogue is peptide nucleic acid (see, e.g., Egholm et al., Nature 363:566 568 (1993); U.S. Pat. No. 5,539,083).

[0085] In some embodiments, nucleic acid probe can be designed to bind to the wild type sequence, so the presence of a mutation in that region can cause a decrease, e.g., measurable decrease, in binding or hybridization by that probe. In another embodiment, a nucleic acid probe can be designed to bind to a mutant sequence, so the presence of a mutation in that region can cause an increase in binding or hybridization by that probe. In other embodiments, a probe and primer set or a primer pair can be designed to bracket a region in a marker that can have a mutation so amplification based on that set or pair can result in nucleic acids which can be sequenced to identify the mutation.

[0086] Primers or nucleic acid probes can be selected using an algorithm that takes into account binding energies, base composition, sequence complexity, cross-hybridization binding energies, and secondary structure (see Friend et al., International Patent Publication WO 01/05935, published Jan. 25, 2001; Hughes et al., Nat. Biotech. 19:342-7 (2001)). Useful primers or nucleic acid probes of the invention bind sequences which are unique for each transcript, e.g., target mutated regions and can be used in PCR for amplifying, detecting and sequencing only that particular nucleic acid, e.g., transcript or mutated transcript. Examples of some mutations of marker genes, e.g., NF2, SMAD4, KDM6A and FBXW7 are found in Tables in the Examples (Tables 8-11). Other mutations are described in reference articles cited herein and in public databases described herein. One of skill in the art can design primers and nucleic acid probes for the markers disclosed herein or related markers with similar characteristics, e.g., markers on the chromosome loci, or mutations in different regions of the same marker gene described herein, using the skill in the art, e.g., adjusting the potential for primer or nucleic acid probe binding to standard sequences, mutants or allelic variants by manipulating degeneracy or GC content in the primer or nucleic acid probe. Computer programs that are well known in the art are useful in the design of primers with the required specificity and optimal amplification properties, such as Oligo version 5.0 (National Biosciences, Plymouth, MN). While perfectly complementary nucleic acid probes and primers can be used for detecting the markers described herein and mutants, polymorphisms or alleles thereof, departures from complete complementarity are contemplated where such departures do not prevent the molecule from specifically hybridizing to the target region. For example, an oligonucleotide primer may have a non-complementary fragment at its 5' end, with the remainder of the primer being complementary to the target region. Alternatively, non-complementary nucleotides may be interspersed into the nucleic acid probe or primer as long as the resulting probe or primer is still capable of specifically hybridizing to the target region.

[0087] An indication of treatment outcome can be assessed by studying the amount of 1 marker, 2 markers, 3 markers or 4 markers, or more, e.g., 5, 6, 7, 8, 9, 10, 15, 20, or 25 markers, or mutated portions thereof e.g., marker genes which participate in or interact with the cullin ring ligase pathway e.g., tumor suppressors, e.g., which can be inactivated by somatic mutation in cancer. Markers can be studied in combination with another measure of treatment outcome, e.g., biochemical markers (e.g., M protein in myeloma, kidney health marker such as proteinuria, serum levels of C-reactive protein or cytokeratin 19, cytokeratin fragment 21-1 (CYFRA21-1) for NSCLC, urine levels of fibrinogen/fibrinogen degradation products for bladder cancer, urine or blood levels of catecholamines for neuroblastoma, serum levels of carbohydrate antigen 19-9 (CA 19-9) or metabolic profiling for pancreatic cancer or blood levels of soluble mesothelin-related peptides (SMRP) in mesothelioma) or histology assessment (e.g., blast count, number of mitotic figures per unit area, depth measurement of invasion of melanoma tumors, esophageal tumors or bladder tumors).

[0088] Statistical methods can assist in the determination of treatment outcome upon measurement of the amount of markers, e.g., measurement of DNA, RNA or protein. The amount of one marker can be measured at multiple timepoints, e.g., before treatment, during treatment, after treatment with an agent, e.g., an NAE inhibitor. To determine the progression of change in expression of a marker from a baseline, e.g., over time, the expression results can be analyzed by a repeated measures linear regression model (Littell, Miliken, Stroup, Wolfinger, Schabenberger (2006) SAS for Mixed Models, 2nd edition. SAS Institute, Inc., Cary, NC):

Equation 1

$$Y_{ijk} - Y_{ij0} = Y_{ij0} + treatment_i + day_k + (treatment * day)_{ik} + \epsilon_{ijk}$$

where Y_{ijk} is the \log_2 transformed expression (normalized to the housekeeping genes) on the k^{th} day of the j^{th} animal in the i^{th} treatment, Y_{ij0} is the defined baseline \log_2 transformed expression (normalized to the housekeeping genes) of the j^{th} animal in the i^{th} treatment, day_k is treated as a categorical variable, and ε_{ijk} is the residual error term. A covariance matrix (e.g., first-order autoregressive, compound symmetry, spatial power law) can be specified to model the repeated measurements on each animal over time. Furthermore, each treatment time point can be compared back to the same time point in the vehicle group to test whether the treatment value was significantly different from vehicle.

[0089] A number of other methods can be used to analyze the data. For instance, the relative expression values could be analyzed instead of the cycle number. These values could be examined as either a fold change or as an absolute difference from baseline. Additionally, a repeated-measures analysis of variance (ANOVA) could be used if the variances are equal across all groups and time points. The observed change from baseline at the last (or other) time point could be analyzed using a paired t-test, a Fisher exact test ($p\text{-value} = \sum P(X=x)$ from $x=1$ to the number of situations, e.g., mutations, tested that show sensitivity to NAE inhibition) for testing significance of data of small sample sizes, or a Wilcoxon signed rank test if the data is not normally distributed, to compare whether a tumor patient was significantly different from a normal subject.

[0090] A difference in amount from one timepoint to the next or from the tumor sample to the normal sample can indicate prognosis of treatment outcome. A baseline level can be determined by measuring expression at 1, 2, 3, 4, or more times prior to treatment, e.g., at time zero, one day, three days, one week and/or two weeks or more before treatment. Alternatively, a baseline level can be determined from a number of subjects, e.g., normal subjects or patients with the same health status or disorder, who do not undergo or have not yet undergone the treatment, as discussed above. Alternatively, one can use expression values deposited with the Gene Expression Omnibus (GEO) program at the National Center for Biotechnology Information (NCBI, Bethesda, MD). For example, datasets of myeloma mRNA expression amounts sampled prior to proteasome inhibition therapy include GEO Accession number GSE9782, also analyzed in Mulligan, et al. (2006) Blood 109:3177-88 and GSE6477, also analyzed by Chng et al. (2007) Cancer Res. 67:292-9. To test the effect of the treatment on the tumor, the expression of the marker can be measured at any time or multiple times after some treatment, e.g., after 1 day, 2 days, 3 days, 5 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months and/or 6 or more months of treatment. For example, the amount of a marker can be measured once after some treatment, or at multiple intervals, e.g., 1-week, 2-week, 4-week or 2-month, 3-month or longer intervals during treatment. In some embodiments, the measurement of a marker during treatment can be compared to the same marker measurement at baseline. In other embodiments, the measurement of a marker during treatment can be compared to the same marker measurement at an earlier timepoint. Conversely, to determine onset of progressive disease after stopping the administration of a therapeutic regimen, the amount of the marker can be measured at any time or multiple times after, e.g., 1 day, 2 days, 3 days, 5 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months and/or 6 or more months after the last treatment. The measurement of a marker after treatment can be compared to the same marker measurement at the end of treatment. One of skill in the art would determine the timepoint or timepoints to assess the amount of the marker depending on various factors, e.g., the pharmacokinetics of the treatment, the treatment duration, pharmacodynamics of the treatment, age of the patient, the nature of the disorder or mechanism of action of the treatment. A trend in the negative direction or a decrease in the amount relative to baseline or a pre-determined standard of expression of a marker of sensitivity to NAE inhibition therapy, e.g., a decrease in a sensitivity marker identified in Table 3, can indicate a decrease in response of the tumor to the therapy, e.g., increase in resistance. A trend toward a favorable outcome relative to the baseline or a pre-determined standard of expression of a marker of treatment outcome indicates usefulness of the therapeutic regimen or continued benefit of the therapy. A trend toward an increase in a resistance marker e.g., an increase in a resistance marker identified in Table 3, can indicate an unfavorable outcome.

[0091] Any marker, e.g., marker gene or combination of marker, e.g., marker genes of the invention, or mutations thereof as well as any known markers in combination with the markers, e.g., marker genes of the invention, may be used in the compositions, kits, and methods of the present invention. In general, markers are selected for as great as possible ability to judge mutational status of a marker gene to predict outcome of treatment with NAE inhibitor. For example, the choice of markers are selected for as great as possible difference between the characteristic, e.g., size, sequence, composition or amount of the marker in samples comprising tumor cells and the characteristic, e.g., size, sequence, composition or amount of the same marker in control cells. Although this difference can be as small as the limit of detection of the method for assessing the amount of the marker, in another embodiment, the difference can be at least greater than the standard error of the assessment method. In the case of RNA or protein amount, a difference can be at least 1.5-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 25-, 100-, 500-, 1000-fold or greater. "Low" RNA or protein amount can be that expression relative to the overall mean across tumor samples (e.g., hematological tumor, e.g., myeloma) is low. In the case of amount of DNA, e.g., copy number, the amount is 0, 1, 2, 3, 4, 5, 6, or more copies. A deletion causes the copy number to be 0 or 1; an amplification causes the copy number to be greater than 2. The difference can be qualified by a confidence level, e.g., $p < 0.05$, $p < 0.02$, $p < 0.01$ or lower p-value.

[0092] Measurement of more than one marker, e.g., a set of 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, or 25 or more markers

can provide an expression profile or a trend indicative of treatment outcome. In some embodiments, the marker set comprises no more than 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, or 25 markers. In some embodiments, the marker set includes a plurality of chromosome loci, a plurality of marker genes, or a plurality of markers of one or more marker genes (e.g., nucleic acid and protein, genomic DNA and mRNA, or various combinations of markers described herein).

5 Analysis of treatment outcome through assessing the amount of markers in a set can be accompanied by a statistical method, e.g., a weighted voting analysis which accounts for variables which can affect the contribution of the amount of a marker in the set to the class or trend of treatment outcome, e.g., the signal-to-noise ratio of the measurement or hybridization efficiency for each marker. A marker set, e.g., a set of 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, or 25 or more markers, can comprise a primer, probe or primers to analyze at least one marker DNA or RNA described herein, e.g., 10 a marker on chromosome 22q from base pair 29999545 to 30094589, chromosome 18q from base pair 48556583 to 48611412, chromosome Xp from base pair 44732423 to 44971847, chromosome 4q from base pair 153242410 to 153456172, chromosome 17p from base pair 7571720 to 7590868, chromosome 9p from base pair 21967751 to 21994490, NF2, SMAD4, KDM6A, FBXW7, TP53, CDKN2A, CDKN2A_p14, or a complement of any of the foregoing. A marker set, e.g., a set of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, or 25 or more markers, can comprise a primer, 15 probe or primers to detect at least one or at least two or more markers, or at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, or 25 or more mutations on the markers e.g., of NF2, SMAD4, KDM6A, TP53, CDKN2A, CDKN2A_p14 and/or FBXW7. In another embodiment, a marker set can comprise markers for assessing characteristics of NF2, SMAD4 and/or KDM6A. In an embodiment, a marker set for cancer of the uterus or cervix comprises at least one marker for assessing at least one characteristic of FBXW7. In an embodiment, a marker set for cancer of the intestine, breast, lung, head and neck, 20 cervix or skin comprises at least one marker for assessing at least one characteristic of TP53. In an embodiment, a marker set for cancer of the intestine comprises markers for assessing at least one characteristic of each of TP53 and APC. In an embodiment, a marker set for cancer of the skin or central nervous system comprises at least one marker for assessing at least one characteristic of CDKN2A_p14. In an embodiment, a marker set for cancer of the head and neck or skin comprises at least one marker for assessing at least one characteristic of CDKN2A. In an embodiment, a 25 marker set for cancer of the head and neck comprises at least one marker for assessing at least one characteristic of SMAD4. Selected marker sets can be assembled from the markers provided herein or selected from among markers using methods provided herein and analogous methods known in the art. A way to qualify a new marker for use in an assay of the invention is to correlate DNA copy number in a sample comprising tumor cells with differences in expression (e.g., fold-change from baseline) of a marker, e.g., a marker gene. A useful way to judge the relationship is to calculate 30 the coefficient of determination r^2 , after solving for r , the Pearson product moment correlation coefficient and/or preparing a least squares plot, using standard statistical methods. A correlation can analyze DNA copy number versus the level of expression of marker, e.g., a marker gene. A gene product can be selected as a marker if the result of the correlation (r^2 , e.g., the linear slope of the data in this analysis), is at least 0.1- 0.2, at least 0.3-0.5, or at least 0.6-0.8 or more. Markers can vary with a positive correlation to response, TTP or survival (i.e., change expression levels in the same manner as copy number, e.g., decrease when copy number is decreased). Markers which vary with a negative correlation 35 to copy number (i.e., change expression levels in the opposite manner as copy number levels, e.g., increase when copy number is decreased) provide inconsistent determination of outcome.

[0093] Another way to qualify a new marker for use in the assay would be to assay the expression of large numbers of markers in a number of subjects before and after treatment with a test agent. The expression results allow identification 40 of the markers which show large changes in a given direction after treatment relative to the pre-treatment samples. One can build a repeated-measures linear regression model to identify the genes that show statistically significant changes or differences. To then rank these significant genes, one can calculate the area under the change from e.g., baseline vs time curve. This can result in a list of genes that would show the largest statistically significant changes. Then several markers can be combined together in a set by using such methods as principle component analysis, clustering methods 45 (e.g., k-means, hierarchical), multivariate analysis of variance (MANOVA), or linear regression techniques. To use such a gene (or group of genes) as a marker, genes which show 2-, 2.5-, 3-, 3.5-, 4-, 4.5-, 5-, 7-, 10- fold, or more differences of expression from baseline would be included in the marker set. An expression profile, e.g., a composite of the expression level differences from baseline or reference of the aggregate marker set would indicate at trend, e.g., if a majority of markers show a particular result, e.g., a significant difference from baseline or reference, e.g., 60%, 70%, 80%, 90%, 50 95% or more markers; or more markers, e.g., 10% more, 20% more, 30% more, 40% more, show a significant result in one direction than the other direction.

[0094] In embodiments when the compositions, kits, and methods of the invention are used for characterizing treatment outcome in a patient, the marker or set of markers of the invention is selected such that a significant result is obtained 55 in at least about 20%, at least about 40%, 60%, or 80%, or in substantially all patients treated with the test agent. The marker or set of markers of the invention can be selected such that a positive predictive value (PPV) of greater than about 10% is obtained for the general population and additional confidence in a marker can be inferred when the PPV is coupled with an assay specificity greater than 80%.

Therapeutic Agents

[0095] The markers and marker sets of the present invention assess the likelihood of favorable outcome of therapy (e.g., sensitivity to a therapeutic agent) in patients, e.g., cancer patients, e.g., patients having a hematological cancer (e.g., multiple myeloma, leukemias, lymphoma, etc) or solid tumor cancer (e.g., skin cancer such as melanoma, head and neck cancer, such as esophageal cancer, bladder cancer, lung cancer, such as non-small cell lung cancer (NSCLC), adenocarcinoma of the lung, central nervous system cancer such as lung metastases in the brain or neuroblastoma, pancreatic cancer, breast cancer, mesothelioma, cervical cancer or intestinal cancer such as colon or rectum adenocarcinoma), based on its ability to affect the characteristic, e.g., composition or amount of a marker or markers of the invention. Using this prediction, cancer therapies can be evaluated to design a therapy regimen best suitable for patients in either category.

[0096] In particular, the methods can be used to predict patient sensitivity to NAE inhibitors as described in earlier sections. The agents tested in the present methods can be a single agent or a combination of agents. The methods of the invention include combination of NAE inhibition therapy with proteasome inhibition therapy and/or other or additional agents, e.g., selected from the group consisting of chemotherapeutic agents. For example, the present methods can be used to determine whether a single chemotherapeutic agent, such as an NAE inhibitor (e.g., MLN4924) can be used to treat a cancer or whether a one or more agents should be used in combination with the NAE inhibitor (e.g., MLN4924). Useful combinations can include agents that have different mechanisms of action, e.g., the use of an anti-mitotic agent in combination with an alkylating agent and an NAE inhibitor.

[0097] As used herein, the term "proteasome inhibitor" refers to any substance which directly inhibits enzymatic activity of the 20S or 26S proteasome *in vitro* or *in vivo*. In some embodiments, the proteasome inhibitor is a peptidyl boronic acid. Examples of peptidyl boronic acid proteasome inhibitors suitable for use in the methods of the invention are disclosed in Adams et al., U.S. Patent Nos. 5,780,454 (1998), 6,066,730 (2000), 6,083,903 (2000); 6,297,217 (2001), 6,465,433 (2002), 6,548,668 (2003), 6,617,317 (2003), and 6,747,150 (2004). In some embodiments, the peptidyl boronic acid proteasome inhibitor is selected from the group consisting of: N (4 morpholine)carbonyl- β -(1-naphthyl)-L-alanine-L-leucine boronic acid; N (8 quinoline)sulfonyl- β -(1-naphthyl)-L-alanine-L-alanine-L-leucine boronic acid; N (pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid, and N (4 morpholine)-carbonyl-[O-(2-pyridylmethyl)]-L-tyrosine-L-leucine boronic acid. In a particular embodiment, the proteasome inhibitor is N (pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid (bortezomib; VELCADE®; formerly known as MLN341 or PS-341). Publications describe the use of the disclosed boronic ester and boronic acid compounds to reduce the rate of muscle protein degradation, to reduce the activity of NF- κ B in a cell, to reduce the rate of degradation of p53 protein in a cell, to inhibit cyclin degradation in a cell, to inhibit the growth of a cancer cell, and to inhibit NF- κ B dependent cell adhesion. Bortezomib specifically and selectively inhibits the proteasome by binding tightly ($K_i=0.6$ nM) to one of the enzyme's active sites. Bortezomib is selectively cytotoxic, and has a novel pattern of cytotoxicity in National Cancer Institute (NCI) *in vitro* and *in vivo* assays. Adams J, et al. Cancer Res 59:2615-22.(1999).

[0098] Additionally, proteasome inhibitors include peptide aldehyde proteasome inhibitors (Stein et al., U.S. Patent No. 5,693,617 (1997); Siman et al., international patent publication WO 91/13904; Iqbal et al., J. Med. Chem. 38:2276-2277 (1995); and Iinuma *et al.*, international patent publication WO 05/105826, peptidyl epoxy ketone proteasome inhibitors (Crews et al., U.S. Patent No. 6,831,099; Smyth et al., international patent publication WO 05/111008; Bennett et al., international patent publication WO 06/045066; Spaltenstein et al. Tetrahedron Lett. 37:1343 (1996); Meng, Proc. Natl. Acad. Sci. 96: 10403 (1999); and Meng, Cancer Res. 59: 2798 (1999)), alpha-ketoamide proteasome inhibitors (Chatterjee and Mallamo, U.S. Patent Nos. 6,310,057 (2001) and 6,096,778 (2000); and Wang et al., U.S. Patent Nos. 6,075,150 (2000) and 6,781,000 (2004)), peptidyl vinyl ester proteasome inhibitors (Marastoni et al., J. Med. Chem. 48:5038 (2005), and peptidyl vinyl sulfone and 2-keto-1,3,4-oxadiazole proteasome inhibitors, such as those disclosed in Rydzewski et al., J. Med. Chem. 49:2953 (2006); and Bogyo et al., Proc. Natl. Acad. Sci. 94:6629 (1997)), azapeptoids and (Bouget et al., Bioorg. Med. Chem. 11:4881 (2003); Baudy-Floc'h *et al.*, international patent publication WO 05/030707; and Bonnemains *et al.*, international patent publication WO 03/018557), efrapeptin oligopeptides (Panthanassiu, international patent publication WO 05/115431), lactacystin and salinosporamide and analogs thereof (Fenteany *et al.*, U.S. Patent Nos. 5,756,764 (1998), 6,147,223 (2000), 6,335,358 (2002), and 6,645,999 (2003); Fenteany et al., Proc. Natl. Acad. Sci. USA (1994)91:3358; Fenical *et al.*, international patent publication WO 05/003137; Palladino *et al.*, international patent publication WO 05/002572; Stadler et al., international patent publication WO 04/071382; Xiao and Patel, U.S. patent publication 2005/023162; and Corey, international patent publication WO 05/099687).

[0099] Additional therapeutic agents for use in combination with an NAE inhibitor (e.g., MLN4924) in the methods of the invention can comprise a known class of therapeutic agents comprising glucocorticoid steroids. Glucocorticoid therapy generally comprises at least one glucocorticoid agent (e.g., dexamethasone). In certain applications of the invention, the agent used in methods of the invention is a glucocorticoid agent. One example of a glucocorticoid utilized in the treatment of multiple myeloma patients as well as other cancer therapies is dexamethasone. Additional glucocorticoids utilized in treatment of hematological and combination therapy in solid tumors include hydrocortisone, prednisolone,

prednisone, and triamcinolone.

[0100] Other therapeutic agents for use in combination with NAE inhibition therapy include chemotherapeutic agents. A "chemotherapeutic agent" is intended to include chemical reagents which inhibit the growth of proliferating cells or tissues wherein the growth of such cells or tissues is undesirable. Chemotherapeutic agents such as antimetabolic agents, e.g., Ara AC, 5-FU and methotrexate, antimetotic agents, e.g., taxane, vinblastine and vincristine, alkylating agents, e.g., melphanlan, Carmustine (BCNU) and nitrogen mustard, Topoisomerase II inhibitors, e.g., VW-26, topotecan and Bleomycin, strand-breaking agents, e.g., doxorubicin and Mitoxantrone (DHAD), cross-linking agents, e.g., cisplatin and carboplatin (CBDCA), radiation and ultraviolet light and are well known in the art (see e.g., Gilman A.G., et al., The Pharmacological Basis of Therapeutics, 8th Ed., Sec 12:1202-1263 (1990)), and are typically used to treat neoplastic diseases. Examples of chemotherapeutic agents generally employed in chemotherapy treatments are listed below in Table 2.

TABLE 2: Chemotherapeutic Agents

CLASS	TYPE OF AGENT	NONPROPRIETARY NAMES (OTHER NAMES)
Alkylating	Nitrogen Mustards	Mechlorethamine (HN ₂) Cyclophosphamide Ifosfamide Melphalan (L-sarcolysin) Chlorambucil
	Ethylenimines And Methylmelamines	Hexamethylmelamine Thiotepa
	Alkyl Sulfonates	Busulfan
Alkylating	Nitrosoureas	Carmustine (BCNU) Lomustine (CCNU) Semustine (methyl-CCNU) Streptozocin (streptozotocin)
Alkylating	Triazines	Decarbazine (DTIC; dimethyltriazenoimidazolecarboxamide)
	Alkylator	cis-diamminedichloroplatinum II (CDDP)
Antimetabolites	Folic Acid Analogs	Methotrexate (amethopterin)
	Pyrimidine Analogues	Fluorouracil (5-fluorouracil; 5-FU) Flouxuridine (fluorode-oxyuridine; FUDR) Cytarabine (cytosine arabinoside)
	Purine Analogs and Related Inhibitors	Mercaptopuine (6-mercaptopurine; 6-MP) Thioguanine (6-thioguanine; TG) Pentostatin (2' - deoxycoformycin)
Natural Products	Vinca Alkaloids	Vinblastin (VLB) Vincristine
	Topoisomerase Inhibitors	Etoposide Teniposide Camptothecin Topotecan 9-amino-campotothecin CPT-11
	Antibiotics	Dactinomycin (actinomycin D) Adriamycin Daunorubicin (daunomycin; rubindomycin) Doxorubicin Bleomycin Plicamycin (mithramycin)

EP 2 775 844 B1

(continued)

CLASS	TYPE OF AGENT	NONPROPRIETARY NAMES (OTHER NAMES)
Natural Products		Mitomycin (mitomycin C) TAXOL Taxotere
	Enzymes	L-Asparaginase
	Biological Response Modifiers	Interfon alfa Interleukin 2
	Platinum Coordination Complexes	cis-diamminedichloroplatinum II (CDDP) Carboplatin
	Anthracendione	Mitoxantrone
	Substituted Urea	Hydroxyurea
Miscellaneous Agents	Methyl Hydraxzine Derivative Adrenocortical Suppressant	Procarbazine (N-methylhydrazine, (MIH)) Mitotane (o,p'-DDD) Aminoglutethimide
Hormones and Antagonists	Progestins	Hydroxyprogesterone caproate Medroxyprogesterone acetate Megestrol acetate
	Estrogens	Diethylstilbestrol Ethinyl estradiol
	Antiestrogen	Tamoxifen
	Androgens	Testosterone propionate Fluoxymesterone
	Antiandrogen	Flutamide
	Gonadotropin-releasing Hormone analog	Leuprolide

[0101] The agents tested in the present methods can be a single agent or a combination of agents. For example, the present methods can be used to determine whether a single chemotherapeutic agent, such as methotrexate, can be used to treat a cancer or whether a combination of two or more agents can be used in combination with an NAE inhibitor (e.g., MLN4924). Useful combinations can include agents that have different mechanisms of action, e.g., the use of an anti-mitotic agent in combination with an alkylating agent and an NAE inhibitor.

[0102] The agents disclosed herein may be administered by any route, including intradermally, subcutaneously, orally, intraarterially or intravenously. In one embodiment, administration will be by the intravenous route. Parenteral administration can be provided in a bolus or by infusion.

[0103] The concentration of a disclosed compound in a pharmaceutically acceptable mixture will vary depending on several factors, including the dosage of the compound to be administered, the pharmacokinetic characteristics of the compound(s) employed, and the route of administration. The agent may be administered in a single dose or in repeat doses. Treatments may be administered daily or more frequently depending upon a number of factors, including the overall health of a patient, and the formulation and route of administration of the selected compound(s).

Screens for NAE inhibitors

[0104] The disclosure provides methods (also referred to herein as "screening assays") for identifying modulators, i.e., candidate or test compounds or agents (e.g., proteins, peptides, peptidomimetics, peptoids, small molecules or other drugs) which bind to NAE, or other E1 enzyme variant proteins, have a stimulatory or inhibitory effect on, for example, NAE, or other E1 enzyme expression or enzyme activity, or have a stimulatory or inhibitory effect on, for example, the expression or activity of a NAE, or other E1 enzyme substrate or proteins in the E1 enzyme pathway, e.g.,

in the NAE pathway, e.g. with a relationship to the activity of a cullin ring ligase. Compounds thus identified can be used to modulate the activity of target gene products (e.g., NAE, or other E1 enzyme genes) in a therapeutic protocol, to elaborate the biological function of the target gene product, or to identify compounds that disrupt NAE, or other E1 enzyme pathway interactions.

[0105] In one description the disclosure provides a method of identifying a compound as an NAE inhibitor, e.g., as an agent that modulates the drug resistance of a cell, by first contacting a cell comprising at least one mutation in at least one marker gene with a test compound and then measuring the viability of the cell or the inhibition of the growth of the cell. In some descriptions, the cell comprises a resistance gene identified in Table 3. In other descriptions, the cell comprises a sensitivity gene identified in Table 3. The effect of the NAE inhibitor can be compared to a control cell not exposed to the compound. In some descriptions, the effect of an agent on a cell comprising a sensitivity marker gene can be compared with the effect of an agent on a cell comprising a resistance marker gene (see, e.g., Table 3). The compound is identified as modulator of drug resistance or an NAE inhibitor agent when the cell viability or cell growth is decreased. The compounds identified as an NAE inhibitor, e.g., as modulating resistance, that are identified in the foregoing methods are also included within the invention.

Detection Methods

[0106] A general principle of prognostic assays involves preparing a sample or reaction mixture that may contain a marker, and a probe, under appropriate conditions and for a time sufficient to allow the marker and probe to interact and bind, thus forming a complex that can be removed and/or detected in the reaction mixture. These assays can be conducted in a variety of ways.

[0107] For example, one method to conduct such an assay would involve anchoring the marker or probe onto a solid phase support, also referred to as a substrate, and detecting target marker/probe complexes anchored on the solid phase at the end of the reaction. In one embodiment of such a method, a sample from a subject, which is to be assayed for presence and/or concentration of marker, can be anchored onto a carrier or solid phase support. In another embodiment, the reverse situation is possible, in which the probe can be anchored to a solid phase and a sample from a subject can be allowed to react as an unanchored component of the assay. One example of such an embodiment includes use of an array or chip which contains a predictive marker or marker set anchored for expression analysis of the sample.

[0108] There are many established methods for anchoring assay components to a solid phase. These include, without limitation, marker or probe molecules which are immobilized through conjugation of biotin and streptavidin. Such biotinylated assay components can be prepared from biotin-NHS (*N*-hydroxy-succinimide) using techniques known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). In certain embodiments, the surfaces with immobilized assay components can be prepared in advance and stored.

[0109] Other suitable carriers or solid phase supports for such assays include any material capable of binding the class of molecule to which the marker or probe belongs. Well-known supports or carriers include, but are not limited to, glass, polystyrene, nylon, polypropylene, nylon, polyethylene, dextran, amyloses, natural and modified celluloses, polyacrylamides, gabbros, and magnetite. One skilled in the art will know many other suitable carriers for binding antibody or antigen, and will be able to adapt such support for use with the present invention. For example, protein isolated from cells can be run on a polyacrylamide gel electrophoresis and immobilized onto a solid phase support such as nitrocellulose. The support can then be washed with suitable buffers followed by treatment with the detectably labeled antibody. The solid phase support can then be washed with the buffer a second time to remove unbound antibody. The amount of bound label on the solid support can then be detected by conventional means.

[0110] In order to conduct assays with the above mentioned approaches, the non-immobilized component is added to the solid phase upon which the second component is anchored. After the reaction is complete, uncomplexed components may be removed (e.g., by washing) under conditions such that any complexes formed will remain immobilized upon the solid phase. The detection of marker/probe complexes anchored to the solid phase can be accomplished in a number of methods outlined herein.

[0111] In an embodiment, the probe, when it is the unanchored assay component, can be labeled for the purpose of detection and readout of the assay, either directly or indirectly, with detectable labels discussed herein and which are well-known to one skilled in the art. The term "labeled", with regard to the probe (e.g., nucleic acid or antibody), is intended to encompass direct labeling of the probe by coupling (*i.e.*, physically linking) a detectable substance to the probe, as well as indirect labeling of the probe by reactivity with another reagent that is directly labeled. An example of indirect labeling includes detection of a primary antibody using a fluorescently labeled secondary antibody. It is also possible to directly detect marker/probe complex formation without further manipulation or labeling of either component (marker or probe), for example by utilizing the technique of fluorescence energy transfer (FET, see, for example, Lakowicz et al., U.S. Patent No. 5,631,169; Stavrianopoulos, et al., U.S. Patent No. 4,868,103). A fluorophore label on the first, 'donor' molecule is selected such that, upon excitation with incident light of appropriate wavelength, its emitted fluorescent

energy will be absorbed by a fluorescent label on a second 'acceptor' molecule, which in turn is able to fluoresce due to the absorbed energy. Alternately, the 'donor' protein molecule may simply utilize the natural fluorescent energy of tryptophan residues. Labels are chosen that emit different wavelengths of light, such that the 'acceptor' molecule label may be differentiated from that of the 'donor'. Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, spatial relationships between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the 'acceptor' molecule label in the assay should be maximal. An FET binding event can be conveniently measured through standard fluorometric detection means well known in the art (e.g., using a fluorimeter).

[0112] In another embodiment, determination of the ability of a probe to recognize a marker can be accomplished without labeling either assay component (probe or marker) by utilizing a technology such as real-time Biomolecular Interaction Analysis (BIA) (see, e.g., Sjolander, S. and Urbaniczky, C. (1991) *Anal. Chem.* 63:2338-2345 and Szabo et al. (1995) *Curr. Opin. Struct. Biol.* 5:699-705). As used herein, "BIA" or "surface plasmon resonance" is a technology for studying biospecific interactions in real time, without labeling any of the interactants (e.g., BIACORE™). Changes in the mass at the binding surface (indicative of a binding event) result in alterations of the refractive index of light near the surface (the optical phenomenon of surface plasmon resonance (SPR)), resulting in a detectable signal which can be used as an indication of real-time reactions between biological molecules.

[0113] Alternatively, in another embodiment, analogous diagnostic and prognostic assays can be conducted with marker and probe as solutes in a liquid phase. In such an assay, the complexed marker and probe are separated from uncomplexed components by any of a number of standard techniques, including but not limited to: differential centrifugation, chromatography, electrophoresis and immunoprecipitation. In differential centrifugation, marker/probe complexes may be separated from uncomplexed assay components through a series of centrifugal steps, due to the different sedimentation equilibria of complexes based on their different sizes and densities (see, for example, Rivas, G., and Minton, A.P. (1993) *Trends Biochem Sci.* 18:284-7). Standard chromatographic techniques also can be utilized to separate complexed molecules from uncomplexed ones. For example, gel filtration chromatography separates molecules based on size, and through the utilization of an appropriate gel filtration resin in a column format, for example, the relatively larger complex may be separated from the relatively smaller uncomplexed components. Similarly, the relatively different charge properties of the marker/probe complex as compared to the uncomplexed components may be exploited to differentiate the complex from uncomplexed components, for example through the utilization of ion-exchange chromatography resins. Such resins and chromatographic techniques are well known to one skilled in the art (see, e.g., Heegaard, N.H. (1998) *J. Mol. Recognit.* 11:141-8; Hage, D.S., and Tweed, S.A. (1997) *J. Chromatogr. B. Biomed. Sci. Appl.* 699:499-525). Gel electrophoresis may also be employed to separate complexed assay components from unbound components (see, e.g., Ausubel et al., ed., *Current Protocols in Molecular Biology*, John Wiley & Sons, New York, 1987-1999). In this technique, protein or nucleic acid complexes are separated based on size or charge, for example. In some embodiments, non-denaturing gel matrix materials and conditions in the absence of reducing agent are used in order to maintain the binding interaction during the electrophoretic process. Appropriate conditions to the particular assay and components thereof will be well known to one skilled in the art.

[0114] The isolated mRNA can be used in hybridization or amplification assays that include, but are not limited to, Southern or Northern analyses, polymerase chain reaction and TAQMAN® gene expression assays (Applied Biosystems, Foster City, CA) and probe arrays. One diagnostic method for the detection of mRNA levels involves contacting the isolated mRNA with a nucleic acid molecule (probe, e.g., a hybridization probe) that can hybridize to the mRNA encoded by the gene or mutant being detected. In some embodiments, nucleic acids comprising mutations of marker genes can be used as probes or primers. The nucleic acid probes or primers of the invention can be single stranded DNA (e.g., an oligonucleotide), double stranded DNA (e.g., double stranded oligonucleotide) or RNA. Primers of the invention refer to nucleic acids which hybridize to a nucleic acid sequence which is adjacent to the region of interest and can be extended over a region of interest, e.g., in a primer extension or amplification reaction, or which covers the region of interest, e.g., a nucleic acid region comprising a marker gene or mutation thereof. A nucleic acid probe can be, for example, a full-length cDNA, or a portion thereof, such as an oligonucleotide of at least 7, 15, 20, 25, 30, 50, 75, 100, 125, 150, 175, 200, 250 or 500 or more consecutive nucleotides of the marker nucleic acid sequence or complement thereof and sufficient to specifically hybridize under stringent conditions to a mRNA or genomic DNA encoding a marker of the present invention or a complement thereof. The exact length of the nucleic acid probe will depend on many factors that are routinely considered and practiced by the skilled artisan. Nucleic acid probes of the invention may be prepared by chemical synthesis using any suitable methodology known in the art, may be produced by recombinant technology, or may be derived from a biological sample, for example, by restriction digestion. Other suitable probes for use in the diagnostic assays of the invention are described herein. The probe can comprise a label group attached thereto, e.g., a radioisotope, a fluorescent compound, an enzyme, an enzyme co-factor, a hapten, a sequence tag, a protein or an antibody. The nucleic acids can be modified at the base moiety, at the sugar moiety, or at the phosphate backbone. An example of a nucleic acid label is incorporated using SUPER™ Modified Base Technology (Nanogen, Bothell, WA, see U.S. Patent No. 7,045,610). The level of expression can be measured as general nucleic acid levels, e.g., after measuring

the amplified DNA levels (e.g. using a DNA intercalating dye, e.g., the SYBR green dye (Qiagen Inc., Valencia, CA) or as specific nucleic acids, e.g., using a probe based design, with the probes labeled. TAQMAN® assay formats can use the probe-based design to increase specificity and signal-to-noise ratio.

[0115] Such primers or probes can be used as part of a diagnostic test kit for identifying cells or tissues which express the protein, such as by measuring amounts of a nucleic acid molecule transcribed in a sample of cells from a subject, e.g., detecting transcript, mRNA levels or determining whether a gene encoding the protein has been mutated or deleted. Hybridization of an RNA or a cDNA with the nucleic acid probe can indicate that the marker in question is being expressed. The invention further encompasses detecting nucleic acid molecules that differ, due to degeneracy of the genetic code, from the nucleotide sequence of nucleic acids encoding a marker protein (e.g., protein having the sequence of the SEQ ID NOs:3, 6, 10, 11, 14, 17, 20, 23 or 26), and thus encode the same protein. It will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequence can exist within a population (e.g., the human population). Such genetic polymorphisms can exist among individuals within a population due to natural allelic variation. An allele is one of a group of genes which occur alternatively at a given genetic locus. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of a given gene. Alternative alleles can be identified by sequencing the gene of interest in a number of different individuals, e.g., normal samples from individuals. This can be readily carried out by using hybridization probes to identify the same genetic locus in a variety of individuals. Detecting any and all such nucleotide variations and resulting amino acid polymorphisms or variations that are the result of natural allelic variation and that do not alter the functional activity are intended to be within the scope of the invention. In addition, it will be appreciated that DNA polymorphisms that affect RNA expression levels can also exist that may affect the overall expression level of that gene (e.g., by affecting regulation or degradation).

[0116] As used herein, the term "hybridizes" is intended to describe conditions for hybridization and washing under which nucleotide sequences that are significantly identical or homologous to each other remain hybridized to each other. In some embodiments, the conditions are such that sequences at least about 70%, at least about 80%, at least about 85%, 90% or 95% identical to each other remain hybridized to each other for subsequent amplification and/or detection. Stringent conditions vary according to the length of the involved nucleotide sequence but are known to those skilled in the art and can be found or determined based on teachings in Current Protocols in Molecular Biology, Ausubel et al., eds., John Wiley & Sons, Inc. (1995), sections 2, 4 and 6. Additional stringent conditions and formulas for determining such conditions can be found in Molecular Cloning: A Laboratory Manual, Sambrook et al., Cold Spring Harbor Press, Cold Spring Harbor, NY (1989), chapters 7, 9 and 11. A non-limiting example of stringent hybridization conditions for hybrids that are at least 10 basepairs in length includes hybridization in 4X sodium chloride/sodium citrate (SSC), at about 65-70°C (or hybridization in 4X SSC plus 50% formamide at about 42-50°C) followed by one or more washes in 1X SSC, at about 65-70°C. A non-limiting example of highly stringent hybridization conditions for such hybrids includes hybridization in 1X SSC, at about 65-70°C (or hybridization in 1X SSC plus 50% formamide at about 42-50°C) followed by one or more washes in 0.3X SSC, at about 65-70°C. A non-limiting example of reduced stringency hybridization conditions for such hybrids includes hybridization in 4X SSC, at about 50-60°C (or alternatively hybridization in 6X SSC plus 50% formamide at about 40-45°C) followed by one or more washes in 2X SSC, at about 50-60°C. Ranges intermediate to the above-recited values, e.g., at 65-70°C or at 42-50°C are also intended to be encompassed by the present invention. Another example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 50-65°C. A further example of stringent hybridization buffer is hybridization in 1 M NaCl, 50 mM 2-(N-morpholino)ethanesulfonic acid (MES) buffer (pH 6.5), 0.5% sodium sarcosine and 30% formamide. SSPE (1xSSPE is 0.15M NaCl, 10mM NaH₂PO₄, and 1.25mM EDTA, pH 7.4) can be substituted for SSC (1xSSC is 0.15M NaCl and 15mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes each after hybridization is complete. The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (T_m) of the hybrid, where T_m is determined according to the following equations. For hybrids less than 18 base pairs in length, T_m(°C) = 2(# of A + T bases) + 4(# of G + C bases). For hybrids between 18 and 49 base pairs in length, T_m(°C) = 81.5 + 16.6(log₁₀[Na⁺]) + 0.41(%G+C) - (600/N), where N is the number of bases in the hybrid, and [Na⁺] is the concentration of sodium ions in the hybridization buffer ([Na⁺] for 1xSSC = 0.165 M). It will also be recognized by the skilled practitioner that additional reagents may be added to hybridization and/or wash buffers to decrease non-specific hybridization of nucleic acid molecules to membranes, for example, nitrocellulose or nylon membranes, including but not limited to blocking agents (e.g., BSA or salmon or herring sperm carrier DNA), detergents (e.g., SDS), chelating agents (e.g., EDTA), Ficoll, polyvinylpyrrolidone (PVP) and the like. When using nylon membranes, in particular, an additional non-limiting example of stringent hybridization conditions is hybridization in 0.25-0.5M NaH₂PO₄, 7% SDS at about 65°C, followed by one or more washes at 0.02M NaH₂PO₄, 1% SDS at 65°C, see e.g., Church and Gilbert (1984) Proc. Natl. Acad. Sci. USA 81:1991-1995, (or alternatively 0.2X SSC, 1% SDS). A primer or nucleic acid probe can be used alone in a detection method, or a primer can be used together with at least one other primer or nucleic acid probe in a detection method. Primers can also be used to amplify at least a portion of a nucleic acid. Nucleic acid probes of the invention refer to nucleic acids which hybridize to the region of interest and which are not further extended. For example, a nucleic

acid probe is a nucleic acid which specifically hybridizes to a mutant region of a biomarker, and which by hybridization or absence of hybridization to the DNA of a patient or the type of hybrid formed can be indicative of the presence or identity of the mutation of the biomarker or the amount of marker activity.

5 [0117] In one format, the RNA is immobilized on a solid surface and contacted with a probe, for example by running the isolated RNA on an agarose gel and transferring the RNA from the gel to a membrane, such as nitrocellulose. In an alternative format, the nucleic acid probe(s) are immobilized on a solid surface and the RNA is contacted with the probe(s), for example, in an AFFYMETRIX® gene chip array or a SNP chip (Santa Clara, CA) or customized array using a marker set comprising at least one marker indicative of treatment outcome. A skilled artisan can readily adapt known RNA and DNA detection methods for use in detecting the amount of the markers of the present invention. For example, 10 the high density microarray or branched DNA assay can benefit from a higher concentration of tumor cell in the sample, such as a sample which had been modified to isolate tumor cells as described in earlier sections. In a related embodiment, a mixture of transcribed polynucleotides obtained from the sample is contacted with a substrate having fixed thereto a polynucleotide complementary to or homologous with at least a portion (e.g., at least 7, 10, 15, 20, 25, 30, 40, 50, 100, 500, or more nucleotide residues) of a marker nucleic acid. If polynucleotides complementary to or homologous with the marker are differentially detectable on the substrate (e.g., detectable using different chromophores or fluorophores, or fixed to different selected positions), then the levels of expression of a plurality of markers can be assessed simultaneously using a single substrate (e.g., a "gene chip" microarray of polynucleotides fixed at selected positions). In an embodiment when a method of assessing marker expression is used which involves hybridization of one nucleic acid with another, the hybridization can be performed under stringent hybridization conditions.

20 [0118] An alternative method for determining the amount of RNA corresponding to a marker of the present invention in a sample involves the process of nucleic acid amplification, e.g., by RT-PCR (the experimental embodiment set forth in Mullis, 1987, U.S. Patent No. 4,683,202), ligase chain reaction (Barany, 1991, Proc. Natl. Acad. Sci. USA, 88:189-193), self sustained sequence replication (Guatelli et al., 1990, Proc. Natl. Acad. Sci. USA 87:1874-1878), transcriptional amplification system (Kwoh et al., 1989, Proc. Natl. Acad. Sci. USA 86:1173-1177), Q-Beta Replicase (Lizardi et al., 25 1988, Bio/Technology 6:1197), rolling circle replication (Lizardi et al., U.S. Patent No. 5,854,033) or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers. As used herein, amplification primers are defined as being a pair of nucleic acid molecules that can anneal to 5' or 3' regions of a gene (plus and minus strands, respectively, or vice-versa) and contain a short region in between. In general, amplification primers are from about 10 to about 30 nucleotides in length and flank a region from about 50 to about 200 nucleotides in length. Under appropriate conditions and with appropriate reagents, such primers permit the amplification of a nucleic acid molecule comprising the nucleotide sequence flanked by the primers.

35 [0119] For *in situ* methods, RNA does not need to be isolated from the cells prior to detection. In such methods, a cell or tissue sample is prepared/processed using known histological methods. The sample is then immobilized on a support, typically a glass slide, and then contacted with a probe that can hybridize to RNA that encodes the marker.

[0120] In another embodiment of the present invention, a polypeptide corresponding to a marker is detected. In some embodiments, an agent for detecting a polypeptide of the invention is an antibody capable of binding to a polypeptide corresponding to a marker of the invention. In related embodiments, the antibody has a detectable label. Antibodies can be polyclonal, or monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')₂) can be used.

40 [0121] A variety of formats can be employed to determine whether a sample contains a protein that binds to a given antibody. Examples of such formats include, but are not limited to, enzyme immunoassay (EIA), radioimmunoassay (RIA), Western blot analysis and enzyme linked immunoabsorbant assay (ELISA). A skilled artisan can readily adapt known protein/antibody detection methods for use in determining whether B cells express a marker of the present invention.

45 [0122] Another method for determining the level of a polypeptide corresponding to a marker is mass spectrometry. For example, intact proteins or peptides, e.g., tryptic peptides can be analyzed from a sample, e.g., a blood sample, a lymph sample or other sample, containing one or more polypeptide markers. The method can further include treating the sample to lower the amounts of abundant proteins, e.g., serum albumin, to increase the sensitivity of the method. 50 For example, liquid chromatography can be used to fractionate the sample so portions of the sample can be analyzed separately by mass spectrometry. The steps can be performed in separate systems or in a combined liquid chromatography/mass spectrometry system (LC/MS, see for example, Liao, et al. (2004) Arthritis Rheum. 50:3792-3803). The mass spectrometry system also can be in tandem (MS/MS) mode. The charge state distribution of the protein or peptide mixture can be acquired over one or multiple scans and analyzed by statistical methods, e.g. using the retention time and mass-to-charge ratio (m/z) in the LC/MS system, to identify proteins expressed at statistically significant levels differentially in samples from patients responsive or non-responsive to NAE inhibition therapy. Examples of mass spectrometers which can be used are an ion trap system (ThermoFinnigan, San Jose, CA) or a quadrupole time-of-flight mass spectrometer (Applied Biosystems, Foster City, CA). The method can further include the step of peptide mass

fingerprinting, e.g. in a matrix-assisted laser desorption ionization with time-of-flight (MALDI-TOF) mass spectrometry method. The method can further include the step of sequencing one or more of the tryptic peptides. Results of this method can be used to identify proteins from primary sequence databases, e.g., maintained by the National Center for Biotechnology Information, Bethesda, MD, or the Swiss Institute for Bioinformatics, Geneva, Switzerland, and based on mass spectrometry tryptic peptide m/z base peaks.

Electronic Apparatus Readable Arrays

[0123] Electronic apparatus, including readable arrays comprising at least one predictive marker of the present invention is also contemplated for use in conjunction with the methods of the invention. As used herein, "electronic apparatus readable media" refers to any suitable medium for storing, holding or containing data or information that can be read and accessed directly by an electronic apparatus. As used herein, the term "electronic apparatus" is intended to include any suitable computing or processing apparatus or other device configured or adapted for storing data or information. Examples of electronic apparatus suitable for use with the present invention and monitoring of the recorded information include stand-alone computing apparatus; networks, including a local area network (LAN), a wide area network (WAN) Internet, Intranet, and Extranet; electronic appliances such as personal digital assistants (PDAs), cellular phone, pager and the like; and local and distributed processing systems. As used herein, "recorded" refers to a process for storing or encoding information on the electronic apparatus readable medium. Those skilled in the art can readily adopt any of the presently known methods for recording information on known media to generate manufactures comprising the markers of the present invention.

[0124] For example, microarray systems are well known and used in the art for assessment of samples, whether by assessment gene expression (e.g., DNA detection, RNA detection, protein detection), or metabolite production, for example. Microarrays for use according to the invention include one or more probes of predictive marker(s) of the invention characteristic of response and/or non-response to a therapeutic regimen as described herein. In one embodiment, the microarray comprises one or more probes corresponding to one or more of markers selected from the group consisting of markers which demonstrate increased expression in short term survivors, and genes which demonstrate increased expression in long term survivors in patients. A number of different microarray configurations and methods for their production are known to those of skill in the art and are disclosed, for example, in U.S. Pat. Nos: 5,242,974; 5,384,261; 5,405,783; 5,412,087; 5,424,186; 5,429,807; 5,436,327; 5,445,934; 5,556,752; 5,405,783; 5,412,087; 5,424,186; 5,429,807; 5,436,327; 5,472,672; 5,527,681; 5,529,756; 5,545,531; 5,554,501; 5,561,071; 5,571,639; 5,593,839; 5,624,711; 5,700,637; 5,744,305; 5,770,456; 5,770,722; 5,837,832; 5,856,101; 5,874,219; 5,885,837; 5,919,523; 5,981,185; 6,022,963; 6,077,674; 6,156,501; 6,261,776; 6,346,413; 6,440,677; 6,451,536; 6,576,424; 6,610,482; 5,143,854; 5,288,644; 5,324,633; 5,432,049; 5,470,710; 5,492,806; 5,503,980; 5,510,270; 5,525,464; 5,547,839; 5,580,732; 5,661,028; 5,848,659; and 5,874,219; Shena, et al. (1998), Tibtech 16:301; Duggan et al. (1999) Nat. Genet. 21:10; Bowtell et al. (1999) Nat. Genet. 21:25; Lipshutz et al. (1999) Nature Genet. 21:20-24, 1999; Blanchard, et al. (1996) Biosensors and Bioelectronics, 11:687-90; Maskos, et al., (1993) Nucleic Acids Res. 21:4663-69; Hughes, et al. (2001) Nat. Biotechnol. 19:342, 2001. A tissue microarray can be used for protein identification (see Hans et al. (2004) Blood 103:275-282). A phage-epitope microarray can be used to identify one or more proteins in a sample based on whether the protein or proteins induce auto-antibodies in the patient (Bradford et al. (2006) Urol. Oncol. 24:237-242).

[0125] A microarray thus comprises one or more probes corresponding to one or more markers identified herein, e.g., those indicative of treatment outcome, e.g., to identify wild type marker genes, normal allelic variants and mutations of marker genes. The microarray can comprise probes corresponding to, for example, at least 2, at least 3, at least 4, at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 75, or at least 100, biomarkers and/or mutations thereof indicative of treatment outcome. The microarray can comprise probes corresponding to one or more biomarkers as set forth herein. Still further, the microarray may comprise complete marker sets as set forth herein and which may be selected and compiled according to the methods set forth herein. The microarray can be used to assay expression of one or more predictive markers or predictive marker sets in the array. In one example, the array can be used to assay more than one predictive marker or marker set expression in a sample to ascertain an expression profile of markers in the array. In this manner, up to about 44,000 markers can be simultaneously assayed for expression. This allows an expression profile to be developed showing a battery of markers specifically expressed in one or more samples. Still further, this allows an expression profile to be developed to assess treatment outcome.

[0126] The array is also useful for ascertaining differential expression patterns of one or more markers in normal and abnormal (e.g., sample, e.g., tumor) cells. This provides a battery of markers that could serve as a tool for ease of identification of treatment outcome of patients. Further, the array is useful for ascertaining expression of reference markers for reference expression levels. In another example, the array can be used to monitor the time course of expression of one or more markers in the array.

[0127] In addition to such qualitative determination, the invention allows the quantification of marker expression. Thus,

predictive markers can be grouped on the basis of marker sets or outcome indications by the amount of the marker in the sample. This is useful, for example, in ascertaining the outcome of the sample by virtue of scoring the amounts according to the methods provided herein.

[0128] The array is also useful for ascertaining the effect of the expression of a marker on the expression of other predictive markers in the same cell or in different cells. This provides, for example, a selection of alternate molecular targets for therapeutic intervention if patient is predicted to have an unfavorable outcome.

Reagents and Kits

[0129] The invention also encompasses kits for detecting the presence of a polypeptide or nucleic acid corresponding to a marker of the invention in a biological sample (e.g. a bone marrow sample, tumor biopsy or a reference sample). Such kits can be used to determine mutational status of at least one marker gene to assess treatment outcome, e.g., determine if a subject can have a favorable outcome, e.g., after NAE inhibitor treatment. For example, the kit can comprise a labeled compound or agent capable of detecting a genomic DNA segment, a polypeptide or a transcribed RNA corresponding to a marker of the invention or a mutation of a marker gene in a biological sample and means for determining the amount of the genomic DNA segment, the polypeptide or RNA in the sample. Suitable reagents for binding with a marker protein include antibodies, antibody derivatives, antibody fragments, and the like. Suitable reagents for binding with a marker nucleic acid (e.g., a genomic DNA, an mRNA, a spliced mRNA, a cDNA, or the like) include complementary nucleic acids. The label can be directly attached to the marker binding agent, e.g., probe, e.g., nucleic acid reagent such as a probe or primer or protein reagent, such as a specific binding agent or antibody, or a secondary reagent can comprise a label for indirect labeling. The kit can also contain a control or reference sample or a series of control or reference samples which can be assayed and compared to the test sample. For example, the kit may have a positive control sample, e.g., including one or more markers or mutations described herein, or reference markers, e.g. housekeeping markers to standardize the assay among samples or timepoints or reference genomes, e.g., from subjects without tumor e.g., to establish diploid copy number baseline or reference expression level of a marker. By way of example, the kit may comprise fluids (e.g., buffer) suitable for annealing complementary nucleic acids or for binding an antibody with a protein with which it specifically binds and one or more sample compartments. The kit of the invention may optionally comprise additional components useful for performing the methods of the invention, e.g., a sample collection vessel, e.g., a tube, and optionally, means for optimizing the amount of marker detected, for example if there may be time or adverse storage and handling conditions between the time of sampling and the time of analysis. For example, the kit can contain means for increasing the number of tumor cells in the sample, as described above, a buffering agent, a preservative, a stabilizing agent or additional reagents for preparation of cellular material or probes for use in the methods provided; and detectable label, alone or conjugated to or incorporated within the provided probe(s). In one exemplary embodiment, a kit comprising a sample collection vessel can comprise e.g., a tube comprising anti-coagulant and/or stabilizer, e.g., an RNA stabilizer, as described above, or known to those skilled in the art. The kit can further comprise components necessary for detecting the detectable label (e.g., an enzyme or a substrate). For marker sets, the kit can comprise a marker set array or chip for use in detecting the biomarkers. Kits also can include instructions for interpreting the results obtained using the kit. The kit can contain reagents for detecting one or more biomarkers, e.g., 2, 3, 4, 5, or more biomarkers described herein.

[0130] In one embodiment, the kit comprises a probe to detect at least one biomarker, e.g., a marker indicative of treatment outcome (e.g., upon NAE inhibitor treatment). In an exemplary embodiment, the kit comprises a nucleic acid probe to detect a marker gene selected from the group consisting of SEQ ID NO: 1, 2, 4, 5, 7, 8, 9, 12, 13, 15, 16, 18, 19, 21, 22, 24, 25 or a sequence on chromosome 22q from base pair 29999545 to 30094589, chromosome 18q from base pair 48556583 to 48611412, chromosome Xp from base pair 44732423 to 44971847, chromosome 4q from base pair 153242410 to 153456172, chromosome 17p from base pair 7571720 to 7590868, chromosome 9p from base pair 21967751 to 21994490, or a complement of any of the foregoing or SEQ ID NO: 3, 6, 10, 11, 14, 17, 20, 23 and/or 26. In some embodiments, the kit comprises a probe to detect a marker selected from the group consisting of NF2, SMAD4, KDM6A, FBXW7, TP53, CDKN2A, CDKN2A_p14 and APC. In other embodiments, the kit comprises a probe to detect a mutation in a marker gene selected from the group consisting of NF2, SMAD4, KDM6A, FBXW7, TP53, CDKN2A, CDKN2A_p14 and APC. In an embodiment, a kit comprises probes to detect a marker set comprising two or more markers from the group consisting of NF2, SMAD4, KDM6A, FBXW7, TP53, CDKN2A, CDKN2A_p14 and APC. In another embodiment, a kit comprises a probe to detect FBXW7 in cancer of the uterus or cervix. In an embodiment, a kit comprises a probe to detect TP53 in cancer of the intestine, breast, lung, head and neck, cervix or skin. In an embodiment, a kit comprises a probe to detect TPC and APC in cancer of the intestine. In an embodiment, a kit comprises a probe to detect CDKN2A_p14 in cancer of the skin or central nervous system. In an embodiment, a kit comprises a probe to detect CDKN2A in cancer of the head and neck or skin. In an embodiment, a kit comprises a probe to detect SMAD4 in cancer of the head and neck. In related embodiments, the kit comprises a nucleic acid probe comprising or derived from (e.g., a fragment, mutant or variant (e.g., homologous or complementary) thereof) a nucleic acid sequence

selected from the group consisting of SEQ ID NOs: 1, 2, 4, 5, 7, 8, 9, 12, 13, 15, 16, 18, 19, 21, 22, 24, and 25. For kits comprising nucleic acid probes, e.g., oligonucleotide-based kits, the kit can comprise, for example: one or more nucleic acid reagents such as an oligonucleotide (labeled or non-labeled) which hybridizes to a nucleic acid sequence corresponding to a marker of the invention, optionally fixed to a substrate; and can optionally further comprise labeled oligonucleotides not bound with a substrate, a primer, a pair of PCR primers, e.g., useful for amplifying a nucleic acid molecule corresponding to a marker of the invention, molecular beacon probes, a marker set comprising oligonucleotides which hybridize to at least two nucleic acid sequences corresponding to markers of the invention, and the like. The kit can contain an RNA-stabilizing agent.

[0131] For kits comprising protein probes, e.g., ligand or antibody-based kits, the kit can comprise, for example: (1) a first antibody (e.g., attached to a solid support) which binds to a polypeptide corresponding to a marker of the invention; and, optionally, (2) a second, different antibody which binds to either the polypeptide or the first antibody and is conjugated to a detectable label. The kit can contain a protein stabilizing agent. The kit can contain reagents to reduce the amount of non-specific binding of non-biomarker material from the sample to the probe. Examples of reagents to reduce non-specific binding include nonionic detergents, non-specific protein containing solutions, such as those containing albumin or casein, or other substances known to those skilled in the art.

[0132] An isolated polypeptide corresponding to a predictive marker of the invention, or a fragment or mutant thereof, can be used as an immunogen to generate antibodies using standard techniques for polyclonal and monoclonal antibody preparation. For example, an immunogen typically is used to prepare antibodies by immunizing a suitable (*i.e.*, immunocompetent) subject such as a rabbit, goat, mouse, or other mammal or vertebrate. In still a further aspect, the invention provides monoclonal antibodies or antigen binding fragments thereof, which antibodies or fragments specifically bind to a polypeptide comprising an amino acid sequence selected from the group consisting of the amino acid sequences of the present invention, an amino acid sequence encoded by the cDNA of the present invention, a fragment of at least 8, 10, 12, 15, 20 or 25 consecutive amino acid residues of an amino acid sequence of the present invention, an amino acid sequence which is at least 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence of the present invention (wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4) and an amino acid sequence which is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule consisting of the nucleic acid molecules of the present invention, or a complement thereof, under conditions of hybridization of 6X SSC at 45°C and washing in 0.2 X SSC, 0.1% SDS at 65°C. The monoclonal antibodies can be human, humanized, chimeric and/or non-human antibodies. An appropriate immunogenic preparation can contain, for example, recombinantly-expressed or chemically-synthesized polypeptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or a similar immunostimulatory agent.

[0133] Methods for making human antibodies are known in the art. One method for making human antibodies employs the use of transgenic animals, such as a transgenic mouse. These transgenic animals contain a substantial portion of the human antibody producing genome inserted into their own genome and the animal's own endogenous antibody production is rendered deficient in the production of antibodies. Methods for making such transgenic animals are known in the art. Such transgenic animals can be made using XENOMOUSE™ technology or by using a "minilocus" approach. Methods for making XENOMICE™ are described in U.S. Pat. Nos. 6,162,963, 6,150,584, 6,114,598 and 6,075,181. Methods for making transgenic animals using the "minilocus" approach are described in U.S. Pat. Nos. 5,545,807, 5,545,806 and 5,625,825; also see International Publication No. WO93/12227.

[0134] Antibodies include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, *i.e.*, molecules that contain an antigen binding site which specifically binds an antigen, such as a polypeptide of the invention, e.g., an epitope of a polypeptide of the invention. A molecule which specifically binds to a given polypeptide of the invention is a molecule which binds the polypeptide, but does not substantially bind other molecules in a sample, e.g., a biological sample, which naturally contains the polypeptide. For example, antigen-binding fragments, as well as full-length monomeric, dimeric or trimeric polypeptides derived from the above-described antibodies are themselves useful. Useful antibody homologs of this type include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab')₂ fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., Nature 341:544-546 (1989)), which consists of a VH domain; (vii) a single domain functional heavy chain antibody, which consists of a VHH domain (known as a nanobody) see e.g., Cortez-Retamozo, et al., Cancer Res. 64: 2853-2857(2004), and references cited therein; and (vii) an isolated complementarity determining region (CDR), e.g., one or more isolated CDRs together with sufficient framework to provide an antigen binding fragment. Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al. Science 242:423-426 (1988); and Huston et al. Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988). Such single chain antibodies are also intended to be encompassed within the term

"antigen-binding fragment" of an antibody. These antibody fragments are obtained using conventional techniques known to those with skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies. Antibody fragments, such as Fv, F(ab')₂ and Fab may be prepared by cleavage of the intact protein, e.g. by protease or chemical cleavage. The invention provides polyclonal and monoclonal antibodies. Synthetic and genetically engineered variants (See U.S. Pat. No. 6,331,415) of any of the foregoing are also contemplated by the present invention. Polyclonal and monoclonal antibodies can be produced by a variety of techniques, including conventional murine monoclonal antibody methodology e.g., the standard somatic cell hybridization technique of Kohler and Milstein, Nature 256: 495 (1975) the human B cell hybridoma technique (see Kozbor et al., 1983, Immunol. Today 4:72), the EBV-hybridoma technique (see Cole et al., pp. 77-96 In Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., 1985) or trioma techniques. See generally, Harlow, E. and Lane, D. (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; and Current Protocols in Immunology, Coligan et al. ed., John Wiley & Sons, New York, 1994. For diagnostic applications, the antibodies can be monoclonal antibodies, e.g., generated in mouse, rat, or rabbit. Additionally, for use in *in vivo* applications the antibodies of the present invention can be human or humanized antibodies. Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind the polypeptide of interest, e.g., using a standard ELISA assay.

[0135] If desired, the antibody molecules can be harvested or isolated from the subject (e.g., from the blood or serum of the subject) and further purified by well-known techniques, such as protein A chromatography to obtain the IgG fraction. Alternatively, antibodies specific for a protein or polypeptide of the invention can be selected or (e.g., partially purified) or purified by, e.g., affinity chromatography to obtain substantially purified and purified antibody. By a substantially purified antibody composition is meant, in this context, that the antibody sample contains at most only 30% (by dry weight) of contaminating antibodies directed against epitopes other than those of the desired protein or polypeptide of the invention, and at most 20%, at most 10%, or at most 5% (by dry weight) of the sample is contaminating antibodies. A purified antibody composition means that at least 99% of the antibodies in the composition are directed against the desired protein or polypeptide of the invention.

[0136] An antibody directed against a polypeptide corresponding to a marker of the invention (e.g., a monoclonal antibody) can be used to detect the marker (e.g., in a cellular sample) in order to evaluate the level and pattern of expression of the marker. The antibodies can also be used diagnostically to monitor protein levels in tissues or body fluids (e.g. in a blood sample or urine) as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ¹²⁵I, ¹³¹I, ³⁵S or ³H.

[0137] Accordingly, in one aspect, the invention provides substantially purified antibodies or fragments thereof, and non-human antibodies or fragments thereof, which antibodies or fragments specifically bind to a polypeptide comprising an amino acid sequence encoded by a marker identified herein. The substantially purified antibodies of the invention, or fragments thereof, can be human, non-human, chimeric and/or humanized antibodies.

[0138] In another aspect, the invention provides non-human antibodies or fragments thereof, which antibodies or fragments specifically bind to a polypeptide comprising an amino acid sequence which is encoded by a nucleic acid molecule of a predictive marker of the invention. Such non-human antibodies can be goat, mouse, sheep, horse, chicken, rabbit, or rat antibodies. Alternatively, the non-human antibodies of the invention can be chimeric and/or humanized antibodies. In addition, the non-human antibodies of the invention can be polyclonal antibodies or monoclonal antibodies.

[0139] The substantially purified antibodies or fragments thereof may specifically bind to a signal peptide, a secreted sequence, an extracellular domain, a transmembrane or a cytoplasmic domain or cytoplasmic loop of a polypeptide of the invention. The substantially purified antibodies or fragments thereof, the non-human antibodies or fragments thereof, and/or the monoclonal antibodies or fragments thereof, of the invention specifically bind to a secreted sequence or an extracellular domain of the amino acid sequences of the present invention.

[0140] The invention also provides a kit containing an antibody of the invention conjugated to a detectable substance, and instructions for use. Still another aspect of the invention is a diagnostic composition comprising a probe of the invention and a pharmaceutically acceptable carrier. In one embodiment, the diagnostic composition contains an antibody of the invention, a detectable moiety, and a pharmaceutically acceptable carrier.

Sensitivity Assays

[0141] A sample of cancerous cells is obtained from a patient. An expression level is measured in the sample for a

marker corresponding to at least one of the markers described herein. A marker set can be utilized comprising markers identified described herein, and put together in a marker set using the methods described herein. Such analysis is used to obtain an expression profile of the tumor in the patient. Evaluation of the expression profile is then used to determine whether the patient is expected to have a favorable outcome and would benefit from treatment, e.g., NAE inhibition therapy (e.g., treatment with a NAE inhibitor (e.g., MLN4924) alone, or in combination with additional agents)), or an alternative agent expected to have a similar effect on survival. Evaluation of the expression profile can also be used to determine whether a patient is expected to have an unfavorable outcome and would benefit from a cancer therapy other than NAE inhibition therapy or would benefit from an altered NAE inhibition therapy regimen. Evaluation can include use of one marker set prepared using any of the methods provided or other similar scoring methods known in the art (e.g., weighted voting, combination of threshold features (CTF), Cox proportional hazards analysis, principal components scoring, linear predictive score, K-nearest neighbor, etc), e.g., using expression values deposited with the Gene Expression Omnibus (GEO) program at the National Center for Biotechnology Information (NCBI, Bethesda, MD). Still further, evaluation can comprise use of more than one prepared marker set. A NAE inhibition therapy will be identified as appropriate to treat the cancer when the outcome of the evaluation demonstrates a favorable outcome or a more aggressive therapy regimen will be identified for a patient with an expected unfavorable outcome.

[0142] In one aspect, the invention features a method of evaluating a patient, e.g., a patient with cancer, e.g. a hematological cancer (e.g., multiple myeloma, leukemias, lymphoma, etc) or solid tumor cancer (e.g., melanoma, esophageal cancer or bladder cancer) for treatment outcome. The method includes providing an evaluation of the expression of the markers in a marker set of markers in the patient, wherein the marker set has the following properties: it includes a plurality of genes, each of which is differentially expressed as between patients with identified outcome and non-afflicted subjects and it contains a sufficient number of differentially expressed markers such that differential amount (e.g., as compared to a level in a non-afflicted reference sample) of each of the markers in the marker set in a subject is predictive of treatment outcome with no more than about 15%, about 10%, about 5%, about 2.5%, or about 1% false positives (wherein false positive means predicting that a patient as responsive or non-responsive when the subject is not); and providing a comparison of the amount of each of the markers in the set from the patient with a reference value, thereby evaluating the patient.

[0143] Examining the amount of one or more of the identified markers or marker sets in a tumor sample taken from a patient during the course of NAE inhibition therapy, it is also possible to determine whether the therapeutic agent is continuing to work or whether the cancer has become non-responsive (refractory) to the treatment protocol. For example, a patient receiving a treatment of MLN4924 would have tumor cells removed and monitored for the expression of a marker or marker set. If the profile of the amount of one or more markers identified herein more typifies favorable outcome in the presence of the agent, e.g., the NAE inhibitor, the treatment would continue. However, if the profile of the amount of one or more markers identified herein more typifies unfavorable outcome in the presence of the agent, then the cancer may have become resistant to therapy, e.g., NAE inhibition therapy, and another treatment protocol should be initiated to treat the patient. For example, the cancer may comprise a mutation in a marker gene associated with resistance to NAE inhibition.

[0144] Importantly, these determinations can be made on a patient-by-patient basis or on an agent-by-agent (or combinations of agents). Thus, one can determine whether or not a particular NAE inhibition therapy is likely to benefit a particular patient or group/class of patients, or whether a particular treatment should be continued.

Use of Information

[0145] In one method of the disclosure, information, e.g., about the mutational status of a patient's tumor, e.g., the patient's marker(s) characteristic, e.g., size, sequence, composition or amount (e.g., the result of evaluating a marker or marker set described herein), or about whether a patient is expected to have a favorable outcome, is provided (e.g., communicated, e.g., electronically communicated) to a third party, e.g., a hospital, clinic, a government entity, reimbursing party or insurance company (e.g., a life insurance company). For example, choice of medical procedure, whether to pay for a medical procedure, payment by a reimbursing party, or cost for a service or insurance can be function of the information. E.g., the third party receives the information, makes a determination based at least in part on the information, and optionally communicates the information or makes a choice of procedure, payment, level of payment, coverage, etc. based on the information. In the method, informative expression level of a marker or a marker set selected from or derived from Table 1 and/or described herein is determined.

[0146] In one description of the disclosure, a premium for insurance (e.g., life or medical) is evaluated as a function of information about one or more marker expression levels, e.g., a marker or marker set, e.g., a level of expression associated with treatment outcome (e.g., the informative amount). For example, premiums can be increased (e.g., by a certain percentage) if the marker genes of a patient or a patient's marker set described herein have different characteristic, e.g., size, sequence, composition or amount between an insured candidate (or a candidate seeking insurance coverage) and a reference value (e.g., a non-afflicted person) or a reference sample, e.g., matched control. Premiums

can also be scaled depending on the result of evaluating a marker or marker set described herein. For example, premiums can be assessed to distribute risk, e.g., as a function of marker, e.g., the result of evaluating a marker or marker set described herein. In another example, premiums are assessed as a function of actuarial data that is obtained from patients that have known treatment outcomes.

[0147] Information about marker characteristic, e.g., size, sequence, composition or amount, e.g., the result of evaluating a marker or marker set described herein (e.g., the informative amount), can be used, e.g., in an underwriting process for life insurance. The information can be incorporated into a profile about a subject. Other information in the profile can include, for example, date of birth, gender, marital status, banking information, credit information, children, and so forth. An insurance policy can be recommended as a function of the information on marker characteristic, e.g., size, sequence, composition or amount, e.g., the result of evaluating a marker or marker set described herein, along with one or more other items of information in the profile. An insurance premium or risk assessment can also be evaluated as function of the marker or marker set information. In one implementation, points are assigned on the basis of expected treatment outcome.

[0148] In one description of the disclosure, information about marker characteristic, e.g., size, sequence, composition or amount, e.g., the result of evaluating a marker or marker set described herein, is analyzed by a function that determines whether to authorize the transfer of funds to pay for a service or treatment provided to a subject (or make another decision referred to herein). For example, the results of analyzing a characteristic, e.g., size, sequence, composition or amount of a marker or marker set described herein may indicate that a subject is expected to have a favorable outcome, suggesting that a treatment course is needed, thereby triggering an result that indicates or causes authorization to pay for a service or treatment provided to a subject. In one example, informative characteristic, e.g., size, sequence, composition or amount of a marker or a marker set selected from or derived from Table 1 and/or described herein is determined and payment is authorized if the informative amount identifies a favorable outcome. For example, an entity, e.g., a hospital, care giver, government entity, or an insurance company or other entity which pays for, or reimburses medical expenses, can use the result of a method described herein to determine whether a party, e.g., a party other than the subject patient, will pay for services (e.g., a particular therapy) or treatment provided to the patient. For example, a first entity, e.g., an insurance company, can use the outcome of a method described herein to determine whether to provide financial payment to, or on behalf of, a patient, e.g., whether to reimburse a third party, e.g., a vendor of goods or services, a hospital, physician, or other care-giver, for a service or treatment provided to a patient. For example, a first entity, e.g., an insurance company, can use the outcome of a method described herein to determine whether to continue, discontinue, enroll an individual in an insurance plan or program, e.g., a health insurance or life insurance plan or program.

[0149] In one description, the disclosure features a method of providing data. The method includes providing data described herein, e.g., generated by a method described herein, to provide a record, e.g., a record described herein, for determining if a payment will be provided. In some descriptions, the data is provided by computer, compact disc, telephone, facsimile, email, or letter. In some descriptions, the data is provided by a first party to a second party. In some descriptions, the first party is selected from the subject, a healthcare provider, a treating physician, a health maintenance organization (HMO), a hospital, a governmental entity, or an entity which sells or supplies the drug. In some descriptions, the second party is a third party payor, an insurance company, employer, employer sponsored health plan, HMO, or governmental entity. In some descriptions, the first party is selected from the subject, a healthcare provider, a treating physician, an HMO, a hospital, an insurance company, or an entity which sells or supplies the drug and the second party is a governmental entity. In some descriptions, the first party is selected from the subject, a healthcare provider, a treating physician, an HMO, a hospital, an insurance company, or an entity which sells or supplies the drug and the second party is an insurance company.

[0150] In another description, the disclosure features a record (e.g., computer readable record) which includes a list and value of characteristic, e.g., size, sequence, composition or amount for the marker or marker set for a patient. In some descriptions, the record includes more than one value for each marker.

[0151] The present invention will now be illustrated by the following Examples, which are not intended to be limiting in any way.

EXAMPLES

Example 1. Cell line panel screens

[0152] To support clinical development and identify potential biomarkers of tumor sensitivity or resistance, two large cancer cell line panels (Panel 1, N=653 (McDermott et al. (2007) PNAS 104:19936-19941); Panel 2, N=240 (O'Day et al. (2010) Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development)) were treated with MLN4924 and cell viability data (IC50, EC50, and POC - Percentage of Control) were generated.

Panel 1 (McDermott et al., *supra*). The cell lines were exposed to three MLN4924 concentrations (20 nM, 200 nM,

EP 2 775 844 B1

and 2 μ M) for 72 hours. Viability, i.e., cell number, was quantified by measuring fluorescence of a cell-permeant nucleic acid stain. Mean of triplicate values for each sample were taken and compared to DMSO control to calculate percentage of control. In the results, control or no activity value is given a value of about 1, sensitivity is indicated by a value less than 1, with 0 as death of the entire cell population and resistance indicated by a value greater than 1. A continuum of viability values was obtained for each concentration, so some values were selected as cut-offs for final determination of sensitivity or resistance. For example, median POC values of less than the median value of all POC's recorded in the panel (<0.34) indicated sensitivity, values of 0.34 to 0.75 indicated borderline sensitivity, values greater than the 3rd quartile of all POC's in the panel (>0.75) insensitivity or resistance. In general, a dose response relationship was observed with sensitive cell lines. Final judgment of cell line as sensitive, insensitive or resistant was determined by its viability at 2 μ M.

Panel 2 (Ricerca Biosciences, Inc., Bothell, WA). MLN4924 was added in half-log dilutions for 10 concentrations and treated for 72 hours. High-content cell screening by fluorescence microscopy included image analysis to generate several types of data. Results included EC50 values (after measurement of cell numbers, the EC50 concentration was calculated from the inflection point of a curve of percent of control (POC) against log of MLN4924 concentration), IC50 values (from the POC-log MLN4924 plot, IC50 is the concentration at 50% maximal possible response), apoptosis (measurement of activation of caspase 3 plotted against log of MLN4924 concentration, determined as the concentration for >5 fold induction), and mitotic activity (determined by measuring the fold increase of phospho-histone 3). A comparison of EC50 to IC50 (Figure 3) allowed assignment of cell lines to sensitive, insensitive or resistant. Final identification of a cell line as sensitive or resistant was based on the EC50 values. The cutoff for sensitivity is a median EC50 of less than the median value of all POC's recorded in the panel (<0.36), borderline sensitivity was associated with median EC50 of 0.36 to 1.67 and insensitive or resistant cell lines were identified by EC50 greater than the 3rd quartile of all POC's in the panel (>1.67).

[0153] Overlapping cell lines between the panels 1 and 2 (114 overlaps) showed consistent growth inhibition effects (Spearman Correlation coefficient = 0.72). In addition, histology and mutation analysis on each cell line panel as a whole (not just overlapping cell lines), also generated consistent observations between the two panels (Figures 4A and B).

[0154] Fisher's Exact Test using median percentage of control values was used to evaluate associations of individual mutations in the cell lines to MLN4924 sensitivity or resistance. See Table 3 for a summary of p values for selected genes. Genes whose mutations were linked to sensitivity in the Fisher Exact test include NF2, SMAD4, KDM6A, CDKN2A and CDKN2A_p14. RB1 and TP53 were linked to insensitivity.

Table 3. Confidence of mutated marker association with response to MLN4924

Mutated Gene	Total N panel 1	Number sensitive panel 1	Panel 1 p-value	Total N panel 2	Number sensitive panel 2	Panel 2 p-value	Phenotype
NF2	10	8	0.067	5	4	0.187	Sensitive
SMAD4	24	15	0.197	11	6	0.509	Sensitive
KDM6A	6	6	0.019	4	4	0.062	Sensitive
RB1	32	12	0.062	14	17	1.00	Resistant*
TP53	235	112	0.013	98	45	0.107	Resistant
CDKN2A	153	94	0.001	68	38	0.146	Sensitive
CDKN2A_p14	114	70	0.01	59	33	0.178	Sensitive

* denotes phenotype for RB1 association not conclusive across all cell types. Some tumor types were more associated with resistance than others: tumors from brain, bladder, bone and lung (NSCLC) have p-values of 0.102, 0.205, 0.226, and 0.281, respectively. The result that RB1 is not a sensitivity marker agrees with the result of Jia et al. ((2011) Neoplasia 13:561-569) which excluded the involvement of RB1 in MLN4924 mechanism.

Example 2. Analysis of Mutation Associations

[0155] One difficulty with correlating mutations of genes in cell lines with sensitivity to a therapeutic agent is that many cell lines have more than one mutated gene. For example, cell line named 8505C from thyroid carcinoma has mutations in BRAF, TP53, NF2 and CDKN2A. In particular, TP53 and CDKN2A mutations co-occurred with other mutations in the cell lines. To learn which mutant is associated with sensitivity or resistance in the cell line panels, sub-analyses were

performed.

[0156] APC vs TP53. In cell line panel 1, 23 cell lines have a mutation in APC. Of these, 18 cell lines also have a mutation in TP53. It was difficult to determine whether APC is a driver of resistance to MLN4924, or just a passenger mutation found frequently in TP53 mutants. Further analysis of the cell lines was undertaken by subtraction of cell lines with double mutants which included TP53 (Table 4).

Table 4. Comparison of TP53 mutant cell lines with APC and other mutant cell lines in panel 1

A.		Subtract TP53 mutants		
Gene	sens(78)	res(51)	p-value	
RB1	0	2	0.154433	
NRAS	7	7	0.285024	
APC	2	3	0.30657	
SMAD4	2	3	0.30657	
BRCA2	0	1	0.395349	
FAM123B	0	1	0.395349	
MAP2K4	0	1	0.395349	
B.		Subtract APC mutants		
Gene	sens(184)	res(158)	p-value	
TP53	108	110	0.0234828	
RB1	12	19	0.0573067	
MAP2K4	2	5	0.1665217	
C.		Double Mutants		
Gene	sens(190)	res(175)	p-value	
APC+TP53	4	14	0.00842	

[0157] As can be seen in Table 4A, subtracting TP53 mutants from the cell line panel leaves an N too small to allow conclusion of association of remaining mutations with resistance of the TP53 wt cell lines to treatment with MLN4924. After removing all 23 APC mutants, TP53 still appears to be associated with resistance (Table 4B). Nevertheless, cell lines with both APC and TP53 mutations show strong association to resistance (Table 4C). Additionally, a majority of the cell lines in the APC+TP53 mutant subgroup are from intestinal cancer tumor samples (Table 5, which also includes cell lines and data from panel 2 and six panel 1 cell lines which were not included in the original subtractive analysis).

Table 5. Subset of cell lines with mutations in APC and TP53

Cell line	Tumor Tissue Source	Tumor Histology	Viability at 2 μ M Panel 1	EC50 Panel 2	Co-occurring mutations
HT55	intestine	colon carcinoma	0.5143		APC:APC:TP53
SW 1116	intestine	colon adenocarcinoma	1.1599	10	APC:APC:KRAS:SMAD4:TP53
COCM1	intestine	colon carcinoma	1.1438		APC:APC:PIK3CA:SMAD4:TP53
LS1034	intestine	adenocarcinoma		3.76	APC:KRAS:TP53
SW 1463	intestine	rectum adenocarcinoma	0.8963		TP53:FBXW7:KRAS:APC

EP 2 775 844 B1

(continued)

Cell line	Tumor Tissue Source	Tumor Histology	Viability at 2 μ M Panel 1	EC50 Panel 2	Co-occurring mutations
NCI-H630	intestine	colorectal adenocarcinoma	0.75		APC:TP53
SW1417	intestine	colon adenocarcinoma	0.6374	9.03	APC:TP53:BRAF:PIK3R1
SW837	intestine	rectum adenocarcinoma	0.702	0.694	APC: APC: FAM123B:TP53: FBXW7:KRAS
SW620	intestine	colon adenocarcinoma	0.4928	0.387	APC:TP53:TP53:KRAS: MAP2K4:SM AD4
NCI-H1581	lung NSCLC	squamous cell carcinoma	0.7365		APC:TP53
HCT-15	intestine	colon adenocarcinoma	0.6654	0.836	APC:BRCA2:FAM123B: KRAS:MSH6: PIK3CA: TP53
C2BBe1	intestine	colorectal adenocarcinoma	0.7159		APC:TP53
T84	intestine	colon carcinoma	0.5777	0.556	KRAS:PIK3CA:TP53:APC
SW626	ovary	adenocarcinoma	0.5541		TP53:KRAS:APC
HT29	intestine	colorectal adenocarcinoma	0.4376	0.25	APC: PIK3CA:TP53: BRAF: SMAD4:AP C
LK-2	lung	lung NSCLC	0.2893		TP53:APC:CDKN2A
MKN28	stomach	metastasis	0.2847		APC:TP53:NF1
COLO-205	intestine	colon adenocarcinoma	0.144	0.0923	TP53:BRAF:APC:SMAD4
HGC-27	stomach	gastric carcinoma	0.1291		TP53:APC:PTEN:PIK3CA
NCIH747	intestine	cecum adenocarcinoma		2.07	APC:APC:KRAS:TP53
SKUT1	smooth muscle	leiomyosarcoma		0.0856	APC:APC:PIK3CA:PTEN: PTEN:RB1:T P53:TP53
SK-MEL-30	skin	malignant melanoma	0.7728		APC:NRAS:TP53
COLO320 HSR	intestine	colon adenocarcinoma		1.78	APC:TP53
NCI-H520	lung NSCLC	squamous cell carcinoma	0.5577	0.261	CDKN2A:APC:TP53
NCI-H1703	lung NSCLC	adenosquamous carcinoma	0.1101		TP53:APC:CDKN2A
NCI-H1975	lung	adenocarcinoma	0.3049		TP53:APC:CDKN2A:PIK3CA: EGFR
RCM-1	intestine	rectum adenocarcinoma	0.7666		TP53:KRAS:APC
SK-OV-3	ovary	adenocarcinoma	0.397	10	TP53:PIK3CA:CDKN2A:APC

[0158] Association with histology. It is possible that some TP53 mutations associate with resistance in some types of tumor more than others. TP53 mutant cell lines were analyzed within tissue types by a Mann-Whitney (nonparametric)

test. As can be seen in Figure 5, TP53 mutations are significantly correlated with resistance to MLN4924 in colon cancer cell lines (p-value = 0.04022).

[0159] Similar analysis of associations in other tissues indicates that TP53 mutation is associated with MLN4924 resistance in breast cancer and lung cancer (NSCLC) cell lines.

[0160] Additional mutations were analyzed for possible association of tumor histology with resistance or sensitivity to MLN4924 treatment. Table 6 provides results from analysis of panel 1 and Table 7 provides results from analysis of panel 2, whose smaller size proved a challenge for this type of analysis. The cutoff of association with the tissues was chosen at p-values of < 0.05.

Table 6. Association of mutation with histology in Panel 1

Tumor Tissue Source	Mutation	N mutants this cancer	N wild type this cancer	N mutants all cancers	N wild type all cancers	Association	p-value
Head_Neck	TP53	15	1	111	79	sensitive	0.0001
Head_Neck	CDKN2A	12	4	94	96	sensitive	0.0072
Head_Neck	SMAD4	3	13	15	175	sensitive	0.0262
Cervix	TP53	1	6	124	51	resistant	0.0027
Lung	RB1	2	4	19	156	resistant	0.0178
Bone	RB1	1	5	12	178	sensitive	0.0477

Table 7. Association of mutation with histology in Panel 2

Tumor Tissue Source	Mutation	N mutants this cancer	N wild type this cancer	N mutants all cancers	N wild type all cancers	Association	p-value
skin	CDKN2A	8	1	30	43	resistant	0.0022
skin	CDKN2A.p14	6	3	26	47	resistant	0.0004
skin	TP53	2	7	53	20	resistant	0.0036
CNS	CDKN2A.p14	5	4	26	47	resistant	0.0466*

* p-value for CNS derived from percent of control viability. For skin, p-value derived from EC50.

[0161] In contrast to the general association of TP53 with resistance to MLN4924, in head and neck cancer, TP53 mutation is associated with sensitivity. A similar contrast was found for CDKN2A mutations in skin and central nervous system (CNS). CDKN2A or CDKN2A.p14 mutations were associated with resistance to MLN4924 treatment in skin and CNS tumor cell lines, despite the general association with CDKN2A mutation and sensitivity to MLN4924 treatment. Tables 6 and 7 also show that TP53 mutations are significantly associated with resistance in cervical cancer and skin cancer; CDKN2A mutations are significantly associated with sensitivity in head and neck cancer; SMAD4 mutations are significantly associated with sensitivity in head and neck cancer; RB1 mutations are significantly associated with resistance in lung cancer; and RB1 mutations are significantly associated with sensitivity in bone cancer.

Example 3. Individual cell line screening results

[0162] The following tables include results of the individual cell line screens which led to conclusions about markers whose mutations confer sensitivity to MLN4924.

Notation of the mutations and explanation of mutation syntax can be found in the COSMIC database.

Table 8. Results of screens of cell lines with mutations in NF2.

Cell line	ORF mutation (SEQ ID NO:2)	Protein mutation (SEQ ID NO:3)	Tumor Tissue Source	Tumor type	Viability at 2 μ M Panel 1	EC50 Panel 2	Phenotype	Co-occurring mutations
647-V	c.115-1G>C	p.?	urinary_tract	primary	0.038	0.283	sensitive	MAP2K4:NF2:RB1:TP53:TP53
ACHN	c.169C>T	p.R57*	kidney	primary	0.0621	0.652	sensitive	CDKN2A:CDKN2a(p14):NF2
CAL-62	c.643G>T	p.E215*	thyroid	primary	0.0676	0.0837	sensitive	CDKN2A:CDKN2a(p14):KRAS:NF2:TP53
NUGC-3	c.683delA	p.K228fs*23	stomach	primary	0.098		sensitive	NF2:TP53
SW1573	c.1_363del363	p.?	lung	primary	0.1114		sensitive	CDKN2A:CDKN2a(p14):CTNNB1:KRAS:N F2:PIK 3CA:SMAD4
8505C	c.385G>T	p.E129*	thyroid	primary	0.1405		sensitive	BRAF:CDKN2A:NF2:TP53
CaR-1	c.115_1737del1623	p.?	large_intestine	primary	0.3244		sensitive	CDKN2A:CDKN2a(p14):NF2:STK11:TP53
SN12C	c.115-1G>C	p.?	kidney	primary	0.3357		sensitive	NF2:TP53
MDA-MB-231	c.691G>T	p.E231*	breast	primary	0.5284	0.871	insensitive	BRAF:CDKN2A:CDKN2a(p14):KRAS:NF2:TP53
S-117	c.221G>A	p.W74*	soft_tissue	primary	0.6412		resistant	CDKN2A:CDKN2a(p14):NF2:TP53
RL95-2	c.514delA c.1084C>T	p.R172fs*2 p.Q362*	endometrium	primary		0.094	sensitive	BRCA2:BRCA2:HRAS:NF2:NF2:PTEN:PTEN:TP5 3:TP53

Table 9. Results of screens of cell lines with mutations in SMAD4.

Cell line	ORF mutation (SEQ ID NO:5)	Protein mutation (SEQ ID NO:6)	Tumor Tissue Source	Tumor type	Viability at 2 μ M Panel 1	EC50 Panel 2	Phenotype	Co-occurring mutations
CAL-27	c.733C>T	p.Q245*	upper_aerodigestive_tract	primary	0.0271	0.139	sensitive	CDKN2A:SMAD4:TP53
KP-4	c.1_1659del1659	p.0?	pancreas	metastasis	0.0518		sensitive	CDKN2A:CDKN2a(p14):KRAS:SMAD4
GAMG	c.1_249del1249	p.?	central_nervous_system	primary	0.0721		sensitive	CDKN2A:CDKN2a(p14):SMAD4:TP53
PANC-03-27	c.905_1659del1755	p.?	pancreas	primary	0.0724		sensitive	CDKN2A:CDKN2a(p14):KRAS:SMAD4:TP53
FADU	c.1_1659del1659	p.0?	upper_aerodigestive_tract	primary	0.073	0.261	sensitive	CDKN2A:SMAD4:TP53:TP53
SW1573	c.1_1659del1659	p.0?	lung	primary	0.1114		sensitive	CDKN2A:CDKN2a(p14):CTNNB1:KRAS:NF2:PIK3CA:SMAD4
KYSE-150	c.788-1G>A	p.?	oesophagus	primary	0.1279		sensitive	SMAD4:TP53
COLO-205	c.1_667del1667	p.?	large_intestine	primary	0.144	0.0923	sensitive	APC:BRAF:SMAD4:TP53
CAL-33	c.766C>T	p.Q256*	upper_aerodigestive_tract	primary	0.1445		sensitive	CDKN2A:PIK3CA:SMAD4:TP53
NCI-N87	c.1_955del1955	p.?	stomach	metastasis	0.1461		sensitive	SMAD4:TP53
CAPAN-1	c.1028C>G	p.S343*	pancreas	metastasis	0.1473	0.365	sensitive?	BRCA2:CDKN2A:CDKN2a(p14):KRAS:SMAD4:TP53
YAPC	c.1543de1A	p.R515fs*22	pancreas	primary	0.1871	0.234	sensitive	CDKN2A:CDKN2a(p14):KRAS:SMAD4:TP53
NCI-H2405	c.1_1659del1659	p.0?	lung	metastasis	0.2554		sensitive	BRAF:CDKN2A:CDKN2a(p14):MAP2K4:SMAD4:TP53

(continued)

Cell line	ORF mutation (SEQ ID NO:5)	Protein mutation (SEQ ID NO:6)	Tumor Tissue Source	Tumor type	Viability at 2 μ M Panel 1	EC50 Panel 2	Phenotype	Co-occurring mutations
CFPAC-1	c.1_1659del1659	p.0?	pancreas	metastasis	0.2822	6.37	sensitive?	KRAS:SMAD4:TP53
MDA-MB-468	c.1_1659del1659	p.0?	breast	metastasis	0.2965	0.0267	sensitive	PTEN:RB1:SMAD4:TP53
MKN45	c.1_1659del1659	p.0?	stomach	metastasis	0.3614		insensitive	CDKN2A:CDKN2a(p14):SMAD4
BxPC-3	c.1_1659del1659	p.0?	pancreas	primary	0.4186	0.251	insensitive	CDKN2A:CDKN2a(p14):MAP2K4:SMAD4:TP53
HT-29	c.931C>T	p.Q311*	large_intestine	primary	0.4376	0.25	insensitive	APC:APC:BRAF:PIK3CA:SMAD4:TP53
UMC-11	c.1606_1612deICTAGACG	p.L536fs*14	lung	primary	0.4472		insensitive	CDKN2A:CDKN2a(p14):SMAD4:STK11:TP53
SW620	c.955+5G>C	p.?	large_intestine	primary	0.4928	0.387	insensitive	APC:KRAS:MAP2K4:SMAD4:TP53:TP53
PANC-08-13	c.366_367insA	p.C123fs*2	pancreas	primary	0.7767		resistant	CDKN2A:CDKN2a(p14):KRAS:SMAD4
COLO-678	c.1_1659del1659	p.0?	large_intestine	metastasis	0.814		resistant	APC:CDKN2A:CDKN2a(p14):FAM123B:KRAS:SMAD4
CoCM-1	c.956_1659del704	p.?	large_intestine	primary	1.1438		resistant	APC:APC:PIK3CA:SMAD4:TP53
SW954	c.378_379delC T	p.V128fs*14	vulva	primary		0.324	sensitive	SMAD4:TP53

Table 10. Results of screens of cell lines with mutations in KDM6A.

Cell line	ORF mutation (SEQ ID NO:8 or 9)	Protein mutation (SEQ NO:10 or 11)	Tumor Tissue Source	Tumor type	Viability at 2 μ M Panel 1	EC50 Panel 2	Phenotype	Co-occurring mutations
HCC180	c.444_564del121	p.0	breast	primary	0.0116		sensitive	CDKN2A:CDKN2a(p14); KDM6A:STK11:TP53
KU-19-19	c.2587C>T	p.Q863*	urinary_tract	primary	0.058		sensitive	CDKN2A:CDKN2a(p14); KDM6A:NRAS
MIA-PaCa-2	c.1_4206del42.06	p.0?	pancreas	primary	0.1145	0.239	sensitive	CDKN2A:CDKN2a(p14); KDM6A:KRAS:TP53
KYSE-450	c.385_654del270	p.0	oesophagus	primary	0.1426		sensitive	CDKN2A:CDKN2a(p14); EGFR:KDM6A:NOTCH1:TP53:TP53
KYSE-180	c.997C>T	p.Q333*	oesophagus	primary	0.2154		sensitive	CDKN2A:CDKN2a(p14); KDM6A:TP53
LS-174T	c.3945_3946ins A	p.E1316fs*17	large_intestine	primary	0.3262	0.137	sensitive	CTNNB1:KDM6A:KRAS:PIK3CA
BV-173	c.226_384del159	p.0	haematopoietic, lymphoid_tissue	primary		0.131	sensitive	CDKN2A:CDKN2a(p14); KDM6A
THP-1	c.1_1923del1923	p.0	haematopoietic, lymphoid_tissue	primary		0.148	sensitive	CDKN2A:CDKN2a(p14); KDM6A:NRAS:TP53

Table 11. Sampling of results of screens of cell lines with mutations in FBXW7.

Cell line	ORF mutation (SEQ ID NO:13)	Protein mutation (SEQ ID NO:14)	Tumor Tissue Source	Tumor type	Viability at 2 μ M Panel 1	EC50 Panel 2	Phenotype	Co-occurring mutations
AN3CA	c.1321C>T	p.R441W	Uterus	metastasis	0.1944		sensitive	PTEN: TP53: PIK3R1
ESS-1	c.1393C>T	p.R465C	Uterus	primary	0.0529		sensitive	FBXW7 : TP53 : PIK3CA : RB1
C-33a	c.1394G>A	p.R465H	Cervix	primary	0.0822		sensitive	RB1 : TP53: MSH2: PIK3CA : PTEN
HuCCT1	c.881C>G	p.S294*	Liver	primary	0.1262		sensitive	TP53: KRAS
MKN1	c.1393C>T	p.R465C	Stomach	metastasis	0.4631		insensitive	TP53: PIK3CA
AsPC-1	c.1393C>T	p.R465C	Pancreas	metastasis	0.9889		resistant	CDKN2A: MAP2K4: KRAS: TP53
RCM-1	c.1513C>T	p.R505C	Intestine	primary	0.7666		resistant	TP53: KRAS
SW1463	c.1436G>A	p.R479Q	Intestine	primary	0.8963		resistant	TP53 : KRAS : APC

Example 4. Association of TP53 deletion with Resistance

[0163] Another approach to determine the role of TP53 in responsiveness to MLN4924 was a study in which the TP53 gene was deleted. In earlier studies, the importance of p53 in the rereplication response to MLN4924 seemed to be dependent on the specific genetic manipulation and was expected to closely mirror that of CDT1 overexpression (Cdt1 is a substrate of two alternative CRL complexes and is stabilized by MLN4924 in many cell lines). In knockdown studies, p53 appeared to behave similarly to CDT1 knockdown at early timepoints, but not later timepoints, unless higher concentrations of MLN4924 were used. Western blotting suggested efficient p53 protein knockdown by the siRNA SMART-pool, although RNAi generally does not result in the complete loss of protein. Therefore, the residual protein may still affect the response to MLN4924, particularly since MLN4924 results in the stabilization of p53 (Liao et al. (2011) Mol. Cell Proteomics 10: 10. 1074/mcp.MI 11.009183). The viability effect of MLN4924 was assessed on HCT-116 cells that were genetically deleted for p53 together with their parental control.

[0164] Paired isogenic HCT-116 cell lines that were either wild-type (+/+) or null (-/-) for p53 expression (HD PAR-018 and HD 104-001, respectively, Horizon Discovery Ltd) were seeded in separate 384-well plates and then treated the following day with a titration of MLN4924 in triplicate, and incubated for 24, 36, 48 or 72 h, with seeding densities of 1600, 1200, 800, and 400 cells/well, respectively. Following compound incubation, viability of HCT-116 cells was assessed by ATPlite assay (Perkin Elmer) according to the manufacturer's instructions using the LEADseeker imaging system (GE Healthcare).

[0165] HCT-116 TP53 +/+ cells (MLN4924 LC₅₀ = 21 \pm 1 nM) demonstrated greater MLN4924 sensitivity at 72 h than HCT-116 TP53 -/- cells (MLN4924 LC₅₀ = 74 \pm 5 nM; Figures 6A-D). These results suggest that p53 deficiency makes HCT-116 less sensitive to MLN4924, suggesting that the overarching role of p53 at 72 h is proapoptotic. Earlier time

points reinforce this interpretation, as *TP53* $-/-$ cells have less cell death at the highest drug concentrations at 24, 36, and 48 h. Western blots showed that p21 was still up-regulated by MLN4924 in *TP53* $-/-$ HCT-116 cells. In HCT-116 cells, the stabilization of p21 may be a direct effect of inhibition of CRL4-Cdt2 (Nishitani et al., 2008; Abbas et al., 2008; Kim et al., 2008).

[0166] This result is contrary to the conclusion in Lin et al. (2010) *Cancer Res.* 70:10310-10320) using the HCT116-/- p53 knockout cells. In that study, it was concluded that the TP53 knockout cells were more susceptible to overall cell death or growth inhibition by MLN4924. The reason the present study comes to a different conclusion than in Lin et al. is the amount of time the cells were treated with MLN4924. In Lin et al, the cells were treated for 8 hours before a washout. In the present studies and in the cell line panels of the earlier examples, the cells were treated with MLN4924 continuously over 72 hours. In the washout, the p53 levels are allowed to stabilize and take advantage of activating alternative pathways than the earlier pathways which were initially inhibited and led to the earlier susceptibility.

Example 5. Isolation of nucleic acid and nucleic acid sequencing methods

[0167] Genomic isolations and DNA sequencing. DNA isolation from cells and tumors is conducted using DNAEASY® isolation kit (Qiagen, Valencia, CA). RNA isolation is conducted using MegaMax (Ambion division of Applied Biosystems, Austin, TX). Genomic isolations are conducted following manufacturer recommend protocols.

[0168] SANGER Sequencing methodology. PCR amplifications are conducted using optimized cycling conditions per gene-exon. Primer extension sequencing is performed using Applied Biosystems BigDye version 3.1. The reactions are then run on Applied Biosystem's 3730x1 DNA Analyzer. Sequencing base calls are done using KBTM Basecaller (Applied Biosystems). Somatic Mutation calls are determined by Mutation Surveyor (SoftGenetics) and confirmed manually by aligning sequencing data with the corresponding reference sequence using Seqman (DNASTAR).

[0169] SEQUENOM sequencing methodology. Sequenom (San Diego, CA) assays are designed using TypePLEX® chemistry with single-base extension. This process consists of three steps: 1) A text file containing the SNPs or mutations of interest and flanking sequence is uploaded at mysequenom.com where it is run through a web based program ProxSNP, 2) The output of ProxSNP is run through PreXTEND and 3) the output of PreXTEND is run through Assay Design which determines the expected mass weight of the extend products to ensure separation between all potential peaks found within a multiplexed reaction.

[0170] PCR primers are then designed to bracket the region identified in the assay design steps. The region of interest is amplified in PCR reactions using the primers. 15 nl of amplified and extended product is spotted on a 384 SpectroCHIP II using a Nanodispenser RS1000. A 3-point calibrant is added to every chip to ensure proper performance of the Sequenom MALDI-tof compact mass spectrometer.

[0171] The SpectroCHIP II is placed in the Sequenom MALDI-TOF compact mass spectrometer. The mass spectrometer is set to fire a maximum of 9 acquisitions for each spot on the 384 well spectroCHIP. TypePLEX Gold kit SpectroCHIP II from Sequenom (10142-2) is used following manufacturers recommended protocols. Analysis is performed using Sequenom analysis software, MassARRAY® Typer Analyzer v4.

[0172] NEXT GENERATION SEQUENCING (NGS) methodology. Targeted NGS using the Illumina platform (Illumina, Inc. San Diego, CA) is used to confirm and identify low frequency mutations in a marker. Primer pairs are designed to amplify coding exons. PCR products are quantified using a PicoGreen assay and combined in equal molar ratios for each sample. The purified products are end-repaired and concatenated by ligation. The concatenated products are used for Hi-Seq 2000 library preparation. The concatenated PCR products are sheared and used to make barcoded Hi-Seq 2000 libraries consisting of 12 barcoded samples per multiplexed pool. The pooled Hi-Seq 2000 libraries undergo clonal amplification by cluster generation on eight lanes of a Hi-Seq 2000 flow cell and are sequenced using 1x100 single-end sequencing on a Hi-Seq 2000. Matching of primary sequencing reads to the human genome build Hg18, as well as SNP analysis are performed using Illumina's CASAVA software version 1.7.1.

General Procedures

Quantitative RT-PCR

[0173] cDNA synthesis and quantitative RT-PCR is performed using ABI Gene Expression Assays, reagents, and ABI PRISM® 7900HT Sequence Detection Systems (Applied Biosystems, Foster City, CA) using the following cycle conditions: hold at 50°C for 2 minutes for AmpErase UNG activation, then 95.0°C for 10 minutes to activate DNA polymerase then run 40 two-part cycles of 95.0°C for 15 seconds and 60.0°C for 1 minute. The dCt is calculated by using the average Ct of control genes B2M (Hs99999907_ml) and RPLPO (Hs99999902_ml). Relative mRNA expression quantification is derived using the Comparative Ct Method (Applied Biosystems). mRNA expression fold change values are generated from a normal sample and corresponding tumor sample.

Sample Handling for myeloma samples

[0174] Upon collection of patient bone marrow aspirate, the myeloma cells are enriched via rapid negative selection. The enrichment procedure employs a cocktail of cell-type specific antibodies coupled with an antibody that binds red blood cells RosetteSep (Stem Cell Technologies). The antibody cocktail has antibodies with the following specificity: CD14 (monocytes), CD2 (T and NK cells), CD33 (myeloid progenitors and monocytes), CD41 (platelets and megakaryocytes), CD45RA (naive B and T cells) and CD66b (granulocytes). The antibodies cross-link the non-myeloma cell types to the red blood cells in the samples. The bound cell types are removed using a modified ficoll density gradient. Myeloma cells are then collected and frozen.

[0175] Total RNA is isolated using a QIAGEN® Group RNEASY® isolation kit (Valencia, CA) and quantified by spectrophotometry.

[0176] DNA is isolated from the flow through fraction of the column used in the RNA isolation method.

Analysis of Myeloma Gene Expression on an Array

[0177] RNA is converted to biotinylated cRNA by a standard T7 based amplification protocol (AFFYMETRIX® Inc., Santa Clara, CA). A small number of samples with $\geq 0.5 - 2.0 \mu\text{g}$ are also labeled and subsequently hybridized if $6 \mu\text{g}$ of cRNA is produced. For the automated T7 amplification procedure, the cDNA and the biotin labeled cRNA are purified using AMPURF® PCR Purification System, following the manufacturer's protocol (AGENCOURT® Bioscience Corporation, Beverly, MA). The cRNA yield is assessed by spectrophotometry and $10 \mu\text{g}$ of cRNA is fragmented and further processed for triplicate hybridization on the AFFYMETRIX® Human Genome HG-U133A and HG-U133B GFNFCHIP® arrays. In cases where cRNA yield ranged between $6 \mu\text{g}$ to $10 \mu\text{g}$, the entire cRNA sample is fragmented.

[0178] cRNA for each sample is hybridized to the U133A/B arrays in triplicate; operators, chip lots, clinical sites and scanners (GENECHIP® Scanner 3000) are controlled throughout. Background subtraction, smoothing adjustment, noise corrections, and signal calculations are performed with AFFYMETRIX® MAS5.0. Quality control metrics include: percent present call (>25) scale factor (< 11), β -actin 3':5' ratio (<15) and background (<120). Samples that fall outside these metrics are excluded from subsequent analysis.

[0179] The myeloma purity score examines expression of genes known in the literature to be expressed highly in myeloma cells (and their normal plasma precursor cells), to expression of genes known to be expressed highly in erythroid cells, neutrophils and T cells - see list of 14 markers below). The myeloma score = expression of myeloma markers (#1-4 below) / erythroid (#5-7) + neutrophil (#8-11) + T cell (#12-14):

1. 205692_s_at CD38 CD38 antigen (p45) myeloma/plasma cell
2. 201286_at SDC1 syndecan-1 myeloma/plasma cell
3. 201891_s_at B2M beta-2 microglobulin myeloma/plasma cell
4. 211528_x_at B2M beta-2 microglobulin myeloma/plasma cell
5. 37986_at EpoR erythropoietin receptor erythroid cell
6. 209962_at EpoR erythropoietin receptor erythroid cell
7. 205838_at GYPA glycoporphinA erythroid cell
8. 203948_s_at MPO myeloperoxidase neutrophil
9. 203591_s_at CSFR3colony stimulating factor 3receptor (granulocyte) neutrophil
10. 204039_at CEBPACCAAT/enhancer bindingprotein (C/EBP), alpha neutrophil
11. 214523_at CEBPECCAAT/enhancer bindingprotein (C/EBP), epsilon neutrophil
12. 209603_at GATA3 GATA binding protein 3 T lymphocyte
13. 209604_s_at GATA4 GATA binding protein 4 T lymphocyte
14. 205456_at CD3ECD3E antigen, epsilon polypeptide T lymphocyte

Samples with a myeloma purity score less than 10 are excluded from further analysis.

Equivalents

[0180] Although embodiments of the invention have been described using specific terms, such description are for illustrative purposes only, and it is to be understood that changes and variations may be made without departing from the invention. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

EP 2 775 844 B1

SEQUENCE LISTING

[0181]

5 <110> Smith, Peter G Blakemore, Stephen J. Li, Bin Mulligan, George J. Schu, Matthew C. Millennium Pharmaceuticals, Inc.

<120> BIOMARKERS OF RESPONSE TO NAE INHIBITORS

10 <130> MPI11-009P1RNWO2M

<150> US 61/552,686

<151> 2011-10-28

15 <160> 26

<170> FastSEQ for Windows Version 4.0

<210> 1

20 <211> 6046

<212> DNA

<213> Homo Sapiens

<400> 1

25

```

tgcgcttccc gcgggcgcgc ggagtgagga cggtgacagc cacgcgcgcg cgtacgcgcc 60
cgatgcagcg cggccccctg accctagtcg gccgctgaga ggcgcgcgga gtctgggccg 120
ctgccgtcta ggggtcccgt cccgaggcgt ccccggcatc tccggcccga atcccggagt 180
gccgggtcgc gcctgcaccg aaggtcccgg ctctctgtcc ctccctgcag ccgtcagggc 240
30 ccgtccccca actccccttt ccgctcaggg agggctctcg cggcccctgc tggccgctgg 300
ggaccgcgc agcccagacc gttcccgggc cgggcagccg gccaccatgg tggccctgag 360
gcctgtgcag caactccagg ggggctaaag ggctcagagt gcaggccgtg gggcgcgagg 420
gtcccgggcc tgagccccgc gccatggccg gggccatcgc ttcccgcgat agcttcagct 480
ctctcaagag gaagcaaccc aagacgttca ccgtgaggat cgtcaccatg gacgccgaga 540
35 tggagttcaa ttgcgagatg aagtggaaa ggaaggacct ctttgatttg gtgtgccgga 600
ctctggggct ccgagaaaacc tggttctttg gactgcagta cacaatcaag gacacagtgg 660
cctggctcaa aatggacaag aaggtactgg atcatgatgt ttcaaaggaa gaaccagtca 720
cctttcactt cttggcctaa ttttatcctg agaatgctga agaggagctg gttcaggaga 780
tcacacaaca tttattcttc ttacaggtaa agaagcagat tttagatgaa aagatctact 840
gcccctcctga ggcttctgtg ctctctggct cttacgccgt ccaggccaag tatggtgact 900
40 acgaccccag tgttcacaag cggggattht tggcccaaga ggaattgctt ccaaaaaggg 960
taataaatct gtatcagatg actccgaaa tgtgggagga gagaattact gcttggtagc 1020
cagagcaccg aggccgagcc agggatgaag ctgaaatgga atatctgaag atagctcagg 1080
acctggagat gtacggtgtg aactactttg caatccgaa taaaaagggc acagagctgc 1140
tgcttgagat ggatgccctg gggcttcaca tttatgacct tgagaacaga ctgacccccca 1200
45 agatctcctt cccgtggaat gaaatccgaa acatctcgtc cagtgacaag gagtttacta 1260
ttaaaccact ggataagaaa attgatgtct tcaagtttaa ctccctcaaag cttcgtgtta 1320
ataagctgat tctccagcta tgtatcggga accatgatct atttatgagg agaaggaaaag 1380
ccgattcttt ggaagttcag cagatgaaag cccaggccag ggaggagaag gctagaaaagc 1440
agatggagcg gcagcgcctc gctcgagaga agcagatgag ggaggaggct gaacgcacga 1500
50 gggatgagtt ggagaggag ctgctgcaga tgaagaaga agcaacaatg gccaacgaag 1560
cactgatgcg gtctgaggag acagctgacc tgttggctga aaaggcccag atcaccgagg 1620
aggaggcaaa acttctggcc cagaaggccg cagaggctga gcaggaaatg cagcgcacga 1680
aggccacagc gattcgcacg gaggaggaga agcgcctgat ggagcagaag gtgctggaag 1740
ccgaggtgct ggcactgaag atggctgagg agtcagagag gagggccaaa gaggcagatc 1800
agctgaagca ggacctgcag gaagcacgcg aggcggagcg aagagccaag cagaagctcc 1860
55 tggagattgc caccaagccc acgtacccgc ccatgaaccc aattccagca ccgttgcctc 1920
ctgacatacc aagcttcaac ctcatgtgtg acagcctgtc tttcgacttc aaagatactg 1980
acatgaagcg gctttccatg gagatagaga aagaaaaagt ggaatacatg gaaaagagca 2040
agcatctgca ggagcagctc aatgaactca agacagaaat cgaggccttg aaactgaaag 2100

```

EP 2 775 844 B1

agagggagac agctctggat attctgcaca atgagaactc cgacaggggt ggcagcagca 2160
 agcacaatac cattaaaaag ctcaccttgc agagcgccaa gtcccagagt gccttctttg 2220
 aagagctcta gcaggtgacc cagccacccc aggacctgcc acttctcctg ctaccgggac 2280
 cgcgggatgg accagatc agagagacca tccataggga gctggctggg ggtttccgtg 2340
 5 ggagctccag aactttcccc agctgagtga agagcccagc ccctcttatg tgcaattgcc 2400
 ttgaactacg accctgtaga gatttctctc atggcgttct agttctctga cctgagtctt 2460
 tgttttaaga agtatattgtc ttcctttgtc taatgtggga ttcctgactc ccttcgtcca 2520
 aggcaccgggt gtgtgtgtgt cttgcaactc agagctgacc tccaccgccc agcctgggaa 2580
 gtcattgtag ggagtgagac actgaagccc tgagaagcca gtgccatcat ccccaccccg 2640
 10 cccagggttc cggaaacattc attccccac cggtagaggac ctggcatgca gcgaagcagc 2700
 ccagcccggc ggatcccagg ccagcacgcc tgccggcttc tcatcgtcag ggagcccgcc 2760
 cacagctcgt gacgagcaag tgctgggtcc ccgcccaggca ccccagggcg gcgctctggc 2820
 tggcagctgg tggggaatag gcagggcagc tgtggctggg gagagacttt aggcagaagc 2880
 tgtgatgcag gctgactgcc agccgagggg ctgggtagtg ccgtgcggga gctgatggtg 2940
 cagggcactc gctgtcccc tccggccacc ctgaccagg gtccgagagg cagggcaggag 3000
 15 ccaactcatgt cttccccatt gcccgacgcc catagacgct ccttctctgt tggggctggg 3060
 gtactccctg gtcgtactgc agtcagcacc cgtaaccggg ctatgaccag ggatctgtaa 3120
 gccctgtggc tccacaggtg ctgcttctca ctggcccaga ctctgagctc caccggcca 3180
 gtctgcacgg cccatctgct tcaccttccc tcccagccac gtgccagtgg ccacagcca 3240
 cttccaacc cactgttga cccaggcctc actttgctgt tgccttgtc cctctcggg 3300
 20 ccctgaattt tctgttccct gggggccagc cagggccctt tgtgccctc ccagcacagg 3360
 cctgatgcag gtgtccactc acaggtggcg ctcacctagg ctgtcacagg acccacctcc 3420
 atgccaggca acagagggcc acagaaccac ccccacggct cactccttgg tctggggcca 3480
 ccttcttgcc ctttcttttt tttttttttt ttttttttcc gagatggagt ctctctctgt 3540
 caccaggtg ggagtgtggg ggcacaatct cggctcactg caacctccac ctctctgagt 3600
 caagcaattc tctgcctca gcctcccaag tagctgggac tacaggcatg caccaccaca 3660
 25 cttggccaat gttctgtatt tttaataggg acggggtttt gccatgtag ctaggctggt 3720
 ctcaaactca cacctgggat tacaggcatg agccactgca cccagcccct tcttgcctt 3780
 tcttttctcc atggctgatg ctgctgtggc cagccagggc ccttgagatc cttccagttt 3840
 ggctgttatg caaagcagggt gatttgtctt aatcagataa aagatagagg ctatgggggc 3900
 ctcaagattt ttggagagca gagggtggtct ctggcaattc catctggttt tgagaaactt 3960
 agcagctcac agagcacaga gatcctgcct tcttctact atcaggctga cctaatgggg 4020
 30 ttgggctgct cggcaactgc ttgggtcacc ttgcccgaag gaaaccagcc ctgggtgcca 4080
 cccagccact tagggtctac aggggtgggac tccagaccta gagcgttaagt atggatggtg 4140
 tggccctgtg tcttctctag gtgacccagc caggagcggg agcttcaggc gtttgtaaag 4200
 tgagctctgg atctgcctcc tccgtttttt ttttttttct gtttctgttt ctttctttt 4260
 tttgagatgg agtctcgctc tgtcgcccag gctggaagtgc agtgtcacga tctcagctca 4320
 35 ctgcaacctc gcctcccag gtacaagaga ttctcctgcc tcagcctccc gagtagctgg 4380
 gactacaggg gtgtgccacc atgcctggct aatttttga ttttttagtag agatgggggt 4440
 tcgccatggt agccagactg gtctcgaact cctgacctca ggtgatcctc ccaccccggc 4500
 ttcccaaagt tctgggatta taggcgtgag ccaccatgcc cggctcttcc tcagtcttga 4560
 agcccatccc tggatttcca ccaggagtta ctttctcct gacctgtaa tttgttctt 4620
 aacaatggct gcaggtggga gcatatgggt gtttataaaa acgctgtcgg gcttttttcc 4680
 40 cttcttttagc tgcctgtctc acttctgaag tctgggaagt gccaagccac gcggcctcaa 4740
 gggagctggc tggtgtttga cctgtggcag aagcaacctg ggctccaggc agcaggctgg 4800
 gaactgcagg acctgtctca gccaggagca cttccccctc cttgaggcag gaatactgag 4860
 gtgcctcccc acagatggag aaggtggaga ggaggatggg cctcaggagc atctcaagcc 4920
 ccagtagcag gagaaagaaa gaaagagatg cctggttttc acagactggt tcctgtggct 4980
 gggatgactg catccttttt tttttttttt tgagacggag tttttgcctt tgtcgcccag 5040
 45 gctggagtgc aatggcgtga tctcggctca ccgcaacctc cgcctcccgg attcaagcaa 5100
 ttctcctgcc tcagcctccc gagtagctgg gattacaggc acgcacctcc acgtccggct 5160
 aattttgtat ttttagtgga gacgggggtt cctcatgtcg gtcaggctgg tctcgaactc 5220
 ccgacctcag gtgatctgcc cacctcggcc tcccaaagtg ctgggattac aggcattgagc 5280
 caccgcgctt ggccagactg cgtccttttt aagcgaacat tttagggcct gggagtttgt 5340
 caagtaagga agtctcaagc ccaaagagca gcgtcctgac catgggtggtt tcattacgag 5400
 50 cccttctgct ggctctcagg cagaagcccc acagcaccgg gaccattcat gaggtcactg 5460
 cccagctcat gatgtccgtg aggtgtcct tttggccagt agccgtgtgc agctgtgtgg 5520
 cacagatggc ttcgttcatc ctgatcaagg ccccacctca gccacagcag tcccccaac 5580
 ctgtgtgtgc caccctatta ttcatgtacc tgcaggccc tgctagatag caccctgtgg 5640
 cattacataa cacttcatga ttggctgtgt cttgtaattt tggggacagg tttctctct 5700
 55 tccctctctt ttttttgtca aaagcccaga gactgacaac cagctgcagt gtctaagtgt 5760
 tctcactgca caggggtggg cctcaccacc cctggaggga gcagcgttgg cagggagaca 5820
 gcctggccca gtgacctg gcccagcca gccctccag ggctttcagg gaagcgcct 5880

EP 2 775 844 B1

ccattttcaa agatgtcaaa cgtcacttct tctctgtaggg cccgagtcct gcctcctatc 5940
 agggccagat catagaaggc tatttttctat tctggggaac gattataact taaatgattg 6000
 ttttaataaa aattctaagc tggaaaataa aaaaaaaaaa aaaaaa 6046

5

<210> 2
 <211> 1788
 <212> DNA
 <213> homo sapiens

10

<400> 2

atggccgggg ccatcgcttc ccgcatgagc ttcagctctc tcaagaggaa gcaacccaag 60
 acgttcaccg tgaggatcgt caccatggac gccgagatgg agttcaattg cgagatgaag 120
 tggaaagggg aggacctctt tgatttgggtg tgccggactc tggggctccg agaaacctgg 180
 ttctttggac tgcagtacac aatcaaggac acagtggcct ggctcaaat ggacaagaag 240
 gtactggatc atgatgtttc aaaggaagaa ccagtcacct ttcacttctt ggccaaattt 300
 tatcctgaga atgctgaaga ggagctgggt caggagatca cacaacattt attcttctta 360
 caggtaaaga agcagatttt agatgaaaag atctactgcc ctctctgaggc ttctgtgctc 420
 ctggcttctt acgccgtcca ggccaagtat ggtgactacg accccagtgt tcacaagcgg 480
 ggatttttgg cccaagagga attgcttcca aaaagggtaa taaatctgta tcagatgact 540
 ccggaaatgt gggagagag aattactgct tggtagcag agcaccgagg ccgagccagg 600
 gatgaagctg aaatggaata tctgaagata gctcaggacc tggagatgta cgggtgtaac 660
 tactttgcaa tccggaataa aaagggcaca gagctgctgc ttggagtgga tgccctgggg 720
 cttcacattt atgaccctga gaacagactg accccaaga tctccttccc gtggaatgaa 780
 atccgaaaca tctcgtacag tgacaaggag ttactatta aaccactgga taagaaaatt 840
 gatgtcttca agtttaactc ctcaaagctt cgtgttaata agctgattct ccagctatgt 900
 atcgggaacc atgatctatt tatgaggaga aggaaagccg attctttgga agttcagcag 960
 atgaaagccc aggccaggga ggagaaggct agaaagcaga tggagcggca gcgcctcgct 1020
 cgagagaagc agatgagggg ggaggctgaa cgcacgaggg atgagttgga gaggaggctg 1080
 ctgcagatga aagaagaagc aacaatggcc aacgaagcac tgatgcggtc tgaggagaca 1140
 gctgacctgt tggctgaaaa ggcccagatc accgaggagg aggcaaaact tctggcccag 1200
 aaggccgcag aggctgagca ggaaatgcag cgcacaaagg ccacagcgat tccgacggag 1260
 gaggagaagc gcctgatgga gcagaaggtg ctggaagccg aggtgctggc actgaagatg 1320
 gctgaggagt cagagaggag ggccaaagag gcagatcagc tgaagcagga cctgcaggaa 1380
 gcacgcgagg cggagcgaag agccaagcag aagctcctgg agattgccac caagcccacg 1440
 taccgcccga tgaacccaat tccagcaccg ttgcctcctg acataccaag cttcaacctc 1500
 attggtgaca gcctgtcttt cgacttcaaa gatactgaca tgaagcggct ttccatggag 1560
 atagagaaag aaaaagtgga atacatggaa aagagcaagc atctgcagga gcagctcaat 1620
 gaactcaaga cagaaatcga ggccttgaag ctgaaagaga gggagacagc tctggatatt 1680
 ctgcacaatg agaactccga caggggtggc agcagcaagc acaataccat taaaagctc 1740
 accttgcaga gcgccaagtc ccgagtggcc ttctttgaag agctctag 1788

45

<210> 3
 <211> 595
 <212> PRT
 <213> Homo sapiens

50

<400> 3

55

EP 2 775 844 B1

	Met	Ala	Gly	Ala	Ile	Ala	Ser	Arg	Met	Ser	Phe	Ser	Ser	Leu	Lys	Arg
	1				5					10					15	
	Lys	Gln	Pro	Lys	Thr	Phe	Thr	Val	Arg	Ile	Val	Thr	Met	Asp	Ala	Glu
				20					25					30		
5	Met	Glu	Phe	Asn	Cys	Glu	Met	Lys	Trp	Lys	Gly	Lys	Asp	Leu	Phe	Asp
			35					40					45			
	Leu	Val	Cys	Arg	Thr	Leu	Gly	Leu	Arg	Glu	Thr	Trp	Phe	Phe	Gly	Leu
	50						55					60				
	Gln	Tyr	Thr	Ile	Lys	Asp	Thr	Val	Ala	Trp	Leu	Lys	Met	Asp	Lys	Lys
10	65					70					75					80
	Val	Leu	Asp	His	Asp	Val	Ser	Lys	Glu	Glu	Pro	Val	Thr	Phe	His	Phe
				85						90					95	
	Leu	Ala	Lys	Phe	Tyr	Pro	Glu	Asn	Ala	Glu	Glu	Glu	Leu	Val	Gln	Glu
				100					105					110		
15	Ile	Thr	Gln	His	Leu	Phe	Phe	Leu	Gln	Val	Lys	Lys	Gln	Ile	Leu	Asp
			115					120					125			

20

25

30

35

40

45

50

55

EP 2 775 844 B1

Glu Lys Ile Tyr Cys Pro Pro Glu Ala Ser Val Leu Leu Ala Ser Tyr
 130 135 140
 Ala Val Gln Ala Lys Tyr Gly Asp Tyr Asp Pro Ser Val His Lys Arg
 145 150 155 160
 5 Gly Phe Leu Ala Gln Glu Glu Leu Leu Pro Lys Arg Val Ile Asn Leu
 165 170 175
 Tyr Gln Met Thr Pro Glu Met Trp Glu Glu Arg Ile Thr Ala Trp Tyr
 180 185 190
 Ala Glu His Arg Gly Arg Ala Arg Asp Glu Ala Glu Met Glu Tyr Leu
 195 200 205
 10 Lys Ile Ala Gln Asp Leu Glu Met Tyr Gly Val Asn Tyr Phe Ala Ile
 210 215 220
 Arg Asn Lys Lys Gly Thr Glu Leu Leu Leu Gly Val Asp Ala Leu Gly
 225 230 235 240
 15 Leu His Ile Tyr Asp Pro Glu Asn Arg Leu Thr Pro Lys Ile Ser Phe
 245 250 255
 Pro Trp Asn Glu Ile Arg Asn Ile Ser Tyr Ser Asp Lys Glu Phe Thr
 260 265 270
 Ile Lys Pro Leu Asp Lys Lys Ile Asp Val Phe Lys Phe Asn Ser Ser
 275 280 285
 20 Lys Leu Arg Val Asn Lys Leu Ile Leu Gln Leu Cys Ile Gly Asn His
 290 295 300
 Asp Leu Phe Met Arg Arg Arg Lys Ala Asp Ser Leu Glu Val Gln Gln
 305 310 315 320
 25 Met Lys Ala Gln Ala Arg Glu Glu Lys Ala Arg Lys Gln Met Glu Arg
 325 330 335
 Gln Arg Leu Ala Arg Glu Lys Gln Met Arg Glu Glu Ala Glu Arg Thr
 340 345 350
 Arg Asp Glu Leu Glu Arg Arg Leu Leu Gln Met Lys Glu Glu Ala Thr
 355 360 365
 30 Met Ala Asn Glu Ala Leu Met Arg Ser Glu Glu Thr Ala Asp Leu Leu
 370 375 380
 Ala Glu Lys Ala Gln Ile Thr Glu Glu Glu Ala Lys Leu Leu Ala Gln
 385 390 395 400
 Lys Ala Ala Glu Ala Glu Gln Glu Met Gln Arg Ile Lys Ala Thr Ala
 405 410 415
 35 Ile Arg Thr Glu Glu Glu Lys Arg Leu Met Glu Gln Lys Val Leu Glu
 420 425 430
 Ala Glu Val Leu Ala Leu Lys Met Ala Glu Glu Ser Glu Arg Arg Ala
 435 440 445
 Lys Glu Ala Asp Gln Leu Lys Gln Asp Leu Gln Glu Ala Arg Glu Ala
 450 455 460
 40 Glu Arg Arg Ala Lys Gln Lys Leu Leu Glu Ile Ala Thr Lys Pro Thr
 465 470 475 480
 Tyr Pro Pro Met Asn Pro Ile Pro Ala Pro Leu Pro Pro Asp Ile Pro
 485 490 495
 45 Ser Phe Asn Leu Ile Gly Asp Ser Leu Ser Phe Asp Phe Lys Asp Thr
 500 505 510
 Asp Met Lys Arg Leu Ser Met Glu Ile Glu Lys Glu Lys Val Glu Tyr
 515 520 525
 Met Glu Lys Ser Lys His Leu Gln Glu Gln Leu Asn Glu Leu Lys Thr
 530 535 540
 50 Glu Ile Glu Ala Leu Lys Leu Lys Glu Arg Glu Thr Ala Leu Asp Ile
 545 550 555 560
 Leu His Asn Glu Asn Ser Asp Arg Gly Gly Ser Ser Lys His Asn Thr
 565 570 575
 Ile Lys Lys Leu Thr Leu Gln Ser Ala Lys Ser Arg Val Ala Phe Phe
 580 585 590
 55 Glu Glu Leu
 595

EP 2 775 844 B1

<210> 4
<211> 8789
<212> DNA
<213> Homo sapiens

5

<400> 4

10

15

20

25

30

35

40

45

50

55

EP 2 775 844 B1

atgctcagtg gcttctcgac aagttggcag caacaacacg gccctggtcg tcgtcgccgc 60
 tgcggtaacg gagcggtttg ggtggcggag cctgcgttcg cgccttcccg ctctcctcgg 120
 gaggcccttc ctgctctccc ctaggctccg cggccgcccc gggggtggga gcgggtgagg 180
 5 ggagccaggc gccagcggag agaggcccc cgccgcaggg cggcccggga gctcgaggcg 240
 gtccggcccc cgcgggcagc ggcgcggcgc tgaggagggg cggcctggcc gggacgcctc 300
 ggggcggggg ccgaggagct ctccgggccg ccggggaaag ctacgggcc ggtgcgtccg 360
 cggaccagca gcgcgggaga gcggactccc ctcgccaccg cccgagccca ggttatcctg 420
 aatacatgtc taacaatddd ccttgcaacg ttagctgttg tttttactg tttccaaagg 480
 atcaaaattg cttcagaaat tggagacata tttgatttaa aaggaaaaac ttgaacaaat 540
 10 ggacaatatg tctattacga atacaccaac aagtaatgat gcctgtctga gcattgtgca 600
 tagtttgatg ttgcatagac aagtgaggaga gagtgaaca tttgcaaaaa gagcaattga 660
 aagtttggtg aagaagctga aggagaaaaa agatgaattg gattctttaa taacagctat 720
 aactacaaat ggagctcatc ctagttaatg tgttaccata cagagaacat tggatgggag 780
 gcttcagggtg gctggtcgga aaggatttcc tcatgtgatc tatgcccgtc tctggagggtg 840
 15 gcctgatctt cacaaaaatg aactaaaaca tgtaaataat tgtcagtatg cgtttgactt 900
 aaaatgtgat agtgtctgtg tgaatccata tcaactacgaa cgagttgtat cacctggaat 960
 tgatctctca ggattaacac tgcagagtaa tgctccatca agtatgatgg tgaaggatga 1020
 atatgtgcat gactttgagg gacagccatc gttgtccact gaaggacatt caattcaaac 1080
 catccagcat ccaccaagta atcgtgcatc gacagagaca tacagcacc cagctctggt 1140
 agccccatct gagtctaata ctaccagcac tgccaacttt cccaacattc ctgtggcttc 1200
 20 cacagtcag cctgccagta tactgggggg cagccatagt gaaggactgt tgcagatagc 1260
 atcaggccct cagccaggac agcagcagaa tggatttact ggtcagccag ctacttacca 1320
 tcataagcgc actaccacct ggactggaag taggactgca ccatacacac ctaattggcc 1380
 tcaccaccaa aacggccatc ttcagcacca cccgcctatg ccgccccatc ccggacatta 1440
 ctggcctggt cacaatgagc ttgcattcca gcctcccatt tccaatcatc ctgctcctga 1500
 25 gtattggtgt tccattgctt actttgaaat ggatggtcag gtaggagaga catttaagggt 1560
 tccttcaagc tgccctattg ttactgttga tggatacgtg gacccttctg gaggagatcg 1620
 cttttgtttg ggtcaactct ccaatgtcca caggacagaa gccattgaga gagcaagggt 1680
 gcacataggc aaaggtgtgc agttggaatg taaagtgaa ggtgatgttt gggtcagggtg 1740
 ccttagtgac cacgcggtct ttgtacagag ttactactta gacagagaag ctgggcgtgc 1800
 30 acctggagat gctgttcata agatctacc ccaagtgcata ataaaggctt ttgatttgcg 1860
 tcagtgatc cgacagatgc agcagcaggc ggctactgca caagctgcag cagctgcccc 1920
 ggcagcagcc gtggcaggaa acatccctgg cccaggatca gtaggtgaa tagctccagc 1980
 tatcagtcgt tcagctgctg ctggaattgc tgttgatgac cttcgtcgtc tatgcatact 2040
 cagtgtagt tttgtgaaag gctggggacc ggattaccba agacagagca tcaaaagaaac 2100
 35 accttgctgg attgaaattc acttacaccg ggccctccag ctccctagacg aagtacttca 2160
 taccatgccg attgcagacc cacaaacttt agactgagg cttttaccgt tggggccctt 2220
 aaccttatca ggatggtgga ctacaaaata caatcctggt tataatctga agatatattt 2280
 cacttttggt ctgctttatc ttttcataaa ggggtgaaaa tgtgtttgct gccttgctcc 2340
 tagcagacag aaactggatt aaaacaattt ttttttccct cttcagaact tgtcaggcat 2400
 ggctcagagc ttgaagatta ggagaaacac attcctatta attcttcacc tgttatgtat 2460
 40 gaaggaatca ttccagtgct agaaaattta gccctttaa acgtcttga gccttttatc 2520
 tgcagaacat cgatatgtat atcattctac agaataatcc agtattgctg attttaaagg 2580
 cagagaagtt ctcaaagtta attcacctat gttatttgt gtacaagttg ttattggtga 2640
 acatacttca aaaataatgt gccatgtggg tgagttaatt ttaccaagag taactttact 2700
 ctgtgtttaa aaagtaagtt aataatgtat tgaatcctt catccaaat atttttgca 2760
 45 agttatatta gtgaagatgg tttcaattca gattgtcttg caacttcagt tttatttttg 2820
 ccaaggcaaaa aaactcttaa tctgtgtgta tattgagaat cccttaaaat taccagacaa 2880
 aaaaatttaa aattacgttt gttattccta gtggatgact gttgatgaag tatacttttc 2940
 ccctgttaaa cagtagttgt attcttctgt attctaggc acaagggttg ttgctaagaa 3000
 gcctataaga ggaatttctt ttccttcatt catagggaaa ggttttgat tttttaaac 3060
 50 actaaaagca gcgtcactct acctaattgtc tcaactgtct gcaaagggtg caatgcttaa 3120
 actaaataat gaataaactg aatattttgg aaactgctaa attctatggt aaatactgtg 3180
 cagaataatg gaaacattac agttcataat aggtagtttg gatatttttg tacttgattt 3240
 gatgtgactt tttttggtat aatgtttaaa tcatgtatgt tatgatattg tttaaaattc 3300
 agtttttgta tcttggggca agactgcaaa cttttttata tcttttggtt attctaagcc 3360
 ctttgccatc aatgatcata tcaattggca gtgactttgt atagagaatt taagtagaaa 3420
 55 agttgcagat gtattgactg taccacagac acaatatgta tgctttttac ctagctggta 3480

EP 2 775 844 B1

	gcataaataa	aactgaatct	caacatacaa	agttgaattc	taggtttgat	ttttaagatt	3540
	ttttttttct	tttgcacttt	tgagtccaat	ctcagtgatg	aggtagcttc	tactaaatga	3600
	caggcaacag	ccagttctat	tgggcagctt	tgtttttttc	cctcacactc	taccgggact	3660
	tccccatgga	cattgtgtat	catgtgtaga	gttggttttt	ttttttttta	attttttatt	3720
5	tactatagca	gaaatagacc	tgattatcta	caagatgata	aatagattgt	ctacagagata	3780
	aatagtatga	aataaaatca	aggattatct	ttcagatgtg	tttacttttg	cctggagaac	3840
	ttttagctat	agaaacactt	gtgtgatgat	agtcctcctt	atatcacctg	gaatgaacac	3900
	agcttctact	gccttgctca	gaaggtcttt	taaatagacc	atcctagaaa	ccactgagtt	3960
	tgcttatttc	tgtgatttaa	acatagatct	tgatccaagc	tacatgactt	ttgtctttaa	4020
	ataacttatc	taccacctca	tttgactctc	tgattactta	caaattcttt	cagtaaacac	4080
10	ctaattttct	tctgtaaaag	tttgggtgatt	taagttttat	tggcagtttt	ataaaaagac	4140
	atcttctcta	gaaattgcta	acttttaggtc	cattttactg	tgaatgagga	ataggagtga	4200
	gtttttagaat	aacagatttt	taaaaatcca	gatgatttga	ttaaaacctt	aatcatacat	4260
	tgacataaatt	cattgcttct	tttttttgag	atatggagtc	ttgctgtggt	gccagggcag	4320
	gagtgacagt	gtatgatctc	agctcactgc	aacctctgcc	tcccgggttc	aactgattct	4380
15	cctgcctcag	cctccctggt	agctaggatt	acaggtgcc	gccaccatgc	ctggctaact	4440
	tttgtagttt	tagtagagac	ggggttttgc	ctgttggcca	ggctggctct	gaactcctga	4500
	cctcaagtga	tccatccacc	ttggcctccc	aaagtgcctg	gattacgggc	gtgagccact	4560
	gtccctggcc	tcattgttcc	cttttctact	ttaaggaaag	ttttcatggt	taatcatctg	4620
	gggaaagtat	gtgaaaata	tttgtaaga	agtactctct	tggagccaag	ccactgtctc	4680
	tggtttcttt	ctactaagag	ccataaagta	tagaaatact	tctagttggt	aagtgcctat	4740
20	atgtgtacct	agatttagtc	acacgccttt	gagaaaacat	ctagtatggt	atgatcagct	4800
	attcctgaga	gcttggttgt	taatctatat	ttctatttct	tagtggtagt	catctttgat	4860
	gaataagact	aaagattctc	acaggtttta	aattttatgt	ctactttaag	ggtaaaatta	4920
	tgaggttatg	gttctgggtg	ggttttctct	agctaattca	tatctcaaag	agtctcaaaa	4980
	tgttgaatth	cagtgcgaagc	tgaatgagag	atgagccatg	tacaccacc	gtaagacctc	5040
25	attccatgth	tgtccagtgc	ctttcagtgc	attatcaaag	ggaatccttc	atgggtgtgc	5100
	ctttattttc	cggggagtag	atcgtgggat	atagctctatc	tcatttttaa	tagtttaccg	5160
	cccctgggat	acaaagataa	tgacaataaa	tcactgccat	ataaccttgc	ttttccaga	5220
	aacatggctg	ttttgtattg	ctgtaaccac	taaataggtt	gcctatacca	ttcctcctgt	5280
	gaacagtgca	gatttacagg	ttgcatggtc	tggcttaagg	agagccatac	ttgagacatg	5340
	tgagtaaact	gaactcatat	tagctgtgct	gcatttcaga	cttaaaatcc	atttttgtgg	5400
30	ggcagggtgt	ggtgtgtaaa	ggggggtgth	tgtaatacaa	gttgaaggca	aaataaaatg	5460
	tcctgtctcc	cagatgatat	acatcttatt	atttttaaag	tttattgcta	attgtaggaa	5520
	ggtgagttgc	aggtatctth	gactatggth	atctggggaa	ggaaaattht	acattttact	5580
	atnaatgth	ctnaatgth	tatggagth	aaagaataaa	atggtaaatg	tttctgtgcc	5640
	tggthtgatg	gtaactggth	aatagthact	accattthta	tgcagagthca	cattagthca	5700
35	caccctthct	gagagcctth	tgggagaagc	agthttatth	tctgagthga	acagagthct	5760
	ttthgttgat	aatthctagth	ttgctccctth	cgthtttgcc	aaactthactg	gcattthatt	5820
	taatgatagc	agattgggaa	aatggcaaat	ttagthtacg	gagthaaatg	agthtatgaa	5880
	agcaattacc	tctaaagcca	gthtaacaath	atthttgtagg	tggggtacac	tcagctthaaa	5940
	gtaatgcatt	tttttttccc	gthaaaggcag	aatccatctth	gthgcagata	gctatcthaa	6000
	taactcata	tcctctthttg	caaagactac	agagaathagg	ctatgacaath	ctgttcaag	6060
40	cctthccatt	ttthtccctg	ataactaagth	aatthctthg	aacatacaca	gaagthtga	6120
	aaaagtccat	ggccttattc	atccacaaaag	tggcatccta	ggcccagcct	tatccctagc	6180
	agthgtccca	gtgctgctag	gthgtcttath	ttgthttatct	ggaatcactg	tggagthgaa	6240
	ttthccacat	catccagaath	tgccttattth	agaagthaaa	acgthtttaath	ttthtagcctth	6300
	ttthtggthg	agthattthaa	tatgtatath	agagthata	ctagatgthga	acattthctth	6360
45	ctgtgctthg	ctatctthtg	ggactthcagg	ggctthctaaa	acagacagga	ctgtgthtgc	6420
	tttactaaath	ggtctgagac	agctatgtht	ttgaathttth	agthttttth	ttthaaccca	6480
	cttcccctcc	tgtctctctc	cctctctgath	aattaccatt	catatgthgag	tgttagthgth	6540
	cctcctthta	gcattthctth	cttctctthc	tgattctthca	ttctgactg	cctaggthcaag	6600
	gaaaccagath	aaccaaaactth	actagaacgth	tctthtaaaac	acaagthaca	actctgggac	6660
	aggacccaag	acactthctc	gtgaagthgct	gaaaaagacc	tcattgthatt	ggcattthgat	6720
	atcagthtga	tgtagctthag	agthgctthcct	gattctthgct	gagthttcagg	tagthtgagath	6780
50	agagagaagth	gagthcatath	catathtttcc	ccctthagaath	aatathtttga	aagthttcat	6840
	tgctthccact	tgaatgctgc	tctthacaaa	actgggthta	caagggthtac	taathtagca	6900
	tcagthagcca	gagthcaatac	cgthgtctgth	aggacaccag	caaacaacac	acaacaagc	6960
	aaaacaacac	ttgggaaact	aaggccattth	gthttgthtt	ggtgthcccct	ttgagccct	7020
	gcctthctg	cttactcctg	tacagathatt	tttgactat	aggtgcttht	atgagaathg	7080
55	agggthctgac	atcctgcccc	aaggagthagc	taagthaaath	gctagthgtht	tcagggattth	7140
	taacatcaga	ctggaathgaa	tgaathgaaac	ttthtgcct	ttthttttct	gthttttttt	7200
	ttctaathgta	gthaaagthca	aggaaaact	ttgthgaa	caathctthc	tctctgthga	7260

EP 2 775 844 B1

	tgtggatact	tttcacaccg	tttattttaa	tgctttctca	ataggtccag	agccagtgtt	7320
	cttgttcaac	ctgaaagtaa	tggctctggg	ttggggccaga	cagttgcact	ctctagtttg	7380
	ccctctgcca	caaatttgat	gtgtgacctt	tgggcaagtc	atttatcttc	tctgggcctt	7440
5	agttgcctca	tctgtaaaat	gagggagttg	gagtagatta	attattccag	ctctgaaatt	7500
	ctaagtgacc	ttggctacct	tgcagcagtt	ttggatttct	tccttatctt	tgttctgctg	7560
	tttgaggggg	ctttttactt	atctccatgt	tattcaaagg	agactaggct	tgatatttta	7620
	ttactgttct	tttatggaca	aaaggttaca	tagtatgccc	ttaagactta	atthtaacca	7680
	aaggcctagc	accaccttag	gggctgcaat	aaacacttaa	cgcgcgctgcg	cacgcgcgcg	7740
	cgcacacaca	cacacacaca	cacacacaca	cacaggtcag	agtttaaggc	tttcgagtca	7800
10	tgacattcta	gcttttgaat	tgctgtcaca	cacacacgca	cgcacacact	ctggtcagag	7860
	tttattaagg	cttttcgagtc	atgacattat	agcttttgag	ttggtgtgtg	tgacaccacc	7920
	ctcctaagtg	gtgtgtgctt	gtaatttttt	ttttcagtga	aatggattg	aaaacctgtt	7980
	gttaatgctt	agtgatatta	tgctcaaaac	aaggaaattc	ccttgaaccg	tgtcaattaa	8040
	actggtttat	atgactcaag	aaaacaatac	cagtagatga	ttattaactt	tattcttggc	8100
15	tcttttttag	tccattttga	ttaagtgact	tttggctgga	tcattcagag	ctctcttcta	8160
	gcctaccctt	ggatgagtac	aattaatgaa	atccatattt	tcaaggacct	gggagccttc	8220
	cttggggctg	ggttgagggt	ggggggttgg	ggagtcctgg	tagaggccag	ctttgtggta	8280
	gctggagagg	aagggatgaa	accagctgct	gttgcaaagg	ctgcttgtca	ttgatagaag	8340
	gactcacggg	cttggattga	ttaagactaa	acatggagtt	ggcaaacttt	cttcaagtat	8400
20	tgagttctgt	tcaatgcatt	ggacatgtga	tttaagggaa	aagtgtgaat	gcttatagat	8460
	gatgaaaacc	tggtgggctg	cagagcccag	tttagaagaa	gtgagttggg	ggttggggac	8520
	agatttggtg	gtggtatctt	ccaactgttt	cctcccctaa	attcagagga	atgcagctat	8580
	gccagaagcc	agagaagagc	cactcgtagc	ttctgctttg	gggacaactg	gtcagttgaa	8640
	agtcccagga	gttcctttgt	ggctttctgt	atacttttgc	ctggttaaag	tctgtggcta	8700
	aaaaatagtc	gaacctttct	tgagaactct	gtaacaaagt	atgtttttga	ttaaaagaga	8760
25	aagccaacta	aaaaaaaaaa	aaaaaaaaaa				8789

<210> 5

<211> 1659

<212> DNA

30 <213> Homo sapiens

<400> 5

35

40

45

50

55

EP 2 775 844 B1

atggacaata tgtctattac gaatacacca acaagtaatg atgcctgtct gagcattgtg 60
 catagtttga tgtgccatag acaaggtgga gagagtgaaa catttgcaaa aagagcaatt 120
 gaaagtttgg taaagaagct gaaggagaaa aaagatgaat tggattcttt aataacagct 180
 5 ataactacaa atggagctca tcctagtaaa tgtgttacca tacagagaac attggatggg 240
 aggcttcagg tggctggtcg gaaaggattt cctcatgtga tctatgcccg tctctggagg 300
 tggcctgatc ttcacaaaaa tgaactaaaa catgttaaat attgtcagta tgcgtttgac 360
 ttaaaatgtg atagtgtctg tgtgaatcca tatcactacg aacgagttgt atcacctgga 420
 attgatctct caggattaac actgcagagt aatgctccat caagtatgat ggtgaaggat 480
 gaatatgtgc atgactttga gggacagcca tcgttgtcca ctgaaggaca ttcaattcaa 540
 10 accatccagc atccaccaag taatcgtgca tcgacagaga catacagcac cccagctctg 600
 ttagcccat ctgagtctaa tgtaccagc atgccaact ttccaacat tcctgtggct 660
 tccacaagtc agcctgccag tatactgggg ggcagccata gtgaaggact gttgcagata 720
 gcatcagggc ctcagccagc acagcagcag aatggattta ctggtcagcc agctacttac 780
 catcataaca gcactaccac ctggactgga agtaggactg caccatacac acctaatttg 840
 15 cctcaccacc aaaacggcca tcttcagcac caccgccta tgccgcccc tcccggacat 900
 tactggcctg ttcacaatga gcttgcattc cagcctccca tttccaatca tcctgctcct 960
 gagtattggt gttccattgc ttactttgaa atggatgttc aggtaggaga gacatttaag 1020
 gttccttcaa gctgccctat tgttactgtt gatggatagc tggacccttc tggaggagat 1080
 cgcttttgtt tgggtcaact ctccaatgtc cacaggacag aagccattga gagagcaagg 1140
 20 ttgcatatag gcaaagggtg gcagttggaa tgtaaagggtg aaggatgatg ttgggtcagg 1200
 tgccttagtg accacgcggt ctttgtacag agttactact tagacagaga agctgggctg 1260
 gcacctggag atgctgttca taagatctac ccaagtgc atataaaggc ctttgatttg 1320
 cgtcagtgtc atcgacagat gcagcagcag gcggctactg cacaagctgc agcagctgcc 1380
 caggcagcag ccgtggcagc aaacatccct ggcccaggat cagtaggtgg aatagctcca 1440
 gctatcagtc tgtcagctgc tgcctggaatt ggtgttgatg accttcgctg cttatgcata 1500
 25 ctcaggatga gttttgtgaa aggctgggga ccggattacc caagacagag catcaaagaa 1560
 acaccttgct ggattgaaat tcacttacac cgggccctcc agctcctaga cgaagtactt 1620
 catacatgct cgattgcaga cccacaacct ttagactga 1659

30 <210> 6
 <211> 552
 <212> PRT
 <213> Homo sapiens

35 <400> 6

40

45

50

55

EP 2 775 844 B1

	Met	Asp	Asn	Met	Ser	Ile	Thr	Asn	Thr	Pro	Thr	Ser	Asn	Asp	Ala	Cys
	1				5					10					15	
	Leu	Ser	Ile	Val	His	Ser	Leu	Met	Cys	His	Arg	Gln	Gly	Gly	Glu	Ser
5				20					25					30		
	Glu	Thr	Phe	Ala	Lys	Arg	Ala	Ile	Glu	Ser	Leu	Val	Lys	Lys	Leu	Lys
			35				40						45			
	Glu	Lys	Lys	Asp	Glu	Leu	Asp	Ser	Leu	Ile	Thr	Ala	Ile	Thr	Thr	Asn
		50					55					60				
10	Gly	Ala	His	Pro	Ser	Lys	Cys	Val	Thr	Ile	Gln	Arg	Thr	Leu	Asp	Gly
		65				70					75					80
	Arg	Leu	Gln	Val	Ala	Gly	Arg	Lys	Gly	Phe	Pro	His	Val	Ile	Tyr	Ala
				85						90					95	
	Arg	Leu	Trp	Arg	Trp	Pro	Asp	Leu	His	Lys	Asn	Glu	Leu	Lys	His	Val
			100						105					110		
15	Lys	Tyr	Cys	Gln	Tyr	Ala	Phe	Asp	Leu	Lys	Cys	Asp	Ser	Val	Cys	Val
			115					120					125			
	Asn	Pro	Tyr	His	Tyr	Glu	Arg	Val	Val	Ser	Pro	Gly	Ile	Asp	Leu	Ser
		130					135						140			
	Gly	Leu	Thr	Leu	Gln	Ser	Asn	Ala	Pro	Ser	Ser	Met	Met	Val	Lys	Asp
20		145				150						155				160
	Glu	Tyr	Val	His	Asp	Phe	Glu	Gly	Gln	Pro	Ser	Leu	Ser	Thr	Glu	Gly
				165						170					175	
	His	Ser	Ile	Gln	Thr	Ile	Gln	His	Pro	Pro	Ser	Asn	Arg	Ala	Ser	Thr
			180						185					190		
25	Glu	Thr	Tyr	Ser	Thr	Pro	Ala	Leu	Leu	Ala	Pro	Ser	Glu	Ser	Asn	Ala
			195					200					205			
	Thr	Ser	Thr	Ala	Asn	Phe	Pro	Asn	Ile	Pro	Val	Ala	Ser	Thr	Ser	Gln
		210					215					220				
	Pro	Ala	Ser	Ile	Leu	Gly	Gly	Ser	His	Ser	Glu	Gly	Leu	Leu	Gln	Ile
		225				230					235					240
30	Ala	Ser	Gly	Pro	Gln	Pro	Gly	Gln	Gln	Gln	Asn	Gly	Phe	Thr	Gly	Gln
				245						250					255	
	Pro	Ala	Thr	Tyr	His	His	Asn	Ser	Thr	Thr	Thr	Trp	Thr	Gly	Ser	Arg
			260						265					270		
	Thr	Ala	Pro	Tyr	Thr	Pro	Asn	Leu	Pro	His	His	Gln	Asn	Gly	His	Leu
			275					280					285			
35	Gln	His	His	Pro	Pro	Met	Pro	Pro	His	Pro	Gly	His	Tyr	Trp	Pro	Val
		290					295					300				
	His	Asn	Glu	Leu	Ala	Phe	Gln	Pro	Pro	Ile	Ser	Asn	His	Pro	Ala	Pro
		305				310					315					320
40	Glu	Tyr	Trp	Cys	Ser	Ile	Ala	Tyr	Phe	Glu	Met	Asp	Val	Gln	Val	Gly
				325						330					335	
	Glu	Thr	Phe	Lys	Val	Pro	Ser	Ser	Cys	Pro	Ile	Val	Thr	Val	Asp	Gly
			340						345					350		
	Tyr	Val	Asp	Pro	Ser	Gly	Gly	Asp	Arg	Phe	Cys	Leu	Gly	Gln	Leu	Ser
			355					360					365			
45	Asn	Val	His	Arg	Thr	Glu	Ala	Ile	Glu	Arg	Ala	Arg	Leu	His	Ile	Gly
		370					375					380				
	Lys	Gly	Val	Gln	Leu	Glu	Cys	Lys	Gly	Glu	Gly	Asp	Val	Trp	Val	Arg
		385				390					395					400
	Cys	Leu	Ser	Asp	His	Ala	Val	Phe	Val	Gln	Ser	Tyr	Tyr	Leu	Asp	Arg
				405						410					415	
50	Glu	Ala	Gly	Arg	Ala	Pro	Gly	Asp	Ala	Val	His	Lys	Ile	Tyr	Pro	Ser
			420						425					430		
	Ala	Tyr	Ile	Lys	Val	Phe	Asp	Leu	Arg	Gln	Cys	His	Arg	Gln	Met	Gln
			435					440					445			
	Gln	Gln	Ala	Ala	Thr	Ala	Gln	Ala	Ala	Ala	Ala	Ala	Gln	Ala	Ala	Ala
55			450				455					460				

EP 2 775 844 B1

Val Ala Gly Asn Ile Pro Gly Pro Gly Ser Val Gly Gly Ile Ala Pro
 465 470 475 480
 Ala Ile Ser Leu Ser Ala Ala Ala Gly Ile Gly Val Asp Asp Leu Arg
 485 490 495
 5 Arg Leu Cys Ile Leu Arg Met Ser Phe Val Lys Gly Trp Gly Pro Asp
 500 505 510
 Tyr Pro Arg Gln Ser Ile Lys Glu Thr Pro Cys Trp Ile Glu Ile His
 515 520 525
 10 Leu His Arg Ala Leu Gln Leu Leu Asp Glu Val Leu His Thr Met Pro
 530 535 540
 Ile Ala Asp Pro Gln Pro Leu Asp
 545 550

15 <210> 7
 <211> 5778
 <212> DNA
 <213> Homo sapiens

20 <400> 7

25

30

35

40

45

50

55

EP 2 775 844 B1

gtgacacaat tacaacaact ttgtgctggt gccggggaag tttgtgtctc caacgaatcc 60
 cctcagtgtc ccccagcccc gcgcgctccg gccgttcccc ccgtccccgc ctgtggctgc 120
 cccctgccca accccgcgat gtgaccctac agccgaaagc cgccgctgcc gaccggggg 180
 ctccgcagcc cctgccgccc ccgcccgcgc cttcaccgcc gccgcgttgg gatttttctg 240
 cgccgcccgc cgcgccggag gaggaggcgg cgataaagtt ggtgtgctgg tcccgcgcgc 300
 agattggggg cgtcactgcg ggccccggtc cgaggggggg tgcggcgctt ggagttgtga 360
 attcgctgcg tttccatgaa atcctgcgga gtgtcgctcg ctaccgccgc cgctgccgcc 420
 gccgctttcg gtgatgagga aaagaaaatg gcggcgggaa aagcgagcgg cgagagcgag 480
 gaggcgtccc ccagcctgac agccgaggag agggaggcgc tcggcggact ggacagccgc 540
 ctctttgggt tcgtgagatt tcatgaagat ggcgccagga cgaaggccct actgggcaag 600
 tttgttccgt gctatgaatc tctaactcta aaagctgaag gaaaagtgga gtctgatttc 660
 tttgttcaat taggtcactt caacctcta ttggaagatt atccaaaagc attatctgca 720
 taccagaggt actacagttt acagtctgac tactggaaga atgctgcctt tttatatggt 780
 cttggtttgg tctacttcca ttataatgca tttcagtggt caattaaagc atttcaggag 840
 gtgctttatg ttgatcccag cttttgtcga gccaaaggaa ttcatttacg acttgggctt 900
 atgttcaaag tgaacacaga ctatgagtct agtttaaagc attttcagtt agctttgggt 960
 gactgtaatc cctgcacttt gtccaatgct gaaattcaat ttcacattgc ccacttatat 1020
 gaaaccacga ggaaatatca ttctgcaaaa gaagcttatg aacaactttt gcagacagag 1080
 aatctttctg cacaagtaaa agcaactgtc ttacaacagt taggttggat gcatcacact 1140
 gtagatctcc tgggagataa agccaccaag gaaagctatg ctattcagta tctccaaaag 1200
 tccttggaag cagatcctaa ttctggccag tcctgggtatt tcctcggag gtgctattca 1260
 agtattggga aagttcagga tgcctttata tcttacaggc agtctattga taatcagaa 1320
 gcaagtgcag atacatggtg ttcaataggt gtgctatata agcagcaaaa tcagcccatg 1380
 gatgctttac aggcctatat ttgtgctgta caattggacc atggccatgc tgcagcctgg 1440
 atggacctag gcactctcta tgaatcctgc aaccagcctc aggatgccat taaatgctac 1500
 ttaaatgcaa ctagaagcaa aagttgtagt aatacctctg cacttgcagc acgaattaag 1560
 tatttacagg ctcagttgtg taaccttcca caaggtagtc tacagaataa aactaaatta 1620
 cttcctagta ttgaggaggc gtggagccta ccaattcccg cagagcttac ctccaggcag 1680
 ggtgccatga acacagcaca gcagaatact tctgacaatt ggagtgggtg acatgctgtg 1740
 tcacatcctc cagtacagca acaagctcat tcatggtggt tgacaccaca gaaattacag 1800
 catttggAAC agctccgcgc aaatagaaat aatttaaatac cagcacagaa actgatgctg 1860
 gaacagctgg aaagtcaagt tgtcttaatg caacaacacc aatgagacc aacaggagtt 1920
 gcacaggtac gatctactgg aattcctaata gggccaacag ctgactcatc actgcctaca 1980
 aactcagtct ctggccagca gccacagctt gctctgacca gagtgcctag cgtctctcag 2040
 cctggagtcc gtccctgctg ccctgggagc cctttggcca atggaccctt ttctgcaggc 2100
 catgttccct gtagcacatc aagaacgctg ggaagtacag aactatattt gataggcaat 2160
 aatcatataa caggaagtgg aagtaatgga aacgtgcctt acctgcagcg aaacgcactc 2220
 actctacctc ataaccgcac aaacctgacc agcagcgcag aggagccgtg gaaaaaccaa 2280
 ctatctaact ccactcaggg gcttcacaaa ggtcagagtt cacattcggc aggtcctaata 2340
 ggtgaacgac ctctctctc cactgggcct tcccagcatc tccaggcagc tggctctgggt 2400
 attcagaatc agaacggaca tcccaccctg ctagcaatt cagtaacaca gggggctgct 2460
 ctcaatcacc tctcctctca cactgctacc tcaggtggac aacaaggcat taccttaacc 2520
 aaagagagca agccttcagc aaacatattg acggtgcctg aaacaagcag gcacactgga 2580

45

50

55

EP 2 775 844 B1

gagacaccta acagcactgc cagtgtcgag ggacttccta atcatgtcca tcagatgacg 2640
 gcagatgctg tttgcagtcc tagccatgga gattctaagt caccaggttt actaagttca 2700
 gacaatcctc agctctctgc cttgttgatg ggaaaagcca ataacaatgt gggactgga 2760
 5 acctgtgaca aagtcaataa catccacca gctgttcata caaagactga taactctgtt 2820
 gcctcttcac catcttcagc catttcaaca gcaacacctt ctccaaaatc cactgagcag 2880
 acaaccacaa acagtgttac cagccttaac agccctcaca gtgggctaca cacaattaat 2940
 ggagaaggga tggagaatc tcagagcccc atgaaaacag atctgcttct ggtaaccac 3000
 aaacctagtc cacagatcat accatcaatg tctgtgtcca tatacccag ctcagcagaa 3060
 gttctgaagg catgcaggaa tctaggtaaa ataggcttat ctaacagtag cattttgttg 3120
 10 gataaatgtc cacctccaag accaccatct tcaccatacc ctcccttgcc aaaggacaag 3180
 ttgaatccac ctacacctag tatttacttg gaaaataaac gtgatgcttt ctttcctcca 3240
 ttacatcaat tttgtacaaa tccgaacaac cctgttacag taatacgtgg ccttgctgga 3300
 gctcttaagt tagacctggg acttttctct actaaaactt tgggtggaagc taacaatgaa 3360
 catatggtag aagtgaggac acagttgttg cagccagcag atgaaaactg ggatcccact 3420
 15 ggaacaaaga aatctggca ttgtgaaagt aatagatctc atactacaat tgctaaatat 3480
 gcacagtacc aggcctcctc attccaggaa tcattgagag aagaaaatga aaaaagaagt 3540
 catcataaag accactcaga tagtgaatct acatcgtcag ataattctgg gaggaggagg 3600
 aaaggacctt ttaaaacat aaagtttggg accaatattg acctatctga tgacaaaaag 3660
 tggagattgc agctacatga gctgactaaa cttcctgctt ttgtgctgtg cgtatcagca 3720
 20 ggaaactctc taagccatgt tggtcatacc atattgggca tgaacacagt tcaactatac 3780
 atgaaagttc cagggagcag aacaccaggt catcaggaaa ataacaactt ctgttcagtt 3840
 aacataaata ttggcccagc tgactgtgaa tggttgttg ttcctgaagg ttactgggt 3900
 gttctgaatg acttctgtga aaaaaataat ttgaatttcc taatgggttc ttgggtggcc 3960
 aatcttgaag atctttatga agcaaatggt ccagtgata ggtttattca gcgacctgga 4020
 gatttggctt ggataaatgc aggcaactgt cattgggttc aggctattgg ctgggtgcaac 4080
 25 aacattgctt ggaatgttgg tccacttaca gcctgccagt ataaattggc agtggaacgg 4140
 tacgaatgga acaaattgca aagtgtgaag tcaatagtac ccatggttca tctttcctgg 4200
 aatatggcac gaaatatcaa ggtctcagat ccaaagcttt ttgaaatgat taagtattgt 4260
 cttctaagaa ctctgaagca atgtcagaca ttgagggag ctctcattgc tgcaggaaaa 4320
 gagattatat ggcatggcg gacaaaagaa gaaccagctc attactgtag catttgtgaa 4380
 30 gtggagggtt ttgatctgct ttttgtcact aatgagagta attcacgaaa gacctacata 4440
 gtacattgcc aagattgtgc acgaaaaaca agcggaaact tggaaaactt tgtggtgcta 4500
 gaacagtaca aaatggagga cctgatgcaa gtctatgacc aatttacatt agctcctcca 4560
 ttaccatccg cctcatcttg atattgttcc atggacatta aatgagacct tttctgctat 4620
 tcaggaaata acccagttct gcaccactgg ttttgtagc tatctcgtaa ggctgctggc 4680
 35 tgaaaactgt gtctatgcaa ccttccaagt gcggagtgtc aaccaactgg acgggagaga 4740
 gtactgctcc tactccagga ctctcacaaa gctgatgagc tgtacttcag aaaaaataa 4800
 taatttccat gttttgtata tatctgacaa aactggcaac atcttacaga ctactgactt 4860
 gaagacaacc tcttttatat ttctctatct ctgggctgat gaatttgttt tcatctgtct 4920
 tttcccctt cagaattttc cttggaaaaa aaactactgc ctactggtc atttctttgt 4980
 aaggtagtta gcaattttta gtctttcttt ggtcaacttt ttttaaatgt gaaaagttag 5040
 40 gtaagacact tttttactgc ttttatgttt ttctgtcttg ttttgagacc atgatggtta 5100
 cacttttggc tcctaaataa aatttaaaaa attaacagcc aagtcacaaa ggtaatggat 5160
 tgcacataga ctaaggaata aacttcagat ttgtgatttt tgtttctaatt gctgatgtaa 5220
 atttacacta ttataaata catatttatt gcttgaaaat atttgtgaat ggaatgctgt 5280
 tattttttcc agatttacct gccattgaaa ttttaaggag ttctgtaatt tcaaacacta 5340
 45 ctctattac attttctatg tgtaaataaa actgcttagc attgtacaga aacttttatt 5400
 aaaattgttt aatgttttaa gagttttcta ttgtttgagt tttaaaaaag actttatgta 5460
 cagtgccag tttttgttca tttttgaaat ctgattatat atattttata tatacttatg 5520
 tatgtatata taatatatat agaaatctgg atatatatgt ataaatcttt agaacttaaa 5580
 tttttctcgt ttttaagtttc acatctatgg tagatttttg aggtgtctac tgtaaagtat 5640
 50 tgcttacaaa aagtatgatt atttttaaag aaatatatat ggtatgtatc ctcaagacct 5700
 aaaatgtcag actggtttat tgtaagtgt caattactgc aatgacagac caataacaa 5760
 ttgctgccaa aaaaaaaaa 5778

<210> 8

<211> 4206

55 <212> DNA

<213> Homo sapiens

<400> 8

EP 2 775 844 B1

atgaaatcct gcggagtgtc gctcgctacc gccgcccgtg ccgcccgcgc ttccggtgat 60
gaggaaaaga aaatggcggc gggaaaagcg agcggcgaga gcgaggaggc gtccccccagc 120

5

10

15

20

25

30

35

40

45

50

55

EP 2 775 844 B1

	ctgacagccg	aggagagggg	ggcgctcggc	ggactggaca	gccgcctcct	tgggttcgtg	180
	agatttcatg	aagatggcgc	caggacgaag	gccctactgg	gcaaggctgt	tcgctgctat	240
	gaatctctaa	tcttaaaagc	tgaaggaaaa	gtggagtctg	atctcttttg	tcaattaggt	300
	cacttcaacc	tcttattgga	agattatcca	aaagcattat	ctgcatacca	gaggctacta	360
5	agtttacagt	ctgactactg	gaagaatgct	gcctttttat	atggctcttg	tttggctctac	420
	ttccattata	atgcatttca	gtgggcaatt	aaagcatttc	aggaggtgct	ttatggtgat	480
	cccagctttt	gtcagacca	ggaaattcat	ttacgacttg	ggcttatggt	caaagtgaac	540
	acagactatg	agtctagttt	aaagcatttt	cagttagctt	tggttgactg	taatccctgc	600
	actttgtcca	atgctgaaat	tcaatttcac	attgccact	tatatgaaac	ccagaggaaa	660
	tatcattctg	caaaagaagc	ttatgaacaa	cttttgca	cagagaatct	ttctgcacaa	720
10	gtaaaagcaa	ctgtcttaca	acagttaggt	tggatgcata	acactgtaga	tctcctggga	780
	gataaagcca	ccaaggaag	ctatgctatt	cagtatctcc	aaaagtcctt	ggaagcagat	840
	cctaattctg	gccagtcctg	gtatttcctc	ggaagtgct	attcaagtat	tgggaaagt	900
	caggatgcct	ttatatctta	caggcagctc	attgataaat	cagaagcaag	tgcatataca	960
	tgggtgtcaa	taggtgtgct	atatcagcag	caaaatcagc	ccatggatgc	tttacaggcc	1020
15	tatatttggt	ctgtacaatt	ggaccatggc	catgctgcag	cctggatgga	cctaggcact	1080
	ctctatgaat	cctgcaacca	gcctcaggat	gccattaaat	gctacttaa	tgcaactaga	1140
	agcaaaagtt	gtagtaatac	ctctgcactt	gcagcacgaa	taaagtattt	acaggctcag	1200
	ttgtgtaacc	ttccacaagg	tagtctacag	aataaaacta	aattacttcc	tagtattgag	1260
	gaggcgtgga	gcctaccaat	tcccgagag	cttacctcca	ggcagggtgc	ctgaacaca	1320
	gcacagcaga	atacttctga	caattggagt	ggtggacatg	ctgtgtcaca	tcctccagta	1380
20	cagcaacaag	ctcattcatg	gtgtttgaca	ccacagaaat	tacagcattt	ggaacagctc	1440
	cgcgcaata	gaaataattt	aaatccagca	cagaaactga	tgctggaaca	gctggaaagt	1500
	cagtttgtct	taatgcaaca	acaccaaag	agaccaacag	gagttgcaca	ggtacgatct	1560
	actggaattc	ctaattgggc	aacagctgac	tcatcactgc	ctacaaactc	agtctctggc	1620
	cagcagccac	agcttgctct	gaccagagtg	cctagcgtct	ctcagcctgg	agtccgtcct	1680
25	gcctgccttg	ggcagccttt	ggccaatgga	cccttttctg	caggccatgt	tcctctgtag	1740
	acatcaagaa	cgctgggaag	tacagacact	attttgatag	gcaataatca	tataacagga	1800
	agtggaaagta	atggaaacgt	gccttacctg	cagcgaacag	cactcactct	acctcataac	1860
	cgcaaaaacc	tgaccagcag	cgagaggag	ccgtggaaaa	accaactatc	taactccact	1920
	caggggcttc	acaaaggtca	gagttcacat	tcggcaggtc	ctaattggtga	acgacctctc	1980
	tcttccactg	ggccttccca	gcatctccag	gcagctggct	ctggatttca	gaatcagaac	2040
30	ggacatccca	ccctgcctag	caattcagta	acacaggggg	ctgctctcaa	tcacctctcc	2100
	tctcacactg	ctacctcagg	tggacaacaa	ggcattacct	taaccaaaaga	gagcaagcct	2160
	tcaggaacaa	tattgacggt	gcctgaaaca	agcaggcaca	ctggagagac	acctaacagc	2220
	actgaaactg	tgaggggact	tcctaactca	gtccatcaga	tgacggcaga	atgtgtttgc	2280
	agtcctagcc	atggagattc	taagtcacca	ggttactaa	gttcagacaa	tcctcagctc	2340
	tctgccttgt	tgatgggaaa	agccaataac	aatgtgggta	ctggaacctg	tgacaaagtc	2400
35	aataacatcc	accagctgtg	tcatacaaag	actgataact	ctgttgctct	ttcaccatct	2460
	tcagccatth	caacagcaac	accttctcca	aatccactg	agcagacaac	cacaaacagt	2520
	gttaccagcc	ttaacagccc	tcacagtggg	ctacacacaa	ttaatggaga	agggatggaa	2580
	gaatctcaga	gccccatgaa	aacagatctg	cttctggtta	accacaaacc	tagtccacag	2640
	atcataccat	caatgtctgt	gtccatatac	cccagctcag	cagaagttct	gaaggcatgc	2700
40	aggaatctag	gtaaaaatgg	cttatctaac	agttagcattt	tgttgataa	atgtccact	2760
	ccaagaccac	catcttcacc	ataccctccc	ttgccaaagg	acaagttgaa	tcacactaca	2820
	cctagatatt	acttgaaaa	taaactgtat	gctttctttc	ctccattaca	tcaattttgt	2880
	acaaatccga	acaaccctgt	tacagtaata	cgtagccttg	ctggagctct	taagttagac	2940
	ctgggacttt	tctctactaa	aactttgggtg	gaagctaaca	atgaacatat	ggtagaagtg	3000
	aggacacagt	tgttgcagcc	agcagatgaa	aactgggatc	ccactggaac	aaagaaaatc	3060
45	tggcattgtg	aaagtaatag	atctcatact	acaattgcta	aatatgcaca	gtaccaggcc	3120
	tcctcattcc	aggaatcatt	gagagaagaa	aatgaaaaaa	gaagtcacat	taagaccac	3180
	tcagatagtg	aatctacatc	gtcagataat	tctgggagga	ggaggaagg	accctttaa	3240
	accataaagt	ttgggaccaa	tattgaccta	tctgatgaca	aaaagtggaa	ggtgcagcta	3300
	catgagctga	ctaaaacttc	tgcttttgtg	cggtctgtat	cagcaggaaa	tcttctaagc	3360
	catggtggct	ataccatatt	gggcatgaac	acagttcaac	tatacatgaa	agttccaggg	3420
50	agcagaacac	caggtcatca	ggaaaataac	aactctgtt	cagttaacat	aatattggc	3480
	ccaggtgact	gtgaatgggt	tgttgttctt	gaaggttact	ggggtgttct	gaatgacttc	3540
	tgtgaaaaaa	ataatttgaa	tttctaatg	ggttcttgg	ggcccaatct	tgaagatctt	3600
	atgaagcaaa	atggtccagt	gtataggttt	attcagcgac	ctggagattt	ggtctgata	3660
	aatgcaggca	ctgttcattg	ggttcaggct	attggctgg	gcaacaacat	tgcttggaa	3720
	gttggtccac	ttacagcctg	ccagtataaa	ttggcagtg	aacggtacga	atggaacaaa	3780
55	ttgcaaagtg	tgaagtcaat	agtaccatg	gttcatcttt	cctggaatat	ggcacgaaat	3840
	atcaaggtct	cagatccaaa	gctttttgaa	atgattaagt	attgtcttct	aagaactctg	3900

EP 2 775 844 B1

5 aagcaatgtc agacattgag ggaagctctc attgctgcag gaaaagagat tatatggcat 3960
gggcggacaa aagaagaacc agctcattac tgtagcattt gtgaagtgga ggTTTTTgat 4020
ctgctTTTTg tactaatga gagtaattca cgaaagacct acatagtaca ttgccaagat 4080
tgtgcacgaa aaacaagcgg aaacttggaa aactttgtgg tgctagaaca gtacaaaatg 4140
gaggacctga tgcaagtcta tgaccaattt acattagctc ctccattacc atccgcctca 4200
tcttga 4206

10 <210> 9
<211> 4206
<212> DNA
<213> Homo sapiens

15 <400> 9

20

25

30

35

40

45

50

55

EP 2 775 844 B1

atgaaatcct gcgagtgct gctcgtacc gccgccgctg ccgccgccgc tttcgggtgat 60
 gaggaaaaga aaatggcggc gggaaaagcg agcggcgaga gcgaggaggc gtccccccagc 120
 ctgacagccg aggagagggg ggcgctcggc ggactggaca gccgcctctt tgggttcgtg 180
 agatttcatg aagatggcgc caggacgaag gccctactgg gcaaggctgt tcgctgctat 240
 5 gaatctctaa tcttaaaagc tgaaggaaaa gtggagctctg atttcttttg tcaattaggt 300
 cacttcaacc tcttattgga agattatcca aaagcattat ctgcatacca gaggtactac 360
 agtttacagt ctgactactg gaagaatgct gcctttttat atggctctgg tttgggtctac 420
 ttccattata atgcatttca gtgggcaatt aaagcatttc aggaggtgct ttatggtgat 480
 cccagctttt gtcgagccaa ggaaattcat ttacgagttg ggcttatggt caaagtgaac 540
 10 acagactatg agtctagtgt aaagcatttt cagttagctt tggttgactg taatccctgc 600
 actttgtcca atgctgaaat tcaatttcac attgccactt tatatgaaac ccagaggaaa 660
 tatcattctg caaaagaagc ttatgaacaa cttttgcaga cagagaatct ttctgcacaa 720
 gtaaaagcaa ctgtcttaca acagttaggt tggatgcatc aactgtaga tctcctggga 780
 gataaagcca ccaaggaaag ctatgctatt cagtatctcc aaaagtcctt ggaagcagat 840
 15 cctaattctg gccagtcctg gtatttcttc ggaaggtgct attcaagtat tgggaaagtt 900
 caggatgcct ttatatctta caggcagtct attgataaat cagaagcaag tgcagataca 960
 tgggtgtcaa taggtgtgct atatcagcag caaaatcagc ccatggatgc tttacaggcc 1020
 tatatttgtg ctgtacaatt ggaccatggc catgctgcag cctggatgga cctaggcact 1080
 ctctatgaat cctgcaacca gcctcagatg gccattaaat gctacttaa tgcagactaga 1140
 agcaaaagtt gtagtaatac ctctgcactt gcagcacgaa ttaagtattt acaggctcag 1200
 20 ttgtgtaacc ttccacaagc tagtctacag aataaaaacta aattacttcc tagtattgag 1260
 gaggcgtgga gcctaccaat tcccgcagag cttacctcca ggcaggggtgc catgaacaca 1320
 gcacagcaga atacttctga caattggagt ggtggacatg ctgtgtcaca tcctccagta 1380
 cagcaacaag ctcatctcat gtgtttgaca ccacagaaat tacagcattt ggaacagctc 1440
 cgcgcaaata gaaataattt aaatccagca cagaaactga tgctggaaca gctggaaagt 1500
 25 cagtttgtct taatgcaaca acaccaaagc agaccaacag gagttgcaca ggtacgatct 1560
 actggaattc ctaatgggcc aacagctgac tcatcactgc ctacaaactc agtctctggc 1620
 cagcagccac agcttgctct gaccagagtg cctagcgtct ctacagcctg agtccgtcct 1680
 gcctgccctg ggcagccttt ggccaatgga cccttttctg caggccatgt tcctcttagc 1740
 acatcaagaa cgcgggggaag tacagacact attttgatag gcaataatca tataacagga 1800
 30 aatgacaagta atggaacgt gccttacctg cagcgaacag cactcactct acctcataac 1860
 cgcacaaaacc tgaccagcag cgcaaaggag ccgtggaaaa accaactatc taactcact 1920
 caggggcttc acaaaaggtca gagtccacat tccggcaggtc ctaatggtga acgacctctc 1980
 tcttccactg ggcttccca gcatctccag gcagctggct ctggtattca gaatcagaac 2040
 ggacatccca ccctgcctag caattcagta acacaggggg ctgctctcaa tcacctctcc 2100
 35 tctcacactg ctacctcagg tggacaacaa ggcattacct taaccaaaga gagcaagcct 2160
 tcaggaaaca tattgacggt gcctgaaaca agcaggcaca ctggagagac acctaacagc 2220
 actgccagtg tcgagggact tctaatcat gtccatcaga tgacggcaga tgctgtttgc 2280
 agtcctagcc atggagattc taagtcacca ggtttactaa gttcagacaa tcctcagctc 2340
 tctgccttgt tgatgggaaa agccaataac aatgtgggtg ctggaacctg tgacaaagtc 2400
 aataacatcc acccagctgt tcatacaaag actgataact ctggtgcctc ttcaccatct 2460
 40 tcagccattt caacagcaac accttctcca aaatccactg agcagacaac cacaaacagt 2520
 gttaccagcc ttaacagccc tcacagtggg ctacacaaa ttaatggaga agggatggaa 2580
 gaatctcaga gccccatgaa aacagatctg cttctgggta accacaaacc tagtccacag 2640
 atcataccat caatgtctgt gtccatatac cccagctcag cagaagttct gaaggcatgc 2700
 aggaatctag gtaaaaatgg cttatctaac agtagcattt tgttgataa atgtccacct 2760
 45 ccaagaccac catcttcacc ataccctccc ttgccaaagg acaagttgaa tccacctaca 2820
 cctagtattt acttgaaaa taaacgtgat gctttctttc ctccattaca tcaattttgt 2880
 acaaatccga acaaccctgt tacagtaata cgtggccttg ctggagctct taagttagac 2940
 ctgggacttt tctctactaa aactttgggtg gaagctaaca atgaacatat ggtagaagtg 3000

50

55

EP 2 775 844 B1

5
 10
 15
 20

```

aggacacagt tgttcagcc agcagatgaa aactgggatc ccactggaac aaagaaaatc 3060
tggcattgtg aaagtaatag atctcatact acaattgcta aatatgcaca gtaccaggcc 3120
tcctcattcc aggaatcatt gagagaagaa aatgaaaaaa gaagtcatca taaagaccac 3180
tcagatagtg aatctacatc gtcagataat tctgggagga ggaggaaagg accctttaa 3240
accataaagt ttgggaccaa tattgaccta tctgatgaca aaaagtggaa gttgcagcta 3300
catgagctga ctaaacttcc tgcttttgtg cgtgtcgtat cagcaggaaa tcttctaagc 3360
catgttggtc ataccatatt gggcatgaac acagttcaac tatacatgaa agttccaggg 3420
agcagaacac caggtcatca ggaaaataac aacttctggt cagttaacat aaatattggc 3480
ccaggtgact gtgaatggtt tgttgttctc gaaggttact ggggtgtttt gaatgacttc 3540
tgtgaaaaaa ataatttgaa tttcctaatt ggttcttggg ggccaatct tgaagatctt 3600
tatgaagcaa atgttccagt gtataggttt attcagcgac ctggagattt ggtctggata 3660
aatgcaggca ctgttcattg ggttcaggct attggctggt gcaacaacat tgcttggat 3720
gttgggtccac ttacagcctg ccagtataaa ttggcagtg aacggtacga atggaacaaa 3780
ttgcaaagtg tgaagtcaat agtaccatg gttcatcttt cctggaatat ggcacgaaat 3840
atcaaggctc cagatccaaa gctttttgaa atgattaagt attgtcttct aagaactctg 3900
aagcaatgtc agacattgag ggaagctctc attgctgcag gaaaagagat tatatggcat 3960
gggcggaaca aagaagaacc agctcattac tgtagcattt gtgaagtgga ggtttttgat 4020
ctgctttttg tcactaatga gagtaattca cgaaagacct acatagtaca ttgccaagat 4080
tgtgcacgaa aaacaagcgg aaacttgaa aactttgtgg tgctagaaca gtacaaaatg 4140
gaggacctga tgcaagtcta tgaccaattt acattagctc ctccattacc atccgcctca 4200
tcttga
  
```

25
 30
 35
 40
 45
 50
 55

```

<210> 10
<211> 1401
<212> PRT
<213> Homo sapiens

<400> 10
  
```

EP 2 775 844 B1

	Met	Lys	Ser	Cys	Gly	Val	Ser	Leu	Ala	Thr	Ala	Ala	Ala	Ala	Ala	Ala
	1				5					10					15	
	Ala	Phe	Gly	Asp	Glu	Glu	Lys	Lys	Met	Ala	Ala	Gly	Lys	Ala	Ser	Gly
			20					25					30			
5	Glu	Ser	Glu	Glu	Ala	Ser	Pro	Ser	Leu	Thr	Ala	Glu	Glu	Arg	Glu	Ala
			35					40					45			
	Leu	Gly	Gly	Leu	Asp	Ser	Arg	Leu	Phe	Gly	Phe	Val	Arg	Phe	His	Glu
	50						55					60				
	Asp	Gly	Ala	Arg	Thr	Lys	Ala	Leu	Leu	Gly	Lys	Ala	Val	Arg	Cys	Tyr
10	65					70					75				80	
	Glu	Ser	Leu	Ile	Leu	Lys	Ala	Glu	Gly	Lys	Val	Glu	Ser	Asp	Phe	Phe
				85						90					95	
	Cys	Gln	Leu	Gly	His	Phe	Asn	Leu	Leu	Leu	Glu	Asp	Tyr	Pro	Lys	Ala
				100						105				110		
	Leu	Ser	Ala	Tyr	Gln	Arg	Tyr	Tyr	Ser	Leu	Gln	Ser	Asp	Tyr	Trp	Lys
15			115					120					125			
	Asn	Ala	Ala	Phe	Leu	Tyr	Gly	Leu	Gly	Leu	Val	Tyr	Phe	His	Tyr	Asn
							135						140			
	Ala	Phe	Gln	Trp	Ala	Ile	Lys	Ala	Phe	Gln	Glu	Val	Leu	Tyr	Val	Asp
	145					150					155					160
20	Pro	Ser	Phe	Cys	Arg	Ala	Lys	Glu	Ile	His	Leu	Arg	Leu	Gly	Leu	Met
				165						170					175	
	Phe	Lys	Val	Asn	Thr	Asp	Tyr	Glu	Ser	Ser	Leu	Lys	His	Phe	Gln	Leu
				180					185					190		
	Ala	Leu	Val	Asp	Cys	Asn	Pro	Cys	Thr	Leu	Ser	Asn	Ala	Glu	Ile	Gln
			195					200					205			
25	Phe	His	Ile	Ala	His	Leu	Tyr	Glu	Thr	Gln	Arg	Lys	Tyr	His	Ser	Ala
		210					215					220				
	Lys	Glu	Ala	Tyr	Glu	Gln	Leu	Leu	Gln	Thr	Glu	Asn	Leu	Ser	Ala	Gln
	225					230					235					240
	Val	Lys	Ala	Thr	Val	Leu	Gln	Gln	Leu	Gly	Trp	Met	His	His	Thr	Val
30					245					250					255	
	Asp	Leu	Leu	Gly	Asp	Lys	Ala	Thr	Lys	Glu	Ser	Tyr	Ala	Ile	Gln	Tyr
			260						265					270		
	Leu	Gln	Lys	Ser	Leu	Glu	Ala	Asp	Pro	Asn	Ser	Gly	Gln	Ser	Trp	Tyr

35

40

45

50

55

EP 2 775 844 B1

		275					280				285					
	Phe	Leu	Gly	Arg	Cys	Tyr	Ser	Ser	Ile	Gly	Lys	Val	Gln	Asp	Ala	Phe
		290					295					300				
5	Ile	Ser	Tyr	Arg	Gln	Ser	Ile	Asp	Lys	Ser	Glu	Ala	Ser	Ala	Asp	Thr
	305				310						315					320
	Trp	Cys	Ser	Ile	Gly	Val	Leu	Tyr	Gln	Gln	Gln	Asn	Gln	Pro	Met	Asp
					325					330					335	
	Ala	Leu	Gln	Ala	Tyr	Ile	Cys	Ala	Val	Gln	Leu	Asp	His	Gly	His	Ala
				340					345					350		
10	Ala	Ala	Trp	Met	Asp	Leu	Gly	Thr	Leu	Tyr	Glu	Ser	Cys	Asn	Gln	Pro
			355					360					365			
	Gln	Asp	Ala	Ile	Lys	Cys	Tyr	Leu	Asn	Ala	Thr	Arg	Ser	Lys	Ser	Cys
	370						375					380				
	Ser	Asn	Thr	Ser	Ala	Leu	Ala	Ala	Arg	Ile	Lys	Tyr	Leu	Gln	Ala	Gln
	385					390					395					400
15	Leu	Cys	Asn	Leu	Pro	Gln	Gly	Ser	Leu	Gln	Asn	Lys	Thr	Lys	Leu	Leu
				405						410					415	
	Pro	Ser	Ile	Glu	Glu	Ala	Trp	Ser	Leu	Pro	Ile	Pro	Ala	Glu	Leu	Thr
				420					425					430		
	Ser	Arg	Gln	Gly	Ala	Met	Asn	Thr	Ala	Gln	Gln	Asn	Thr	Ser	Asp	Asn
			435					440					445			
20	Trp	Ser	Gly	Gly	His	Ala	Val	Ser	His	Pro	Pro	Val	Gln	Gln	Gln	Ala
	450					455						460				
	His	Ser	Trp	Cys	Leu	Thr	Pro	Gln	Lys	Leu	Gln	His	Leu	Glu	Gln	Leu
	465					470					475					480
	Arg	Ala	Asn	Arg	Asn	Asn	Leu	Asn	Pro	Ala	Gln	Lys	Leu	Met	Leu	Glu
				485						490						495
25	Gln	Leu	Glu	Ser	Gln	Phe	Val	Leu	Met	Gln	Gln	His	Gln	Met	Arg	Pro
				500					505					510		
	Thr	Gly	Val	Ala	Gln	Val	Arg	Ser	Thr	Gly	Ile	Pro	Asn	Gly	Pro	Thr
			515					520						525		
	Ala	Asp	Ser	Ser	Leu	Pro	Thr	Asn	Ser	Val	Ser	Gly	Gln	Gln	Pro	Gln
		530					535					540				
30	Leu	Ala	Leu	Thr	Arg	Val	Pro	Ser	Val	Ser	Gln	Pro	Gly	Val	Arg	Pro
	545					550					555					560
	Ala	Cys	Pro	Gly	Gln	Pro	Leu	Ala	Asn	Gly	Pro	Phe	Ser	Ala	Gly	His
				565						570						575
35	Val	Pro	Cys	Ser	Thr	Ser	Arg	Thr	Leu	Gly	Ser	Thr	Asp	Thr	Ile	Leu
				580					585					590		
	Ile	Gly	Asn	Asn	His	Ile	Thr	Gly	Ser	Gly	Ser	Asn	Gly	Asn	Val	Pro
			595					600					605			
	Tyr	Leu	Gln	Arg	Asn	Ala	Leu	Thr	Leu	Pro	His	Asn	Arg	Thr	Asn	Leu
		610					615						620			
40	Thr	Ser	Ser	Ala	Glu	Glu	Pro	Trp	Lys	Asn	Gln	Leu	Ser	Asn	Ser	Thr
		625				630					635					640
	Gln	Gly	Leu	His	Lys	Gly	Gln	Ser	Ser	His	Ser	Ala	Gly	Pro	Asn	Gly
				645						650					655	
	Glu	Arg	Pro	Leu	Ser	Ser	Thr	Gly	Pro	Ser	Gln	His	Leu	Gln	Ala	Ala
				660					665					670		
45	Gly	Ser	Gly	Ile	Gln	Asn	Gln	Asn	Gly	His	Pro	Thr	Leu	Pro	Ser	Asn
			675					680						685		
	Ser	Val	Thr	Gln	Gly	Ala	Ala	Leu	Asn	His	Leu	Ser	Ser	His	Thr	Ala
		690					695						700			
	Thr	Ser	Gly	Gly	Gln	Gln	Gly	Ile	Thr	Leu	Thr	Lys	Glu	Ser	Lys	Pro
		705				710					715					720
50	Ser	Gly	Asn	Ile	Leu	Thr	Val	Pro	Glu	Thr	Ser	Arg	His	Thr	Gly	Glu
				725							730				735	
	Thr	Pro	Asn	Ser	Thr	Ala	Ser	Val	Glu	Gly	Leu	Pro	Asn	His	Val	His
				740					745					750		
	Gln	Met	Thr	Ala	Asp	Ala	Val	Cys	Ser	Pro	Ser	His	Gly	Asp	Ser	Lys
			755					760					765			
55	Ser	Pro	Gly	Leu	Leu	Ser	Ser	Asp	Asn	Pro	Gln	Leu	Ser	Ala	Leu	Leu
							775						780			

EP 2 775 844 B1

	Met	Gly	Lys	Ala	Asn	Asn	Asn	Val	Gly	Thr	Gly	Thr	Cys	Asp	Lys	Val
	785					790					795					800
	Asn	Asn	Ile	His	Pro	Ala	Val	His	Thr	Lys	Thr	Asp	Asn	Ser	Val	Ala
					805					810					815	
5	Ser	Ser	Pro	Ser	Ser	Ala	Ile	Ser	Thr	Ala	Thr	Pro	Ser	Pro	Lys	Ser
				820					825					830		
	Thr	Glu	Gln	Thr	Thr	Thr	Asn	Ser	Val	Thr	Ser	Leu	Asn	Ser	Pro	His
			835				840						845			
	Ser	Gly	Leu	His	Thr	Ile	Asn	Gly	Glu	Gly	Met	Glu	Glu	Ser	Gln	Ser
		850					855					860				
10	Pro	Met	Lys	Thr	Asp	Leu	Leu	Leu	Val	Asn	His	Lys	Pro	Ser	Pro	Gln
						870					875					880
	Ile	Ile	Pro	Ser	Met	Ser	Val	Ser	Ile	Tyr	Pro	Ser	Ser	Ala	Glu	Val
					885					890					895	
	Leu	Lys	Ala	Cys	Arg	Asn	Leu	Gly	Lys	Asn	Gly	Leu	Ser	Asn	Ser	Ser
				900					905					910		
15	Ile	Leu	Leu	Asp	Lys	Cys	Pro	Pro	Pro	Arg	Pro	Pro	Ser	Ser	Pro	Tyr
			915					920					925			
	Pro	Pro	Leu	Pro	Lys	Asp	Lys	Leu	Asn	Pro	Pro	Thr	Pro	Ser	Ile	Tyr
							935						940			
	Leu	Glu	Asn	Lys	Arg	Asp	Ala	Phe	Phe	Pro	Pro	Leu	His	Gln	Phe	Cys
						950						955				960
20	Thr	Asn	Pro	Asn	Asn	Pro	Val	Thr	Val	Ile	Arg	Gly	Leu	Ala	Gly	Ala
						965				970					975	
	Leu	Lys	Leu	Asp	Leu	Gly	Leu	Phe	Ser	Thr	Lys	Thr	Leu	Val	Glu	Ala
				980					985					990		
	Asn	Asn	Glu	His	Met	Val	Glu	Val	Arg	Thr	Gln	Leu	Leu	Gln	Pro	Ala
25									1000					1005		
	Asp	Glu	Asn	Trp	Asp	Pro	Thr	Gly	Thr	Lys	Lys	Ile	Trp	His	Cys	Glu
							1015						1020			
	Ser	Asn	Arg	Ser	His	Thr	Thr	Ile	Ala	Lys	Tyr	Ala	Gln	Tyr	Gln	Ala
						1030						1035				1040
30	Ser	Ser	Phe	Gln	Glu	Ser	Leu	Arg	Glu	Glu	Asn	Glu	Lys	Arg	Ser	His
						1045					1050					1055
	His	Lys	Asp	His	Ser	Asp	Ser	Glu	Ser	Thr	Ser	Ser	Asp	Asn	Ser	Gly
						1060				1065					1070	
	Arg	Arg	Arg	Lys	Gly	Pro	Phe	Lys	Thr	Ile	Lys	Phe	Gly	Thr	Asn	Ile
								1080						1085		
35	Asp	Leu	Ser	Asp	Asp	Lys	Lys	Trp	Lys	Leu	Gln	Leu	His	Glu	Leu	Thr
							1095						1100			
	Lys	Leu	Pro	Ala	Phe	Val	Arg	Val	Val	Ser	Ala	Gly	Asn	Leu	Leu	Ser
							1110					1115				1120
	His	Val	Gly	His	Thr	Ile	Leu	Gly	Met	Asn	Thr	Val	Gln	Leu	Tyr	Met
						1125					1130					1135
40	Lys	Val	Pro	Gly	Ser	Arg	Thr	Pro	Gly	His	Gln	Glu	Asn	Asn	Asn	Phe
									1145						1150	
	Cys	Ser	Val	Asn	Ile	Asn	Ile	Gly	Pro	Gly	Asp	Cys	Glu	Trp	Phe	Val
									1160					1165		
	Val	Pro	Glu	Gly	Tyr	Trp	Gly	Val	Leu	Asn	Asp	Phe	Cys	Glu	Lys	Asn
45							1175						1180			
	Asn	Leu	Asn	Phe	Leu	Met	Gly	Ser	Trp	Trp	Pro	Asn	Leu	Glu	Asp	Leu
							1190						1195			1200
	Tyr	Glu	Ala	Asn	Val	Pro	Val	Tyr	Arg	Phe	Ile	Gln	Arg	Pro	Gly	Asp
						1205				1210						1215
	Leu	Val	Trp	Ile	Asn	Ala	Gly	Thr	Val	His	Trp	Val	Gln	Ala	Ile	Gly
50															1230	
	Trp	Cys	Asn	Asn	Ile	Ala	Trp	Asn	Val	Gly	Pro	Leu	Thr	Ala	Cys	Gln
									1240					1245		
	Tyr	Lys	Leu	Ala	Val	Glu	Arg	Tyr	Glu	Trp	Asn	Lys	Leu	Gln	Ser	Val
							1255						1260			
	Lys	Ser	Ile	Val	Pro	Met	Val	His	Leu	Ser	Trp	Asn	Met	Ala	Arg	Asn
55							1270						1275			1280
	Ile	Lys	Val	Ser	Asp	Pro	Lys	Leu	Phe	Glu	Met	Ile	Lys	Tyr	Cys	Leu

EP 2 775 844 B1

					1285					1290					1295	
	Leu	Arg	Thr	Leu	Lys	Gln	Cys	Gln	Thr	Leu	Arg	Glu	Ala	Leu	Ile	Ala
					1300					1305					1310	
5	Ala	Gly	Lys	Glu	Ile	Ile	Trp	His	Gly	Arg	Thr	Lys	Glu	Glu	Pro	Ala
					1315					1320					1325	
	His	Tyr	Cys	Ser	Ile	Cys	Glu	Val	Glu	Val	Phe	Asp	Leu	Leu	Phe	Val
					1330					1335					1340	
	Thr	Asn	Glu	Ser	Asn	Ser	Arg	Lys	Thr	Tyr	Ile	Val	His	Cys	Gln	Asp
					1345					1350					1355	
10	Cys	Ala	Arg	Lys	Thr	Ser	Gly	Asn	Leu	Glu	Asn	Phe	Val	Val	Leu	Glu
					1365					1370					1375	
	Gln	Tyr	Lys	Met	Glu	Asp	Leu	Met	Gln	Val	Tyr	Asp	Gln	Phe	Thr	Leu
					1380					1385					1390	
	Ala	Pro	Pro	Leu	Pro	Ser	Ala	Ser	Ser							
15					1395					1400						

<210> 11

<211> 1401

<212> PRT

20 <213> Homo sapiens

<400> 11

25

30

35

40

45

50

55

EP 2 775 844 B1

	Met	Lys	Ser	Cys	Gly	Val	Ser	Leu	Ala	Thr	Ala	Ala	Ala	Ala	Ala	Ala
	1				5					10					15	
	Ala	Phe	Gly	Asp	Glu	Glu	Lys	Lys	Met	Ala	Ala	Gly	Lys	Ala	Ser	Gly
				20					25					30		
5	Glu	Ser	Glu	Glu	Ala	Ser	Pro	Ser	Leu	Thr	Ala	Glu	Glu	Arg	Glu	Ala
								40					45			
	Leu	Gly	Gly	Leu	Asp	Ser	Arg	Leu	Phe	Gly	Phe	Val	Arg	Phe	His	Glu
	50						55					60				
	Asp	Gly	Ala	Arg	Thr	Lys	Ala	Leu	Leu	Gly	Lys	Ala	Val	Arg	Cys	Tyr
10	65					70					75				80	
	Glu	Ser	Leu	Ile	Leu	Lys	Ala	Glu	Gly	Lys	Val	Glu	Ser	Asp	Phe	Phe
				85						90					95	
	Cys	Gln	Leu	Gly	His	Phe	Asn	Leu	Leu	Leu	Glu	Asp	Tyr	Pro	Lys	Ala
				100					105					110		
15	Leu	Ser	Ala	Tyr	Gln	Arg	Tyr	Tyr	Ser	Leu	Gln	Ser	Asp	Tyr	Trp	Lys
			115				120						125			
	Asn	Ala	Ala	Phe	Leu	Tyr	Gly	Leu	Gly	Leu	Val	Tyr	Phe	His	Tyr	Asn
	130						135					140				
	Ala	Phe	Gln	Trp	Ala	Ile	Lys	Ala	Phe	Gln	Glu	Val	Leu	Tyr	Val	Asp
	145					150					155				160	
20	Pro	Ser	Phe	Cys	Arg	Ala	Lys	Glu	Ile	His	Leu	Arg	Val	Gly	Leu	Met
				165						170					175	
	Phe	Lys	Val	Asn	Thr	Asp	Tyr	Glu	Ser	Ser	Leu	Lys	His	Phe	Gln	Leu
				180					185					190		
	Ala	Leu	Val	Asp	Cys	Asn	Pro	Cys	Thr	Leu	Ser	Asn	Ala	Glu	Ile	Gln
			195				200						205			
25	Phe	His	Ile	Ala	His	Leu	Tyr	Glu	Thr	Gln	Arg	Lys	Tyr	His	Ser	Ala
	210						215					220				
	Lys	Glu	Ala	Tyr	Glu	Gln	Leu	Leu	Gln	Thr	Glu	Asn	Leu	Ser	Ala	Gln
	225					230					235				240	
30	Val	Lys	Ala	Thr	Val	Leu	Gln	Gln	Leu	Gly	Trp	Met	His	His	Thr	Val
				245						250					255	
	Asp	Leu	Leu	Gly	Asp	Lys	Ala	Thr	Lys	Glu	Ser	Tyr	Ala	Ile	Gln	Tyr
				260					265					270		
	Leu	Gln	Lys	Ser	Leu	Glu	Ala	Asp	Pro	Asn	Ser	Gly	Gln	Ser	Trp	Tyr
			275					280					285			
35	Phe	Leu	Gly	Arg	Cys	Tyr	Ser	Ser	Ile	Gly	Lys	Val	Gln	Asp	Ala	Phe
	290						295					300				
	Ile	Ser	Tyr	Arg	Gln	Ser	Ile	Asp	Lys	Ser	Glu	Ala	Ser	Ala	Asp	Thr
	305					310					315					320

40

45

50

55

EP 2 775 844 B1

Trp Cys Ser Ile Gly Val Leu Tyr Gln Gln Gln Asn Gln Pro Met Asp
 325 330 335
 Ala Leu Gln Ala Tyr Ile Cys Ala Val Gln Leu Asp His Gly His Ala
 340 345 350
 5 Ala Ala Trp Met Asp Leu Gly Thr Leu Tyr Glu Ser Cys Asn Gln Pro
 355 360 365
 Gln Asp Ala Ile Lys Cys Tyr Leu Asn Ala Thr Arg Ser Lys Ser Cys
 370 375 380
 Ser Asn Thr Ser Ala Leu Ala Ala Arg Ile Lys Tyr Leu Gln Ala Gln
 385 390 395 400
 10 Leu Cys Asn Leu Pro Gln Gly Ser Leu Gln Asn Lys Thr Lys Leu Leu
 405 410 415
 Pro Ser Ile Glu Glu Ala Trp Ser Leu Pro Ile Pro Ala Glu Leu Thr
 420 425 430
 Ser Arg Gln Gly Ala Met Asn Thr Ala Gln Gln Asn Thr Ser Asp Asn
 435 440 445
 15 Trp Ser Gly Gly His Ala Val Ser His Pro Pro Val Gln Gln Gln Ala
 450 455 460
 His Ser Trp Cys Leu Thr Pro Gln Lys Leu Gln His Leu Glu Gln Leu
 465 470 475 480
 20 Arg Ala Asn Arg Asn Asn Leu Asn Pro Ala Gln Lys Leu Met Leu Glu
 485 490 495
 Gln Leu Glu Ser Gln Phe Val Leu Met Gln Gln His Gln Met Arg Pro
 500 505 510
 Thr Gly Val Ala Gln Val Arg Ser Thr Gly Ile Pro Asn Gly Pro Thr
 515 520 525
 25 Ala Asp Ser Ser Leu Pro Thr Asn Ser Val Ser Gly Gln Gln Pro Gln
 530 535 540
 Leu Ala Leu Thr Arg Val Pro Ser Val Ser Gln Pro Gly Val Arg Pro
 545 550 555 560
 Ala Cys Pro Gly Gln Pro Leu Ala Asn Gly Pro Phe Ser Ala Gly His
 565 570 575
 30 Val Pro Cys Ser Thr Ser Arg Thr Arg Gly Ser Thr Asp Thr Ile Leu
 580 585 590
 Ile Gly Asn Asn His Ile Thr Gly Asn Gly Ser Asn Gly Asn Val Pro
 595 600 605
 Tyr Leu Gln Arg Asn Ala Leu Thr Leu Pro His Asn Arg Thr Asn Leu
 610 615 620
 35 Thr Ser Ser Ala Lys Glu Pro Trp Lys Asn Gln Leu Ser Asn Ser Thr
 625 630 635 640
 Gln Gly Leu His Lys Gly Gln Ser Ser His Ser Ala Gly Pro Asn Gly
 645 650 655
 Glu Arg Pro Leu Ser Ser Thr Gly Pro Ser Gln His Leu Gln Ala Ala
 660 665 670
 40 Gly Ser Gly Ile Gln Asn Gln Asn Gly His Pro Thr Leu Pro Ser Asn
 675 680 685
 Ser Val Thr Gln Gly Ala Ala Leu Asn His Leu Ser Ser His Thr Ala
 690 695 700
 Thr Ser Gly Gly Gln Gln Gly Ile Thr Leu Thr Lys Glu Ser Lys Pro
 705 710 715 720
 45 Ser Gly Asn Ile Leu Thr Val Pro Glu Thr Ser Arg His Thr Gly Glu
 725 730 735
 Thr Pro Asn Ser Thr Ala Ser Val Glu Gly Leu Pro Asn His Val His
 740 745 750
 50 Gln Met Thr Ala Asp Ala Val Cys Ser Pro Ser His Gly Asp Ser Lys
 755 760 765
 Ser Pro Gly Leu Leu Ser Ser Asp Asn Pro Gln Leu Ser Ala Leu Leu
 770 775 780
 Met Gly Lys Ala Asn Asn Val Gly Thr Gly Thr Cys Asp Lys Val
 785 790 795 800
 55 Asn Asn Ile His Pro Ala Val His Thr Lys Thr Asp Asn Ser Val Ala
 805 810 815
 Ser Ser Pro Ser Ser Ala Ile Ser Thr Ala Thr Pro Ser Pro Lys Ser

EP 2 775 844 B1

	His	Tyr	Cys	Ser	Ile	Cys	Glu	Val	Glu	Val	Phe	Asp	Leu	Leu	Phe	Val
			1330				1335					1340				
	Thr	Asn	Glu	Ser	Asn	Ser	Arg	Lys	Thr	Tyr	Ile	Val	His	Cys	Gln	Asp
5	1345					1350					1355				1360	
	Cys	Ala	Arg	Lys	Thr	Ser	Gly	Asn	Leu	Glu	Asn	Phe	Val	Val	Leu	Glu
					1365					1370					1375	
	Gln	Tyr	Lys	Met	Glu	Asp	Leu	Met	Gln	Val	Tyr	Asp	Gln	Phe	Thr	Leu
				1380					1385					1390		
10	Ala	Pro	Pro	Leu	Pro	Ser	Ala	Ser	Ser							
			1395					1400								

<210> 12

<211> 3896

<212> DNA

15 <213> Homo sapiens

<400> 12

20

25

30

35

40

45

50

55

EP 2 775 844 B1

ccttccgcag ctgccgcttc agtccgaagg aggaagggaa ccaaccctact ttctcggcgc 60
 cgcggtctctt ttctaaaagt aatgtgaaaa cctttgcatc ttctgatagt ctagccaagg 120
 tccaagaagt agcaagctgg cttttggaaa tgaatcagga actgctctct gtgggcagca 180
 5 aaagacgacg aactggaggc tctctgagag gtaacccttc ctcaagccag gtagatgaag 240
 aacagatgaa tcgtgtggtg gaggaggaac agcaacagca actcagacaa caagaggagg 300
 agcacactgc aaggaatggt gaagtgtgtg gtagtagaacc tagacctgga ggccaaaatg 360
 attcccagca aggacagtgt gaagaaaaca ataatagatt tatttcggta gatgaggact 420
 cctcaggaaa ccaagaagaa caagaggaag atgaagaaca tgctggtgaa caagatgagg 480
 10 aggatgagga ggaggaggag atggaccagg agagtgacga ttttgatcag tctgatgata 540
 gtagcagaga agatgaacat acacatacta acagtgtcac gaactccagt agtattgtgg 600
 acctgcccgt tcaccaactc tctccccat tctatacaaa aacaacaaaa atgaaaagaa 660
 agttggacca tggttctgag gtccgctctt tttctttggg aaagaaacca tgcaaagtct 720
 cagaatatac aagtaccact gggcttgtac catgttcagc aacaccaaca acttttgggg 780
 acctcagagc agccaatggc caagggcaac aacgacgccg aattacatct gtccagccac 840
 15 ctacaggcct ccaggaatgg ctaaaaatgt ttcagagctg gtagtgacca gagaaattgc 900
 ttgctttaga tgaactcatt gatagttgtg aaccaacaca agtaaacat atgatgcaag 960
 tgatagaacc ccagtttcaa cgagacttca tttcattgct ccctaaagag ttggcactct 1020
 atgtgctttc attcctggaa cccaaagacc tgctacaagc agctcagaca tgtcgcactact 1080
 ggagaatfff ggctgaagac aaccttctct ggagagagaa atgcaaagaa gaggggattg 1140
 20 atgaaccatt gcacatcaag agaagaaaag taataaaacc aggtttcata cacagtccat 1200
 ggaaaagtgc atacatcaga cagcacagaa ttgatactaa ctggaggcga ggagaactca 1260
 aatctcctaa ggtgctgaaa ggacatgatg atcatgtgat cacatgctta cagttttgtg 1320
 gcaaccgaat agttagtggg tctgatgaca acactttaa agtttgggtca gcaatcagag 1380
 gcaaatgtct gagaacatta gtgggacata caggtggagt atggtcatca caaatgagag 1440
 25 acaacatcat cattagtgga tctacagatc ggacactcaa agtgtggaat gcagagactg 1500
 gagaatgtat acacacctta tatgggcata cttccactgt gcgttgtatg catcttcatg 1560
 aaaaaagagt tgtagcggg tctcgagatg ccactcttag ggtttgggat attgagacag 1620
 gccagtgttt acatgttttg atgggtcatg ttgcagcagt ccgctgtgtt caatatgatg 1680
 gcaggagggg tgtagtgga gcatatgatt ttatggtaaa ggtgtgggat ccagagactg 1740
 aaacctgtct acacacgttg caggggcata ctaatagagt ctattcatta cagtttgatg 1800
 30 gtatccatgt ggtgagtgga tctcttgata catcaatccg tgtttgggat gtggagacag 1860
 ggaattgcat tcacacgtta acagggcacc agtcgttaac aagtggaatg gaactcaaag 1920
 acaatattct tgtctctggg aatgcagatt ctacagttaa aatctgggat atcaaaacag 1980
 gacagtgttt acaaacattg caaggtccca acaagcatca gagtgtctg acctgtttac 2040
 agttcaacaa gaactttgta attaccagct cagatgatgg aactgtaaaa ctatgggact 2100
 35 tgaaaacggg tgaatttatt cgaaacctag tcacattgga gagtggggg agtgggggag 2160
 ttgtgtggcg gatcagagcc tcaaacacaa agctggtgtg tgcagttggg agtcggaatg 2220
 ggactgaaga aaccaagctg ctggtgctgg actttgatgt ggacatgaag tgaagagcag 2280
 aaaagatgaa tttgtccaat tgtgtagacg atatactccc tgccttccc cctgcaaaaa 2340
 gaaaaaaga aaagaaaaag aaaaaaatcc cttgttctca gtggtgcagg atgttggtct 2400
 40 ggggcaacag attgaaaaga cctacagact aagaaggaaa agaagaagag atgacaaacc 2460
 ataactgaca agagagggcgt ctgctgtctc atcacataaa aggcttccact tttgactgag 2520
 ggcagctttg caaaatgaga ctttctaata caaaccaggt gcaattattt ctttattttc 2580
 ttctccagtg gtcattgggc agtgttaatg ctgaaacatc attacagatt ctgctagcct 2640
 gttcttttac cactgacagc tagacaccta gaaaggaact gcaataatat caaaacaagt 2700

45

50

55

EP 2 775 844 B1

actggttgac tttctaatta gagagcatct gcaacaaaaa gtcatttttc tggagtggaa 2760
 aagcttaaaa aaattactgt gaattgtttt tgtacagtta tcatgaaaag cttttttttt 2820
 tttttttttg ccaaccattg ccaatgtcaa tcaatcacag tattagcctc tgtaaatcta 2880
 tttactgttg cttccatata cattcttcaa tgcatatggt gctcaaaggt ggcaagttgt 2940
 5 cctgggttct gtgagtcctg agatggattt aattcttgat gctggtgcta gaagtaggtc 3000
 ttcaaatatg ggattgttgt cccaaccctg tactgtactc ccagtggcca aacttattta 3060
 tgctgctaaa tgaaagaaag aaaaaagcaa attatttttt tttatttttt ttctgctgtg 3120
 acgttttagt ccagactga attccaaatt tgctctagtt tggttatgga aaaaagactt 3180
 tttgccactg aaacttgagc catctgtgcc tctaagaggc tgagaatgga agagtttcag 3240
 10 ataataaaga gtgaagtttg cctgcaagta aagaattgag agtgtgtgca aagcttattt 3300
 tcttttatct gggcaaaaat taaaacacat tccttggaac agagctatta cttgcctggt 3360
 ctgtggagaa acttttcttt ttgagggctg tggatgaatgg atgaacgtac atcgtaaaac 3420
 tgacaaaata ttttaaaaat atataaaaca caaaatataa ataaagttgc tggtcagtct 3480
 tagtgtttta cagtatttgg gaaaacaact gttacagttt tattgctctg agtaactgac 3540
 15 aaagcagaaa ctattcagtt tttgtagtaa aggcgtcaca tgcaaacaaa caaatgaat 3600
 gaaacagtca aatggtttgc ctcatctccc aagagccaca actcaagctg aactgtgaaa 3660
 gtggtttaac actgtatcct aggcgatctt ttttctcct tctgtttatt tttttgtttg 3720
 ttttatttat agtctgattt aaaacaatca gattcaagtt ggtaattttt agttatgtaa 3780
 caacctgaca tgatggagga aaacaacctt taaagggatt gtgtctatgg tttgattcac 3840
 20 ttagaaattt tatttttctta taacttaagt gcaataaaat gtgttttttc atgtta 3896

<210> 13
 <211> 2124
 <212> DNA
 <213> Homo sapiens
 25
 <400> 13

30

35

40

45

50

55

EP 2 775 844 B1

atgaatcagg aactgctctc tgtgggcagc aaaagacgac gaactggagg ctctctgaga 60
 ggtaaccctt cctcaagcca ggtagatgaa gaacagatga atcgtgtggt agaggaggaa 120
 cagcaacagc aactcagaca acaagaggag gagcacactg caaggaatgg tgaagttggt 180
 5 ggagtagaac ctagacctgg aggccaaaat gattcccagc aaggacagtt ggaagaaaac 240
 aataatagat ttatttcggt agatgaggac tcctcaggaa accaagaaga acaagaggaa 300
 gatgaagaac atgctggtga acaagatgag gaggatgagg aggaggagga gatggaccag 360
 gagagtgacg attttgatca gtctgatgat agtagcagag aagatgaaca tacacatact 420
 aacagtgtca cgaactccag tagtattgtg gacctgcccg ttcaccaact ctccctccca 480
 10 ttctatacaa aaacaacaaa aatgaaaaga aagttggacc atggttctga ggtccgctct 540
 ttttctttgg gaaagaaaacc atgcaaagt cagaatata caagtaccac tgggcttgta 600
 ccatgttcag caacaccaac aacttttggg gacctcagag cagccaatgg ccaagggcaa 660
 caacgacgcc gaattacatc tgtccagcca cctacaggcc tccaggaatg gctaaaaatg 720
 tttcagagct ggagtggacc agagaaaattg cttgctttag atgaactcat tgatagttgt 780
 gaaccaacac aagtaaaaaca tatgatgcaa gtgatagaac cccagtttca acgagacttc 840
 15 atttcattgc tccctaaaaga gttggcactc tatgtgcttt cattcctgga acccaaagac 900
 ctgctacaag cagctcagac atgtcgctac tggagaatth tggctgaaga caaccttctc 960
 tggagagaga aatgcaaaga agaggggatt gatgaacat tgcacatcaa gagaagaaaa 1020
 gtaataaaac caggtttcat acacagtcca tggaaaagtg catacatcag acagcacaga 1080
 attgatacta actggaggcg aggagaactc aaatctccta aggtgctgaa aggacatgat 1140
 20 gatcatgtga tcacatgctt acagttttgt ggtaaccgaa tagttagtgg ttctgatgac 1200
 aacactttaa aagtttggtc agcagtccca ggcaaatgtc tgagaacatt agtgggacat 1260
 acagggtggag tatggtcatc acaaatgaga gacaacatca tcattagtgg atctacagat 1320
 cggacactca aagtgtggaa tgcagagact ggagaatgta tacacacctt atatgggcat 1380
 acttccactg tgcgttgat gcacatctcat gaaaaaagag ttgttagcgg ttctcgagat 1440
 gccactctta gggtttgga tattgagaca ggccagtgtt tacatgtttt gatgggtcat 1500
 25 gttgcagcag tccgctgtgt tcaatatgat ggacaggagg ttgttagtgg agcatatgat 1560
 tttatggtaa aggtgtggga tccagagact gaaacctgtc tacacacgtt gcaggggcat 1620
 actaatagag tctattcatt acagtttgat ggtatccatg tggtgagtgg atctcttgat 1680
 acatcaatcc gtgtttggga tgtggagaca gggaaattgca ttcacacgtt aacagggcac 1740
 cagtcgttaa caagtggaat ggaactcaaa gacaatattc ttgtctctgg gaatgcagat 1800
 30 tctacagtta aaatctggga tatcaaaaca ggacagtgtt tacaacatt gcaaggtccc 1860
 aacaagcatc agagtgtgt gacctgttta cagttcaaca agaactttgt aattaccagc 1920
 tcagatgatg gaactgtaaa actatgggac ttgaaaacgg gtgaatttat tcgaaaccta 1980
 gtcacattgg agagtggggg gagtggggga gttgtgtggc ggatcagagc ctcaaacaca 2040
 aagctggtgt gtgcagttgg gagtcggaat gggactgaag aaaccaagct gctggtgctg 2100
 35 gactttgatg tggacatgaa gtga 2124

<210> 14
 <211> 707
 <212> PRT
 <213> Homo sapiens

<400> 14

EP 2 775 844 B1

	Met	Asn	Gln	Glu	Leu	Leu	Ser	Val	Gly	Ser	Lys	Arg	Arg	Arg	Thr	Gly
	1				5					10					15	
	Gly	Ser	Leu	Arg	Gly	Asn	Pro	Ser	Ser	Ser	Gln	Val	Asp	Glu	Glu	Gln
				20					25					30		
5	Met	Asn	Arg	Val	Val	Glu	Glu	Glu	Gln	Gln	Gln	Gln	Leu	Arg	Gln	Gln
			35					40					45			
	Glu	Glu	Glu	His	Thr	Ala	Arg	Asn	Gly	Glu	Val	Val	Gly	Val	Glu	Pro
		50					55					60				
	Arg	Pro	Gly	Gly	Gln	Asn	Asp	Ser	Gln	Gln	Gly	Gln	Leu	Glu	Glu	Asn
10	65					70						75				80
	Asn	Asn	Arg	Phe	Ile	Ser	Val	Asp	Glu	Asp	Ser	Ser	Gly	Asn	Gln	Glu
				85						90					95	
	Glu	Gln	Glu	Glu	Asp	Glu	Glu	His	Ala	Gly	Glu	Gln	Asp	Glu	Glu	Asp
				100					105					110		
15	Glu	Glu	Glu	Glu	Glu	Met	Asp	Gln	Glu	Ser	Asp	Asp	Phe	Asp	Gln	Ser
				115				120					125			
	Asp	Asp	Ser	Ser	Arg	Glu	Asp	Glu	His	Thr	His	Thr	Asn	Ser	Val	Thr
						130		135					140			
	Asn	Ser	Ser	Ser	Ile	Val	Asp	Leu	Pro	Val	His	Gln	Leu	Ser	Ser	Pro
						145		150				155				160
20	Phe	Tyr	Thr	Lys	Thr	Thr	Lys	Met	Lys	Arg	Lys	Leu	Asp	His	Gly	Ser
				165							170				175	
	Glu	Val	Arg	Ser	Phe	Ser	Leu	Gly	Lys	Lys	Pro	Cys	Lys	Val	Ser	Glu
				180					185					190		
	Tyr	Thr	Ser	Thr	Thr	Gly	Leu	Val	Pro	Cys	Ser	Ala	Thr	Pro	Thr	Thr
25			195					200					205			
	Phe	Gly	Asp	Leu	Arg	Ala	Ala	Asn	Gly	Gln	Gly	Gln	Gln	Arg	Arg	Arg
			210				215					220				
	Ile	Thr	Ser	Val	Gln	Pro	Pro	Thr	Gly	Leu	Gln	Glu	Trp	Leu	Lys	Met
						225		230				235				240
30	Phe	Gln	Ser	Trp	Ser	Gly	Pro	Glu	Lys	Leu	Leu	Ala	Leu	Asp	Glu	Leu
				245						250					255	
	Ile	Asp	Ser	Cys	Glu	Pro	Thr	Gln	Val	Lys	His	Met	Met	Gln	Val	Ile
				260					265					270		
	Glu	Pro	Gln	Phe	Gln	Arg	Asp	Phe	Ile	Ser	Leu	Leu	Pro	Lys	Glu	Leu
				275				280					285			
35	Ala	Leu	Tyr	Val	Leu	Ser	Phe	Leu	Glu	Pro	Lys	Asp	Leu	Leu	Gln	Ala
				290			295					300				
	Ala	Gln	Thr	Cys	Arg	Tyr	Trp	Arg	Ile	Leu	Ala	Glu	Asp	Asn	Leu	Leu
				305			310					315				320
	Trp	Arg	Glu	Lys	Cys	Lys	Glu	Glu	Gly	Ile	Asp	Glu	Pro	Leu	His	Ile
				325						330					335	
40	Lys	Arg	Arg	Lys	Val	Ile	Lys	Pro	Gly	Phe	Ile	His	Ser	Pro	Trp	Lys
				340					345					350		
	Ser	Ala	Tyr	Ile	Arg	Gln	His	Arg	Ile	Asp	Thr	Asn	Trp	Arg	Arg	Gly
				355				360					365			
45	Glu	Leu	Lys	Ser	Pro	Lys	Val	Leu	Lys	Gly	His	Asp	Asp	His	Val	Ile
		370					375					380				
	Thr	Cys	Leu	Gln	Phe	Cys	Gly	Asn	Arg	Ile	Val	Ser	Gly	Ser	Asp	Asp
				385			390					395				400
	Asn	Thr	Leu	Lys	Val	Trp	Ser	Ala	Val	Thr	Gly	Lys	Cys	Leu	Arg	Thr
				405							410				415	
50	Leu	Val	Gly	His	Thr	Gly	Gly	Val	Trp	Ser	Ser	Gln	Met	Arg	Asp	Asn
				420					425					430		
	Ile	Ile	Ile	Ser	Gly	Ser	Thr	Asp	Arg	Thr	Leu	Lys	Val	Trp	Asn	Ala
				435				440						445		

55

EP 2 775 844 B1

Glu Thr Gly Glu Cys Ile His Thr Leu Tyr Gly His Thr Ser Thr Val
 450 455 460
 Arg Cys Met His Leu His Glu Lys Arg Val Val Ser Gly Ser Arg Asp
 465 470 475 480
 5 Ala Thr Leu Arg Val Trp Asp Ile Glu Thr Gly Gln Cys Leu His Val
 485 490 495
 Leu Met Gly His Val Ala Ala Val Arg Cys Val Gln Tyr Asp Gly Arg
 500 505 510
 Arg Val Val Ser Gly Ala Tyr Asp Phe Met Val Lys Val Trp Asp Pro
 515 520 525
 10 Glu Thr Glu Thr Cys Leu His Thr Leu Gln Gly His Thr Asn Arg Val
 530 535 540
 Tyr Ser Leu Gln Phe Asp Gly Ile His Val Val Ser Gly Ser Leu Asp
 545 550 555 560
 15 Thr Ser Ile Arg Val Trp Asp Val Glu Thr Gly Asn Cys Ile His Thr
 565 570 575
 Leu Thr Gly His Gln Ser Leu Thr Ser Gly Met Glu Leu Lys Asp Asn
 580 585 590
 Ile Leu Val Ser Gly Asn Ala Asp Ser Thr Val Lys Ile Trp Asp Ile
 595 600 605
 20 Lys Thr Gly Gln Cys Leu Gln Thr Leu Gln Gly Pro Asn Lys His Gln
 610 615 620
 Ser Ala Val Thr Cys Leu Gln Phe Asn Lys Asn Phe Val Ile Thr Ser
 625 630 635 640
 Ser Asp Asp Gly Thr Val Lys Leu Trp Asp Leu Lys Thr Gly Glu Phe
 645 650 655
 25 Ile Arg Asn Leu Val Thr Leu Glu Ser Gly Gly Ser Gly Gly Val Val
 660 665 670
 Trp Arg Ile Arg Ala Ser Asn Thr Lys Leu Val Cys Ala Val Gly Ser
 675 680 685
 30 Arg Asn Gly Thr Glu Glu Thr Lys Leu Leu Val Leu Asp Phe Asp Val
 690 695 700
 Asp Met Lys
 705

35 <210> 15
 <211> 2591
 <212> DNA
 <213> Homo sapiens

40 <400> 15

45

50

55

EP 2 775 844 B1

gatgggattg gggttttccc ctcccatgtg ctcaagactg gcgctaaaag ttttgagctt 60
 ctcaaaagt c tagagccacc gtccaggag caggtagctg ctgggctccg gggacacttt 120
 gcgttcgggc tgggagcgtg ctttccacga cggtgacacg cttccctgga ttggcagcca 180
 gactgccttc cgggtcactg ccatggagga gccgcagtca gatcctagcg tcgagcccc 240
 5 tctgagtcag gaaacat ttt cagacctatg gaaactactt cctgaaaaca acgttctgtc 300
 ccccttgccg tcccaagcaa tggatgattt gatgctgtcc ccggacgata ttgaacaatg 360
 gttcactgaa gaccaggtc cagatgaagc tcccagaatg ccagaggctg ctccccctg 420
 ggcccctgca ccagcagctc ctacaccggc ggcccctgca ccagccccct cctggcccc 480
 gtcatcttct gtcccttccc agaaaacct a ccagggcagc tacggtttcc gtctgggctt 540
 10 cttgcattct gggacagcca agtctgtgac ttgcacgtac tcccctgcc tcaacaagat 600
 gttttgccaa ctggccaaga cctgccctgt gcagctgtgg gttgattcca cccccccg 660
 cggcaccgc gtccgcgcca tggccatcta caagcagtca cagcacatga cggaggttgt 720
 gaggcgctgc ccccaccatg agcgtctgtc agatagcgat ggtctggccc ctctcagca 780
 tcttatccga gtggaaggaa atttgctgtg ggagtattg gatgacagaa acacttttctg 840
 15 acatagtgtg gtggtgccct atgagccgcc tgaggttggc tctgactgta ccaccatcca 900
 ctacaactac atgtgtaaca gttcctgcat gggcggcatg aaccggaggc ccaccctcac 960
 catcatcaca ctggaagact ccagtggtaa tctactggga cggaacagct ttgaggtgcg 1020
 tgtttgtgcc tgtcctggga gagaccggcg cacagaggaa gagaatctcc gcaagaaagg 1080
 ggagcctcac cacgagctgc cccagggag cactaagcga gactgcccc acaaccagg 1140
 ctctctccc cagccaaaga agaaaccact ggtaggagaa tatttcacc ttcagatccg 1200
 20 tgggcgtgag cgcttcgaga tgttccgaga gctgaatgag gccttggaac tcaaggatgc 1260

ccaggctggg aaggagccag gggggagcag ggctcactcc agccacctga agtccaaaaa 1320
 gggtcagtct acctcccgcc ataaaaaact catgttcaag acagaagggc ctgactcaga 1380
 25 ctgacattct cacttcttg ttccccactg acagcctccc acccccactc tccctcccc 1440
 tgccattttg ggttttgggt ctttgaacc ttgcttgcaa taggtgtgcg tcagaagcac 1500
 ccaggacttc catttgcttt gtcccggggc tccactgaac aagttggcct gcactgggtg 1560
 tttgttggg ggaggaggat ggggagttag acataccagc ttagatttta aggtttttac 1620
 tgtgagggat gtttgggaga tgaagaaat gttcttgcag ttaagggtta gtttacaatc 1680
 agccacattc taggtagggg cccacttcac cgtactaacc agggaagctg tccctcactg 1740
 30 ttgaattttc tctaacttca aggccatat ctgtgaaatg ctggcatttg cacctacctc 1800
 acagagtgca ttgtgagggt taatgaaata atgtacatct ggccttgaac ccacctttta 1860
 ttacatgggg tctagaactt gacccccttg agggtgcttg ttccctctcc ctgttggtcg 1920
 gtgggttggg agtttctaca gttgggcagc tggttaggta gagggagttg tcaagtctct 1980
 gctggcccag ccaaaccctg tctgacaacc tcttgggtgaa ccttagtacc taaaaggaaa 2040
 35 tctcacccca tcccacacc tggaggattt catctcttgt atatgatgat ctggatccac 2100
 caagacttgt tttatgctca ggtcaattt ctttttctt ttttttttt ttttttctt 2160
 ttctttgaga ctgggtctcg ctttgttgcc caggctggag tggagtggcg tgatcttggc 2220
 ttactgcagc ctttgccctc ccggctcgag cagtccctgc tcagcctccg gagtagctgg 2280
 gaccacaggt tcatgccacc atggccagcc aacttttgca tgttttgtag agatggggtc 2340
 tcacagtgtt gccaggtcgt gtctcaaact cctgggctca ggcgatccac ctgtctcagc 2400
 40 ctcccagagt gctgggatta caattgtgag ccaccacgtc cagctggaag ggtcaacatc 2460
 ttttacattc tgcaagcaca tctgcat ttt caccaccctc tctccctttt 2520
 tataatccat ttttatatcg atctcttatt ttacaataaa actttgctgc cacctgtgtg 2580
 tctgaggggt g 2591

45 <210> 16
 <211> 1182
 <212> DNA
 <213> Homo sapiens

50 <400> 16

55

EP 2 775 844 B1

```

atggaggagc cgcagtcaga tcctagcgtc gagccccctc tgagtcagga aacattttca 60
gacctatgga aactacttcc tgaaaacaac gttctgtccc ccttgccgtc ccaagcaatg 120
gatgatttga tgctgtcccc ggacgatatt gaacaatggt tcaactgaaga cccaggtcca 180
gatgaagctc ccagaatgcc agaggctgct ccccgctggg cccctgcacc agcagtcctc 240
5 acaccggcgg cccctgcacc agccccctcc tggccccctgt catcttctgt cccttcccag 300
aaaacctacc agggcagcta cggtttccgt ctgggcttct tgcattctgg gacagccaag 360
tctgtgactt gcacgtactc ccctgccctc aacaagatgt ttgccaaact ggccaagacc 420
tgccctgtgc agctgtgggt tgattccaca cccccgccg gcacccgctg ccgcgccatg 480
gccatctaca agcagtcaca gcacatgacg gaggttgtga ggcgctgcc ccaccatgag 540
10 cgctgctcag atagcgatgg tctggcccct cctcagcatc ttatccgagt ggaaggaaat 600
ttgcgtgtgg agtatttggg tgacagaaac acttttcgac atagtgtggg ggtgccctat 660
gagccgcctg aggttggctc tgactgtacc accatccact acaactacat gtgtaacagt 720
tcttgcacatg gcggcatgaa ccggaggccc atcctcacca tcatcacact ggaagactcc 780
agtggtaatc tactgggacg gaacagcttt gaggtgctgt tttgtgcctg tcctgggaga 840
15 gaccggcgca cagaggaaga gaatctccgc aagaaagggg agcctcacca cgagctgcc 900
ccagggagca ctaagcgagc actgcccaac aacaccagct cctctcccca gccaaagaag 960
aaaccactgg atggagaata tttcaccctt cagatccgtg ggcgtgagcg cttcgagatg 1020
ttccgagagc tgaatgaggc cttggaactc aaggatgccc aggctgggaa ggagccaggg 1080
gggagcaggg ctactccag ccacctgaag tccaaaaagg gtcagtctac ctcccgccat 1140
20 aaaaaactca tgttcaagac agaagggcct gactcagact ga 1182

```

```

<210> 17
<211> 393
<212> PRT
<213> Homo sapiens

```

```

<400> 17

```

```

Met Glu Glu Pro Gln Ser Asp Pro Ser Val Glu Pro Pro Leu Ser Gln
1 5 10 15
30 Glu Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro Glu Asn Asn Val Leu
20 25 30
Ser Pro Leu Pro Ser Gln Ala Met Asp Asp Leu Met Leu Ser Pro Asp
35 40 45

```

EP 2 775 844 B1

Asp Ile Glu Gln Trp Phe Thr Glu Asp Pro Gly Pro Asp Glu Ala Pro
 50 55 60
 Arg Met Pro Glu Ala Ala Pro Arg Val Ala Pro Ala Pro Ala Ala Pro
 65 70 75 80
 5 Thr Pro Ala Ala Pro Ala Pro Ala Pro Ser Trp Pro Leu Ser Ser Ser
 85 90 95
 Val Pro Ser Gln Lys Thr Tyr Gln Gly Ser Tyr Gly Phe Arg Leu Gly
 100 105 110
 Phe Leu His Ser Gly Thr Ala Lys Ser Val Thr Cys Thr Tyr Ser Pro
 115 120 125
 10 Ala Leu Asn Lys Met Phe Cys Gln Leu Ala Lys Thr Cys Pro Val Gln
 130 135 140
 Leu Trp Val Asp Ser Thr Pro Pro Pro Gly Thr Arg Val Arg Ala Met
 145 150 155 160
 15 Ala Ile Tyr Lys Gln Ser Gln His Met Thr Glu Val Val Arg Arg Cys
 165 170 175
 Pro His His Glu Arg Cys Ser Asp Ser Asp Gly Leu Ala Pro Pro Gln
 180 185 190
 His Leu Ile Arg Val Glu Gly Asn Leu Arg Val Glu Tyr Leu Asp Asp
 195 200 205
 20 Arg Asn Thr Phe Arg His Ser Val Val Val Pro Tyr Glu Pro Pro Glu
 210 215 220
 Val Gly Ser Asp Cys Thr Thr Ile His Tyr Asn Tyr Met Cys Asn Ser
 225 230 235 240
 Ser Cys Met Gly Gly Met Asn Arg Arg Pro Ile Leu Thr Ile Ile Thr
 245 250 255
 25 Leu Glu Asp Ser Ser Gly Asn Leu Leu Gly Arg Asn Ser Phe Glu Val
 260 265 270
 Arg Val Cys Ala Cys Pro Gly Arg Asp Arg Arg Thr Glu Glu Glu Asn
 275 280 285
 30 Leu Arg Lys Lys Gly Glu Pro His His Glu Leu Pro Pro Gly Ser Thr
 290 295 300
 Lys Arg Ala Leu Pro Asn Asn Thr Ser Ser Ser Pro Gln Pro Lys Lys
 305 310 315 320
 Lys Pro Leu Asp Gly Glu Tyr Phe Thr Leu Gln Ile Arg Gly Arg Glu
 325 330 335
 35 Arg Phe Glu Met Phe Arg Glu Leu Asn Glu Ala Leu Glu Leu Lys Asp
 340 345 350
 Ala Gln Ala Gly Lys Glu Pro Gly Gly Ser Arg Ala His Ser Ser His
 355 360 365
 Leu Lys Ser Lys Lys Gly Gln Ser Thr Ser Arg His Lys Lys Leu Met
 370 375 380
 40 Phe Lys Thr Glu Gly Pro Asp Ser Asp
 385 390

<210> 18
 <211> 1267
 <212> DNA
 <213> Homo sapiens

<400> 18

EP 2 775 844 B1

5
 10
 cgagggctgc ttccggctgg tgccccggg ggagacccaa cctggggcga cttcaggggt 60
 gccacattcg ctaagtgctc ggagttaata gcacctcctc cgagcactcg ctcacggcgt 120
 ccccttgctc ggaaagatac cgcgggtccct ccagaggatt tgagggacag ggtcggaggg 180
 ggctcttccg ccagcaccgg aggaagaaaag aggaggggct ggctggtcac cagaggggtgg 240
 ggcggaccgc gtgctgctcg cggctgctgga gagggggaga gcaggcagcg ggcggcgggg 300
 agcagcatgg agccggcggc ggggagcagc atggagcctt cggctgactg gctggccacg 360
 gccgcggccc ggggtcgggt agaggagggt cgggcgctgc tggaggcggg ggcgctgcc 420
 aacgcaccga atagttacgg tcggaggccg atccaggcca tgatgatggg cagcgcaccga 480
 gtggcgggag tgctgctgct ccacggcgcg gagcccaact gcgccgacc cgcactctc 540
 acccgaccgg tgcacgacgc tgcccgggag ggcttcctgg acacgctggg ggtgctgcac 600
 cgggcggggg cgcggtgga cgtgctcgat gcctggggcc gtctgcccgt ggacctggct 660

15
 20
 gaggagctgg gccatcgcga tgtcgcacgg tacctgcgcg cggctgcggg gggcaccaga 720
 ggcagtaacc atgcccgc atgagtcgcg gaaggtccct cagacatccc cgattgaaag 780
 aaccagagag gctctgagaa acctcgggaa acttagatca tcagtcaccg aaggtcctac 840
 agggccacaa ctgccccgc cacaaccac cccgcttctg tagttttcat ttagaaaata 900
 gagcttttaa aaatgtcctg ccttttaacg tagatatatg ccttccccca ctaccgtaa 960
 tgtccattta tatcattttt tatatattct tataaaaatg taaaaaagaa aaacaccgct 1020
 tctgcctttt cactgtgttg gagttttctg gactgagcac tcacgcccta agcgcacatt 1080
 catgtgggca tttcttgcca gcctcgcagc ctccggaagc tgtcgacttc atgacaagca 1140
 ttttgtgaac tagggaagct caggggggtt actggcttct cttgagtcac actgctagca 1200
 aatggcagaa ccaaagctca aataaaaata aaataatttt cattcattca ctcaaaaaaa 1260
 aaaaaaa 1267

25
 <210> 19
 <211> 471
 <212> DNA
 <213> Homo sapiens

30
 <400> 19

35
 atggagccgg cggcggggag cagcatggag ccttcggctg actggctggc cacggccgcg 60
 gcccggggtc gggtagagga ggtgcgggag ctgctggagg cgggggcgct gcccacacga 120
 ccgaatagtt acggctcggag gccgatccag gtcagatga tgggcagcgc ccgagtgagg 180
 gagctgctgc tgctccacgg cgcggagccc aactgcgccc accccgccac tctcaccgga 240
 cccgtgcacg acgctgcccg ggagggcttc ctggacacgc tgggtggtgct gcaccgggcc 300
 ggggcgcggc tggacgtgag cgatgcctgg ggccgtctgc ccgtggacct ggctgaggag 360
 ctgggccatc gcgatgtcgc acggtacctg cgcgcggctg cggggggcac cagaggcagt 420
 aacctgccc gcatagatgc cgcggaaggt ccctcagaca tccccgattg a 471

40
 <210> 20
 <211> 156
 <212> PRT
 <213> Homo sapiens

45
 <400> 20

50

55

EP 2 775 844 B1

Met Glu Pro Ala Ala Gly Ser Ser Met Glu Pro Ser Ala Asp Trp Leu
 1 5 10 15
 Ala Thr Ala Ala Ala Arg Gly Arg Val Glu Glu Val Arg Ala Leu Leu
 20 25 30
 5 Glu Ala Gly Ala Leu Pro Asn Ala Pro Asn Ser Tyr Gly Arg Arg Pro
 35 40 45
 Ile Gln Val Met Met Met Gly Ser Ala Arg Val Ala Glu Leu Leu Leu
 50 55 60
 10 Leu His Gly Ala Glu Pro Asn Cys Ala Asp Pro Ala Thr Leu Thr Arg
 65 70 75 80
 Pro Val His Asp Ala Ala Arg Glu Gly Phe Leu Asp Thr Leu Val Val
 85 90 95
 Leu His Arg Ala Gly Ala Arg Leu Asp Val Arg Asp Ala Trp Gly Arg
 100 105 110
 15 Leu Pro Val Asp Leu Ala Glu Glu Leu Gly His Arg Asp Val Ala Arg
 115 120 125
 Tyr Leu Arg Ala Ala Ala Gly Gly Thr Arg Gly Ser Asn His Ala Arg
 130 135 140
 Ile Asp Ala Ala Glu Gly Pro Ser Asp Ile Pro Asp
 145 150 155

<210> 21
 <211> 1164
 <212> DNA
 <213> Homo Sapiens

<400> 21

cgctcaggggaggcgggtgcg cgcctgctggc ggcggagatg ggcagggggc ggtgcgtggg 60
 tcccagctctg cagttaaggg ggcaggagtg ggcgtgctca cctctggtgc caaagggcgg 120

cgcagcggct gccgagctcg gccctggagg cggcgagaac atggtgcgca gtttcttggg 180
 gacctccgg attcggcgcg cgtgcggccc gccgcgagt agggttttcg tggttcacat 240
 35 cccgcggctc acgggggagt gggcagcgcc aggggcgccc gccgctgtgg ccctcgtgct 300
 gatgctactg aggagccagc gtctagggca gcagccgctt cctagaagac caggtcatga 360
 tgatgggcag cgcccagtg gcggagctgc tgctgctcca cggcgcggag cccaactgcg 420
 ccgacccgc cactctcacc cgacccgtgc acgacgctgc ccgggagggc ttcttgaca 480
 cgctggtggg gctgcaccgg gccggggcgc ggctggacgt gcgcgatgcc tggggccgctc 540
 tgcccgtgga cctggctgag gagctgggccc atcgcgatgt cgcacggtac ctgcgcgcgg 600
 40 ctgcggggggg caccagaggc agtaaccatg cccgcataga tgccgcggaa ggtccctcag 660
 acatccccga ttgaaagaac cagagaggct ctgagaaacc tcgggaaact tagatcatca 720
 gtcaccgaag gtcctacagg gccacaactg cccccgccac aaccacccc gctttcgtag 780
 ttttcattta gaaaatagag cttttaaaaa tgcctgcct tttaacgtag atatatgctt 840
 tccccacta ccgtaaatgt ccatttatat cattttttat atattcttat aaaaatgtaa 900
 45 aaaagaaaaa caccgcttct gcctttcac tgtggtggag ttttctggag tgagcactca 960
 cgccctaagc gcacattcat gtgggcattt cttgcgagcc tcgcagcctc cggaagctgt 1020
 cgacttcatg acaagcattt tgtgaactag ggaagctcag gggggttact ggcttctctt 1080
 gagtcacact gctagcaaat ggcagaacca aagctcaaat aaaaataaaa taattttcat 1140
 tcattcactc aaaaaaaaaa aaaa 1164

<210> 22
 <211> 522
 <212> DNA
 <213> Homo sapiens

<400> 22

EP 2 775 844 B1

5
10
atgggcaggg ggcggtgcgt ggggccaggt ctgcagttaa gggggcagga gtggcgctgc 60
tcacctctgg tgccaaaggg cggcgcagcg gctgccgagc tcggccctgg aggcggcgag 120
aacatgggtgc gcaggttctt ggtgaccctc cggattcggc gcgcgtgagg cccgccgcga 180
gtgagggttt tcgtggttca catcccgcgg ctccaggggg agtgggcagc gccagggggc 240
cccgccgctg tggccctcgt gctgatgcta ctgaggagcc agcgtctagg gcagcagccg 300
cttcctagaa gaccaggcca tgatgatggg cagcgcccga gtggcgaggc tgctgctgct 360
ccacggcgcg gagcccaact gcgcccagcc cgccactctc acccgaccgg tgcacgacgc 420
tgcccgggag ggcttcctgg acacgctggg ggtgctgcac cgggccgggg cgcggtgga 480
cgtgcgcgat gcctggggcc gtctgcccgt ggacctggct ga 522

<210> 23
<211> 173
<212> PRT
<213> Homo sapiens

<400> 23

20
25
30
35
Met Gly Arg Gly Arg Cys Val Gly Pro Ser Leu Gln Leu Arg Gly Gln
1 5 10 15
Glu Trp Arg Cys Ser Pro Leu Val Pro Lys Gly Gly Ala Ala Ala
20 25 30
Glu Leu Gly Pro Gly Gly Gly Glu Asn Met Val Arg Arg Phe Leu Val
35 40 45
Thr Leu Arg Ile Arg Arg Ala Cys Gly Pro Pro Arg Val Arg Val Phe
50 55 60
Val Val His Ile Pro Arg Leu Thr Gly Glu Trp Ala Ala Pro Gly Ala
65 70 75 80
Pro Ala Ala Val Ala Leu Val Leu Met Leu Leu Arg Ser Gln Arg Leu
85 90 95
Gly Gln Gln Pro Leu Pro Arg Arg Pro Gly His Asp Asp Gly Gln Arg
100 105 110
Pro Ser Gly Gly Ala Ala Ala Ala Pro Arg Arg Gly Ala Gln Leu Arg
115 120 125
Arg Pro Arg His Ser His Pro Thr Arg Ala Arg Arg Cys Pro Gly Gly
130 135 140
Leu Pro Gly His Ala Gly Gly Ala Ala Pro Gly Arg Gly Ala Ala Gly
145 150 155 160
Arg Ala Arg Cys Leu Gly Pro Ser Ala Arg Gly Pro Gly
165 170

40
<210> 24
<211> 10740
<212> DNA
<213> Homo sapiens

45
<400> 24

EP 2 775 844 B1

gtattggtgc agcccgccag ggtgtcactg gagacagaat ggaggtgctg cgggactcgg 60
 aaatggggtc caagggtagc caaggatggc tgcagcttca tatgatcagt tgttaaagca 120
 agttgaggca ctgaagatgg agaactcaa tcttcgacaa gagctagaag ataattccaa 180
 5 tcatcttaca aaactggaaa ctgaggcatc taatatgaag gaagtactta aacaactaca 240
 aggaagtatt gaagatgaag ctatggcttc ttctggacag attgatttat tagagcgtct 300
 taaagagctt aacttagata gcagtaattt ccctggagta aaactgcggg caaaaatgtc 360
 cctccgttct tatggaagcc ggaagggatc tgtatcaagc cgttctggag agtgcagtcc 420
 tgttcctatg ggttcatttc caagaagagg gtttgtaaat ggaagcagag aaagtactgg 480
 atatttagaa gaacttgaga aagagaggtc attgcttctt gctgatcttg acaaagaaga 540
 10 aaaggaaaaa gactggattt acgctcaact tcagaatctc actaaaagaa tagatagtct 600
 tcctttaact gaaaattttt ccttacaac agatatgacc agaaggcaat tggaaatga 660
 agcaaggcaa atcagagttg cgatggaaga acaactaggt acctgccagg atatgaaaa 720
 acgagcacag cgaagaatag ccagaattca gcaaatcgaa aaggacatac ttcgtatacg 780
 acagctttta cagtcccaag caacagaagc agagaggtca tctcagaaca agcatgaaac 840
 15 cggctcacat gatgctgagc ggcaaatga aggtcaagga gtgggagaaa tcaacatggc 900
 aacttctggg aatggtcagg gttcaactac acgaatggac catgaaacag ccagtgtttt 960
 gagttctagt agcacacact ctgcacctcg aaggctgaca agtcatctgg gaaccaaggt 1020
 ggaaatgggtg tattcattgt tgtcaatgct tggactcat gataaggatg atatgtcgcg 1080
 aactttgcta gctatgtcta gctcccaaga cagctgtata tccatgcgac agtctggatg 1140
 20 tcttcctctc ctcatccagc ttttcatatg caatgacaaa gactctgtat tgttgggaaa 1200
 ttcccggggc agtaaagagg ctccggccag ggccagtga gcaactccaca acatcattca 1260
 ctcaagcct tactgcaaga gaggcaggcg tgaatccga gtccttcac ttttggaaa 1320
 gatacgcgct tactgtgaaa cctgttggga tgggcaggaa gctcatgaac caggcatgga 1380
 ccaggacaaa aatccaatgc cagctcctgt tgaacatcag atctgtcctg ctgtgtgtgt 1440
 tctaagaaa ctttcatttg atgaagagca tagacatgca atgaatgaac tagggggact 1500
 25 acaggccatt gcagaattat tgcaagtgga ctgtgaaatg tatgggctta ctaatgacca 1560
 ctacagtatt aactaagac gatatgctgg aatggctttg acaaacttga cttttggaga 1620
 tgtagccaac aaggctacgc tatgctctat gaaaggctgc atgagagcac ttgtggccca 1680
 actaaaatct gaaagtgaag acttacagca ggttattgcg agtgttttga ggaatttgtc 1740
 ttggcgagca gatgtaata gtaaaaagac gttgcgagaa gttggaagtg tgaaagcatt 1800
 30 gatggaatgt gctttagaag ttaaaaagga atcaaccctc aaaagcgtat tgagtgcctt 1860
 atggaatttg tcagcacatt gcaactgagaa taaagctgat atatgtgctg tagatgggtgc 1920
 acttgcattt ttggttggca ctcttactta ccggagccag acaaacactt tagccattat 1980
 tgaagtgga ggtgggatat tacggaatgt gtcagcttg atagctaaa atgagacca 2040
 caggcaaatc ctaagagaga acaactgtct acaaaacttta ttacaacact taaaatctca 2100
 tagtttgaca atagtcaag atgcatgtgg aactttgtgg aatctctcag caagaaatcc 2160
 35 taaagaccag gaagcattat gggacatggg ggcagttagc atgctcaaga acctcattca 2220
 ttcaaagcac aaaatgattg ctatgggaag tgctgcagct ttaaggaatc tcatggcaaa 2280
 taggcctgcg aagtacaagg atgccaatat tatgtctcct ggctcaagct tgccatctct 2340
 tcatgttagg aaacaaaaag ccctagaagc agaattagat gctcagcact tatcagaac 2400
 ttttgacaat atagacaatt taagtcccaa ggcatctcat cgtagtaagc agagacacaa 2460
 40 gcaagctctc tatggtgatt atgtttttga caccaatcga catgatgata ataggtcaga 2520
 caattttaat actggcaaca tgactgtcct ttcaccatata ttgaacta cagtgttacc 2580
 cagctcctct tcatcaagag gaagcttaga tagttctcgt tctgaaaaag atagaagttt 2640
 ggagagagaa cgcggaattg gtctaggcaa ctaccatcca gcaacagaaa atccaggaac 2700
 ttcttcaaag cgaggtttgc agatctccac cactgcagcc cagattgcca aagtcatgga 2760
 45 agaagtgtca gccattcata cctctcagga agacagaagt tctgggtcta ccaactgaatt 2820
 acattgtgtg acagatgaga gaaatgcact tagaagaagc tctgctgccc atacacattc 2880
 aaacacttac aatttacta agtccgaaaa ttcaaatagg acatgttcta tgccttatgc 2940
 caaattagaa tacaagagat cttcaaatga tagttttaat agtgtcagta gtagttagtg 3000
 ttatggtaaa agaggtcaaa tgaaaccctc gattgaaatc tattctgaag atgatgaaag 3060
 50 taagttttgc agttatggtc aataccagc cgacctagcc cataaaatc atagtgcaaa 3120
 tcatatggat gataatgatg gagaactaga tacaccaata aattatagtc ttaaatattc 3180
 agatgagcag ttgaactctg gaaggcaaaag tccttcacag aatgaaagat gggcaagacc 3240
 caaacacata atagaagatg aaataaaaaca aagtgagcaa agacaatcaa ggaatcaaag 3300

55

EP 2 775 844 B1

	tacaacttat	cctgtttata	ctgagagcac	tgatgataaa	cacctcaagt	tccaaccaca	3360
	ttttggacag	caggaatgtg	tttctccata	caggtcacgg	ggagccaatg	gttcagaaac	3420
	aaatcgagtg	ggttctaata	atggaattaa	tcaaaatgta	agccagtctt	tgtgtcaaga	3480
	agatgactat	gaagatgata	agcctacca	ttatagtga	cgttactctg	aagaagaaca	3540
5	gcatgaagaa	gaagagagac	caacaaatta	tagcataaaa	tataatgaag	agaaacgtca	3600
	tgtggatcag	cctattgatt	atagtttaaa	atatgccaca	gatattcctt	catcacagaa	3660
	acagtcattt	tcattctcaa	agagttcatc	tggacaaaagc	agtaaaaccg	aacatatgtc	3720
	ttcaagcagt	gagaatacgt	ccacaccttc	atctaatagcc	aagaggcaga	atcagctcca	3780
	tccaagttct	gcacagagta	gaagtgggtca	gcctcaaaaag	gctgccactt	gcaaagtttc	3840
10	ttctattaac	caagaaacaa	tacagactta	ttgtgtagaa	gatactccaa	tatgtttttc	3900
	aagatgtagt	tcattatcat	ctttgtcatc	agctgaagat	gaaataggat	gtaatcagac	3960
	gacacaggaa	gcagattctg	ctaataccct	gcaaatagca	gaaataaaag	aaaagattgg	4020
	aactaggtca	gctgaagatc	ctgtgagcga	agttccagca	gtgtcacagc	accctagaac	4080
	caaatccagc	agactgcagg	gttctagttt	atcttcagaa	tcagccaggc	acaaagctgt	4140
	tgaattttct	tcaggagcga	aatctccctc	caaaagtgg	gctcagacac	ccaaaagtcc	4200
15	acctgaacac	tatgttcagg	agacccact	catgtttagc	agatgtactt	ctgtcagttc	4260
	acttgatagt	tttgagagtc	gttcgattgc	cagctccgtt	cagagtgaac	catgcagtg	4320
	aatggtaagt	ggcattataa	gccccagtga	tcttccagat	agccctggac	aaacatgcc	4380
	accaagcaga	agtaaaacac	ctccaccacc	tcctcaaaaca	gctcaaacca	agcgagaagt	4440
	acctaataat	aaagcaccta	ctgctgaaa	gagagagagt	ggacctaacg	aagctgcagt	4500
	aaatgctgca	gttcagaggg	tccaggttct	tccagatgct	gatactttat	tacattttgc	4560
20	cacggaaagt	actccagatg	gattttcttg	ttcatccagc	ctgagtgctc	tgagcctcga	4620
	tgagccattt	atacagaag	atgtggaatt	agaataatg	cctccagttc	aggaaaatga	4680
	caatgggaat	gaaacagaat	cagagcagcc	taagaatca	aatgaaaacc	aagagaaaga	4740
	ggcagaaaaa	actattgatt	ctgaaaagga	cctattagat	gattcagatg	atgatgatat	4800
	tgaataacta	gaagaatgta	ttatttctgc	catgccaca	aagtcatcac	gtaaagcaaa	4860
25	aaagccagcc	cagactgctt	caaaattacc	tccacctgtg	gcaaggaaac	caagtcaact	4920
	gcctgtgtac	aaacttctac	catcacaata	caggttgcaa	ccccaaaagc	atgttagttt	4980
	tacaccgggg	gatgatatgc	catcgggtga	ttgtgtgaa	gggacacct	taaaactttc	5040
	cacagctaca	tctctaagtg	atctaacaat	cgaatcccct	ccaaatgagt	tagctgctgg	5100
	agaaggagtt	agaggagggg	cacagtcagg	tgaatttgaa	aaacgagata	ccattcctac	5160
	agaaggcaga	agtacagatg	aggctcaagg	aggaaaaacc	tcatctgtaa	ccatacctga	5220
30	attggatgac	aataaagcag	aggaaggtga	tattcttgca	gaatgcatta	attctgctat	5280
	gccc aaaggg	aaaagtcaca	agcctttccg	tgtgaaaaag	ataatggacc	aggtccagca	5340
	agcatctgcc	tcttcttctg	cacccaacaa	aatcagttta	gatggtaaga	aaaagaaacc	5400
	tacttcacca	gtaaaaccta	taccacaaaa	ttagtaatat	aggacacgtg	aaaagtaaaa	5460
	tgacagactca	aaaaataaatt	taaatgctga	gagagttttc	tcagacaaca	aagattcaaa	5520
35	gaaacagaat	ttgaaaaata	attccaaggt	cttcaatgat	aagctcccaa	ataatgaaga	5580
	tagagtcaaga	ggaagttttg	cttttgattc	acctcatcat	tacacgccta	ttgaaggaa	5640
	tccttactgt	ttttcacgaa	atgattcttt	gagttctcta	gattttgatg	atgatgatgt	5700
	tgacctttcc	agggaaaagg	ctgaattaag	aaaggcaaaa	gaaaataagg	aatcagaggc	5760
	taaagttacc	agccacacag	aactaacctc	caaccaacaa	tcagctaata	agacacaagc	5820
	tattgcaaac	cagccaataa	atcgaggtca	gcctaaacc	atacttcaga	aacatccac	5880
40	ttttccccag	tcatccaaag	acataccaga	cagaggggca	gcaactgatg	aaaagttaca	5940
	gaattttgct	attgaaaata	ctccggtttg	cttttctcat	aattcctctc	tgagttctct	6000
	cagtgacatt	gaccaagaaa	acaacaataa	agaaaatgaa	cctatcaaag	agactgagcc	6060
	ccctgactca	cagggagaac	caagtaaacc	tcaagcatca	ggctatgctc	ctaaatcatt	6120
	tcatgttgaa	gataccccag	tttgtttctc	aagaaacagt	tctctcagtt	ctcttagtat	6180
	tgactctgaa	gatgacctgt	tgcaggaatg	tataagctcc	gcaatgcca	aaaagaaaaa	6240
45	gccttcaaga	ctcaaggggtg	ataatgaaaa	acatagctcc	agaaatatgg	gtggcatatt	6300
	aggtgaagat	ctgacacttg	atgtgaaaga	tatacagaga	ccagattcag	aacatggtct	6360
	atccccctgat	tcagaaaatt	ttgattgga	agctattcag	gaaggtgcaa	attccatagt	6420
	aagtagttta	catcaagctg	ctgctgctgc	atgtttatct	agacaagctt	cgtctgattc	6480
	agattccatc	ctttccctga	aatcaggaat	ctctctggga	tcaccatttc	atcttacacc	6540
	tgatcaagaa	gaaaaaccct	ttacaagtaa	taaaggccca	cgaattctaa	aaccagggga	6600
50	gaaaagtaca	ttggaaacta	aaaagataga	atctgaaagt	aaaggaatca	aaggaggaaa	6660
	aaaagtttat	aaaagtttga	ttactggaaa	agttcgatct	aattcagaaa	tttcaggcca	6720
	aatgaaacag	ccccttcaag	caaacatgcc	ttcaatctct	cgaggcagga	caatgattca	6780
	tattccagga	gttcgaaata	gctcctcaag	tacaagtcct	gtttctaaaa	aaggcccacc	6840
	ccttaagact	ccagcctcca	aaagccttag	tgaaggtcaa	acagccacca	cttctcctag	6900
55	aggagccaag	ccatctgtga	aatcagaatt	aagcctgtt	gccaggcaga	catcccaaat	6960
	aggtgggtca	agttaaagcac	cttctagatc	aggatctaga	gattcgacc	cttcaagacc	7020
	tgcccagcaa	ccattaagta	gacctataca	gtctcctggc	cgaaactcaa	tttccccctgg	7080

EP 2 775 844 B1

	tagaaatgga	ataagtcctc	ctaacaaatt	atctcaactt	ccaaggacat	catcccctag	7140
	tactgcttca	actaagtcct	caggttctgg	aaaaatgtca	tatacatctc	caggtagaca	7200
	gatgagccaa	cagaacctta	ccaaacaaac	aggtttatcc	agaatgcca	gtagtattcc	7260
5	aagaagtgag	tctgcctcca	aaggactaaa	tcagatgaat	aatggtaatg	gagccaataa	7320
	aaaggtagaa	ctttctagaa	tgtcttcaac	taaatcaagt	ggaagtgaat	ctgatatagc	7380
	agaaagacct	gtattagtac	gccagtcaac	tttcatcaaa	gaagctccaa	gcccaacctt	7440
	aagaagaaaa	ttggaggaat	ctgcttcatt	tgaatctctt	tctccatcat	ctagaccagc	7500
	ttctcccact	aggctccagg	cacaaactcc	agttttaagt	ccttcccttc	ctgatatgtc	7560
	tctatccaca	cattcgtctg	ttcaggctgg	tggatggcga	aaactcccac	ctaactctcag	7620
10	tcccactata	gagtataatg	atggaagacc	agcaaagcgc	catgatattg	cacggctctca	7680
	ttctgaaagt	ccttctagac	ttccaatcaa	taggtcagga	acctggaaac	gtgagcacag	7740
	caaacattca	tcatcccttc	ctogagtaag	cacttgagga	agaactggaa	gttcatcttc	7800
	aattctttct	gcttcatcag	aatccagtga	aaaagcaaaa	agtgaggatg	aaaaacatgt	7860
	gaactctatt	tcaggaacca	aacaaagtaa	agaaaaccaa	gtatccgcaa	aaggaacatg	7920
	gagaaaaata	aaagaaaatg	aattttctcc	cacaaatagt	acttctcaga	ccgtttctcc	7980
15	aggtgctaca	aatggtgctg	aatcaaagac	tctaatttat	caaatggcac	ctgatgtttc	8040
	taaaacagag	gatggttggg	tgagaattga	ggagatgtcc	attaacaatc	ctagatctgg	8100
	aagatctccc	acaggttaata	ctccccgggt	gattgacagt	gtttcagaaa	aggcaaatcc	8160
	aaacattaaa	gattcaaaaag	ataatcaggg	aaaacaaaat	gtgggtaatg	gcagtgttcc	8220
	catgctgacc	gtgggtttgg	aaaatcgctt	gaactccttt	attcaggtgg	atgccctga	8280
20	ccaaaagga	actgagataa	aaccaggaca	aaataatcct	gtccctgtat	cagagactaa	8340
	tgaaagttct	atagtggaac	gtaccccatt	cagttctagc	agctcaagca	aacacagttc	8400
	acctagtggg	actggtgctg	ccagagtgc	tccttttaat	tacaacccaa	gccctaggaa	8460
	aagcagcgca	gatagcactt	cagctcggcc	atctcagatc	ccaactccag	tgaataacaa	8520
	cacaaagaag	cgagattcca	aaactgacag	cacagaatcc	agtggaaacc	aaagtcttaa	8580
	gcgccattct	gggtcttacc	ttgtgacatc	tgtttaaaag	agaggaagaa	tgaaactaag	8640
25	aaaattctat	gttaattaca	actgctatat	agacattttg	tttcaaatga	aactttaaaa	8700
	gactgaaaaa	ttttgtaaat	aggtttgatt	cttgttagag	ggtttttgtt	ctggaagcca	8760
	tatttgatag	tatactttgt	cttcaactgg	cttattttgg	gaggcactct	tgatggttag	8820
	gaaaaaata	gtaaagccaa	gtatgtttgt	acagtatggt	ttacatgtat	ttaaagtagc	8880
	atcccatccc	aacttccttt	aattattgct	tgtcttaaaa	taatgaacac	tacagataga	8940
30	aaatatgata	tattgctggt	atcaatcatt	tctagattat	aaactgacta	aacttacatc	9000
	agggaaaaat	tggtatttat	gcaaaaaaaa	atgtttttgt	ccttgtgagt	ccatctaaca	9060
	tcataattaa	tcatgtggct	gtgaaattca	cagtaatatg	gttcccgatg	aacaagttta	9120
	cccagcctgc	tttgctttac	tgcatgaatg	aaactgatgg	ttcaatttca	gaagtaatga	9180
	ttaacagtta	tgtggtcaca	tgatgtgcac	agactgatct	aaactgtaat	aatttacact	9240
35	attttgctct	ccaaacaaaa	caaaaactctg	tgtaactgta	aaacattgaa	tgaactatt	9300
	ttacctgaac	tagattttat	ctgaaagtag	gtagaatttt	tgctatgctg	taatttgttg	9360
	tatattctgg	tatttgaggt	gagatggctg	ctcttttatt	aatgagacat	gaattgtgtc	9420
	tcaacagaaa	ctaaatgaac	atttcagaat	aaattattgc	tgtatgtaaa	ctgttactga	9480
	aattggtatt	tgtttgaagg	gtcttgtttc	acatttgat	taataattgt	ttaaaatgcc	9540
	tcttttaaaa	gcttatataa	attttttct	tcagcttcta	tgcatthaaga	gtaaaattcc	9600
40	tcttactgta	ataaaaacaa	ttgaagaaga	ctgttgccac	ttaaccattc	catgcggttg	9660
	cacttatcta	ttcctgaaat	ttcttttatg	tgattagctc	atcttgattt	ttaatatatt	9720
	tccacttaaa	cttttttttc	ttactccact	ggagctcagt	aaaagtaaat	tcatgtaata	9780
	gcaatgcaag	cagcctagca	cagactaagc	attgagcata	ataggcccac	ataatctcct	9840
	ctttcttaat	attatagaat	tctgtacttg	aaattgatcc	ttagacattg	cagtctcttc	9900
45	gaggctttac	agtgtaaact	gtcttgcccc	ttcatcttct	tgttgcaact	gggtctgaca	9960
	tgaacacttt	ttatcacctt	gtatgtagg	gcaagatctc	agcagtgaag	tataatcagc	10020
	actttgccat	gctcagaaaa	ttcaaatac	atggaacttt	agaggtagat	ttaatcagat	10080
	taagatattc	agaagtatat	tttagaatcc	ctgcctgtta	aggaaacttt	atgtgtggta	10140
	ggtacagttc	tggggtacat	gttaagtgtc	cccttataca	gtggagggaa	gtcttccttc	10200
	ctgaaggaaa	ataaaactgac	acttattaac	taagataaatt	tacttaatat	atcttccctg	10260
50	atgtgtttta	aaagatcaga	gggtgactga	tgatacatgc	atacatattt	gttgaataaaa	10320
	tgaaaattta	tttttagtga	taagattcat	acactctgta	tttggggagg	gaaaaccttt	10380
	ttaagcatgg	tggggcactc	agataggagt	gaatacacct	acctggtgcc	ttgaaaatca	10440
	catcaagtag	ttaattatct	acccttacc	tgtgtttata	acttccaggt	aatgagaatg	10500
	atttttttta	aagctaaaat	gccagtaaat	aaaagtgtca	tgacttgagc	taagatattt	10560
	gactccaatg	cctgtactgt	gtctactgca	ccactttgta	aacacttcaa	tttactatct	10620
55	ttgaaatgat	tgacctttaa	atttttgcca	aatgttatct	gaaattgtct	atgaatacca	10680
	tctacttctg	ttgttttccc	aggcttccat	aaacaatgga	gatacatgca	aaaaaaaaaa	10740

EP 2 775 844 B1

<210> 25
<211> 8532
<212> DNA
<213> Homo sapiens

5

<400> 25

10

15

20

25

30

35

40

45

50

55

EP 2 775 844 B1

atggctgcag cttcatatga tcagttgtta aagcaagttg aggcactgaa gatggagaac 60
 tcaaatcttc gacaagagct agaagataat tccaatcatc ttacaaaact ggaaactgag 120
 gcatctaata tgaaggaagt acttaaacaa ctacaaggaa gtattgaaga tgaagctatg 180
 gcttcttctg gacagattga tttattagag cgtcttaaag agcttaactt agatagcagt 240
 aatttccctg gagtaaaact gcggtcaaaa atgtccctcc gttcttatgg aagccgggaa 300
 ggatctgtat caagccgttc tggagagtgc agtcctgttc ctatgggttc atttccaaga 360
 agagggtttg taaatggaag cagagaaagt actggatatt tagaagaact tgagaaagag 420
 aggtcattgc ttcttgctga tcttgacaaa gaagaaaagg aaaaagactg gtattacgct 480
 caacttcaga atctcactaa aagaatagat agtcttcctt taactgaaa tttttcctta 540
 caacagata tgaccagaag gcaattggaa tatgaagcaa ggcaaatcag agttgcgatg 600
 gaagaacaac taggtacctg ccaggatag gaaaaacgag cacagcgaag aatagccaga 660
 attcagcaaaa tcgaaaagga catactctgt atacgacagc ttttacagtc ccaagcaaca 720
 gaagcagaga ggatcatctca gaacaagcat gaaaccggct cacatgatgc tgagcggcag 780
 aatgaaggtc aaggagtggg agaaatcaac atggcaactt ctggtaatgg tcagggttca 840
 actacacgaa tggaccatga aacagccagt gttttgagtt ctagtagcac acactctgca 900
 cctcgaaggc tgacaagtca tctgggaacc aaggtggaaa tgggtgattc attgttgtca 960
 atgcttggta ctcatgataa ggatgatatg tcgcaactt tgctagctat gtctagctcc 1020
 caagacagct gtatatccat gcgacagtct ggatgtcttc ctctcctcat ccagctttta 1080
 catggcaatg acaaagactc tgtattgttg ggaaattccc ggggcagtaa agaggctcgg 1140
 gccagggcca gtgcagcact ccacaacatc attcactcac agcctgatga caagagaggc 1200
 aggcgtgaaa tccgagtcct tcatcttttg gaacagatac gcgcttactg tgaaacctgt 1260
 tgggagtggc aggaagctca tgaaccaggc atggaccagg acaaaaatcc aatgccagct 1320
 cctgttgaac atcagatctg tctgtctgtg tgtgttctaa tgaaactttc atttgatgaa 1380
 gagcatagac atgcaatgaa tgaactaggg ggactacagg ccattgcaga attattgcaa 1440
 gtggactgtg aatgtacgg gcttactaat gaccactaca gtattacact aagacgatat 1500
 gctggaatgg ctttgacaaa cttgactttt ggagatgtag ccaacaaggc tacgctatgc 1560
 tctatgaaag gctgcatgag agcacttgtg gcccaactaa aatctgaaag tgaagactta 1620
 cagcaggtta ttgcaagtgt tttgaggaat ttgtcttggc gagcagatgt aaatagtaaa 1680
 aagacgttgc gagaaagtgg aagtgtgaaa gcattgatgg aatgtgcttt agaagttaaa 1740
 aaggaatcaa ccctcaaaaag cgtattgagt gccttatgga atttgtcagc acattgcaact 1800
 gagaataaag ctgatatatg tgctgtagat ggtgcacttg cttttttggt tggcactctt 1860
 acttaccgga gccagacaaa cacttttagcc attattgaaa gtggagggtg gatattacgg 1920
 aatgtgtcca gcttgatagc taaaaatgag gaccacaggc aaatcctaag agagaacaac 1980
 tgtctacaaa ctttattaca acacttaaaa tctcattagt tgacaatagt cagtaatgca 2040
 tgtggaactt tgtggaatct ctgagcaaga aatcctaagg accaggaagc attatgggac 2100
 atggggggcag ttagcatgct caagaacctc attcattcaa agcacaanaat gattgctatg 2160
 ggaagtgtcag cagctttaag gaatctcatg gcaaataggc ctgcaagta caaggatgcc 2220
 aatattatgt ctccctggctc aagcttgcca tctcttcatg ttaggaaca aaaagcccta 2280
 gaagcagaat tagatgctca gcacttatca gaaacttttg acaatataga caatttaagt 2340
 cccaaggcat ctcatcgtag taagcagaga cacaagcaaa gtctctatgg tgattatggt 2400
 tttgacacca atcgacatga tgataatagg tcagacaatt ttaatactgg caacatgact 2460
 gtccctttcac catatttgaa tactacagtg ttaccagct cctcttcatc aagaggaagc 2520
 ttagatagtt ctctgttctga aaaagataga agtttggaga gagaacgagg aattggtcta 2580
 ggcaactacc atccagcaac agaaaatcca ggaacttctt caaagcgagg tttgcagatc 2640
 tccaccactg cagcccagat tgccaaaagc atggaagaag tgtcagccat tcatacctct 2700
 caggaagaca gaagtctctg gtctaccact gaattacatt gtgtgacaga tgagagaaat 2760
 gcacttagaa gaagctctgc tgccataca cattcaaca cttacaattt cactaagtcg 2820
 gaaaattcaa ataggacatg ttctatgcct tatgccaat tagaatacaa gagatcttca 2880
 aatgatagtt taaatagtgt cagtagtagt gatggttatg gtaaaagagg tcaaatgaaa 2940
 ccctcgattg aatcctattc tgaagatgat gaaagtaagt tttgcagtta tgggtcaatac 3000
 ccagccgacc tagcccataa aatacatagt gcaaatcata tggatgataa tgatggagaa 3060
 ctagatacac caataaatta tagtcttaaa tattcagatg agcagttgaa ctctggaagg 3120
 caaagtcctt cacagaatga aagatgggca agaccnaaac acataataga agatgaaata 3180
 aaacaaagtg agcaaaagaca atcaaggaat caaagtacaa cttatcctgt ttatactgag 3240
 agcactgatg ataaacacct caagttccaa ccacattttg gacagcagga atgtgtttct 3300
 ccatacaggc cacgggggagc caatggttca gaaacaaatc gagtgggttc taatcatgga 3360
 attaatacaa atgtaagcca gtctttgtgt caagaagatg actatgaaga tgataagcct 3420

55

EP 2 775 844 B1

	accaattata	gtgaacgtta	ctctgaagaa	gaacagcatg	aagaagaaga	gagaccaaca	3480
	aattatagca	taaaatataa	tgaagagaaa	cgatcatgtg	atcagcctat	tgattatagt	3540
	ttaaaatagc	ccacagatat	tccttcatca	cagaacacag	cattttcatt	ctcaaagagt	3600
	tcattctggc	aaagcagtaa	aaccgaacat	atgcttcaa	gcagtgcaga	tacgtccaca	3660
5	ccctcatcta	atgccaagag	gcagaatcag	ctccatcaa	gttctgcaca	gtagtaaga	3720
	ggtcagcctc	aaaagcgtgc	cacttgcaaa	gtttcttcta	ttaaccaaga	aacaatacag	3780
	acttattgtg	tagaagatac	tccaatagt	ttttcaagat	gtagttcatt	atcatctttg	3840
	tcattcagctg	aagatgaaat	aggatgtaat	cagacgacac	aggaagcaga	ttctgcta	3900
	accctgcaaa	tagcagaaat	aaaagaaaag	attggaacta	ggtcagctga	agatcctgtg	3960
	agcgaagttc	cagcagtgtc	acagcaccct	agaaccaa	ccagcagact	gcagggttct	4020
10	agtttatctt	cagaatcagc	caggcaca	gctgttgaat	tttcttcagg	agcgaatct	4080
	ccctccaaa	gtggtgctca	gacacccaa	agtccactg	aacactatgt	tcaggagacc	4140
	ccactcatgt	ttagcagatg	tacttctgtc	agttcacttg	atagtttga	gagtcgttcg	4200
	attgccagct	ccgttcagag	tgaaccatgc	agtggaatgg	taagtggcat	tataagcccc	4260
	agtgatcttc	cagatagccc	tggacaaacc	atgccaccaa	gcagaagtaa	aacacctcca	4320
15	ccacctcctc	aaacagctca	aaccaagcga	gaagtaccta	aaaataaagc	acctactgct	4380
	gaaaagagag	agagtggacc	taagcaagct	gcagtaaatg	ctgcagttca	gagggctccag	4440
	gttcttccag	atgctgatac	tttattacat	tttgccacgg	aaagtactcc	agatggattt	4500
	tcttgttcat	ccagcctgag	tgctctgagc	ctcgatgagc	catttataca	gaaagatgtg	4560
	gaattaaaga	taatgcctcc	agttcaggaa	aatgacaatg	ggaatgaaat	agaatcagag	4620
	cagcctaag	aatcaaatga	aaaccaagag	aaagaggcag	aaaaaactat	tgattctgaa	4680
20	aaggacctat	tagatgattc	agatgatgat	gatattgaaa	tactagaaga	atgtattatt	4740
	tctgccatgc	caacaaagtc	atcacgtaaa	gcaaaaaagc	cagcccagac	tgcttcaaaa	4800
	ttacctccac	ctgtggcaag	gaaaccaagt	cagctgcctg	tgtacaaact	tctaccatca	4860
	caaaacaggt	tgcaacccca	aaagcatggt	agttttacac	cgggggatga	tatgccacgg	4920
	gtgtattgtg	ttgaagggac	acctataaac	ttttccacag	ctacatctct	aagtgatcta	4980
	acaatcgaat	cccctccaaa	tgagttagct	gctggagaag	gagttagagg	aggagcacag	5040
25	tcaggtgaat	ttgaaaaacg	agataccatt	cctacagaag	gcagaagtac	agatgaggct	5100
	caaggaggaa	aaacctcatc	tgtaaccata	ctgaattgg	atgacaataa	agcagaggaa	5160
	ggtgatattc	ttgcagaatg	cattaattct	gctatgcca	aagggaaaag	tcacaagcct	5220
	ttccgtgtga	aaaagataat	ggaccaggtc	cagcaagcat	ctgogtcgtc	ttctgcaccc	5280
	aacaaaaatc	agttagatgg	taagaaaaag	aaaccaactt	caccagtaaa	acctatacca	5340
30	caaaatactg	aatataggac	acgtgtaaga	aaaaatgcag	actcaaaaaa	taatttaaat	5400
	gctgagagag	ttttctcaga	caacaaagat	tcaaagaaac	agaatttgaa	aaataattcc	5460
	aaggacttca	atgataagct	cccaaataat	gaagatagag	tcagaggaag	ttttgctttt	5520
	gattcacctc	atcattacac	gcctattgaa	ggaactcctt	actgtttttc	acgaaatgat	5580
	tctttgagtt	ctctagattt	tgatgatgat	gatgttgacc	ttccagggga	aaaggctgaa	5640
	ttaagaaagg	caaaagaaaa	taaggaatca	gaggctaaag	ttaccagcca	cacagaacta	5700
35	acctccaacc	aacaatcagc	taataagaca	caagctattg	caaagcagcc	aataaatcga	5760
	ggtcagccta	aaccatact	tcagaaacaa	tccacttttc	cccagtcatc	caaagacata	5820
	ccagacagag	ggcagcaaac	tgatgaaaag	ttacagaatt	ttgctattga	aaatactcca	5880
	gtttgctttt	ctcataatc	ctctctgagt	tctctcagtg	acattgacca	agaaaacaac	5940
	aataaagaaa	atgaacctat	caaagagact	gagccccctg	actcacaggg	agaaccaagt	6000
40	aaacctcaag	catcaggcta	tgctcctaaa	tcatttcatg	ttgaagatac	cccagtttgt	6060
	ttctcaagaa	acagttctct	cagttctctt	agtattgact	ctgaagatga	cctgttgacg	6120
	gaatgtataa	gctccgcaat	gccccaaaag	aaaaagcctt	caagactcaa	gggtgataat	6180
	gaaaaacata	gtcccagaaa	tatgggtggc	atattaggtg	aagatctgac	acttgatttg	6240
	aaagatatac	agagaccaga	ttcagaacat	ggtctatccc	ctgattcaga	aaattttgat	6300
	tggaaagcta	ttcaggaagg	tgcaaatcc	atagtaagta	gtttacatca	agctgctgct	6360
45	gctgcatggt	tatctagaca	agcttctgtt	gattcagatt	ccatcctttc	cctgaaatca	6420
	ggaatctctc	tgggatcacc	atctcatctt	acacctgatc	agaagaaaa	accctttaca	6480
	agtaataaag	gcccacgaat	tctaaaacca	ggggagaaaa	gtacattgga	aactaaaaag	6540
	atagaatctg	aaagtaaaag	aatcaaagga	ggaaaaaaag	tttataaaag	tttgattact	6600
	ggaaaagttc	gatctaattc	agaaatttca	ggccaaatga	aacagcccct	tcaagcaaac	6660
	atgccttcaa	tctctcgagg	caggacaatg	attcatattc	caggagttcg	aatagctcc	6720
50	tcaagtacaa	gtcctgtttc	taaaaaaggc	ccaccctta	agactccagc	ctccaaaagc	6780
	cctagtgaag	gtcaaacagc	caccacttct	cctagaggag	ccaagccatc	tgtgaaatca	6840
	gaattaagcc	ctgttgccag	gcagacatcc	caaataggtg	ggtcaagtaa	agcaccttct	6900
	agatcaggt	ctagagattc	gacccttca	agacctgccc	agcaaccatt	agtagacct	6960
	atacagtctc	ctggccgaaa	ctcaatttcc	cctggtagaa	atggaataag	tcctcctaac	7020
	aaattatctc	aacttccaag	gacatcatcc	cctagtactg	cttcaactaa	gtcctcaggt	7080
55	tctggaaaaa	tgtcatatac	atctccaggt	agacagatga	gccaacagaa	ccttaccaaa	7140
	caaacaggtt	tatccaagaa	tgccagtagt	attccaagaa	gtgagctg	ctccaaagga	7200

EP 2 775 844 B1

ctaaatcaga tgaataatgg taatggagcc aataaaaagg tagaactttc tagaatgtct 7260
 tcaactaaat caagtggaag tgaatctgat agatcagaaa gacctgtatt agtacgccag 7320
 tcaactttca tcaaagaagc tccaagcca accttaagaa gaaaattgga ggaatctgct 7380
 5 tcaattggaat ctctttctcc atcatctaga ccagcttctc ccactaggtc ccaggcacia 7440
 actccagttt taagtccttc ccttcctgat atgtctctat ccacacattc gtctgttcag 7500
 gctggtggat ggcgaaaact cccaccta atctcagtcctc ctatagagta taatgatgga 7560
 agaccagcaa agcgccatga tattgcacgg tctcattctg aaagtccttc tagacttcca 7620
 atcaataggt caggaacctg gaaacgtgag cacagcaaac attcatcatc ccttcctcga 7680
 gtaagcactt ggagaagaac tggaaagtca tcttcaattc tttctgcttc atcagaatcc 7740
 10 agtgaaaaaag caaaaagtga ggatgaaaaa catgtgaact ctatttcagg aaccaaacia 7800
 agtaaagaaa accaagtatc cgcaaaaagga acatggagaa aaataaaaaga aatgaattt 7860
 tctcccacia atagtacttc tcagaccgtt tcctcagggtg ctacaaatgg tgctgaatca 7920
 aagactctaa tttatcaaat ggcacctgct gtttctaaaa cagaggatgt ttgggtgaga 7980
 attgaggact gtcccattaa caatcctaga tctggaagat ctcccacagg taatactccc 8040
 15 ccggtgattg acagtgtttc agaaaaggca aatccaaaca ttaaagattc aaaagataat 8100
 caggcaaaac aaaatgtggg taatggcagt gttcccatgc gtaccgtggg tttggaaaat 8160
 cgcctgaact cctttattca ggtggatgcc cctgaccaa aaggaactga gataaaacca 8220
 ggacaaaata atcctgtccc tgtatcagag actaatgaaa gttctatagt ggaacgtacc 8280
 ccattcagtt cttagcagctc aagcaaacac agttcaccta gtgggactgt tgctgccaga 8340
 gtgactcctt ttaattacia cccaagccct aggaaaagca gcgcagatag cacttcagct 8400
 20 cggccatctc agatcccaac tccagtgaat aacaacacia agaagcgaga ttccaaaact 8460
 gacagcacag aatccagtgg aacccaaagt cctaagcgcc attctgggtc ttaccttgtg 8520
 acatctgttt aa 8532

<210> 26
 25 <211> 2843
 <212> PRT
 <213> Homo sapiens

30 <400> 26

35

40

45

50

55

EP 2 775 844 B1

Met Ala Ala Ala Ser Tyr Asp Gln Leu Leu Lys Gln Val Glu Ala Leu
 1 5 10
 Lys Met Glu Asn Ser Asn Leu Arg Gln Glu Leu Glu Asp Asn Ser Asn
 20 25 30
 5 His Leu Thr Lys Leu Glu Thr Glu Ala Ser Asn Met Lys Glu Val Leu
 35 40 45
 Lys Gln Leu Gln Gly Ser Ile Glu Asp Glu Ala Met Ala Ser Ser Gly
 50 55 60
 10 Gln Ile Asp Leu Leu Glu Arg Leu Lys Glu Leu Asn Leu Asp Ser Ser
 65 70 75 80
 Asn Phe Pro Gly Val Lys Leu Arg Ser Lys Met Ser Leu Arg Ser Tyr
 85 90 95
 Gly Ser Arg Glu Gly Ser Val Ser Ser Arg Ser Gly Glu Cys Ser Pro
 100 105 110
 15 Val Pro Met Gly Ser Phe Pro Arg Arg Gly Phe Val Asn Gly Ser Arg
 115 120 125
 Glu Ser Thr Gly Tyr Leu Glu Glu Leu Glu Lys Glu Arg Ser Leu Leu
 130 135 140
 20 Leu Ala Asp Leu Asp Lys Glu Glu Lys Glu Lys Asp Trp Tyr Tyr Ala
 145 150 155 160
 Gln Leu Gln Asn Leu Thr Lys Arg Ile Asp Ser Leu Pro Leu Thr Glu
 165 170 175
 Asn Phe Ser Leu Gln Thr Asp Met Thr Arg Arg Gln Leu Glu Tyr Glu
 180 185 190
 25 Ala Arg Gln Ile Arg Val Ala Met Glu Glu Gln Leu Gly Thr Cys Gln
 195 200 205
 Asp Met Glu Lys Arg Ala Gln Arg Arg Ile Ala Arg Ile Gln Gln Ile
 210 215 220
 Glu Lys Asp Ile Leu Arg Ile Arg Gln Leu Leu Gln Ser Gln Ala Thr
 225 230 235 240
 30 Glu Ala Glu Arg Ser Ser Gln Asn Lys His Glu Thr Gly Ser His Asp
 245 250 255
 Ala Glu Arg Gln Asn Glu Gly Gln Gly Val Gly Glu Ile Asn Met Ala

35

40

45

50

55

EP 2 775 844 B1

Leu Ser Glu Thr Phe Asp Asn Ile Asp Asn Leu Ser Pro Lys Ala Ser
 770 775 780
 His Arg Ser Lys Gln Arg His Lys Gln Ser Leu Tyr Gly Asp Tyr Val
 785 790 795 800
 5 Phe Asp Thr Asn Arg His Asp Asp Asn Arg Ser Asp Asn Phe Asn Thr
 805 810 815
 Gly Asn Met Thr Val Leu Ser Pro Tyr Leu Asn Thr Thr Val Leu Pro
 820 825 830
 Ser Ser Ser Ser Ser Arg Gly Ser Leu Asp Ser Ser Arg Ser Glu Lys
 835 840 845
 10 Asp Arg Ser Leu Glu Arg Glu Arg Gly Ile Gly Leu Gly Asn Tyr His
 850 855 860
 Pro Ala Thr Glu Asn Pro Gly Thr Ser Ser Lys Arg Gly Leu Gln Ile
 865 870 875 880
 Ser Thr Thr Ala Ala Gln Ile Ala Lys Val Met Glu Glu Val Ser Ala
 885 890 895
 15 Ile His Thr Ser Gln Glu Asp Arg Ser Ser Gly Ser Thr Thr Glu Leu
 900 905 910
 His Cys Val Thr Asp Glu Arg Asn Ala Leu Arg Arg Ser Ser Ala Ala
 915 920 925
 His Thr His Ser Asn Thr Tyr Asn Phe Thr Lys Ser Glu Asn Ser Asn
 930 935 940
 20 Arg Thr Cys Ser Met Pro Tyr Ala Lys Leu Glu Tyr Lys Arg Ser Ser
 945 950 955 960
 Asn Asp Ser Leu Asn Ser Val Ser Ser Ser Asp Gly Tyr Gly Lys Arg
 965 970 975
 Gly Gln Met Lys Pro Ser Ile Glu Ser Tyr Ser Glu Asp Asp Glu Ser
 980 985 990
 25 Lys Phe Cys Ser Tyr Gly Gln Tyr Pro Ala Asp Leu Ala His Lys Ile
 995 1000 1005
 His Ser Ala Asn His Met Asp Asp Asn Asp Gly Glu Leu Asp Thr Pro
 1010 1015 1020
 30 Ile Asn Tyr Ser Leu Lys Tyr Ser Asp Glu Gln Leu Asn Ser Gly Arg
 1025 1030 1035 1040
 Gln Ser Pro Ser Gln Asn Glu Arg Trp Ala Arg Pro Lys His Ile Ile
 1045 1050 1055
 Glu Asp Glu Ile Lys Gln Ser Glu Gln Arg Gln Ser Arg Asn Gln Ser
 1060 1065 1070
 35 Thr Thr Tyr Pro Val Tyr Thr Glu Ser Thr Asp Asp Lys His Leu Lys
 1075 1080 1085
 Phe Gln Pro His Phe Gly Gln Gln Glu Cys Val Ser Pro Tyr Arg Ser
 1090 1095 1100
 Arg Gly Ala Asn Gly Ser Glu Thr Asn Arg Val Gly Ser Asn His Gly
 1105 1110 1115 1120
 40 Ile Asn Gln Asn Val Ser Gln Ser Leu Cys Gln Glu Asp Asp Tyr Glu
 1125 1130 1135
 Asp Asp Lys Pro Thr Asn Tyr Ser Glu Arg Tyr Ser Glu Glu Glu Gln
 1140 1145 1150
 His Glu Glu Glu Glu Arg Pro Thr Asn Tyr Ser Ile Lys Tyr Asn Glu
 1155 1160 1165
 45 Glu Lys Arg His Val Asp Gln Pro Ile Asp Tyr Ser Leu Lys Tyr Ala
 1170 1175 1180
 Thr Asp Ile Pro Ser Ser Gln Lys Gln Ser Phe Ser Phe Ser Lys Ser
 1185 1190 1195 1200
 Ser Ser Gly Gln Ser Ser Lys Thr Glu His Met Ser Ser Ser Ser Glu
 1205 1210 1215
 50 Asn Thr Ser Thr Pro Ser Ser Asn Ala Lys Arg Gln Asn Gln Leu His
 1220 1225 1230
 Pro Ser Ser Ala Gln Ser Arg Ser Gly Gln Pro Gln Lys Ala Ala Thr
 1235 1240 1245
 55 Cys Lys Val Ser Ser Ile Asn Gln Glu Thr Ile Gln Thr Tyr Cys Val
 1250 1255 1260
 Glu Asp Thr Pro Ile Cys Phe Ser Arg Cys Ser Ser Leu Ser Ser Leu

EP 2 775 844 B1

	1265					1270						1275				1280
	Ser	Ser	Ala	Glu	Asp	Glu	Ile	Gly	Cys	Asn	Gln	Thr	Thr	Gln	Glu	Ala
					1285					1290						1295
5	Asp	Ser	Ala	Asn	Thr	Leu	Gln	Ile	Ala	Glu	Ile	Lys	Glu	Lys	Ile	Gly
				1300					1305					1310		
	Thr	Arg	Ser	Ala	Glu	Asp	Pro	Val	Ser	Glu	Val	Pro	Ala	Val	Ser	Gln
				1315				1320					1325			
	His	Pro	Arg	Thr	Lys	Ser	Ser	Arg	Leu	Gln	Gly	Ser	Ser	Leu	Ser	Ser
				1330				1335				1340				
10	Glu	Ser	Ala	Arg	His	Lys	Ala	Val	Glu	Phe	Ser	Ser	Gly	Ala	Lys	Ser
	1345				1350						1355					1360
	Pro	Ser	Lys	Ser	Gly	Ala	Gln	Thr	Pro	Lys	Ser	Pro	Pro	Glu	His	Tyr
				1365						1370						1375
	Val	Gln	Glu	Thr	Pro	Leu	Met	Phe	Ser	Arg	Cys	Thr	Ser	Val	Ser	Ser
				1380				1385						1390		
15	Leu	Asp	Ser	Phe	Glu	Ser	Arg	Ser	Ile	Ala	Ser	Ser	Val	Gln	Ser	Glu
				1395				1400					1405			
	Pro	Cys	Ser	Gly	Met	Val	Ser	Gly	Ile	Ile	Ser	Pro	Ser	Asp	Leu	Pro
				1410				1415				1420				
	Asp	Ser	Pro	Gly	Gln	Thr	Met	Pro	Pro	Ser	Arg	Ser	Lys	Thr	Pro	Pro
	1425				1430						1435					1440
20	Pro	Pro	Pro	Gln	Thr	Ala	Gln	Thr	Lys	Arg	Glu	Val	Pro	Lys	Asn	Lys
				1445						1450						1455
	Ala	Pro	Thr	Ala	Glu	Lys	Arg	Glu	Ser	Gly	Pro	Lys	Gln	Ala	Ala	Val
				1460				1465						1470		
	Asn	Ala	Ala	Val	Gln	Arg	Val	Gln	Val	Leu	Pro	Asp	Ala	Asp	Thr	Leu
				1475				1480					1485			
25	Leu	His	Phe	Ala	Thr	Glu	Ser	Thr	Pro	Asp	Gly	Phe	Ser	Cys	Ser	Ser
				1490				1495				1500				
	Ser	Leu	Ser	Ala	Leu	Ser	Leu	Asp	Glu	Pro	Phe	Ile	Gln	Lys	Asp	Val
	1505				1510						1515					1520
	Glu	Leu	Arg	Ile	Met	Pro	Pro	Val	Gln	Glu	Asn	Asp	Asn	Gly	Asn	Glu
				1525						1530						1535
30	Thr	Glu	Ser	Glu	Gln	Pro	Lys	Glu	Ser	Asn	Glu	Asn	Gln	Glu	Lys	Glu
				1540				1545						1550		
	Ala	Glu	Lys	Thr	Ile	Asp	Ser	Glu	Lys	Asp	Leu	Leu	Asp	Asp	Ser	Asp
				1555				1560					1565			
	Asp	Asp	Asp	Ile	Glu	Ile	Leu	Glu	Glu	Cys	Ile	Ile	Ser	Ala	Met	Pro
35				1570				1575				1580				
	Thr	Lys	Ser	Ser	Arg	Lys	Ala	Lys	Lys	Pro	Ala	Gln	Thr	Ala	Ser	Lys
	1585				1590						1595					1600
	Leu	Pro	Pro	Pro	Val	Ala	Arg	Lys	Pro	Ser	Gln	Leu	Pro	Val	Tyr	Lys
				1605						1610						1615
40	Leu	Leu	Pro	Ser	Gln	Asn	Arg	Leu	Gln	Pro	Gln	Lys	His	Val	Ser	Phe
				1620					1625					1630		
	Thr	Pro	Gly	Asp	Asp	Met	Pro	Arg	Val	Tyr	Cys	Val	Glu	Gly	Thr	Pro
				1635				1640					1645			
	Ile	Asn	Phe	Ser	Thr	Ala	Thr	Ser	Leu	Ser	Asp	Leu	Thr	Ile	Glu	Ser
				1650				1655				1660				
45	Pro	Pro	Asn	Glu	Leu	Ala	Ala	Gly	Glu	Gly	Val	Arg	Gly	Gly	Ala	Gln
	1665				1670						1675					1680
	Ser	Gly	Glu	Phe	Glu	Lys	Arg	Asp	Thr	Ile	Pro	Thr	Glu	Gly	Arg	Ser
				1685						1690						1695
	Thr	Asp	Glu	Ala	Gln	Gly	Gly	Lys	Thr	Ser	Ser	Val	Thr	Ile	Pro	Glu
				1700				1705						1710		
50	Leu	Asp	Asp	Asn	Lys	Ala	Glu	Glu	Gly	Asp	Ile	Leu	Ala	Glu	Cys	Ile
				1715				1720					1725			
	Asn	Ser	Ala	Met	Pro	Lys	Gly	Lys	Ser	His	Lys	Pro	Phe	Arg	Val	Lys
				1730			1735					1740				
	Lys	Ile	Met	Asp	Gln	Val	Gln	Gln	Ala	Ser	Ala	Ser	Ser	Ser	Ala	Pro
55	1745				1750						1755					1760
	Asn	Lys	Asn	Gln	Leu	Asp	Gly	Lys	Lys	Lys	Lys	Pro	Thr	Ser	Pro	Val
				1765						1770						1775

EP 2 775 844 B1

Lys Pro Ile Pro Gln Asn Thr Glu Tyr Arg Thr Arg Val Arg Lys Asn
 1780 1785 1790
 Ala Asp Ser Lys Asn Asn Leu Asn Ala Glu Arg Val Phe Ser Asp Asn
 1795 1800 1805
 5 Lys Asp Ser Lys Lys Gln Asn Leu Lys Asn Asn Ser Lys Val Phe Asn
 1810 1815 1820
 Asp Lys Leu Pro Asn Asn Glu Asp Arg Val Arg Gly Ser Phe Ala Phe
 1825 1830 1835 1840
 Asp Ser Pro His His Tyr Thr Pro Ile Glu Gly Thr Pro Tyr Cys Phe
 1845 1850 1855
 10 Ser Arg Asn Asp Ser Leu Ser Ser Leu Asp Phe Asp Asp Asp Val
 1860 1865 1870
 Asp Leu Ser Arg Glu Lys Ala Glu Leu Arg Lys Ala Lys Glu Asn Lys
 1875 1880 1885
 Glu Ser Glu Ala Lys Val Thr Ser His Thr Glu Leu Thr Ser Asn Gln
 1890 1895 1900
 15 Gln Ser Ala Asn Lys Thr Gln Ala Ile Ala Lys Gln Pro Ile Asn Arg
 1905 1910 1915 1920
 Gly Gln Pro Lys Pro Ile Leu Gln Lys Gln Ser Thr Phe Pro Gln Ser
 1925 1930 1935
 Ser Lys Asp Ile Pro Asp Arg Gly Ala Ala Thr Asp Glu Lys Leu Gln
 1940 1945 1950
 20 Asn Phe Ala Ile Glu Asn Thr Pro Val Cys Phe Ser His Asn Ser Ser
 1955 1960 1965
 Leu Ser Ser Leu Ser Asp Ile Asp Gln Glu Asn Asn Asn Lys Glu Asn
 1970 1975 1980
 25 Glu Pro Ile Lys Glu Thr Glu Pro Pro Asp Ser Gln Gly Glu Pro Ser
 1985 1990 1995 2000
 Lys Pro Gln Ala Ser Gly Tyr Ala Pro Lys Ser Phe His Val Glu Asp
 2005 2010 2015
 Thr Pro Val Cys Phe Ser Arg Asn Ser Ser Leu Ser Ser Leu Ser Ile
 2020 2025 2030
 30 Asp Ser Glu Asp Asp Leu Leu Gln Glu Cys Ile Ser Ser Ala Met Pro
 2035 2040 2045
 Lys Lys Lys Lys Pro Ser Arg Leu Lys Gly Asp Asn Glu Lys His Ser
 2050 2055 2060
 Pro Arg Asn Met Gly Gly Ile Leu Gly Glu Asp Leu Thr Leu Asp Leu
 2065 2070 2075 2080
 35 Lys Asp Ile Gln Arg Pro Asp Ser Glu His Gly Leu Ser Pro Asp Ser
 2085 2090 2095
 Glu Asn Phe Asp Trp Lys Ala Ile Gln Glu Gly Ala Asn Ser Ile Val
 2100 2105 2110
 Ser Ser Leu His Gln Ala Ala Ala Ala Cys Leu Ser Arg Gln Ala
 2115 2120 2125
 40 Ser Ser Asp Ser Asp Ser Ile Leu Ser Leu Lys Ser Gly Ile Ser Leu
 2130 2135 2140
 Gly Ser Pro Phe His Leu Thr Pro Asp Gln Glu Glu Lys Pro Phe Thr
 2145 2150 2155 2160
 Ser Asn Lys Gly Pro Arg Ile Leu Lys Pro Gly Glu Lys Ser Thr Leu
 2165 2170 2175
 45 Glu Thr Lys Lys Ile Glu Ser Glu Ser Lys Gly Ile Lys Gly Gly Lys
 2180 2185 2190
 Lys Val Tyr Lys Ser Leu Ile Thr Gly Lys Val Arg Ser Asn Ser Glu
 2195 2200 2205
 50 Ile Ser Gly Gln Met Lys Gln Pro Leu Gln Ala Asn Met Pro Ser Ile
 2210 2215 2220
 Ser Arg Gly Arg Thr Met Ile His Ile Pro Gly Val Arg Asn Ser Ser
 2225 2230 2235 2240
 Ser Ser Thr Ser Pro Val Ser Lys Lys Gly Pro Pro Leu Lys Thr Pro
 2245 2250 2255
 55 Ala Ser Lys Ser Pro Ser Glu Gly Gln Thr Ala Thr Thr Ser Pro Arg
 2260 2265 2270
 Gly Ala Lys Pro Ser Val Lys Ser Glu Leu Ser Pro Val Ala Arg Gln

EP 2 775 844 B1

		2275					2280				2285					
	Thr	Ser	Gln	Ile	Gly	Gly	Ser	Ser	Lys	Ala	Pro	Ser	Arg	Ser	Gly	Ser
		2290					2295					2300				
5	Arg	Asp	Ser	Thr	Pro	Ser	Arg	Pro	Ala	Gln	Gln	Pro	Leu	Ser	Arg	Pro
	2305					2310					2315				2320	
	Ile	Gln	Ser	Pro	Gly	Arg	Asn	Ser	Ile	Ser	Pro	Gly	Arg	Asn	Gly	Ile
					2325					2330					2335	
	Ser	Pro	Pro	Asn	Lys	Leu	Ser	Gln	Leu	Pro	Arg	Thr	Ser	Ser	Pro	Ser
				2340					2345					2350		
10	Thr	Ala	Ser	Thr	Lys	Ser	Ser	Gly	Ser	Gly	Lys	Met	Ser	Tyr	Thr	Ser
		2355						2360					2365			
	Pro	Gly	Arg	Gln	Met	Ser	Gln	Gln	Asn	Leu	Thr	Lys	Gln	Thr	Gly	Leu
		2370					2375					2380				
	Ser	Lys	Asn	Ala	Ser	Ser	Ile	Pro	Arg	Ser	Glu	Ser	Ala	Ser	Lys	Gly
	2385					2390					2395				2400	
15	Leu	Asn	Gln	Met	Asn	Asn	Gly	Asn	Gly	Ala	Asn	Lys	Lys	Val	Glu	Leu
				2405					2410						2415	
	Ser	Arg	Met	Ser	Ser	Thr	Lys	Ser	Ser	Gly	Ser	Glu	Ser	Asp	Arg	Ser
			2420					2425						2430		
	Glu	Arg	Pro	Val	Leu	Val	Arg	Gln	Ser	Thr	Phe	Ile	Lys	Glu	Ala	Pro
		2435					2440						2445			
20	Ser	Pro	Thr	Leu	Arg	Arg	Lys	Leu	Glu	Glu	Ser	Ala	Ser	Phe	Glu	Ser
		2450					2455					2460				
	Leu	Ser	Pro	Ser	Ser	Arg	Pro	Ala	Ser	Pro	Thr	Arg	Ser	Gln	Ala	Gln
	2465					2470					2475				2480	
	Thr	Pro	Val	Leu	Ser	Pro	Ser	Leu	Pro	Asp	Met	Ser	Leu	Ser	Thr	His
				2485					2490						2495	
25	Ser	Ser	Val	Gln	Ala	Gly	Gly	Trp	Arg	Lys	Leu	Pro	Pro	Asn	Leu	Ser
			2500						2505					2510		
	Pro	Thr	Ile	Glu	Tyr	Asn	Asp	Gly	Arg	Pro	Ala	Lys	Arg	His	Asp	Ile
		2515					2520						2525			
	Ala	Arg	Ser	His	Ser	Glu	Ser	Pro	Ser	Arg	Leu	Pro	Ile	Asn	Arg	Ser
	2530					2535					2540					
30	Gly	Thr	Trp	Lys	Arg	Glu	His	Ser	Lys	His	Ser	Ser	Ser	Leu	Pro	Arg
	2545					2550					2555				2560	
	Val	Ser	Thr	Trp	Arg	Arg	Thr	Gly	Ser	Ser	Ser	Ser	Ile	Leu	Ser	Ala
				2565					2570					2575		
	Ser	Ser	Glu	Ser	Ser	Glu	Lys	Ala	Lys	Ser	Glu	Asp	Glu	Lys	His	Val
			2580					2585					2590			
35	Asn	Ser	Ile	Ser	Gly	Thr	Lys	Gln	Ser	Lys	Glu	Asn	Gln	Val	Ser	Ala
		2595						2600					2605			
	Lys	Gly	Thr	Trp	Arg	Lys	Ile	Lys	Glu	Asn	Glu	Phe	Ser	Pro	Thr	Asn
	2610					2615						2620				
40	Ser	Thr	Ser	Gln	Thr	Val	Ser	Ser	Gly	Ala	Thr	Asn	Gly	Ala	Glu	Ser
	2625					2630					2635				2640	
	Lys	Thr	Leu	Ile	Tyr	Gln	Met	Ala	Pro	Ala	Val	Ser	Lys	Thr	Glu	Asp
				2645					2650					2655		
	Val	Trp	Val	Arg	Ile	Glu	Asp	Cys	Pro	Ile	Asn	Asn	Pro	Arg	Ser	Gly
			2660					2665					2670			
45	Arg	Ser	Pro	Thr	Gly	Asn	Thr	Pro	Pro	Val	Ile	Asp	Ser	Val	Ser	Glu
		2675						2680					2685			
	Lys	Ala	Asn	Pro	Asn	Ile	Lys	Asp	Ser	Lys	Asp	Asn	Gln	Ala	Lys	Gln
	2690					2695					2700					
	Asn	Val	Gly	Asn	Gly	Ser	Val	Pro	Met	Arg	Thr	Val	Gly	Leu	Glu	Asn
	2705					2710					2715				2720	
50	Arg	Leu	Asn	Ser	Phe	Ile	Gln	Val	Asp	Ala	Pro	Asp	Gln	Lys	Gly	Thr
				2725						2730					2735	
	Glu	Ile	Lys	Pro	Gly	Gln	Asn	Asn	Pro	Val	Pro	Val	Ser	Glu	Thr	Asn
				2740					2745					2750		
	Glu	Ser	Ser	Ile	Val	Glu	Arg	Thr	Pro	Phe	Ser	Ser	Ser	Ser	Ser	Ser
		2755						2760					2765			
55	Lys	His	Ser	Ser	Pro	Ser	Gly	Thr	Val	Ala	Ala	Arg	Val	Thr	Pro	Phe
		2770					2775						2780			

EP 2 775 844 B1

Asn Tyr Asn Pro Ser Pro Arg Lys Ser Ser Ala Asp Ser Thr Ser Ala
2785 2790 2795 2800
Arg Pro Ser Gln Ile Pro Thr Pro Val Asn Asn Asn Thr Lys Lys Arg
2805 2810 2815
5 Asp Ser Lys Thr Asp Ser Thr Glu Ser Ser Gly Thr Gln Ser Pro Lys
2820 2825 2830
Arg His Ser Gly Ser Tyr Leu Val Thr Ser Val
2835 2840

10

15

20

25

30

35

40

45

50

55

Claims

1. A method for identifying a cancer patient for treatment with a NEDD8-activating enzyme (NAE) inhibitor comprising:

- 5 a) determining a mutational status of at least one marker gene in a sample comprising tumor cells obtained from the cancer patient, wherein the at least one marker gene is a tumor suppressor in a cullin ring ligase pathway;
- b) determining whether the mutational status is indicative of a favorable outcome of treatment with the NAE inhibitor, wherein the NAE inhibitor is ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulphamate; and
- 10 c) identifying the patient for treatment with the NAE inhibitor if the mutational status indicates a favorable outcome of treatment with the NAE inhibitor;

wherein the at least one marker gene is selected from the group consisting of *TP53*, *CDKN2A*, *CDKN2A_p14* and *APC*.

- 15 2. The method of claim 1, wherein the mutational status of the at least one marker gene is mutant.
3. The method of claim 1, wherein the mutational status of the at least one marker gene is wild type.
- 20 4. The method of claim 2, wherein the mutant is an inactivating mutant.
5. The method of any one of the preceding claims, wherein the sample comprises hematological tumor cells or solid tumor cells.
- 25 6. The method of claim 5, wherein the sample comprising hematological tumor cells is blood.
7. The method of any one of claims 1-6, wherein the at least one marker gene is at least two marker genes.
8. The method of claim 2, wherein the at least one marker gene is *CDKN2A* or *CDKN2A_p14*.
- 30 9. The method of claim 3, wherein the at least one marker gene is *TP53*.
10. The method of claim 7, wherein the at least two marker genes are at least *TP53* and *APC*.
- 35 11. The method of any one of the preceding claims, wherein the mutational status is determined by measuring at least one characteristic of at least one marker associated with the at least one marker gene.
12. The method of claim 11, wherein the at least one characteristic is selected from the group consisting of size, sequence, composition, and amount.
- 40 13. The method of claim 11 or 12, wherein the at least one marker is selected from the group consisting of a chromosome locus, a nucleic acid, and a protein associated with the at least one marker gene.
14. The method of claim 13, wherein the nucleic acid is genomic DNA, mRNA, or cDNA.
- 45 15. The method of any one of claims 11-14, wherein the at least one characteristic is a sequence and the at least one marker is a nucleic acid.
16. The method of any one of claims 1 to 4, wherein the cancer patient has a hematological cancer or a solid tumor cancer.
- 50 17. The method of claim 16, wherein the hematological cancer is acute or chronic myelogenous leukemia.
18. The method of claim 16, wherein the hematological cancer is myelodysplastic syndrome.
- 55 19. The method of claim 16, wherein the solid tumor cancer is head and neck cancer.
20. The method of any one of the preceding claims, further comprising:

- a) identifying a mutational status of the at least one marker gene in a second sample from the patient, wherein the patient has been treated with the NAE inhibitor prior to the second sample being obtained;
 b) determining whether the mutational status is indicative of a favorable outcome of treatment with the NAE inhibitor; and
 c) determining to continue treatment with the NAE inhibitor if the mutational status of the second sample indicates a favorable outcome of treatment with the NAE inhibitor.

21. Use of a kit in identifying a cancer patient for treatment with a NEDD8-activating enzyme (NAE) inhibitor, the kit comprising a reagent to determine a mutational status of at least one marker gene in a sample comprising tumor cells obtained from the cancer patient, wherein the NAE inhibitor is a 1- substituted methyl sulfamate, wherein the at least one marker gene is a tumor suppressor in a cullin ring ligase pathway, and wherein the at least one marker gene is selected from the group consisting of *TP53*, *CDKN2A*, *CDKN2A_p14* and *APC*.

22. The use of the kit of claim 21, wherein the mutational status is determined by measurement of at least one characteristic of at least one marker of the at least one marker gene, wherein the at least one marker is selected from the group consisting of nucleic acid and protein associated with the at least one marker gene.

23. The use of the kit of any one of claims 21-22, the kit further comprising a stabilizer to add to the sample.

24. The use of the kit of claim 22, wherein the at least one marker is nucleic acid and the reagent is at least one primer.

25. The use of the kit of claim 24, wherein the at least one primer hybridizes to a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 2, 4, 5, 7, 8, 9, 12, 13, 15, 16, 18, 19, 21, 22, 24, 25 or a sequence on chromosome 22q from base pair 29999545 to 30094589, chromosome 18q from base pair 48556583 to 48611412, chromosome Xp from base pair 44732423 to 44971847, chromosome 4q from base pair 153242410 to 153456172, chromosome 17p from base pair 7571720 to 7590868, chromosome 9p from base pair 21967751 to 21994490, and a complement of any of the foregoing.

26. An NAE inhibitor for use in a method of treating a cancer patient, the method comprising:

- a) using the mutational status of at least one marker gene in a patient's tumor, wherein the at least one marker gene is selected from the group consisting of *TP53*, *CDKN2A*, *CDKN2A_p14* and *APC*, to select a cancer patient who is expected to have a favorable outcome of treatment with the NAE inhibitor, and
 b) treating the cancer patient with the NAE inhibitor, wherein the NAE inhibitor is a 1-substituted methyl sulfamate.

27. The NAE inhibitor for use according to claim 26, wherein the NAE inhibitor is ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulphamate.

28. The NAE inhibitor for use of claim 26 or 27, wherein the cancer patient has a hematological cancer or a solid tumor cancer.

29. The NAE inhibitor for use of claim 28, wherein the hematological cancer is acute or chronic myelogenous leukemia.

30. The NAE inhibitor for use of claim 28, wherein the hematological cancer is myelodysplastic syndrome.

31. The NAE inhibitor for use of claim 28, wherein the solid tumor cancer is head and neck cancer.

Patentansprüche

1. Verfahren zum Identifizieren eines Krebspatienten für eine Behandlung mit einem NEDD8-aktivierendes-Enzym(NAE)-Inhibitor, umfassend:

- a) Bestimmen eines Mutationsstatus mindestens eines Markergens in einer Tumorzellen umfassenden Probe, die von dem Krebspatienten erhalten wurde, wobei das mindestens eine Markergens ein Tumorsuppressor in einem Cullin-Ring-Ligase-Weg ist;
 b) Bestimmen, ob der Mutationsstatus für ein günstiges Ergebnis einer Behandlung mit dem NAE-Inhibitor indikativ ist, wobei der NAE-Inhibitor ((1S,2S,4R)-4-{4-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-

EP 2 775 844 B1

d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methylsulfamat ist; und

c) Identifizieren des Patienten für eine Behandlung mit dem NAE-Inhibitor, wenn der Mutationsstatus auf ein günstiges Ergebnis einer Behandlung mit dem NAE-Inhibitor hindeutet;

- 5 wobei das mindestens eine Markergen aus der Gruppe ausgewählt ist bestehend aus *TP53*, *CDKN2A*, *CDKN2A_p14* und *APC*.
2. Verfahren nach Anspruch 1, wobei der Mutationsstatus des mindestens einen Markergens mutiert ist.
- 10 3. Verfahren nach Anspruch 1, wobei der Mutationsstatus des mindestens einen Markergens Wildtyp ist.
4. Verfahren nach Anspruch 2, wobei die Mutante eine inaktivierende Mutante ist.
5. Verfahren nach einem der vorhergehenden Ansprüche, wobei die Probe hämatologische Tumorzellen oder solide
15 Tumorzellen umfasst.
6. Verfahren nach Anspruch 5, wobei die Probe, die hämatologische Tumorzellen umfasst, Blut ist.
7. Verfahren nach einem der Ansprüche 1-6, wobei das mindestens eine Markergen mindestens zwei Markergene ist.
20
8. Verfahren nach Anspruch 2, wobei das mindestens eine Markergen *CDKN2A* oder *CDKN2A_p14* ist.
9. Verfahren nach Anspruch 3, wobei das mindestens eine Markergen *TP53* ist.
- 25 10. Verfahren nach Anspruch 7, wobei die mindestens zwei Markergene mindestens *TP53* und *APC* sind.
11. Verfahren nach einem der vorhergehenden Ansprüche, wobei der Mutationsstatus durch Messen mindestens eines Merkmals mindestens eines mit dem mindestens einen Markergen assoziierten Markers bestimmt wird.
- 30 12. Verfahren nach Anspruch 11, wobei das mindestens eine Merkmal aus der Gruppe ausgewählt ist bestehend aus Größe, Sequenz, Zusammensetzung und Menge.
13. Verfahren nach Anspruch 11 oder 12, wobei der mindestens eine Marker aus der Gruppe ausgewählt ist bestehend
35 aus einem Chromosomenlocus, einer Nukleinsäure und einem Protein, die mit dem mindestens einen Markergen assoziiert sind.
14. Verfahren nach Anspruch 13, wobei die Nukleinsäure genomische DNA, mRNA oder cDNA ist.
15. Verfahren nach einem der Ansprüche 11-14, wobei das mindestens eine Merkmal eine Sequenz ist und der min-
40 destens eine Marker eine Nukleinsäure ist.
16. Verfahren nach einem der Ansprüche 1 bis 4, wobei der Krebspatient einen hämatologischen Krebs oder einen Krebs in Form eines soliden Tumors hat.
- 45 17. Verfahren nach Anspruch 16, wobei der hämatologische Krebs akute oder chronische myeloische Leukämie ist.
18. Verfahren nach Anspruch 16, wobei der hämatologische Krebs myelodysplastisches Syndrom ist.
19. Verfahren nach Anspruch 16, wobei der Krebs in Form eines soliden Tumors Kopf- und Halskrebs ist.
50
20. Verfahren nach einem der vorhergehenden Ansprüche, ferner umfassend:
- a) Identifizieren eines Mutationsstatus des mindestens eines Markergens in einer zweiten Probe von dem
55 Patienten, wobei der Patient vor der Entnahme der zweiten Probe mit dem NAE-Inhibitor behandelt wurde;
- b) Bestimmen, ob der Mutationsstatus für ein günstiges Ergebnis einer Behandlung mit dem NAE-Inhibitor
indikativ ist, und
- c) Ermitteln der Fortsetzung der Behandlung mit dem NAE-Inhibitor, wenn der Mutationsstatus der zweiten
Probe auf ein günstiges Ergebnis der Behandlung mit dem NAE-Inhibitor hindeutet.

EP 2 775 844 B1

- 5
21. Verwendung eines Kits beim Identifizieren eines Krebspatienten für eine Behandlung mit einem NEDD8-aktivierenden-Enzym(NAE)-Inhibitor, wobei das Kit ein Reagenz zum Bestimmen eines Mutationsstatus mindestens eines Markergens in einer Tumorzellen umfassenden Probe, die von dem Krebspatienten erhalten wurde, umfasst, wobei der NAE-Inhibitor ein 1-substituiertes Methylsulfamat ist, wobei das mindestens eine Markergen ein Tumorsuppressor in einem Cullin-Ring-Ligase-Weg ist und wobei das mindestens eine Markergen aus der Gruppe ausgewählt ist bestehend aus *TP53*, *CDKN2A*, *CDKN2A_p14* und *APC*.
- 10
22. Verwendung des Kits nach Anspruch 21, wobei der Mutationsstatus durch Messen mindestens eines Merkmals mindestens eines Markers des mindestens einen Markergens bestimmt wird, wobei der mindestens eine Marker aus der Gruppe ausgewählt ist bestehend aus Nukleinsäure und Protein, die mit dem mindestens einen Markergen assoziiert sind.
- 15
23. Verwendung des Kits nach einem der Ansprüche 21-22, wobei das Kit ferner einen Stabilisator für die Zugabe zur Probe umfasst.
- 20
24. Verwendung des Kits nach Anspruch 22, wobei der mindestens eine Marker Nukleinsäure ist und das Reagenz mindestens ein Primer ist.
- 25
25. Verwendung des Kits nach Anspruch 24, wobei der mindestens eine Primer an eine Nukleinsäuresequenz hybridisiert, ausgewählt aus der Gruppe bestehend aus SEQ ID NO: 1, 2, 4, 5, 7, 8, 9, 12, 13, 15, 16, 18, 19, 21, 22, 24, 25 oder einer Sequenz auf Chromosom 22q von Basenpaar 29999545 bis 30094589, Chromosom 18q von Basenpaar 48556583 bis 48611412, Chromosom Xp von Basenpaar 44732423 bis 44971847, Chromosom 4q von Basenpaar 153242410 bis 153456172, Chromosom 17p von Basenpaar 7571720 bis 7590868, Chromosom 9p von Basenpaar 21967751 bis 21994490 und einem Komplement eines der Vorstehenden.
- 30
26. NAE-Inhibitor zur Verwendung bei einem Verfahren zur Behandlung eines Krebspatienten, wobei das Verfahren Folgendes umfasst:
a) Verwenden eines Mutationsstatus mindestens eines Markergens in einem Tumor des Patienten, wobei das mindestens eine Markergen aus der Gruppe ausgewählt ist bestehend aus *TP53*, *CDKN2A*, *CDKN2A_p14* und *APC*, um einen Krebspatienten auszuwählen, bei dem ein günstiges Ergebnis einer Behandlung mit dem NAE-Inhibitor zu erwarten ist, und
b) Behandeln des Krebspatienten mit dem NAE-Inhibitor, wobei der NAE-Inhibitor ein 1-substituiertes Methylsulfamat ist.
- 35
27. NAE-Inhibitor zur Verwendung nach Anspruch 26, wobei der NAE-Inhibitor ((1S,2S,4R)-4-{4-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methylsulfamat ist.
- 40
28. NAE-Inhibitor zur Verwendung nach Anspruch 26 oder 27, wobei der Krebspatient einen hämatologischen Krebs oder einen Krebs in Form eines soliden Tumors hat.
- 45
29. NAE-Inhibitor zur Verwendung nach Anspruch 28, wobei der hämatologische Krebs akute oder chronische myeloische Leukämie ist.
- 30
30. NAE-Inhibitor zur Verwendung nach Anspruch 28, wobei der hämatologische Krebs myelodysplastisches Syndrom ist.
- 50
31. NAE-Inhibitor zur Verwendung nach Anspruch 28, wobei der Krebs in Form eines soliden Tumors Kopf- und Halskrebs ist.

Revendications

- 55
1. Méthode d'identification d'un patient cancéreux pour un traitement par un inhibiteur de l'enzyme d'activation de NEDD8 (NAE), comprenant :
a) la détermination d'un état mutationnel d'au moins un gène marqueur dans un échantillon comprenant des cellules tumorales obtenues auprès du patient cancéreux, où le au moins un gène marqueur est un suppresseur

EP 2 775 844 B1

tumoral dans une voie de la ligase culline-RING ;

b) la détermination du fait que l'état mutationnel constitue ou non une indication d'une issue favorable de traitement par l'inhibiteur de NAE, où l'inhibiteur de NAE est le sulfamate de ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-indén-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)méthyle ; et

c) l'identification du patient pour un traitement par l'inhibiteur de NAE si l'état mutationnel indique une issue favorable d'un traitement par l'inhibiteur de NAE ;

dans laquelle le au moins un gène marqueur est choisi dans le groupe constitué par *TP53*, *CDKN2A*, *CDKN2A_p14* et *APC*.

2. Méthode selon la revendication 1, dans laquelle l'état mutationnel du au moins un gène marqueur est mutant.
3. Méthode selon la revendication 1, dans laquelle l'état mutationnel du au moins un gène marqueur est de type sauvage.
4. Méthode selon la revendication 2, dans laquelle le mutant est un mutant inactivant.
5. Méthode selon l'une quelconque des revendications précédentes, dans laquelle l'échantillon comprend des cellules de tumeurs hématologiques ou des cellules de tumeurs solides.
6. Méthode selon la revendication 5, dans laquelle l'échantillon comprenant des cellules de tumeurs hématologiques est constitué de sang.
7. Méthode selon l'une quelconque des revendications 1-6, dans laquelle le au moins un gène marqueur est constitué d'au moins deux gènes marqueurs.
8. Méthode selon la revendication 2, dans laquelle le au moins un gène marqueur est *CDKN2A* ou *CDKN2A_p14*.
9. Méthode selon la revendication 3, dans laquelle le au moins un gène marqueur est *TP53*.
10. Méthode selon la revendication 7, dans laquelle les au moins deux gènes marqueurs sont au moins *TP53* et *APC*.
11. Méthode selon l'une quelconque des revendications précédentes, dans laquelle l'état mutationnel est déterminé par la mesure d'au moins une caractéristique d'au moins un marqueur associé au au moins un gène marqueur.
12. Méthode selon la revendication 11, dans laquelle la au moins une caractéristique est choisie dans le groupe constitué par la taille, la séquence, la composition, et la quantité.
13. Méthode selon la revendication 11 ou 12, dans laquelle le au moins un marqueur est choisi dans le groupe constitué par un locus de chromosome, un acide nucléique, et une protéine associée au au moins un gène marqueur.
14. Méthode selon la revendication 13, dans laquelle l'acide nucléique est un ADN génomique, un ARNm, ou un ADNc.
15. Méthode selon l'une quelconque des revendications 11-14, dans laquelle la au moins une caractéristique est une séquence et le au moins un marqueur est un acide nucléique.
16. Méthode selon l'une quelconque des revendications 1 à 4, dans laquelle le patient cancéreux souffre d'un cancer hématologique ou d'un cancer à tumeur solide.
17. Méthode selon la revendication 16, dans laquelle le cancer hématologique est une leucémie myéloïde chronique ou aiguë.
18. Méthode selon la revendication 16, dans laquelle le cancer hématologique est un syndrome myélodysplasique.
19. Méthode selon la revendication 16, dans laquelle le cancer à tumeur solide est un cancer de la tête et du cou.
20. Méthode selon l'une quelconque des revendications précédentes, comprenant en outre :

a) l'identification d'un état mutationnel du au moins un gène marqueur dans un deuxième échantillon issu du

EP 2 775 844 B1

patient, où le patient a été traité par l'inhibiteur de NAE préalablement à l'obtention du deuxième échantillon ;
b) la détermination du fait que l'état mutationnel constitue ou non une indication d'une issue favorable de traitement par l'inhibiteur de NAE ; et

c) la détermination de la poursuite du traitement par l'inhibiteur de NAE, si l'état mutationnel du deuxième échantillon indique une issue favorable de traitement par l'inhibiteur de NAE.

21. Utilisation d'un kit dans l'identification d'un patient cancéreux pour un traitement par un inhibiteur de l'enzyme d'activation de NEDD8 (NAE), le kit comprenant un réactif destiné à déterminer un état mutationnel d'au moins un gène marqueur dans un échantillon comprenant des cellules tumorales obtenues auprès du patient cancéreux, où l'inhibiteur de NAE est un sulfamate de méthyle 1-substitué, où le au moins un gène marqueur est un suppresseur tumoral dans une voie de la ligase culline-RING, et où le au moins un gène marqueur est choisi dans le groupe constitué par *TP53*, *CDKN2A*, *CDKN2A_p14* et *APC*.

22. Utilisation du kit selon la revendication 21, dans laquelle l'état mutationnel est déterminé par la mesure d'au moins une caractéristique d'au moins un marqueur du au moins un gène marqueur, où le au moins un marqueur est choisi dans le groupe constitué par un acide nucléique et une protéine associée au au moins un gène marqueur.

23. Utilisation du kit selon l'une quelconque des revendications 21-22, le kit comprenant en outre un stabilisant à ajouter à l'échantillon.

24. Utilisation du kit selon la revendication 22, dans laquelle le au moins un marqueur est un acide nucléique et le réactif est au moins une amorce.

25. Utilisation du kit selon la revendication 24, dans laquelle la au moins une amorce s'hybride avec une séquence d'aide nucléique choisie dans le groupe constitué par SEQ ID n° 1, 2, 4, 5, 7, 8, 9, 12, 13, 15, 16, 18, 19, 21, 22, 24, 25 ou une séquence sur le chromosome 22q des paires de base 29999545 à 30094589, le chromosome 18q des paires de base 48556583 à 48611412, le chromosome Xp des paires de base 44732423 à 44971847, le chromosome 4q des paires de base 153242410 à 153456172, le chromosome 17p des paires de base 7571720 à 7590868, le chromosome 9p des paires de base 21967751 à 21994490, et un complément de l'un quelconque parmi ce qui précède.

26. Inhibiteur de NAE pour une utilisation dans une méthode de traitement d'un patient cancéreux, la méthode comprenant :

a) l'utilisation de l'état mutationnel d'au moins un gène marqueur dans une tumeur du patient, où le au moins un gène marqueur est choisi dans le groupe constitué par *TP53*, *CDKN2A*, *CDKN2A_p14* et *APC*, afin de sélectionner un patient cancéreux qui est prévu comme présentant une issue favorable vis-à-vis d'un traitement par l'inhibiteur de NAE ; et

b) le traitement du patient cancéreux par l'inhibiteur de NAE, où l'inhibiteur de NAE est un sulfamate de méthyle 1-substitué.

27. Inhibiteur de NAE pour une utilisation selon la revendication 26, l'inhibiteur de NAE étant le sulfamate de ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-indén-1-yl-amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)méthyle.

28. Inhibiteur de NAE pour une utilisation selon la revendication 26 ou 27, où le patient cancéreux souffre d'un cancer hématologique ou d'un cancer à tumeur solide.

29. Inhibiteur de NAE pour une utilisation selon la revendication 28, où le cancer hématologique est une leucémie myéloïde chronique ou aiguë.

30. Inhibiteur de NAE pour une utilisation selon la revendication 28, où le cancer hématologique est un syndrome myélodysplasique.

31. Inhibiteur de NAE pour une utilisation selon la revendication 28, où le cancer à tumeur solide est un cancer de la tête et du cou.




Figure 1




FIG. 2




FIG. 3

FIG4A.




FIG4B.




FIG. 4

Intestine: TP53wt v. TP53mut




FIG. 5

FIG. 6A




FIG. 6B




FIG. 6C





FIG. 6D



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 61552686 [0001]
- WO 2011068863A1 PCT [0008]
- US 700614, Langston S. [0029]
- WO 07092213 PCT [0029]
- WO 06084281 A [0029]
- WO 2008019124 A [0029]
- US 4843155 A, Chomczynski [0075]
- US 5346994 A [0075]
- US 5539083 A [0084]
- WO 0105935 A [0086]
- US 5780454 A, Adams [0097]
- US 6066730 A [0097]
- US 6083903 A [0097]
- US 2000 A [0097]
- US 6297217 B [0097]
- US 6465433 B [0097]
- US 6548668 B [0097]
- US 6617317 B [0097]
- US 6747150 B [0097]
- US 5693617 A, Stein [0098]
- WO 9113904 A, Siman [0098]
- WO 05105826 A [0098]
- US 6831099 B, Crews [0098]
- WO 05111008 A, Smyth [0098]
- WO 06045066 A [0098]
- US 6310057 B [0098]
- US 2001 A [0098]
- US 6096778 A [0098]
- US 6075150 A, Wang [0098]
- US 6781000 B [0098]
- WO 05030707 A [0098]
- WO 03018557 A [0098]
- WO 05115431 A [0098]
- US 5756764 A [0098]
- US 6147223 A [0098]
- US 6335358 B [0098]
- US 6645999 B [0098]
- WO 05003137 A [0098]
- WO 05002572 A [0098]
- WO 04071382 A [0098]
- US 2005023162 A [0098]
- WO 05099687 A [0098]
- US 5631169 A, Lakowicz [0111]
- US 4868103 A, Stavrianopoulos [0111]
- US 7045610 B [0114]
- US 4683202 A, Mullis [0118]
- US 5854033 A, Lizardi [0118]
- US 5242974 A [0124]
- US 5384261 A [0124]
- US 5405783 A [0124]
- US 5412087 A [0124]
- US 5424186 A [0124]
- US 5429807 A [0124]
- US 5436327 A [0124]
- US 5445934 A [0124]
- US 5556752 A [0124]
- US 5472672 A [0124]
- US 5527681 A [0124]
- US 5529756 A [0124]
- US 5545531 A [0124]
- US 5554501 A [0124]
- US 5561071 A [0124]
- US 5571639 A [0124]
- US 5593839 A [0124]
- US 5624711 A [0124]
- US 5700637 A [0124]
- US 5744305 A [0124]
- US 5770456 A [0124]
- US 5770722 A [0124]
- US 5837832 A [0124]
- US 5856101 A [0124]
- US 5874219 A [0124]
- US 5885837 A [0124]
- US 5919523 A [0124]
- US 5981185 A [0124]
- US 6022963 A [0124]
- US 6077674 A [0124]
- US 6156501 A [0124]
- US 6261776 B [0124]
- US 6346413 B [0124]
- US 6440677 B [0124]
- US 6451536 B [0124]
- US 6576424 B [0124]
- US 6610482 B [0124]
- US 5143854 A [0124]
- US 5288644 A [0124]
- US 5324633 A [0124]
- US 5432049 A [0124]
- US 5470710 A [0124]
- US 5492806 A [0124]
- US 5503980 A [0124]
- US 5510270 A [0124]
- US 5525464 A [0124]
- US 5547839 A [0124]
- US 5580732 A [0124]
- US 5661028 A [0124]
- US 5848659 A [0124]
- US 6162963 A [0133]

- US 6150584 A [0133]
- US 6114598 A [0133]
- US 6075181 A [0133]
- US 5545807 A [0133]
- US 5545806 A [0133]
- US 5625825 A [0133]
- WO 9312227 A [0133]
- US 6331415 B [0134]
- US 61552686 B [0181]

Non-patent literature cited in the description

- Affymetrix GeneChip Human Genome U133 Array Set HGU133A. *NCBI*, 11 March 2002, 61, , 243, , 418 [0006]
- **BIGNELL, G. R. et al.** Signatures of mutation and selection in the cancer genome. *Nature*, 2010, vol. 463 (7283), 893 [0007]
- **PAN et al.** *Oncogene*, 2004, vol. 23, 1985-97 [0026]
- **SOUCY et al.** *Genes & Cancer*, 2010, vol. 1, 708-716 [0026]
- **SOUCY et al.** *Nature*, 2009, vol. 458, 732-736 [0030]
- **MILHOLLEN et al.** *Cancer Res.*, 2011, vol. 71, 3042-3051 [0030]
- **LIN et al.** *Nature*, 2010, vol. 464, 374-379 [0030]
- **LIN et al.** *Cancer Res.*, 2010, vol. 70, 10310-20 [0030]
- **MILHOLLEN et al.** *Blood*, 2010, vol. 116, 1515-1523 [0030]
- **SWORDS et al.** *Blood*, 2010, vol. 115, 3796-3800 [0030]
- **AHRONOWITZ et al.** *Human Mutation*, 2007, vol. 28, 1-2 [0031]
- **HAAFTEN et al.** *Nat. Genet.*, 2009, vol. 41, 521-523 [0031]
- **MIYAKI ; KUROKI.** *Biochem. Biophys. Res. Commun.*, 2003, vol. 306, 799-804 [0031]
- **LI et al.** *Cell*, 2010, vol. 140, 477-490 [0032]
- **SAMBROOK et al.** *Molecular Cloning: A Laboratory Manual.* Cold Spring Harbor Laboratory Press, 2000 [0042]
- **HARLOW, E. ; LANE, D.** *Antibodies: A Laboratory Manual.* Cold Spring Harbor Laboratory Press, 1988 [0042] [0134]
- **BLADE et al.** *Br J Haematol.*, 1998, vol. 102, 1115-23 [0052]
- **EISENHAUER et al.** *E. J. Canc.*, 2009, vol. 45, 228-247 [0052]
- **AML, CHESON et al.** *J.Clin. Oncol.*, 2003, vol. 21, 4642-4649 [0052]
- **CHESON et al.** *J.Clin. Oncol.*, 2007, vol. 25, 579-596 [0052]
- **PILARSKI et al.** *Blood*, 2000, vol. 95, 1056-65 [0067]
- **RIGOLIN et al.** *Blood*, 2006, vol. 107, 2531-5 [0067]
- **ALIZADEH et al.** *Nature*, 2000, vol. 403, 503-511 [0069]
- **MCDERMOTT et al.** *PNAS*, 2007, vol. 104, 19936-19941 [0069] [0152]
- **ZHANG et al.** *J. Genet. Genomics*, 2011, vol. 38, 95-109 [0072]
- **SHENDURE ; HANLEE.** *Nature Biotech.*, 2008, vol. 26, 1135-1145 [0072]
- **AUSUBEL et al.** *Current Protocols in Molecular Biology.* John Wiley & Sons, 1987 [0075]
- **CHOMCZYNSKI ; SACCHI.** *Anal. Biochem.*, 1987, vol. 162, 156-159 [0075]
- **CHIRGWIN et al.** *Biochemistry.* 1979, vol. 18, 5294-99 [0076]
- **SAMBROOK et al.** *Molecular Cloning-A Laboratory Manual.* Cold Spring Harbor Laboratory, 1989 [0076]
- **AUSUBEL et al.** *Current Protocols In Molecular Biology.* Current Protocols Publishing, 1994, vol. 2 [0076]
- **SEO et al.** *Exp. Biol. Med.*, 2009, vol. 234, 255-262 [0079]
- **KUANG ; CHEN.** *Oncogene*, 2004, vol. 23, 1021-1029 [0079]
- **HONG et al.** *PNAS*, 2007, vol. 104, 18439-18444 [0079]
- **EGHOLM et al.** *Nature*, 1993, vol. 363, 566-568 [0084]
- **HUGHES et al.** *Nat. Biotech.*, 2001, vol. 19, 342-7 [0086]
- **LITTELL ; MILIKEN ; STROUP ; WOLFINGER ; SCHABENBERGER.** *SAS for Mixed Models.* SAS Institute, Inc, 2006 [0088]
- **MULLIGAN et al.** *Blood*, 2006, vol. 109, 3177-88 [0090]
- **CHNG et al.** *Cancer Res.*, 2007, vol. 67, 292-9 [0090]
- **ADAMS J et al.** *Cancer Res*, 1999, vol. 59, 2615-22 [0097]
- **IQBAL et al.** *J. Med. Chem.*, 1995, vol. 38, 2276-2277 [0098]
- **SPALTENSTEIN et al.** *Tetrahedron Lett.*, 1996, vol. 37, 1343 [0098]
- **MENG.** *Proc. Natl. Acad. Sci.*, 1999, vol. 96, 10403 [0098]
- **MENG.** *Cancer Res.*, 1999, vol. 59, 2798 [0098]
- **MARASTONI et al.** *J. Med. Chem.*, 2005, vol. 48, 5038 [0098]
- **RYDZEWSKI et al.** *J. Med. Chem.*, 2006, vol. 49, 2953 [0098]
- **BOGYO ; 1997 et al.** *Proc. Natl. Acad. Sci.*, vol. 94, 6629 [0098]
- **BOUGET et al.** *Bioorg. Med. Chem.*, 2003, vol. 11, 4881 [0098]
- **FENTEANY et al.** *Proc. Natl. Acad. Sci. USA*, 1994, vol. 91, 3358 [0098]

- **GILMAN A.G. et al.** The Pharmacological Basis of Therapeutics. 1990, 1202-1263 [0100]
- **SJOLANDER, S. ; URBANICZKY, C.** *Anal. Chem.*, 1991, vol. 63, 2338-2345 [0112]
- **SZABO et al.** *Curr. Opin. Struct. Biol.*, 1995, vol. 5, 699-705 [0112]
- **RIVAS, G. ; MINTON, A.P.** *Trends Biochem Sci.*, 1993, vol. 18, 284-7 [0113]
- **HEEGAARD, N.H.** *J. Mol. Recognit.*, 1998, vol. 11, 141-8 [0113]
- **HAGE, D.S. ; TWEED, S.A.** *J. Chromatogr. B. Biomed. Sci. Appl.*, 1997, vol. 699, 499-525 [0113]
- Current Protocols in Molecular Biology. John Wiley & Sons, 1987-1999 [0113]
- Current Protocols in Molecular Biology. John Wiley & Sons, Inc, 1995 [0116]
- **SAMBROOK et al.** Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Press, 1989 [0116]
- **CHURCH ; GILBERT.** *Proc. Natl. Acad. Sci. USA*, 1984, vol. 81, 1991-1995 [0116]
- **BARANY.** *Proc. Natl. Acad. Sci. USA*, 1991, vol. 88, 189-193 [0118]
- **GUATELLI et al.** *Proc. Natl. Acad. Sci. USA*, 1990, vol. 87, 1874-1878 [0118]
- **KWOH et al.** *Proc. Natl. Acad. Sci. USA*, 1989, vol. 86, 1173-1177 [0118]
- **LIZARDI et al.** *Bio/Technology*, 1988, vol. 6, 1197 [0118]
- **LIAO et al.** *Arthritis Rheum.*, 2004, vol. 50, 3792-3803 [0122]
- **SHENA et al.** *Tibtech*, 1998, vol. 16, 301 [0124]
- **DUGGAN et al.** *Nat. Genet.*, 1999, vol. 21, 10 [0124]
- **BOWTELL et al.** *Nat. Genet.*, 1999, vol. 21, 25 [0124]
- **LIPSHUTZ et al.** *Nature Genet.*, 1999, vol. 21, 20-24 [0124]
- **BLANCHARD et al.** *Biosensors and Bioelectronics*, 1996, vol. 11, 687-90 [0124]
- **MASKOS et al.** *Nucleic Acids Res.*, 1993, vol. 21, 4663-69 [0124]
- **HUGHES et al.** *Nat. Biotechnol.*, 2001, vol. 19, 342 [0124]
- **HANS et al.** *Blood*, 2004, vol. 103, 275-282 [0124]
- **BRADFORD et al.** *Urol. Oncol.*, 2006, vol. 24, 237-242 [0124]
- **WARD et al.** *Nature*, 1989, vol. 341, 544-546 [0134]
- **CORTEZ-RETAMOZO et al.** *Cancer Res.*, 2004, vol. 64, 2853-2857 [0134]
- **BIRD et al.** *Science*, 1988, vol. 242, 423-426 [0134]
- **HUSTON et al.** *Proc. Natl. Acad. Sci. USA*, 1988, vol. 85, 5879-5883 [0134]
- **KOHLER ; MILSTEIN.** *Nature*, 1975, vol. 256, 495 [0134]
- **KOZBOR et al.** *Immunol. Today*, 1983, vol. 4, 72 [0134]
- **COLE et al.** Monoclonal Antibodies and Cancer Therapy. Alan R. Liss, Inc, 1985, 77-96 [0134]
- Current Protocols in Immunology. John Wiley & Sons, 1994 [0134]
- **O'DAY et al.** *Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development*, 2010 [0152]
- **JIA et al.** *Neoplasia*, 2011, vol. 13, 561-569 [0154]
- **LIAO et al.** *Mol. Cell Proteomics*, 2011, vol. 10, 10 [0163]
- **LIN et al.** *Cancer Res.*, 2010, vol. 70, 10310-10320 [0166]

专利名称(译)	对nae抑制剂起反应的生物标志物		
公开(公告)号	EP2775844A4	公开(公告)日	2015-12-09
申请号	EP2012844605	申请日	2012-10-26
[标]申请(专利权)人(译)	米伦纽姆医药公司		
申请(专利权)人(译)	千年制药, INC. 马萨诸塞州总医院		
当前申请(专利权)人(译)	千年制药, INC. 马萨诸塞州总医院		
[标]发明人	BENES CYRIL H BLAKEMORE STEPHEN J BLANK JONATHAN L LIGHTCAP ERIC S MULLIGAN GEORGE J SCHU MATTHEW C SMITH PETER G SETTLEMAN JEFFREY E		
发明人	BENES, CYRIL, H. BLAKEMORE, STEPHEN, J. BLANK, JONATHAN, L. LIGHTCAP, ERIC, S. MULLIGAN, GEORGE, J. SCHU, MATTHEW, C. SMITH, PETER, G. SETTLEMAN, JEFFREY E.		
IPC分类号	A01N43/90 A61K31/519 C12Q1/68 G01N33/53 G01N33/50		
CPC分类号	C12Q1/68886 C12Q2600/106 C12Q2600/156 G01N33/57484 G01N2800/52 G01N2800/60 A61K31/519 G06F19/328		
优先权	61/552686 2011-10-28 US		
其他公开文献	EP2775844A1 EP2775844B1		
外部链接	Espacenet		

摘要(译)

本文公开了其突变状态与对NAE抑制剂治疗的敏感性相关的标志物。通过测量与标记基因相关的标记的特征来确定突变状态。提供组合物和方法以评估标志物基因的标志物以预测对NAE抑制治疗的反应。

